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Abstract 
Aims: To provide insights into optimal treatments, glycaemic targets, and experiences of women with 
gestational diabetes mellitus (GDM) to guide clinical management. 
Optimal treatments for women with GDM 
Method: An overview of Cochrane systematic reviews to synthesise evidence on treatments for women 
with GDM. 
 
Findings: Eight systematic reviews were eligible and included a total of 62 randomised trials involving 
9133 women, 8373 babies and 767 children. High-quality evidence suggested that lifestyle interventions 
were ineffective for reducing the likelihood of induction of labour compared with usual diet/diet alone. 
Exercise compared with control was ineffective in improving the return to pre-pregnancy weight. No 
other high-quality evidence was found.  
 
Promising interventions included lifestyle interventions (reduced risk of large for gestational age) and 
the DASH diet (reduced rate of caesarean section). 
Glycaemic treatment targets for women with GDM 
Method: A Cochrane systematic review to synthesise evidence from randomised controlled trials on the 
effect of different glycaemic targets for women with GDM and their children.  
 
Findings: One randomised trial with 180 women was eligible and included. Based on limited data it 
remains unclear which glycaemic targets to recommend for women with GDM for improving their health 
and that of their babies.  
Views, experiences, barriers, and enablers of women with GDM on achieving optimal 
glycaemic control 
Methods: Sixty women with GDM completed the survey and semi-structured interview.  
 
Findings: The survey highlighted how the 60 women viewed adherence to their glycaemic targets and 
identified ten enablers and nine barriers. Thematic analysis using the Theoretical Domains Framework 
from the semi-structured interviews provided insights of the women’s first reaction to a diagnosis of GDM 
and identified multiple barriers and enablers for women with GDM trying to achieve optimal glycaemic 
control within ten relevant Theoretical Domains. 
Conclusions 
This thesis found limited evidence for effective treatments and glycaemic targets for women with GDM. 
A need for high-quality research with long-term follow-up was identified. Women with GDM in New 
Zealand identified multiple enablers and barriers to achieving optimal glycaemic control that need to be 
considered when providing health care. 
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Chapter 1: Orientation to the studies 
1.1 Introduction 
The worldwide prevalence of gestational diabetes mellitus (GDM) is increasing and has been 
documented with variations between 5.2% to 31.6% depending on the ethnicity of the population and 
diagnostic criteria used (Cheung 2003; Ferrara 2007; Boyadzhieva 2012; Sacks 2012; Tran 2013; NICE 
2015; Melchior 2017).  
In 2015, 58,957 women in New Zealand gave birth (Ministry of Health 2017) and 9% were diagnosed 
with GDM. This has been reported as one in every 11 pregnant women being diagnosed with GDM 
(ADHB 2016). The incidence of GDM for pregnant women was higher in Indian (16%), Asian (15%), 
Pacific peoples (8%) compared to European (5%) and Māori (4.5%) (ADHB 2016).  Maternal 
hyperglycaemia, associated with GDM, is a serious complication of pregnancy and a strong predictor 
for future type 2 diabetes mellitus (T2DM) (IADPSG 2010; ADHB 2016; Jowitt 2016). Given the 
prevalence, effective interventions for treatments for women with GDM for reducing adverse maternal 
and infant health outcomes are imperative. 
1.2 Definition of gestational diabetes mellitus (GDM) 
Gestational diabetes mellitus (GDM) is a medical condition that usually occurs in the second half of the 
pregnancy (Holt 2014). The World Health Organization defines GDM as a ‘carbohydrate intolerance 
resulting in hyperglycaemia or any degree of glucose intolerance with onset or first recognition during 
pregnancy, usually from 24 weeks gestation onwards’, (WHO 2013, p. 20) and resolves following the 
birth of the baby (Kampmann 2015). This definition excludes women with previously undiagnosed pre-
existing type 1 (T1DM), type 2 diabetes (T2DM) or other form of diabetes first detected during screening 
earlier in pregnancy (Nankervis 2014; ADA 2017). 
1.3 Pathophysiology of GDM 
The continuous supply of appropriate and balanced nutrients from the pregnant woman to the fetus is 
essential for optimal health and growth. Glucose is the primary energy substrate for the fetus. Fetal 
glucose production is minimal and is dependent on placental supply of glucose from the maternal 
circulation, the key transporter being glucose transporters (GLUT) (Lager 2012). The regulation of fetal 
glucose metabolism requires the maintenance of maternal glucose concentration through increasing 
 2 
maternal glucose production and at the same time developing maternal glucose intolerance and insulin 
resistance (Wilcox 2005). GLUTs transfer glucose to the fetus across the placenta for the production of 
fetal insulin and uptake of glucose into adipose tissue and skeletal muscle. The maternal-fetal gradient 
for transfer of glucose favours the fetus (Suman Rao 2013), that would result in the transport of high 
concentrations of glucose to the fetus in the case of severe and prolonged maternal hyperglycaemia.  
1.3.1 Insulin resistance in pregnancy 
Insulin, a peptide hormone secreted by the β cells of the pancreatic islets of Langerhans, maintains 
normal blood glucose levels by facilitating cellular glucose uptake, regulating carbohydrate, lipid, and 
protein metabolism, and promoting cell division and growth through its mitogenic effects (Wilcox 2005). 
Either inadequate insulin secretion, such as in T1DM, or insulin resistance (such as in T2DM or GDM), 
defined as insulin acting less effectively in promoting glucose uptake, such as in T2DM or GDM, can 
result in hyperglycaemia (Devlieger 2008; Petry 2010). Insulin resistance increases with advancing 
gestation (Catalano 2014). Late in pregnancy insulin sensitivity falls by about 50% (Di Cianni 2003; Lain 
2007). It is believed that this is a normal physiologic response ensuring that the growing fetus receives 
sufficient glucose and other nutrients. At this point, maternal insulin resistance may occur as the 
pregnant woman cannot compensate with the increased demand for insulin (Ragnarsdottir 2010; 
McCance 2011).  
1.3.2 Contributors to insulin resistance 
The two main contributors to insulin resistance are increased maternal adiposity and the insulin 
desensitizing effects of hormones produced by the placenta (Lapolla 2005). GDM usually resolves 
following the birth, with insulin resistance decreasing rapidly postnatally (Hare 2014). This rapid 
decrease suggests that the major contributors to insulin resistance are the placental hormones, including 
tumour necrosis factor-alpha (TNF-α), placental lactogen, placental growth hormone human chorionic 
somatomammotropin (HCS), cortisol, oestrogen, and progesterone (Devlieger 2008; NICE 2015). HCS 
stimulates pancreatic secretion of insulin in the fetus and inhibits peripheral uptake of glucose in the 
mother (Lapolla 2005). As the placenta grows during pregnancy, so does the production of the placental 
hormones, leading to a more insulin-resistant state (Evans 2009). If the pregnant woman’s metabolic 
processes cannot compensate adequately, maternal hyperglycaemia results. In the literature several 
risk factors for developing GDM have been identified.  
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1.4 Risk factors for developing GDM 
Recognised non-modifiable risk factors for pregnant women to develop GDM include advanced maternal 
age (Morisset 2010), specific ethnicities such as Asian, African American, Native American, Hispanic, 
and Pacific Island  women (Carolan 2012a; Schneider 2012; Chamberlain 2013; Kim 2013), a family 
history of diabetes mellitus (Anand 2017), maternal high or low birthweight, polycystic ovarian syndrome 
(Cypryk 2008; Petry 2010), a history of having a previous macrosomic infant (birthweight 4000 grams 
or more) (Oster 2009; Zhang 2010) and a previous history of GDM (Ehrlich 2011). 
Modifiable risk factors for pregnant women to develop GDM include maternal overweight (body mass 
index (BMI) equal to or greater than 25 kg/m²) or obesity (equal to or greater than 30 kg/m²) (Rosenberg 
2005; Athukorala 2010; Kim 2010), physical inactivity (Chasan-Taber 2008), having a low-fibre and high-
glycaemic load diet (Zhang 2006), and excessive weight gain during pregnancy, especially for those 
who are already overweight or obese (Hedderson 2010). It has been reported in the literature that the 
risk of developing GDM for pregnant women is 2.14-fold higher in overweight pregnant women, 3.56-
fold higher in obese pregnant women, and 8.56-fold higher in severely obese pregnant women 
compared to pregnant women with a normal weight (Chu 2007; Mitanchez 2015a). 
The New Zealand Health Survey, for the years 2011-2013, ‘Understanding excess body weight’ 
identified that six percent of women had an BMI of ≥40 kg/m2 (considered morbidly obese) with a steep 
increase in the morbid obesity rate in the 25 to 34-year-old age group, the period of active child bearing. 
Pacific adults were five times as likely to be extremely obese as non-Pacific adults. All ethnic groups 
had higher rates of extreme obesity among women compared to men; 21 percent of Pacific, 12 percent 
of Māori and four percent of European/other females were extremely obese (Ministry of Health 2015b) 
(Table 1.1). These results are concerning and identify factors for increased maternal and infant health 
risks. 
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Table 1.1: Body mass index/waist circumference ratio - adults 
Classification by BMI  Waist circumference 
Normal 
(< 94 cm in males, 
< 80 cm in females) 
High 
(94–101 cm in males, 
80–87 cm in females) 
Very high 
(≥ 102 cm in males, 
≥ 88 cm in females) 
Underweight (< 18.5 kg/m2)  Underweight 
(not applicable) 
Underweight 
(not applicable) 
Underweight 
(not applicable) 
Healthy weight (18.5–24.9 
kg/m2)  
No increased risk No increased risk Increased risk 
Overweight (25.0–29.9 
kg/m2)  
No increased risk Increased risk High risk 
Obese1 (30.0–39.9 kg/m2)  Increased risk High risk Very high risk 
Extremely obese (≥ 40.0 
kg/m2)  
Very high risk Very high risk Very high risk 
Source: adapted from Ministry of Health 2015b 
1.5 Maternal and infant health risks from GDM 
There are a wide range of known short- and long-term health implications for the woman and her baby 
(Crowther 2005; Harder 2009; Landon 2009; Nolan 2011; Nankervis 2014; NICE 2015).  
1.5.1 Maternal health risks from GDM  
For women with GDM, the health risks include a higher risk of developing gestational hypertension 
and/or pre-eclampsia during her pregnancy, having an increased risk of induction of labour (IOL), 
preterm birth, caesarean section, perineal trauma, and postpartum haemorrhage (Crowther 2005; 
HAPO 2008; McCance 2011; NICE 2015). Evidence from published cohort studies indicates an 
increased risk of postpartum depression (Kozhimannil 2009; Nicklas 2013).  Significant long-term risks 
from GDM include developing cardiovascular and metabolic disease (Garrison 2015; Wahlberg 2016) 
and half of the women with GDM are at risk of developing T2DM within five to 10 years, with up to a 
seven-fold increase in the risk of T2DM compared to normoglycemic pregnancies (Bellamy 2009; 
Rayanagoudar 2016).  
1.5.2 Infant health risks from GDM 
Health implications for the baby born to a mother who had GDM include an increased risk of being born 
macrosomic or large for gestational age (LGA) (Ornoy 2005; Koyanagi 2013; Young 2013; Wahlberg 
2016), birth trauma that includes shoulder dystocia, bone fractures and nerve palsy (Athukorala 2010), 
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hyperbilirubinemia (Hedderson 2006; Mitanchez 2015b), respiratory distress syndrome (Landon 2009) 
and neonatal hypoglycaemia (Devlieger 2008; HAPO 2008; Harris 2013). Neonatal hypoglycaemia may 
be associated with developmental delay in childhood (Lucas 1988; Ornoy 2015). Long-term health risks 
include higher rates of obesity, development of T2DM in childhood (Page 2014) and in adulthood, 
hypertension, and cardiovascular disease (Ornoy 2011). Observational studies of children whose 
mothers had diabetes, including women with GDM, reported a higher rate of neurosensory disability, 
including gross and fine motor abnormalities, attention deficit hyperactivity disorder (ADHD), learning 
and language difficulties, and possibly autism spectrum disorder (ASD) (Gardener 2009; Krakowiak 
2012; Nomura 2012; Abou-Elsaad 2017). Given the associated health risks from GDM, appropriate 
screening diagnosis and provision of appropriate treatment for GDM is an important global public health 
issue, with high-quality evidence needed for policy and practice decisions. 
1.6 Screening and diagnosis for GDM 
1.6.1 Screening and diagnosis of GDM internationally 
Screening for GDM aims to achieve an early diagnosis for treatment to start as soon as possible (Tieu 
2017). Recommendations regarding screening for GDM and diagnostic criteria vary internationally (Tran 
2013) with several screening and diagnostic tests being used to identify hyperglycaemia during 
pregnancy (IADPSG 2010; WHO 2013; Nankervis 2014; NICE 2015; Hughes 2016; ADA 2017; Hannah 
2017). 
1.6.2 Screening and diagnosis of GDM in New Zealand 
In 2014 the New Zealand Ministry of Health published a national clinical practice guideline ‘Screening, 
Diagnosis and Management of Gestational Diabetes in New Zealand’. The guideline attempted to 
provide evidence-based recommendations for the diagnosis of previously undiagnosed diabetes in early 
pregnancy and of GDM mid-trimester (Ministry of Health 2014). The guideline recommends that all 
pregnant women be tested for haemoglobin A1c (HbA1c) concentrations, also known as glycated 
haemoglobin) at < 20 weeks of pregnancy (usually at the first antenatal booking) to exclude undiagnosed 
pre-existing diabetes (Ministry of Health 2014) (Figure 1.1). Further guidance recommends that between 
24-28 weeks of pregnancy women undertake either a Glucose Challenge Test (GCT, also known as 
Polycose test), when the HbA1c results were normal, or a diagnostic Oral Glucose Tolerance Test 
(OGTT) when the HbA1c results were between 41 and 49 mmol/mol and a previous history of GDM 
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(Figure 1.1). The recommended New Zealand OGTT thresholds of fasting plasma glucose (FPG) ≥ 5.5 
mmol/l (99 mg/dl) and 2-h post prandial plasma glucose ≥ 9.0 mmol/l (162 mg/dl) differ from the 
international recommendations for diagnostic thresholds (IADPSG 2010; WHO 2013). The guideline 
identified that robust evidence was needed for screening and diagnosing GDM (Ministry of Health 2014).  
Figure 1.1: Flow chart of screening and diagnostic recommendations for diabetes in pregnancy 
in New Zealand 
  
Source: adapted from Ministry of Health 2014, p. xiii 
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1.7 Treatment options for women with GDM 
Women with GDM and health professionals providing care for women with GDM want to know which 
treatments are effective in achieving optimal glycaemic control and reduce short- and long-term risks of 
GDM (Farrar 2017). There are multiple recommended interventions in the literature, which include 
different diets, a range of physical exercise advice, lifestyle interventions and pharmacological 
hypoglycaemic agents (Crowther 2005; Landon 2009; Horvath 2010; Hartling 2013; ADA 2017; Farrar 
2017). This wealth of information provides a challenge for busy clinicians and women with GDM seeking 
evidence about optimal treatments.  
1.7.1 Dietary and exercise advice for women with GDM  
The first-line treatment for women with GDM is usually individualised dietary modification (Bonomo 
2005; Crowther 2005; Landon 2009; Ministry of Health 2014; NICE 2015; ADA 2017). Dietary advice 
aims to ensure a woman’s diet normalises capillary blood glucose (CBG) concentrations, provides 
sufficient energy and nutrients to enable normal fetal growth and minimises excessive maternal weight 
gain (Dornhorst 2002; Ministry of Health 2014; NICE 2015; ADA 2017). It is recommended in the 
literature that all women diagnosed with GDM need to have the opportunity to consult with a diabetes 
specialised dietitian to determine the appropriate individualised diet recommendations (Cheung 2009; 
NICE 2015).  
Physical activity is usually recommended as low-impact activities, such as swimming, walking stationary 
cycling and aerobics (ACOG 2015; Padayachee 2015). Regular and sustained physical activity effects 
the shifting of fuel usage by muscle movement from non-esterified fatty acids (NEFAs) to a blend of 
NEFAs, glucose, and muscle glycogen (Sigal 2004; Asano 2014). This improves insulin sensitivity (Sigal 
2004; Clapp 2006). Like dietary interventions, physical activity aims to achieve optimal glycaemic control 
for the woman with GDM to improve maternal and infant outcomes.   
1.7.2 Lifestyle interventions for women with GDM 
Lifestyle interventions are frequently referred to as a combination of physical activity and dietary 
interventions (Garrison 2015; Piper 2017). This is a limited definition as others in the literature refer to it 
as needing to include additional interventions such as psychosocial care, smoking cessation, diabetes 
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self-management education (DSME) and diabetes self-management support (DSMS) (Haas 2013; ADA 
2017).  
When optimal glycaemic control is unachievable by dietary and exercise interventions or combined with 
other lifestyle management for women with GDM, pharmacological hypoglycaemic agents are 
considered. These are usually subcutaneous insulin or oral hypoglycaemic agents (OHA’s) (NICE 2015; 
ADA 2017; Farrar 2017).  
1.7.3 Pharmacological treatments for women with GDM 
Subcutaneous insulin is the recommended first-line medication for treating hyperglycaemia for women 
with GDM because it does not cross the placenta to a measurable extent (Mpondo 2015; ADA 2017). 
However, there has been an increase in the use of OHA’s as an alternative to subcutaneous insulin for 
the treatment of women with GDM due to lower costs, ease of administration and acceptability 
(Ogunyemi 2011; Berggren 2013; Ryu 2014; Balsells 2015). This has been guided mainly by clinical 
preference and national clinical practice guidelines (Ministry of Health 2014; NICE 2015). The most 
commonly used OHA’s are metformin (a biguanide) and glyburide (glibenclamide, a sulfonylurea). Both 
OHA agents cross the placenta to the fetus, with metformin likely crossing to a greater extent than 
glyburide (ADA 2017). Several publications have investigated the safety of using metformin and 
glyburide and compared to subcutaneous insulin in pregnancy for GDM and found both OHA’s are not 
associated with short term adverse morbidity or mortality (Rowan 2008; Dhulkotia 2010; Maymone 2011; 
Kavitha 2013; Davoren 2014; Holt 2014; Kalra 2015). There is limited high-quality evidence for the long-
term health of the children exposed in utero to metformin or glyburide.  
1.7.4 Other supplementations for women with GDM 
There is an increasing interest in the literature about the effect of nutraceutical supplementations to 
strengthening metabolic support or prevent metabolic disorders including GDM (LakshmanaPrabu 
2012). Myo-inositol, which is an isomer of inositol, has been reported from small randomised controlled 
trials to reduce insulin resistance (Croze 2013). Further high-quality research of supplementations is 
needed to establish if any improve health outcomes and are safe for mothers and babies. 
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1.7.5 Cochrane systematic reviews  
Published evidence from multiple Cochrane systematic reviews add to the body of evidence about 
treatment options from randomised controlled trials for women with GDM. These include different types 
of dietary advice for women with GDM (Han 2017), exercise for pregnant women with GDM (Brown 
2017c), oral anti-diabetic pharmacological therapies for the treatment of women with GDM (Brown 
2017a), dietary supplementation with myo-inositol in women during pregnancy for treating GDM (Brown 
2016a), lifestyle interventions for treatment for women with GDM (Brown 2017b) and elective delivery 
in diabetic pregnant women (Boulvain 2001). 
It is challenging for busy health professionals, consumer and guideline developers to summarise and 
interpret the available information from multiple Cochrane systematic reviews. Synthesising the 
evidence from Cochrane systematic reviews on treatments for women with GDM would facilitate the 
aggregation of available evidence. This could be addressed in generating a Cochrane Overview of 
reviews, providing a one-stop shop for the evidence of optimal treatment interventions for women with 
GDM and their effects on short and long-term maternal and infant health. 
1.8 Cochrane Overview 
Overviews of reviews bring together multiple systematic reviews addressing a set of related 
interventions, conditions, populations, or outcomes. It provides a map of the existing evidence (Becker 
2011). A Cochrane overview of reviews uses explicit and systematic methods to search for, and identify, 
multiple Cochrane intervention reviews (and non-Cochrane systematic reviews, where applicable) on a 
similar topic for the purpose of extracting and analysing their results across important outcomes (Becker 
2011). This includes quality assessments. Overviews of reviews have been used as an effective 
methodology to summarise evidence for complex interventions relating to pregnancy and childbirth. 
These include pain management for women in labour (Jones 2012); antenatal and intrapartum 
interventions for preventing cerebral palsy (Shepherd 2017) and interventions during the antenatal 
period for preventing stillbirth (Ota 2012). An Overview of reviews focusing on treatments for women 
with GDM and their effects on short- and long-term maternal and infant health would meet the current 
need for synthesised evidence. In summary, a Cochrane Overview addressing the research question of 
which treatments are effective for women with GDM would: 
• Summarise effectiveness of multiple systematic reviews  
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• Provide a map of the existing evidence 
• Summarise most effective interventions 
• Be useful for clinicians, consumers, and clinical guideline developers in an area where evidence is 
scattered across many sources 
• Highlight methodological issues regarding the appropriate conduct of systematic reviews 
• Highlight the existence of other systematic reviews  
• Encourage accessing individual systematic reviews for additional details 
• Identifies potential research or evidence gaps 
1.9 Glycaemic treatment targets for women with GDM 
Glycaemic targets are essential for guiding the treatment of women with GDM to stabilise glucose 
metabolism and reduce the short- and long-term risks associated with GDM for the woman and her child 
(IADPSG 2010; Stewart 2014).  Glycaemic control is usually measured by monitoring capillary blood 
glucose (CBG) concentrations to ensure they are maintained within a pre-defined threshold (Metzger 
2008). Recommendations for the timing of CBG testing for women with GDM vary between diabetes in 
pregnancy health care providers. Recommendations may include testing CBG four to six times daily, 
testing on waking (fasting); before a meal (pre-prandial) and one- or two-hours after a meal (post-
prandial) (Poomalar 2015; ADA 2017). 
1.9.1 Glycaemic treatment target recommendations for GDM internationally 
Worldwide recommendations for glycaemic treatment targets for women with GDM vary significantly 
(Table 1.2). These recommendations are based on consensus as there is currently a lack of high quality 
evidence (Metzger 2007; IADPSG 2010; Nankervis 2014; NICE 2015). Professional organisations are 
increasingly advocating lowering glycaemic targets for women with GDM with the aim of reducing 
morbidity for the women and their children (Hernandez 2015; ADA 2017). The need for high-quality trials 
comparing different glycaemic targets assessing short- and long-term outcomes for the women and their 
children is recognised (NICE 2015; Ministry of Health 2014). 
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Table 1.2: Treatment targets for glycaemic control from Clinical Practice Guidelines 
 
Fasting plasma 
glucose 
(mmol/L) 
1-hour postprandial 
(mmol/L) 
2-hour postprandial 
(mmol/L) 
Australasian Diabetes in 
Pregnancy Society 
(Nankervis 2013; 2014) 
and Ministry of Health New 
Zealand (2014) 
≤ 5.0 ≤ 7.4 ≤ 6.7 
Canadian Diabetes 
Association  
(CDA 2013) 
< 5.3 < 7.8 < 6.7 
National Institute of Health 
and Clinical Excellence 
(NICE 2015) 
5.3 < 7.8 < 6.4 
American Diabetes 
Association 
(ADA 2013) 
≤ 5.3 ≤ 7.8 ≤ 6.7 
5th International Workshop on 
GDM 
(Metzger 2007) 
5.0 to 5.5 < 7.8 < 6.7 to 7.1 
Scottish Intercollegiate 
Guidelines Network 
(SIGN 2014) 
4.0 to 6.0 < 8.0 < 7.0 
German Diabetes Association 
(DDA) 
(Kleinwechter 2014) 
3.6 to 5.3 < 7.8 < 6.7 
Source: as adapted from Martis 2016a 
1.9.2 Glycaemic treatment target recommendations for GDM in New Zealand 
The lack of high-quality evidence for glycaemic targets in pregnant women with GDM was highlighted 
in the Ministry of Health (2014) guideline publication of ‘Screening, Diagnosis and Management of 
Gestational Diabetes in New Zealand: A Clinical Practice Guideline’. The multidisciplinary guideline 
panel recommended the use of the following glycaemic treatment targets for women with GDM: fasting 
plasma glucose ≤5.0 mmol/L; 1-hour postprandial ≤7.4 mmol/L and 2-hour postprandial ≤6.7 mmol/L 
(Ministry of Health 2014). This recommendation was reached by consensus, identified in the guideline 
as a good practice point (GPP) as there was no high-quality evidence available from randomised 
controlled trials to make an evidence-based recommendation. The guideline included a research 
recommendation for a randomised control trial comparing less tight with tighter glycaemic targets in 
women with GDM for maternal and infant well-being (Ministry of Health 2014), as also proposed the 
following year in the NICE guideline (NICE 2015). Given the reported lack of high-quality evidence in 
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the literature, a systematic review critically analysing the evidence from randomised controlled trials may 
clarify the effectiveness of different glycaemic targets for women with GDM. This will provide clearer 
evidence to inform clinical practice addressing the research question of which glycaemic treatment 
targets best benefit the health of women diagnosed with GDM and their babies. 
1.10 Consumer involvement  
The New Zealand’s Health and Disability Commissioner has identified that consumer involvement is a 
priority in health decision making (Coney 2004). Rationales for consumer participation apart from the 
relevant legislation, include empowerment of consumers to make informed choices, increasing 
accountability for the consumer and health professionals, increased treatment understanding and 
adherence by the consumer, more relevant service provision for the consumer resulting in improved 
quality of health care (Coney 2004; Kelson 2005; NICE 2013; Hack 2017). 
Legislations such as the Health and Disability Commissioner Act (1994) and the Health and Disability 
Services Consumers' Rights Regulation (1996) support this. The Cochrane Collaboration, an 
international organisation, concurs (Morley 2016). It is therefore recommended that in any research 
involving health consumers, their experiences are investigated to support the research results. 
Definitions of ‘consumers’ vary in the literature but most often is defined as ‘a user of health care’ (Coney 
2004; Kelson 2012). This can mean: an individual patient, caregivers, the patients’ family and friends, 
members of the public, community organisations, advocates representing the interests of patients, and 
are distinct from health professionals and providers of health services (Coney 2004; Kelson 2012). 
In 2015 the National Institute for Health and Care Excellence (NICE) published their up-dated guideline 
for Diabetes in pregnancy: management from preconception to the postnatal period and recommends 
further robust qualitative studies are needed to explore barriers and enablers for women with GDM to 
maintain optimal glycaemic control (NICE 2015).  
The New Zealand TARGET Trial, is a randomised control trial, that is investigating different glycaemic 
targets for maternal and infant well-being. Following the NICE (2015) research recommendation for 
explorations of barriers and enabler for women with GDM in maintaining optimal glycaemic control, this 
provided the opportunity to conduct a survey and interview with women diagnosed with GDM.  
 13 
1.10.1 The New Zealand TARGET Trial 
Based on the Ministry of Health (2014) and NICE (2015) research recommendations, and in an attempt 
to provide better quality evidence, the TARGET Trial (Optimal glycaemic targets for gestational diabetes: 
a step-wedged randomised trial) is being conducted to assess if tighter glycaemic targets compared 
with less tight glycaemic targets for women with GDM will reduce perinatal morbidity without adverse 
health consequences (Australian New Zealand Trials Registry – ACTRN 12615000282583; New 
Zealand Health and Disability Ethics committee (HDEC) Ref. 14/NTA/163 and research registration 
number 1965).  
The glycaemic targets compared in the TARGET Trial are:  
• for the less tight glycaemic targets: fasting plasma glucose <5.5 mmol/L; 1-hour postprandial <8.0 
mmol/L; 2-hour postprandial <7.0 mmol/L (as recommended for current glycaemic treatment targets 
by the American Diabetes Association (ADA 2013) and  
• for the tighter glycaemic targets of fasting plasma glucose ≤5.0 mmol/L; 1-hour postprandial 
≤7.4mmol/L; 2-hour postprandial ≤ 6.7mmol/L (as recommended by the New Zealand Ministry of 
Health (Ministry of Health 2014). 
The TARGET Trial through its randomised stepped wedge research approach will implement tighter 
glycaemic targets for women with GDM in New Zealand. It is important to explore what hinders or 
enables women with GDM in achieving these tighter glycaemic targets. Diabetes in Pregnancy services 
and health professionals would be able to consider how best to support women to self-manage in 
achieving optimal glycaemic control. Self-management is an important aspect for optimal glycaemic 
control as the woman learns to test her capillary blood glucose and adjust her lifestyle to stay within the 
recommended glycaemic targets. This has not been investigated in New Zealand. 
1.10.2 Women’s views and experiences, barriers, and enablers, with glycaemic 
treatment target for current GDM - in the literature 
An in-depth literature search of four relevant databases (MEDLINE (Ovid)/Pubmed, Embase, CINAHL, 
Google Scholar) for peer reviewed articles published between 1980 and 2017 using the search terms: 
gestational diabetes mellitus, women’s’ views, self-management, capillary blood glucose control, 
glycaemic control, enablers and barriers with a number of different word combinations and truncations 
was conducted and up-dated 30th October 2017 (Figure 1.2). A total of 15 published primary studies 
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were considered relevant (Table 1.3) and three systematic reviews. Three studies were conducted in 
Australia, two studies each in Canada, United Kingdom (UK) and USA and one study each in Austria, 
Brazil, Italy, Sweden, Thailand, and Vietnam. No New Zealand studies were identified within this search. 
Two of the 15 primary studies reported the recommended glycaemic targets for the participating women 
with GDM (Table 1.3). One Australian study (Carolan 2012b; Carolan 2013) published two articles with 
results from the same cohort of 15 pregnant women with GDM and was counted as one publication 
(Table 1.3).  
Figure 1.2: Literature search - PRISMA flow diagram  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: as adapted from Moher 2009 
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Table 1.3: Included publications of primary studies from literature search 
Author 
Title of Study 
Design/Method Setting Participants Results/Findings Glycaemic 
Targets 
1. Jirojwong 2017 
Going up, going down: the 
experience, control, and 
management of gestational 
diabetes mellitus among 
Southeast Asian migrant women 
living in urban Australia 
Qualitative, 
face-to-face interviews with 
bilingual research assistants 
Antenatal clinics at two 
metropolitan hospitals in 
Sydney, NSW, Australia 
19 women diagnosed with 
GDM who were born in 
Vietnam, Cambodia, Thailand, 
or Lao People’s Democratic 
Republic (Laos) 
A diagnosis of GDM conferred an 
unanticipated ‘up and down’ 
experience for this group of 
Southeast Asian women. 
Not reported 
2. Youngwanichsetha 2017 
Lived experience of blood glucose 
self-monitoring among pregnant 
women with gestational diabetes 
mellitus: a phenomenological 
research 
Qualitative,  
semi- structured interviews 
Antenatal care units, 
diabetes clinics and 
obstetric wards at two 
government hospitals in 
southern Thailand which 
are the referral centres 
providing management 
of pregnancy 
complicated with GDM 
30 Thai women with GDM 
practising capillary blood 
glucose self-monitoring, 
diagnosed between 24-30 
weeks gestation  
Three themes:  
1. Being worried about diabetes and 
blood testing  
2. Trying to control it  
3. Being patient for the child  
Post prandial 
5.0 - 6.6 
mmol/l 
 
3. Yee 2016 
Which factors promote diabetes 
self-care among low-income, 
minority pregnant women? 
Qualitative, 
in-depth semi-structured 
interviews 
Chicago, USA, 
urban academic 
medicaid-funded 
perinatology clinic, low-
income community 
 
10 English-speaking pregnant 
women ages 18 and over, with 
GDM or Type 2 diabetes 
mellitus (T2DM) (5 women with 
GDM and 5 women with T2DM) 
30 weeks gestation. 
1. Diabetes self-efficacy and 
knowledge  
2. External motivation  
3. Supportive environment  
4. Self-regulation 
Not identified 
4. De Silvia Sousa 2016 
Does information retention after 
attending a multidisciplinary group 
with health professionals increase 
adherence to treatment for 
women with GDM? 
Quantitative,  
phone survey 
São Paulo, Brazil  
(no further information) 
122 women with GDM 119/122 (97.5%) women were 
managing to do self-glucose 
monitoring  
21/122 (17.2%) women reported 
having difficulty with finger pricking  
24/122 (19.7%) women found it too 
difficult to follow the diet 
23/122 (18.9%) women unable to 
reach meal frequency  
47/122 (38.5%) women reported 
having ingested sugar in the days 
following the guidance in 
multidisciplinary group. 
Conclusion suggests closer long-
term follow-up and clearer 
information given. 
Not identified 
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Author 
Title of Study 
Design/Method Setting Participants Results/Findings Glycaemic 
Targets 
5. Draffin 2016 
Exploring the needs, concerns 
and knowledge of women 
diagnosed with gestational 
diabetes: A qualitative study 
Qualitative,  
five focus groups 
At outpatient diabetes 
care clinics at three 
National Health Service 
(NHS) hospitals in the 
United Kingdom 
(Ireland) 
19 women, multi-ethnic, either 
with current GDM diagnosis or 
postnatal with recent history of 
GDM 
1. Women experienced a steep 
learning curve when initially 
diagnosed and eventually became 
skilled at managing their disease 
effectively.  
2. The use of insulin was associated 
with fear and guilt.  
3. Diet advice was sometimes 
complex and not culturally 
appropriate.  
4. Women appeared not to be fully 
aware of short or long-term 
consequences of GDM. 
Not reported 
6. Hirst 2015 
Does a smartphone-based, 
interactive blood glucose 
management system for women 
with GDM increase glucose 
monitoring satisfaction? 
Quantitative,  
structured questionnaire, 
the Oxford Maternity 
Diabetes Treatment 
Satisfaction Questionnaire 
(OMDTSQ) with free text at 
the end 
Oxford University 
Hospitals NHS Trust, 
Oxford, United Kingdom 
(England) 
 
52 women with GDM, English 
speaking, not requiring 
pharmacological therapy, after 
one week of CBG monitoring, 
diagnosed prior to 34 weeks 
gestation 
1.  Intervention promoted women’s 
satisfaction with care. 
2. Encouraging results need 
confirmation in a larger clinical 
study.  
Not reported 
7. Kaptein 2015 
The subjective impact of a GDM 
among ethnically diverse pregnant 
women: A qualitative study 
Qualitative, 
semi structured telephone 
interviews 
Women’s College 
Hospital, Toronto, 
Canada 
19 women with GDM of diverse 
backgrounds 
1.  Heightened pressure to fulfil 
multiple roles, financial impact, 
and a disconnect between 
diabetes-prevention 
recommendations and their 
cultural practices.  
2. GDM diagnosis positive effects: to 
make health behaviour changes 
after a GDM diagnosis viewing it 
as a wake-up call to modify 
lifestyles.  
Not reported 
8. Hui 2014 
Barriers and coping strategies of 
women with gestational diabetes 
to follow dietary advice 
Qualitative, 
Food Choice Map (FCM); 
semi-structured interview 
and demographic 
questionnaire 
Department of Internal 
Medicine, University of 
Manitoba, Winnipeg, 
Canada  
30 women with GDM from the 
Winnipeg area 
Barriers: 
1. Personal food preference 
conflicted with dietary advice;  
2. Eating in different social 
environments where food choice 
and portions were out of control 
and food choice decisions were 
affected by social norms 
Not reported 
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Author 
Title of Study 
Design/Method Setting Participants Results/Findings Glycaemic 
Targets 
3. Lack of knowledge and skills in 
dietary management and lack of a 
tailored dietary plan. 
9. Carolan 2013 
Women’s experiences of 
gestational diabetes self-
management: A qualitative study 
Qualitative, 
semi-structured interviews 
and one focus group 
Sunshine Hospital, 
Melbourne, Australia 
15 women diagnosed with 
GDM between 28-38 weeks 
gestation 
Themes identified: 
1. The shock of diagnosis;  
2. Coming to terms with GDM  
3. Working it out/learning strategies 
4. Looking to the future.  
5. Having a supportive environment 
Not reported 
9. Carolan 2012b 
Women’s experiences of factors 
that facilitate or inhibit gestational 
diabetes self-management 
Qualitative, 
semi structured interviews 
and one focus group 
Sunshine Hospital, 
Melbourne, Australia 
15 women diagnosed with 
GDM between 28-38 weeks 
gestation 
Barriers included: 
1. Time pressures; 
2. Physical constraints; 
3. Social constraints; 
4. Limited comprehension of 
requirements; 
5. Insulin seen as an easier option.  
Enablers included:  
1. Thinking about the baby; 
2. Psychological support from 
partners and families. 
Not reported 
10. Hirst 2012 
Women with gestational diabetes 
in Vietnam: a qualitative study to 
determine attitudes and health 
behaviours 
Qualitative,  
four focus groups 
Hung Vuong Hospital, 
Ho Chi Minh City, 
Vietnam 
34 women with GDM 
diagnosed between 28-38 
weeks gestation 
1. Women felt confusion, anxiety, 
and guilt about GDM 
2. Many perceived their baby to be at 
increased risk of death 
3. Advice to reduce dietary starch 
was confusing 
4. Being hungry or starving most of 
the time 
5. Unaware of appropriate food 
substitutions 
5. Concerned about transmission of 
GDM through breast milk.  
6. Small group sessions and 
information leaflets could benefit  
7. There is a need for culturally 
appropriate clinical education and 
health promotion activities for 
women with GDM in Vietnam. 
Not reported 
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Author 
Title of Study 
Design/Method Setting Participants Results/Findings Glycaemic 
Targets 
11. Lapolla 2012 
Quality of life, wishes, and needs 
in women with gestational 
diabetes: Italian DAWN 
Pregnancy Study  
Quantitative,  
questionnaire.  
Comparison between Italian 
and immigrant women with 
GDM 
10 Italian centres 
specialised in the care 
of pregnant women with 
diabetes including GDM. 
Department of Medicine, 
University of Padova, 
Italy 
198 Italian women and 88 
Immigrant women (with 27 
different nationalities) with 
GDM diagnosed between 25-29 
weeks gestation 
In both groups:  
1. GDM caused anxiety 
2. One-third of women feared their 
child could contract diabetes at 
delivery and/or have congenital 
malformations 
3. Some women had trouble in 
following treatment regimens: the 
major concern being dietary 
advice and blood glucose testing. 
4. Most women were satisfied (34%) 
or highly satisfied (60%)  
5. The degree of co-operation 
between diabetes specialists and 
gynaecologists was considered 
unsatisfactory.  
5. To optimise maternal and fetal 
outcomes, educational projects, 
and improved communication 
between women with GDM and 
the healthcare provider team are 
recommended. 
6. Only difference was the women 
who had immigrated had better 
family support 
FPG < 5.3 mM 
and 2-hour 
post-prandial 
plasma 
glucose 
< 6.7 mM 
12. Trutnovsky 2012 
Gestational diabetes: women’s 
concerns, mood state, quality 
of life and treatment satisfaction 
Qualitative and quantitative, 
semi-structured interview 
and three questionnaires 
University of Graz GDM 
specialist clinic, Graz, 
Austria 
27 diet-treated and 18 insulin-
treated women with GDM 
1. Most dominant concern identified 
as the baby’s health and was the 
main motivational treatment factor.  
2. Treatment satisfaction was 
generally high and further 
Increased over time 
3. Quality of life and mood state 
significantly dropped over time. 
4. Low awareness of personal long-
term implications 
5. Specific postpartum information 
seems necessary to ensure 
prompt recognition and treatment 
of any recurrence of diabetes. 
Not reported 
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Author 
Title of Study 
Design/Method Setting Participants Results/Findings Glycaemic 
Targets 
13. Bandyopadhyay 2011a 
Lived experience of gestational 
diabetes mellitus among 
immigrant South Asian women in 
Australia 
Qualitative, 
face-to-face in-depth 
interviews 
The Royal Women’s 
Hospital, Parkville, 
Victoria, Australia 
 
17 immigrant women from 
South Asia recently diagnosed 
with GDM living in Australia, 
able to speak 
Hindi, Bengali or English 
 
1. Women and their partners were 
upset by the diagnosis.  
2. Importance of cultural appropriate 
dietary advice  
3. Effective support for fluctuating 
glucose levels, as these raised 
significant concerns for the 
women fearing the 
commencement of insulin 
injections.  
4. Different attitudes to exercise in 
pregnancy  
5. Diabetes in Pregnancy services 
should consider the use of 
bilingual diabetes advocates and 
the appropriate use of interpreters. 
Not identified 
 
14. Persson 2010 
From stun to gradual balance – 
women’s experiences of living 
with gestational diabetes mellitus 
Qualitative,  
semi-structured interviews 
32 local health care 
centres, Umea, North 
Sweden 
10 women with current GDM 
diagnosed around 28 weeks 
gestation 
1. From ‘stun to gradual balance’ 
emerged as the core category.  
2. Being diagnosed with GDM was 
not only perceived as a medical 
complication threatening the 
pregnancy 
3. Also seen as an indicator of a 
future Type 2 diabetes mellitus  
Not reported 
15. Spirito 1992 
Does diabetes knowledge 
increase regimen compliance and 
metabolic control during 
pregnancy for women with GDM 
and pre-existing diabetes? 
Qualitative and quantitative, 
interviews and completion 
of an adapted version of the 
Diabetes Compliance 
Questionnaire and Diabetes 
in Pregnancy Knowledge 
Screen  
Rhode Island Hospital, 
USA. 
72 women English speaking 
(27 women with pre-existing 
insulin-dependent and 
noninsulin-dependent diabetes 
mellitus and 45 women with 
GDM), between 28 and 40 
weeks gestation.  
 
1. Efforts to increase knowledge of 
diabetes in pregnant women may 
result in compliance improvement 
in selected aspects of the diabetic 
regimen. 
2. Age and socioeconomic status, 
knowledge appears to affect 
regimen compliance.  
Not reported 
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Three publications reported results from surveys (Table 1.3). One UK based survey explored, with 52 
women with GDM, if a smart-phone based interactive glucose management system would increase 
satisfaction with glucose monitoring (Hirst 2015). Findings appear to increase women’s satisfaction with 
care and a recommendation for a larger clinical study is posed. The second survey based in Brazil 
investigated if information retention after attending a multidisciplinary group with health professionals 
increased adherence to treatment for women with GDM (De Silvia Sousa 2016). One hundred and 
twenty-two women with GDM were surveyed and findings suggest that the women with GDM in their 
study needed closer long-term follow up and had a need for clearer information. The third survey 
reported findings from 199 Italian women with GDM and 88 immigrant women with GDM (27 different 
nationalities) and compared if there were any different experiences between the two groups (Lapolla 
2012). The findings suggested the only difference was that the women who had immigrated identified 
better family support. The conclusions were for optimising maternal and fetal outcomes, for both groups, 
there is a need for improved communication between women with GDM and between the healthcare 
providers. 
Seven qualitative studies used either semi-structured interviews or focus groups to elicit experiences 
from pregnant women living with GDM and used thematic analysis to analyse their findings (Persson 
2010; Bandyopadhyay 2011a; Hirst 2012; Carolan 2013; Kaptein 2015; Draffin 2016; Jirojwong 2017) 
(Table 1.3). Themes identified were similar among these studies in that women diagnosed with GDM 
were initially shocked, moved through to acceptance of their diagnosis as time passed, were motivated 
by their babies and that a supportive environment made a difference. Glycaemic treatment targets for 
the women in the included studies were not reported. 
Three qualitative studies specifically investigated enablers and barriers for women with GDM through 
either face-to-face or phone semi-structured interviews (Carolan 2012b; Hui 2014; Yee 2016) (Table 
1.3). Hui (2014) investigated enablers and barriers for 30 Canadian women with GDM to follow dietary 
advice. Thematic analysis identified a lack of an individualised dietary plan and difficulty following dietary 
advice when food preference conflicted with dietary advice at home and in different social settings.  
A USA study of 10 minority, low-income pregnant women with diabetes (five women with GDM and five 
women with T2DM) investigated what factors promoted diabetes self-care and found long-term goal 
setting, supportive environment, external motivation, and knowledge as enabling (Yee 2016).  
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A qualitative study with 15 Australian women with GDM identified barriers as time, physical and social 
constraints, limited understanding of requirements and seeing insulin as an easier option. Enablers 
facilitating self-management included being motivated by the baby and psychological support from 
partners and family (Carolan 2012b). 
A further two-mixed method studies (interviews and questionnaires) were identified through the search 
(Table 1.3). One study based at Rhode Island, USA, investigated specifically if diabetes knowledge 
increased treatment compliance with 72 women with diabetes (45 women with GDM and 27 women with 
pre-existing diabetes) (Spirito 1992). The combined results from two questionnaires and interviews 
found that efforts to increase knowledge of diabetes may result in improved compliance for selected 
aspects of the diabetic regimen (undefined). The authors found that age, socioeconomic status and 
knowledge specific to the diabetic treatment during pregnancy, appeared to affect regimen compliance. 
This is a relatively old study and with the event of the information explosion via the internet this may 
result in different findings if the study would be repeated.  
The second mixed-method study from Austria was interested in the mood state and quality of life for 
women with GDM and included 27 diet-treated and 18 insulin-treated women with GDM (Trutnovsky 
2012). The authors found similar findings to the thematic analysis in the qualitative studies above that 
the baby motivates treatment factors. Additionally, they found for both groups the quality of life and mood 
state significantly dropped over time and the existence of low awareness for personal long-term health 
implications. Recommendations included for health professionals to increase their assessment of 
mental well-being for women with GDM and ensure clear information for long-term risks is provided.  
Only one qualitative study from Thailand, focused on the lived experience of CBG monitoring among 30 
pregnant women diagnosed with GDM (Youngwanichsetha 2017) (Table 1.3). Through semi-structured 
face-to-face interviews emerging themes included being worried about diabetes and blood testing, trying 
to control it and being patient for the child. Only postprandial targets (timing not identified) were stated 
as needing to be between 5.0 - 6.6 mmol/l for all women involved in the study.  
The search identified three systematic literature reviews. One review identified 42 qualitative and 
quantitative studies with data from 7949 women in number of countries with the aim to identify enablers 
and barriers for women who had experienced GDM to postpartum healthcare seeking (Van Ryswyk 
2015). While this literature review did not include pregnant women with current GDM, which is of interest 
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for this thesis, it is relevant to note that one of the findings identified that women still remembered that 
the diagnosis of GDM was a concerning or upsetting experience. This appears to be a recurring theme 
in the literature. The authors concluded that provision of improved GDM education, as well as positive 
and pro-active care from diagnosis until postpartum follow-up may increase healthcare seeking by 
women with recent GDM.  
Another literature review, which included 15 qualitative and four quantitative studies, exploring the 
beliefs, values, perceptions, and experiences of women with a diagnosis or history of GDM found that 
women’s initial reaction to being diagnosed with GDM generated negative feelings, which overtime led 
to accepting and adapting of the condition (Devsam 2013). The review did not report on how many 
women or studies were prospective or retrospective nor made an attempt to compare if healthcare 
seeking beliefs for future T2DM made a difference according when women were interviewed. It did 
propose a framework for clinical assessments and care of women diagnosed with GDM that may be 
used by midwives. 
Women’s perceptions of future diabetes risk and views on diabetes prevention was explored by Parsons 
2014. The review reported on 16 qualitative studies with 302 women apparently diagnosed with GDM. 
It became evident to the thesis author through reading the review that some of the studies included 
women who had a history of GDM. Some of the included studies reported the experiences for women 
diagnosed with GDM and the findings recommend addressing the emotional impact of GDM as this 
would improve diabetes prevention behaviour and offering an intervention that fits with women’s multiple 
roles as caregivers, workers, and patients, and focuses on the health of the whole family. 
There is limited evidence of qualitative and quantitative explorations of women’s views, experiences, 
barriers, and enablers with current GDM relating specifically to their ability to stay within their 
recommended glycaemic treatment targets. There have been no studies published in New Zealand to 
date. Maternity care varies greatly from country to country. For example, maternity care in the USA is 
provided to a large extent by obstetricians being the lead professional including uncomplicated 
pregnancies and births. In contrast to New Zealand, midwives are the lead carer for women with 
uncomplicated pregnancies and often provide shared-care for women with GDM (NZCOM n.d.; Ministry 
of Health 2012). There is a need to investigate pregnant women’s views and experiences, barriers, and 
enablers with current GDM including a comparison about their glycaemic treatment targets for the New 
Zealand context. 
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1.11 Implementation science/knowledge translation 
Implementation science or knowledge translation, as it is increasingly known (Grimshaw 2012; Strauss 
2013; Khalil 2016), refers to the study of methods to promote the integration and uptake of research 
findings and evidence through optimal approaches into clinical practice and health care policy (WHO 
2014; NIH 2016).  The overarching goal is to create generalisable knowledge that can be contextualised 
and applied across settings to achieve sustained health improvements and reduce the evidence gap 
(Madon 2007; Burke 2012; Wensing 2013). Key stakeholders in knowledge translation include not only 
health professionals, researchers, policy makers but also consumers, as this can ensure that the 
information is understandable from the consumer perspective and relevant to their context (Tugwell 
2007; Pearson 2012; Légaré 2014). Implementation science or knowledge translation has an important 
role in identifying enablers and barriers for effective health programming, policy making and evidenced-
based treatment implementations (Grimshaw 2012; Légaré 2014; WHO 2014). For women with GDM 
enabler and barrier identification may support and enable effective behaviour change in achieving 
optimal glycaemic control. 
1.11.1 Barriers and enablers identification 
Implementation science or knowledge translation has contributed to the growing interest in the literature 
to the identification of enablers and barriers to guide effective implementation of practice and behaviour 
change (Grol 2003; NICS 2006; Michie 2011; Cane 2012; Nielsen 2012). Translating knowledge into 
practice needs to be tailored to specific enablers and barriers in order for clinical practice to change or 
adherence to treatment to be achieved (Wensing 2010; Straus 2013; Baker 2015). Only “14% of 
significant research findings ever enter the real-word context” (p. 178) and this is believed to be due to 
the lack of clear understanding of how to implement the research results without local contextual enabler 
and barrier identification (Gitlin 2013). This highlights the importance that knowledge translation requires 
to be evidence-informed through contextual and meaningful enablers and barriers underpinned by a 
theoretical approach with a clear validated framework (Baker 2015; Nilsen 2015).  
1.11.2 Theoretical Domains Framework for barrier and enabler identification for women 
with GDM 
The use of the Theoretical Domains Framework (TDF) has been identified in the literature as an effective 
tool to identify enablers and barriers and to understand, inform and facilitate effective behavioural 
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change and health service provision (Michie 2005; Michie 2008; Michie 2011). It resulted from an 
increasing belief that applying psychological explanations for behaviour change, based on health and 
social psychology theories, may explain health-related behaviour change more effectively and result in 
a more targeted and informed implementation strategy, rather than applying single models to predict 
behaviour (Michie 2005; Davies 2010; Atkins 2017). The TDF was developed using an expert consensus 
process and validation to identify psychological and organisational theory relevant to behaviour change 
(Michie 2005; Michie 2008; Michie 2011; Cane 2012).  The most recent validated version of the TDF 
includes 14 domains and their component constructs (Cane 2012, Atkins 2017) (Table 1.3). The TDF 
has been used in health care to identify factors influencing health practitioner’s clinical behaviour and 
behaviour change (Davies 2010; Cane 2012; French 2012) but is increasingly used to identify enablers 
and barriers for the consumer in order to understand their experiences and views to adherence of 
treatment and lifestyle changes (Burgess 2014; Nicholson 2014; Penn 2014; McGoldrick 2016). 
Table 1.4: Refined Theoretical Domains Framework and its constructs 
Theoretical Domains  Generic Definitions Constructs 
Knowledge An awareness of the existence of 
something 
- Knowledge (including knowledge 
  of condition/scientific rationale) 
- Procedural knowledge 
- Knowledge of task environment 
Skills An ability or proficiency acquired 
through practice 
- Skills 
- Skills development 
- Competence 
- Ability 
- Interpersonal skills 
- Practice 
- Skill assessment 
Social/Professional  
Role & Identity 
A coherent set of behaviours and 
displayed personal qualities of an 
individual in a social or work setting 
- Professional identity 
- Professional role 
- Social identity 
- Identity 
- Professional boundaries 
- Professional confidence 
- Group identity 
- Leadership 
- Organisational commitment 
Beliefs about capabilities Acceptance of the truth, reality or 
validity about an ability, talent, or 
facility that a person can put to 
constructive use 
- Self-confidence 
- Perceived competence 
- Self-efficacy 
- Perceived behavioural control 
- Beliefs 
- Self-esteem 
- Empowerment 
- Professional confidence 
Optimism The confidence that things will happen 
for the best or that desired goals will 
be attained 
- Optimism 
- Pessimism 
- Unrealistic optimism 
- Identity 
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Theoretical Domains  Generic Definitions Constructs 
Beliefs about consequences Acceptance of the truth, reality, or 
validity about outcomes of a behaviour 
in a given situation 
- Beliefs 
- Outcome expectancies 
- Characteristics of outcome 
  expectancies 
- Anticipated regret 
- Consequents 
Reinforcement Increasing the probability of a 
response by arranging a dependent 
relationship, or contingency, between 
the response and a given stimulus 
- Rewards (proximal/distal, valued/not 
  valued, probable/improbable) 
- Incentives 
- Punishment 
- Consequents 
- Reinforcement 
- Contingencies 
- Sanctions 
Intentions A conscious decision to perform a 
behavior or a resolve to act in a 
certain way 
- Stability of intentions 
- Stages of change model 
- Transtheoretical model and 
   stages of change 
Goals Mental representations of outcomes or 
end states that an individual wants to 
achieve 
- Goals (distal/proximal) 
- Goal priority 
- Goal/target setting 
- Goals (autonomous/controlled) 
- Action planning 
- Implementation intention 
Memory, attention,  
and decision  
processes 
The ability to retain information, focus 
selectively on aspects of the 
environment and choose between two 
or more alternatives 
- Memory 
- Attention 
- Attention control 
- Decision making 
- Cognitive overload/tiredness 
Environmental context and 
resources 
Any circumstance of a person’s 
situation or environment that 
discourages or encourages the 
development of skills and abilities, 
independence, social competence, 
and adaptive behaviour 
- Environmental stressors 
- Resources/material resources 
- Organisational culture/climate 
- Salient events/critical incidents 
- Person × environment interaction 
- Barriers and facilitators 
Social influences  Those interpersonal processes that 
can cause individuals to change their 
thoughts, feelings or behaviours 
- Social pressure 
- Social norms 
- Group conformity 
- Social comparisons 
- Group norms 
- Social support 
- Power 
- Intergroup conflict 
- Alienation 
- Group identity 
- Modelling 
Emotion A complex reaction pattern, involving 
experiential, behavioural and 
physiological elements, by which the 
individual attempts to deal with a 
personally significant matter or event 
- Fear 
- Anxiety 
- Affect 
- Stress 
- Depression 
- Positive/negative affect 
- Burn-out 
Behavioural regulation Anything aimed at managing or 
changing objectively observed or 
measured actions 
- Self-monitoring 
- Breaking habit 
- Action planning 
Source: as adapted from Cane 2012; Atkins 2017 
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1.12 Conclusion 
Short- and long-term health implications for the woman diagnosed with GDM and her baby have been 
consistently reported. The prevalence of GDM is increasing globally and in New Zealand. Evidence-
based practice requires accurate knowledge translation of treatments to affect the reduction of the health 
risks for women with GDM and their children. The impact of the evidence for effective treatments and 
optimal glycaemic control for women with GDM appears to be limited due to the difficulty of accessibility 
to the evidence as it is either published in multiple systematic reviews for treatments for women with 
GDM, in several randomised controlled trials for glycaemic treatment targets for women with GDM or 
no publications available for New Zealand women’s view, experience, enablers and barriers to achieving 
optimal glycaemic control. 
Therefore, this thesis has the following key aims: 
1.13 Thesis aims and research questions 
1. To synthesise the current research evidence of Cochrane systematic reviews on treatments 
for women with GDM and to identify specific research gaps of treatments for women with 
GDM requiring further primary research.  
To achieve this aim, I will conduct a Cochrane Overview of reviews to summarise effective 
treatment options for women with GDM from published Cochrane systematic reviews. The 
Overview will be used to highlight where there are current knowledge gaps in the evidence and 
focuses on the research question:  
• Which treatments are effective for women with GDM? 
2. To synthesise and assess the current research evidence from randomised controlled trials 
on the effect of different glycaemic targets for women with GDM and their children and to 
identify specific research gaps of glycaemic targets to guide treatment for women with GDM 
requiring further primary research.  
To achieve this aim, I will conduct a Cochrane systematic review that synthesises the current 
evidence from randomised controlled trials of different treatment targets for glycaemic control and 
their effective outcomes for women with GDM and their babies, including the identifying any gaps 
of knowledge in the evidence and focuses on the research question of:  
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• Which glycaemic treatment targets best benefit the health of women diagnosed with GDM and 
their babies? 
3.  To investigate how women with GDM view their glycaemic treatment targets and identify the 
barriers and enablers for them in achieving optimal glycaemic control. 
 
To achieve this aim, I will conduct a face-to-face survey to investigate barriers and enablers 
focusing on the research question:  
• What do women with GDM say are the barriers and enablers for their glycaemic targets, from 
a quantitative research perspective? 
4.  To examine behavioural factors impacting on women with GDM in achieving optimal 
glycaemic control.  
 
To achieve this aim, I will conduct semi-structured interviews with women with GDM investigating 
their experiences, barriers, and enablers in achieving their recommended glycaemic treatment 
targets, from a qualitative perspective, using the TDF framework for analysis focusing on research 
questions:  
 
• What are women’s experiences, barriers, and enablers with their glycaemic targets?  
• What is it like for a woman with GDM to monitor her capillary blood glucose (CBG) 
concentration?  
• What affects a woman’s CBG concentrations and how does she maintain optimal CBG control 
with this knowledge?  
• What support have women found helpful/not helpful in learning about and maintaining optimal 
CBG control? 
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Chapter 2: Synthesising the evidence from Cochrane systematic reviews 
on treatments for women with gestational diabetes mellitus 
2.1 Preface 
This chapter presents an Overview of Cochrane systematic reviews published in the Cochrane 
Database of Systematic Reviews entitled ‘Treatments for women with gestational diabetes mellitus: 
an overview of Cochrane systematic reviews’. The chapter includes the completed Cochrane 
Overview, prepared following production of the overview protocol that was peer reviewed and published 
in the Cochrane Library (Martis 2016b). This Overview summarises the available evidence from existing 
Cochrane systematic reviews on the effectiveness of treatments for women with GDM and their infants. 
It includes quality assessments for the included studies and the pre-specified primary and secondary 
outcomes. 
 
The chapter aims to address Research Question 1: Which treatments are effective for women with 
GDM? 
 
The chapter contains the unaltered manuscript submitted for publication. The abstract and key words 
were removed as directed by the University of Auckland (2016) Guide to thesis and dissertations. The 
‘Plain Language Summary’ from the submitted manuscript is presented at the end of the chapter. 
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2.2 Treatments for women with gestational diabetes mellitus: 
an overview of Cochrane systematic reviews 
2.2.1 Background 
Gestational diabetes mellitus (GDM) is a condition that may occur in the second half of pregnancy when 
blood glucose control is more difficult to achieve, leading to hyperglycaemia (abnormally high 
concentration of glucose in the blood) that may affect the woman and her baby (ADA 2004; Holt 2014). 
The World Health Organization (WHO 2013) defines GDM as "Carbohydrate intolerance resulting in 
hyperglycaemia or any degree of glucose intolerance with onset or first recognition during pregnancy 
usually from 24 weeks gestation onwards" and resolves following the birth of the baby. This definition 
clearly excludes women who may have undiagnosed pre-existing type 1 (T1DM) or type 2 diabetes 
(T2DM) first detected during screening in pregnancy (Nankervis 2013). 
Recognised risk factors for developing GDM include obesity, advanced maternal age, weight gain in 
pregnancy, family history of diabetes and previous history of GDM, macrosomia (large baby), or 
unexplained stillbirth (Mokdad 2003; Yogev 2004; Boney 2005; Rosenberg 2005; Zhang 2010; Teh 
2011). Certain ethnicities, such as Asian, African American, Native American, Hispanic, and Pacific 
Island women have an increased risk (Rosenberg 2005; Schneider 2012). 
The prevalence of GDM is increasing globally and has been documented with significant variation 
between 2% to 26% depending on the ethnicity of the population screened and the diagnostic criteria 
used (Cheung 2003; Ferrara 2007; Sacks 2012; Nankervis 2013; Ministry of Health 2014; NICE 2015). 
The reported global obesity epidemic is likely to increase the incidence of GDM (Zhang 2010; Schneider 
2012) and a recurrent GDM diagnosis in subsequent pregnancies for women who have had previously 
been diagnosed with GDM (Bottalico 2007; England 2015; Poomalar 2015). Therefore, GDM is a serious 
public health issue. 
Successful glycaemic treatments for GDM have the potential to significantly impact on the short- and 
long-term health for the woman and her baby. Treatments for GDM aim to keep glucose levels within 
the recommended glycaemic reference range to prevent maternal hyper- or hypoglycaemia. Treatments 
may include dietary and exercise advice, subcutaneous insulin, oral hypoglycaemic agents, such as 
pharmacological medications, dietary supplements or nutraceuticals, antenatal breast milk expression, 
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induction of labour or caesarean section (Horvath 2010; Kavitha 2013; Bas-Lando 2014; Forster 2014; 
Ryu 2014; Kalra 2015). 
Currently there are several Cochrane systematic reviews assessing different treatment for women with 
GDM. This makes it difficult for clinicians, consumers, and guideline developers to easily interpret the 
available information. A Cochrane overview of systematic reviews would provide summary evidence of 
the effectiveness for each treatment for women with GDM and the effects on relevant health outcomes 
as a one-stop resource for health professionals, consumers, and guideline developers to simplify clinical 
treatment decision-making, and assist with the process of guideline development. 
Description of the condition 
During pregnancy the continuous supply of appropriate and balanced nutrients from the pregnant 
woman to her baby is essential for optimal health and growth. Glucose is the primary source of energy 
for the fetus (Wilcox 2005; Hay 2006). Insulin is a peptide hormone secreted by the β cells of the 
pancreatic islets of Langerhans and maintains normal glucose concentration by facilitating cellular 
glucose uptake, regulating carbohydrate, lipid, and protein metabolism, and promoting cell division and 
growth (Wilcox 2005). Either inadequate insulin secretion (such as in T1DM) or insulin resistance (such 
as in T2DM or GDM) (Devlieger 2008; Petry 2010) can result in hyperglycaemia. During the second half 
of pregnancy, insulin sensitivity falls by about 50% (Di Cianni 2003; Lain 2007). This is a normal 
physiologic response ensuring that the growing fetus receives sufficient glucose and other nutrients from 
the mother via the placenta (Buchanan 1991). In some pregnant women abnormal insulin resistance 
may occur if they are unable to compensate for the increased demand of insulin (Ragnarsdottir 2010; 
McCance 2011; Catalano 2014). This results in GDM (ADA 2004; Holt 2014). It is known that the 
maternal-fetal placental glucose transfer favours the fetus (Suman Rao 2013; Sadovsky 2015). Women 
with GDM therefore transfer higher amounts of glucose to the fetus when uncontrolled severe and 
prolonged maternal hyperglycaemia is present (Wilcox 2005), resulting in a baby born large-for-
gestational age (Ornoy 2005; Metzger 2008; Young 2013). 
Lapolla 2005 suggests the two main contributors to insulin resistance include increased maternal 
adiposity and the insulin desensitising effects of hormones produced in the pregnancy, especially in the 
placenta. As the placenta grows during the pregnancy, so does the production of the placental 
hormones, leading to an insulin-resistant state (Evans 2009). GDM usually resolves promptly following 
the birth of the baby and the placenta, indicating insulin resistance decreases rapidly after birth. The 
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identified hormones are tumour necrosis factor-alpha (TNF-α), placental lactogen, placental growth 
hormone human chorionic somatomammotropin (HCS), cortisol, oestrogen, and progesterone (Clapp 
2006; Devlieger 2008). HCS stimulates pancreatic secretion of insulin in the fetus and inhibits peripheral 
uptake of glucose in the mother (Lapolla 2005). If the pregnant woman’s metabolism cannot compensate 
adequately for this, maternal hyperglycaemia results. 
Maternal hyperglycaemia of varying degrees of severity has short- and long-term health implications for 
the woman and her baby. For the woman, these include a higher risk of developing gestational 
hypertension and pre-eclampsia during her pregnancy, having an increased risk of induction of labour, 
preterm birth, caesarean section, perineal trauma, postpartum haemorrhage (Crowther 2005; HAPO 
2008; McCance 2011; NICE 2015), and a significant long-term risk of developing cardiovascular disease 
with half the women with GDM at risk of developing type 2 diabetes within five to 10 years (Bellamy 
2009; Garrison 2015). Health implications for the baby include an increased risk of being born 
macrosomic and large-for-gestational age (Ornoy 2005; Young 2013), birth trauma (e.g. shoulder 
dystocia, bone fractures and nerve palsy) (Athukorala 2010), hyperbilirubinaemia (Harris 1997; 
Hedderson 2006), respiratory distress syndrome (Landon 2009) and neonatal hypoglycaemia (Devlieger 
2008; Harris 2013). Neonatal hypoglycaemia may be associated with developmental delay in childhood 
(Lucas 1988), and, if prolonged or severe, may cause brain injury. Long-term health risks include higher 
rates of obesity, development of type 2 diabetes in childhood (Page 2014) and late onset diabetes, 
hypertension, and cardiovascular disease in adulthood (Ornoy 2011). 
Description of the interventions 
Effective interventions for treatment of GDM aim to reduce the risks of GDM for the mother and baby by 
normalising maternal glycaemia through treating maternal hyperglycaemia (Farrar 2017). Glucose 
control is usually measured by monitoring capillary blood glucose concentrations to ensure glucose 
concentrations are maintained within pre-defined glycaemic thresholds (Garrison 2015). This may be 
achieved through interventions such as the use of diet modifications (American Dietetic Association 
2001; Ministry of Health 2014; NICE 2015), physical exercises (Harris 2005), pharmacological 
interventions such as oral hypoglycaemic medications or subcutaneous insulin (ACOG 2013; Ministry 
of Health 2014; NICE 2015), nutraceuticals (Thomas 2005; Hui 2009; Bagchi 2015) or other dietary 
supplements (D'Anna 2015; Paivaa 2015). 
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Different types of diet 
The main treatment recommended for women with GDM is dietary modification (Bonomo 2005; 
Crowther 2005; Landon 2009; Ministry of Health 2014; NICE 2015). Dietary advice is aimed at 
preventing maternal hyperglycaemia and ensuring the woman’s diet provides sufficient energy and 
nutrients to enable normal fetal growth while avoiding accelerated fetal growth patterns, and minimising 
excessive maternal weight gain (Dornhorst 2002). The recommendation is that all women diagnosed 
with GDM need to consult with a diabetic specialised dietitian or experienced nutritionist to determine 
the appropriate individualised diet, taking cultural preferences into account (Cheung 2009; Serlin 2009). 
Different types of diets recommended for treatment include low or moderate glycaemic index (GI) diets, 
high fibre or high-fibre enriched diets, energy restricted diets, low carbohydrate diet or high complex 
carbohydrate diet and/or low monounsaturated fat diets (Rae 2000; Zhang 2006; Radesky 2008; Wolff 
2008; Cheung 2009; Moses 2009; Louie 2011; Moreno-Castilla 2013; Asemi 2014b; Hernandez 2014; 
Viana 2014; Jamilian 2015; Ma 2015; Markovic 2016; NICE 2015). 
Physical activity 
It is unusual for GDM treatment recommendation to advise any physical activity modification alone. 
There are some trials evaluating the effects of physical exercises for women with GDM or type 2 
diabetes. Physical exercises are usually recommended as low-impact activities, such as walking, 
swimming, stationary cycling, or special exercise classes for pregnant women (Davenport 2008; Mottola 
2008; de Barros 2010; Manders 2010; Barakat 2012; Stafne 2012; ACOG 2015; Garrison 2015; 
Padayachee 2015). 
Combined dietary modification and exercise 
While often the initial treatment recommendation for women diagnosed with GDM is diet modification, it 
is common in clinical practice to combine this with exercise advice during pregnancy (ACOG 2013; 
Ministry of Health 2014; Garrison 2015; NICE 2015). This is often referred to as dietary and lifestyle 
advice (Artal 2007) or lifestyle modification programmes (LMP) where women participate in a 
comprehensive program on nutrition, exercise, and appropriate weight gain in pregnancy (Harris 2005; 
Cheung 2009; Shirazian 2010). 
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Pharmacological hypoglycaemic agents 
Oral hypoglycaemic agents 
When glycaemic treatment targets are unable to be achieved, pharmacological hypoglycaemic agents 
may be considered. While this traditionally has meant subcutaneous insulin for the woman with GDM, 
there has been an increase in the use of oral pharmacological hypoglycaemic agents as an alternative 
(Tieu 2010; Ogunyemi 2011). Oral agents have lower costs, are easier to administer and have greater 
acceptability for women with GDM (Ryu 2014). The most commonly used oral agents are 
sulphonylureas, which include acetohexamide, chlorpropamide, tolazamide, tolbutamide (first 
generation, usually not used to treat women with GDM) and glyburide (glibenclamide), glipizide and 
glimepiride (second generation) (Holt 2014; Kalra 2015); and biguanide (metformin) (Cheung 2009; 
Simmons 2015). Other oral hypoglycaemic agents used less frequently include alpha-glucosidase 
inhibitors (acarbose and miglitol) (Kalra 2015); thiazolidinedione’s (TZDs) (pioglitazone and 
rosiglitazone) and meglitinides (repaglinide and nateglinide) (Kavitha 2013). 
Trials have compared different oral pharmacological hypoglycaemic agents with each other or with 
placebo or with subcutaneous insulin and/or physical exercise and different diets (Langer 2000; Bertini 
2005; Moretti 2008; Cheung 2009; Balsells 2015; Carroll 2015; Casey 2015). 
Despite the wide use of oral pharmacological hypoglycaemic agents, these are not licensed for use 
during pregnancy in many countries (including the USA, UK, Australia, New Zealand) (Berggren 2013). 
This is due to the concern that they can cross the placenta, in particular the first-generation oral 
hypoglycaemic agents. At this stage, randomised controlled trials conducted with glyburide (second-
generation sulphonylureas) and biguanide(metformin) have not demonstrated short-term harm to the 
mother or her growing baby (Langer 2000; Bertini 2005; Blumer 2013; Kelley 2015), but the information 
on long-term safety of these drugs remains limited. 
Insulin 
Women with GDM, who have difficulty controlling their glucose concentrations with lifestyle changes, 
such as diet and exercise, with or without the addition of an oral pharmacological agent require insulin 
(Mpondo 2015). Human insulin does not cross the placenta in clinically significant amounts and therefore 
is considered safe for the fetus when administered subcutaneously in pregnancy (Menon 1990; ADA 
2015; Garrison 2015; Kelley 2015). Subcutaneous exogenous insulin is designed to mimic the 
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physiological secretion of endogenous insulin (Magon 2014; Home 2015). Some studies with insulin 
analogues indicate that they can cross the placenta when they form an antigen-antibody complex with 
immunoglobulins, which can carry the insulin analogues though the placenta (Jovanovic 2007, Durnwald 
2013; Lv 2015).There is a need for large randomised controlled trials to establish the safe use in 
pregnancy of long-acting insulin analogues (glargine and detemir), as the effect of the transplacental 
insulin bound IgA's is unclear (Balsells 1997; Negrato 2012; Durnwald 2013). While fetal macrosomia 
has been identified in some observational and randomised controlled studies of long-acting insulin 
analogues, other concerns, including fetal death, have been raised (Gamson 2004; Negrato 2012; 
Coiner 2014). 
There are several methods of administering insulin analogues. Historically and currently, they have been 
administered subcutaneously as a basal-bolus regimen (given prior to each meal) as this provides the 
most effective glycaemic control (Nachum 1999; Cheung 2009). These daily multiple subcutaneous 
injections may include rapid- (lispro, aspart, glulisine), intermediate- (neutral protamine hagedorn 
(NPH)) and long-acting (glargine and detemir) insulin analogues (Singh 2007; Horvath 2010). Fast-
acting and intermediate-acting insulin analogues are currently the preferred choice of treatment for 
women with GDM as there is only limited data available for long-acting insulin in pregnancy (Jovanovic 
2007; Durnwald 2013). 
An alternative insulin administration method is via a continuous subcutaneous insulin infusion pump 
(CSII). Modern pumps are small and lightweight, battery operated and hold enough insulin for several 
days, which means frequent daily injections are not required. CSII pumps aim to maintain the basal rate 
of insulin, reducing the risk of maternal hypoglycaemia and decreasing the risk of fasting hyperglycaemia 
and are not associated with worse maternal and perinatal outcomes (Simmons 2001; Secher 2010; 
Bernasko 2012; Kesavadev 2016). Women using a CSII pump during their pregnancy for GDM and 
T2DM treatment preferred the flexible lifestyle with comparable healthcare costs (Gabbe 2000; Gonalez 
2002; Wollitzer 2010). 
Oral and nasal insulin are other alternatives to subcutaneous insulin and are currently under 
development because of their convenience, quick liver absorption and potentially avoiding adverse 
effects of weight gain and hypoglycaemia (Woodley 1994; Wang 1996; Carino 1999; Arbit 2004; Iyer 
2010; Heinemann 2011; Fonte 2013). Although some pharmaceutical companies have stopped 
developing inhaled (nasal) insulin, some trials are still ongoing (Hompesh 2009; Rosenstock 2009; 
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Hollander 2010). It must be noted that research trials for oral and nasal insulin do not include women 
with GDM at this stage but are being considered for future research. 
Other interventions 
Other interventions reported in the literature for preventing GDM or treating women with GDM include 
dietary supplements and nutraceuticals. The term nutraceutical was created by Dr Stephen DeFelice, 
chairperson of the Foundation for Innovation in Medicine in 1989, who combined the terms nutrition and 
pharmaceutical. Nutraceuticals are marketed as nutritional supplements and sold with the intent to treat 
or prevent disease (Brower 1999; Gupta 2010; LakshmanaPrabu 2012). They are not governmentally 
regulated or licensed (Zeisel 1999; Rajasekaran 2008). Currently over 470 nutraceutical products are 
available with reported health benefits (Brower 1999; Eskin 2005; Gupta 2010). While randomised 
controlled trials involving nutraceuticals are scant in the literature for the treatment or prevention of GDM, 
there is some evidence from mainly observational studies. Dietary fibres from psyllium has been used 
for glucose control and reducing lipid levels in hyperlipidaemia (Hamid 2000; Baljit 2007; Rajasekaran 
2008; Babio 2010). Omega-3 fatty acids have been suggested to reduce glucose tolerance for humans 
predisposed to diabetes, as insulin is required for synthesis of the long chain n-3 fatty acids (Sirtori 
2002). The omega-3 fatty acid docosahexaenoic acid (DHA) involved with regulating insulin resistance 
has been recommended for women with GDM (Coleman 2001; Sirtori 2002; Thomas 2006; Gupta 2010). 
Magnesium has been shown to improve insulin sensitivity in non-diabetic participants (Guerrero-Romer 
2004; Mooren 2011; Wang 2013), as has chromium picolinate (Broadhurst 2006; Martin 2006; Paivaa 
2015), calcium and vitamin D (Dror 2011; Burris 2012; Poel 2012; Asemi 2014a; Burris 2014). Cinnamon 
and extracts of bitter melon may have some effect as co-treatments in the prevention of diabetes 
(Rajasekaran 2008; Hui 2009). Nutraceuticals should not be confused with the term dietary supplement, 
which is a product that is intended to supplement the diet that contains one or more ingredients such as 
vitamins, minerals, a herb, an amino acid or a concentrate, metabolite, constituent, extract or 
combinations of these (Rajasekaran 2008). 
Myo-inositol, an isomer of inositol, is a dietary supplement of naturally occurring sugar commonly found 
in cereals, corn, legumes, and meat. Small randomised studies of low quality have shown a potential 
beneficial effect on improving insulin sensitivity and suggests that myo-inositol may be useful for women 
in preventing GDM but not for treatment of GDM (Facchinetti 2013; Malvasi 2014; Crawford 2015b; 
D'Anna 2015).  
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How the interventions might work  
Treatment for women with GDM aims to normalise maternal fasting and postprandial glucose 
concentrations and modify fetal physiological responses to maternal hyperglycaemia, thereby reducing 
maternal and associated fetal and neonatal short-term morbidity. Two large randomised trials (Crowther 
2005; Landon 2009) demonstrated reductions in birthweight and large-for-gestational-age infants in 
women with GDM who received treatment compared with women with GDM who were not treated. Any 
intervention that helps normalises maternal glucose concentrations therefore may be a useful treatment 
for women with GDM. 
Human insulin stimulates glucose and amino acid uptake from the blood to various tissues and 
stimulation of anabolic processes for glycogen, protein, and lipid synthesis. Glucagon has opposing 
effects, causing release of glucose from glycogen, release of fatty acids from stored triglycerides and 
stimulation of gluconeogenesis. Metabolic homeostasis is maintained by the balance between insulin 
and glucagon (Wahlqvist 1978; Bantle 1983). 
Different types of diet 
One of the aims of dietary advice for women with GDM is to prevent maternal hyperglycaemia. Different 
types of diets recommended for treatment include low or moderate GI diets, high fibre or high-fibre 
enriched diets, energy restricted diets, low carbohydrate diet or high complex carbohydrate diet and/or 
low monounsaturated fat diets. 
Carbohydrates absorbed following digestion are converted into glucose (Wahlqvist 1978; Bantle 1983). 
Current recommendations for women with GDM are for carbohydrate-controlled and low-GI diets, evenly 
distributed throughout the day, when remaining within the recommended glucose treatment targets 
(Clapp 2002; Dornhorst 2002; Ludwig 2002). Glycaemic index quantitatively defines the effect of 
carbohydrate-based foods on glucose concentrations (Foster-Powell 2002). Consumption of 
carbohydrates triggers the release of insulin and inhibits secretion of glucagon. Glucagon stimulates 
gluconeogenesis and release of the newly formed glucose from the liver into the blood. These actions 
produce a rapid return to fasting blood glucose levels and storage of glucose as glycogen or lipid 
(Kershaw 2006; Duncan 2007). 
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Likewise, a protein-rich meal leads to the release of insulin and glucagon. This rise of insulin associated 
with the protein meal stimulates uptake of the glucose formed in the liver by muscle and fat tissue (Nuttall 
1984; van Loon 2000). 
Other different types of diets such as fat (polyunsaturated fatty acids may be protective against impaired 
glucose tolerance, while saturated fatty acids can increase glucose and insulin concentrations) and 
soluble fibre (which may lower blood cholesterol by binding to it bile acids) are also thought to influence 
blood glucose concentrations (Zhang 2006; Babio 2010; Kim 2010). 
Physical activity  
Physical activity results in shifting fuel usage by the working muscle from primarily non-esterified fatty 
acids (NEFAs) to a blend of NEFAs, glucose, and muscle glycogen and improves insulin sensitivity in 
skeletal muscle and glucose control (Sigal 2004; Asano 2014). Glucose enters skeletal muscle cells via 
facilitated diffusion through a glucose transporter (GLUT4) and peripheral clearance of glucose in 
skeletal muscle depending on the blood flow to muscle through glycolysis and glycogenesis (Sakamoto 
2002; Rose 2005; Richter 2013). Translocation of the GLUT4 transporter is induced by insulin and 
insulin-independent mechanisms (Richter 2001; Sigal 2004; Richter 2013). The improvements in insulin 
sensitivity after regular and sustained exercise, which improves blood supply to active skeletal muscle, 
include a decrease of insulin secretion and an increase of glucagon (Coderre 1995; Wojtaszewski 2002; 
Sigal 2004; Clapp 2006). 
Oral hypoglycaemic agents 
Second-generation sulphonylureas such as glyburide (glibenclamide), glipizide and glimepiride (Holt 
2014; Kalra 2015) work by lowering glucose concentration through stimulating the release of insulin by 
binding to specific receptors in pancreatic β cell plasma membrane (Simonson 1984; Groop 1987; Groop 
1991). First-generation sulphonylureas have been identified in the literature as crossing the placenta, 
being secreted in breast milk and have been associated with prolonged neonatal hypoglycaemia 
(Kemball 1970; Christesen 1998). Second-generation sulphonylureas are reported in the literature as 
less likely to cross the placenta (Elliott 1991; Langer 2000; Kraemer 2006; Cheung 2009; Schwartz 
2013; Kalra 2015). 
Biguanide (metformin) increases insulin sensitivity through the rate of hepatic glucose production, 
hepatic glycogenolysis and by increasing insulin-stimulated uptake of glucose in skeletal muscles (Sirtori 
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1994; Langer 2007; Cheung 2009; Kavitha 2013; Kalra 2015; Simmons 2015). This process reduces 
insulin resistance. Biguanide does not stimulate the fetal pancreatic β cells to produce insulin and hence 
is not associated with neonatal hyperinsulinaemia (Sirtori 1994; Ho 2007; Kavitha 2013). 
Alpha-glucosidase inhibitors (acarbose and miglitol) reduce postprandial hyperglycaemia by slowing the 
absorption of carbohydrates in the intestines (Lebovitz 1997; Ho 2007; Kalra 2015). The effects of alpha-
glucosidase inhibitors have not been studied well in pregnancy. Animal studies suggest that alpha-
glucosidase inhibitors are not teratogenic (Young 2009; Holt 2014; Kalra 2015; Simmons 2015). 
Thiazolidenediones (pioglitazone and rosiglitazone, Kavitha 2013) activate the peroxisome proliferator-
activated receptor (PPAR) (a group of nuclear receptor proteins) reducing insulin resistance (Young 
2009). The pharmacodynamics of these drugs are similar to glyburide (a second-generation 
sulphonylurea). Thiazolidenediones are bound to plasma proteins (99.8 %) and are metabolised in the 
liver (Stumvoll 2003; Langer 2007). While it appears that thiazolidinediones are not teratogenic, a high 
risk of placental transfer and an association with fetal death and growth restriction have been reported 
(Chan 2005; Holt 2014). 
Meglitinides (repaglinide and nateglinide, Kavitha 2013) act similarly to sulphonylurea but use different 
receptors by stimulating the pancreas to release insulin in response to a meal. They block ATP-
dependent potassium channels in functioning pancreatic β cells leading to the opening of calcium 
channels resulting in an influx of calcium. Increased intracellular calcium initiates and enhances insulin 
secretion (Rendell 2004; Kavitha 2013). Meglitinides agents have only been studied in non-pregnant 
T2DM participants showing some improvements with postprandial glycaemic results and HbA1c 
(Goldberg 1998; Rosenstock 2004). At this stage, meglitinides cannot be recommended for use in 
pregnancy (Kavitha 2013). 
Insulin 
Human insulin is a pancreatic hormone (secreted by the β cells of the pancreatic islets of Langerhans) 
that regulates the movement of glucose from blood into cells. Insulin lowers glucose concentration by 
stimulating peripheral glucose uptake and by inhibiting glucose production and release by the liver. 
Insulin inhibits lipolysis, proteolysis and gluconeogenesis and increases protein synthesis and 
conversion of excess glucose into fat (Kersten 2001; Wilcox 2005; Proud 2006). Treatment with 
exogenous subcutaneous insulin for women with GDM aims to achieve as close as possible 
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physiological profile by mimicking the pancreatic basal insulin release. However, this is based on 
average plasma insulin profiles and it is difficult to factor in the individual variability of absorption, dietary 
intake, and exercise (Hartman 2008; Grunberger 2013; Pagliuca 2014). Insulin treatment for women 
with GDM can include short- or rapid- (lispro, aspart, glulisine) and intermediate- and long acting- 
(neutral protamine hagedorn (NPH), glargine, detemir) insulin analogues (Singh 2007; Horvath 2010; 
Pollex 2011; Ansar 2013; Magon 2014) given usually by daily multiple or single subcutaneous injections 
guided by recommended glycaemic targets. Table 2.1 identifies how the different subcutaneous insulin 
analogues act to achieve a more physiological profile. Please note that some studies results cited in 
Table 2.1 are for pregnant women who have either T1DM or T2DM only. More studies are needed that 
include women with GDM. 
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Table 2.1:Type of subcutaneous insulin and action towards achieving a physiological profile 
Type of Insulin Action 
Short- and rapid-acting insulin 
Lispro Amino acid substitutions (inverting lysine at position 28 and proline at position 29 on the β-chain of the insulin molecule), monomeric 
in tissues (Magon 2014; Home 2015). Peak insulin action achieved within 1 hour after injection and duration of action 2 to 4 hours 
(Durnwald 2008). Antibody levels not increased over those seen with regular human insulin. Does not seem to cross the placenta 
(Jovanovic 2007). 
Aspart Amino acid substitutions (proline at position 28 on the β-chain of the insulin molecule with negatively charged aspartic acid), 
monomeric in tissues (Magon 2014; Home 2015). Peak action 31-70 minutes for 2 to 4 hours and lowers postprandial glucose levels 
significantly better than human insulin (Jovanovic 2007; Magon 2014). No evidence that insulin aspart is teratogenic (Hod 2005). 
Glulisine Amino acid substitutions and reformulation, rapidly monomeric in tissues (Home 2015). Produces peak blood glucose level at 15-20 
minutes and lowers postprandial glucose levels significantly better than human insulin (Jovanovic 2007). Adverse effects on embryo-
fetal development were only seen at animal maternal toxic dose levels inducing hypoglycaemia. No clinical data currently available 
for the use of Insulin glulisine in pregnancy (Magon 2014). 
Intermediate- and long-acting insulin 
Neutral Protamine Hagedorn (NPH) Protamine crystal suspension (Home 2015). NPH has an onset of action approximately after 90 minutes and a duration of action up 
to 16 to 18 hours (Jovanovic 2007; Magon 2014). No randomised controlled trials currently to confirm safety during pregnancy but 
several case reports and one case-control study indicate no fetal morbidity or macrosomia (Magon 2014). 
Detemir Slowly absorbed and binds to albumin through a fatty-acid chain attached to the lysine at residue B29 resulting in reduction in its free 
level which slows distribution to peripheral target tissues with a duration of action of up to 24 hours (Magon 2014). Significant 
improvement in fasting plasma glucose with insulin detemir during pregnancy for T1DM without an increased incidence of 
hypoglycaemia, including at night. No adverse maternal or neonatal effects were identified (Mathiesen 2012; Callesen 2013; Hod 
2014). Suffecool 2015 conducted a small study including 11 women with GDM and five women with type 2 diabetes receiving detemir 
assessing maternal and cord blood at birth. The results showed that while maternal detemir levels were in the expected range for 
adults, the hormone was undetectable in the cord blood, indicating that detemir does not cross the human placenta. Larger studies 
and randomised controlled trials are needed to confirm. 
Glargine Slowly absorbed and replaces the human insulin amino acid asparagine at position A21 of the A chain with glycine and two arginine 
molecules are added to one end (C-terminal) of the B-chain with onset of action approximately after 90 minutes of injection and 
lasting for about 24 hours (Price 2007; Ansar 2013). Studies in non-pregnant participants have indicated that insulin glargine has a 
smooth peak-free profile of action, with a reduced incidence of nocturnal hypoglycaemia and better glycaemic control (Woolderink 
2005, Graves 2006; Magon 2014). Concerns regarding insulin glargine’s use in pregnancy are raised from case-control, case reports 
and retrospective studies (including women with T1DM, T2DM and some with GDM) that have shown six- to eight-fold increased 
affinity for insulin growth factor (IGF)-1 receptor compared with human insulin. However, results of these studies found no association 
with increased fetal macrosomia or neonatal morbidity with the use of glargine in pregnancy (Bolli 2000; Pöyhönen-Alho 2007; 
Egerman 2009; Lv 2015). No randomised controlled trials currently to confirm safety during pregnancy. 
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Other interventions 
Supplemental nutraceuticals are believed to support the chemical food elements (nutrients) needed for 
the human body's metabolism and prescribed when there is a diagnosis of a nutrient depletion or 
required for strengthening the metabolism or prevention of disease (LakshmanaPrabu 2012). Currently 
there are over 470 nutraceuticals available including supplements for GDM (Eskin 2005; Gupta 2010). 
The mechanism of action for nutraceuticals and other dietary supplements are often not clear and further 
high-quality research is needed. 
Myo-inositol is required for cell membrane formation and works on the insulin receptors of each cell, so 
insulin can bind effectively thus reducing insulin resistance (Croze 2013). It is involved with mediating 
the pathway of intracellular insulin signals increasing cellular effectiveness of insulin within the cell 
(Larner 2010). Small randomised trials of low quality conducted in Italy have shown some effect in 
preventing GDM (D'Anna 2013; Facchinetti 2013; Malvasi 2014; D'Anna 2015). Further high-quality 
research is needed to establish if myo-inositol improves health outcomes for mothers and their babies. 
Why it is important to do this overview   
There are several Cochrane systematic reviews regarding treatments for women with GDM. These 
include different types of diet, exercise, subcutaneous insulin, oral hypoglycaemic agents and other oral 
supplements as well as management recommendations such as induction of labour, caesarean section, 
antenatal breast milk expression and blood glucose monitoring. This makes it difficult for clinicians, 
consumers and guideline developers to easily interpret the available information. A Cochrane overview 
of systematic reviews would provide summary evidence of the effective on relevant health outcomes of 
different treatments for women with GDM as a one-stop resource for health professionals, consumers 
and guideline developers aiding the simplifying of clinical treatment decision-making and assisting with 
the process of guideline development. 
2.2.2 Objectives 
The objective of this overview is to provide a comprehensive synthesis of evidence from randomised 
controlled trials in relevant published Cochrane systematic reviews of interventions for treating women 
with GDM and their effects on important health outcomes relevant to women with GDM and their babies, 
and to report any adverse effects associated with these treatments. A further aim is to identify specific 
significant research gaps requiring further primary research of treatment for women with GDM. 
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2.2.3 Methods 
The methodology for data collection and analysis is based on Chapter 22 (Overviews of Reviews) of the 
Cochrane Handbook of Systematic Reviews of Interventions (Becker 2011). Only published Cochrane 
systematic reviews of randomised controlled trials focusing on treatments for women with GDM were 
considered in this overview noting their publication and search dates. We did not attempt to update 
individual Cochrane systematic reviews that were due for updates (two years since publication). 
We contacted the Cochrane Pregnancy and Childbirth group to identify any relevant new reviews and 
review updates that were being undertaken and/or near completion for inclusion of the most up-date 
versions of reviews. Cochrane protocols and title registrations for interventions for women with GDM 
were identified through the same process to identify future inclusions and were classified as ongoing 
Cochrane systematic reviews. They will be considered for inclusion in the update of this overview.  
Similarly, reviews with pre-specified overview outcomes but with no outcome data (either no studies 
found or women with GDM did not feature in the included trial(s)) were classified as reviews awaiting 
classification and will be added to this overview when future up-dates if the reviews include relevant 
data. 
Criteria for considering reviews for inclusion    
Participants 
The participants in the Cochrane systematic reviews were women diagnosed with GDM receiving any 
form of treatment for GDM (as identified by the review). Women with type 1 and type 2 diabetes were 
excluded. 
Interventions 
We considered all treatments for women with GDM including: 
• Any dietary modifications (including low-moderate GI diet, high-moderate GI diet, energy-restricted 
diet, no energy restricted diet, DASH diet (Dietary Approaches to Stop Hypertension), low-
carbohydrate diet, high-carbohydrate diet, high unsaturated fat diet, low unsaturated fat diet, low GI 
diet, high fibre moderate GI diet, soy protein-enriched diet, high fibre diet, ethnic-specific diet). 
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• Any physical exercises (including brisk walking, resistance exercises, circuit workouts, elastic band 
exercises, any form of bicycling, low-intensity aerobic exercises, home-based exercises, 
mindfulness yoga). 
• Pharmacological interventions (oral hypoglycaemic agents including metformin, glibenclamide, 
acarbose, tolbutamide, chlorpropamide or combination of these therapies or subcutaneous insulin). 
• Nutraceuticals or other dietary supplements (including myo-inositol). 
• Other interventions as identified by included reviews (including glycaemic treatment targets for 
GDM, management of labour and birth for women with GDM, lifestyle interventions). 
For further description of possible interventions see under ‘Description of the interventions’ on page 31. 
Outcomes 
The outcomes for this overview review were agreed by consensus of authors of Cochrane systematic 
reviews relating to GDM (Bain 2016), including the outcomes that were used in the 'Grading of 
Recommendations Assessment, Development and Evaluation' (GRADEpro). 
Primary outcomes 
Maternal 
• Hypertensive disorders of pregnancy (including pre-eclampsia, pregnancy-induced hypertension, 
eclampsia as defined in reviews). 
• Caesarean section. 
• Development of type 2 diabetes. 
Neonatal 
• Perinatal (fetal and neonatal death) and later infant mortality. 
• Large-for-gestational age (as defined in reviews). 
• Death or serious morbidity composite (as defined in reviews, e.g. perinatal or infant death, shoulder 
dystocia, bone fracture or nerve palsy). 
• Neurosensory disability in later childhood (as defined in reviews). 
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Secondary outcomes 
Maternal 
• Use of additional pharmacotherapy. 
• Maternal hypoglycaemia (as defined in the reviews). 
• Glycaemic control during/end of treatment (as defined in the reviews). 
• Weight gain in pregnancy. 
• Adherence to the intervention. 
• Induction of labour. 
• Placental abruption. 
• Postpartum haemorrhage (as defined in the reviews). 
• Postpartum infection. 
• Perineal trauma/tearing. 
• Breastfeeding at discharge, six weeks postpartum, six months or longer. 
• Maternal mortality. 
• Sense of well-being and quality of life. 
• Behavioural changes associated with the treatment. 
• Women's view of the intervention. 
• Relevant biomarker changes associated with the intervention (including adiponectin, free fatty acids, 
triglycerides, high-density lipoproteins, low-density lipoproteins, insulin). 
Maternal long-term outcomes 
• Postnatal depression. 
• Body mass index (BMI). 
• Postnatal weight retention or return to pre-pregnancy weight. 
• Development of type 2 diabetes. 
• Impaired glucose tolerance. 
• Subsequent gestational diabetes. 
• Cardiovascular health (as defined in the reviews including blood pressure, hypertension, 
cardiovascular disease, metabolic syndrome). 
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Fetal/neonatal outcomes 
• Stillbirth. 
• Neonatal death. 
• Macrosomia (greater than 4000 g; or as defined in the reviews). 
• Small-for-gestational age (as defined in the reviews). 
• Birth trauma (e.g. shoulder dystocia, bone fracture, nerve palsy). 
• Gestational age at birth. 
• Preterm birth (< 37 weeks’ gestation and < 32 weeks’ gestation). 
• Five-minute Apgar < 7. 
• Birthweight and z score. 
• Head circumference and z score. 
• Length and z score. 
• Ponderal index. 
• Adiposity (including skinfold thickness measurements (mm), fat mass). 
• Neonatal hypoglycaemia (as defined in the reviews). 
• Respiratory distress syndrome. 
• Neonatal jaundice (hyperbilirubinaemia) (as defined in the reviews). 
• Hypocalcaemia (as defined in the reviews). 
• Polycythaemia (as defined in the reviews). 
• Relevant biomarker changes associated with the treatment (including insulin, cord c-peptide). 
Later infant/childhood outcomes 
• Weight and z scores. 
• Height and z scores. 
• Head circumference and z scores. 
• Adiposity (including BMI, skinfold thickness, fat mass). 
• Educational attainment. 
• Blood pressure. 
• Development of type 1 diabetes. 
• Development of type 2 diabetes. 
• Impaired glucose tolerance. 
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• Dyslipidaemia or metabolic syndrome. 
Child as an adult outcomes 
• Weight and z scores. 
• Height and z scores. 
• Adiposity (including BMI, skinfold thickness, fat mass). 
• Cardiovascular health (as defined in the reviews including blood pressure, hypertension, 
cardiovascular disease, metabolic syndrome). 
• Employment, education and social status/achievement. 
• Dyslipidaemia or metabolic syndrome. 
• Development of type 1 diabetes. 
• Development of type 2 diabetes. 
• Impaired glucose tolerance. 
Health service use 
• Number of antenatal visits or admissions. 
• Number of hospital or health professional visits (including midwife, obstetrician, physician, dietician, 
diabetic nurse). 
• Admission to neonatal intensive care unit/nursery. 
• Length of stay in neonatal intensive care unit or special care baby unit. 
• Length of antenatal stay. 
• Length of postnatal stay (maternal). 
• Length of postnatal stay (baby). 
• Cost of maternal care. 
• Cost of neonatal/child/adult care. 
• Costs associated with the treatment. 
• Costs to families associated with the treatment (e.g. change of diet, extra antenatal visits, etc). 
For Cochrane systematic reviews to be eligible for inclusion in this overview review, a review had to pre-
specify some or all of the overview primary and secondary outcomes and have reported data for 
treatments for women with GDM from at least one included trial. 
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Cochrane systematic reviews that had pre-specified some or all of the overview outcomes, but had no 
reported data or no included trials, have been listed as reviews awaiting for further classifications and 
will be re-considered in future up-dates of this overview review. 
Search methods for identification of reviews 
We searched the Cochrane Database of Systematic Reviews on 28 June 2017 using the term 
'gestational diabetes' with the Title, Abstract, Keywords and the 'all text' function and identified from this 
search which reviews, and protocols related to treatment for women with GDM. We did not apply any 
language or date restrictions. 
Data collection and analysis   
Cochrane systematic reviews published addressing any treatments for women diagnosed with GDM 
were selected. Reviews and studies including treatment for pregnant women with known Type I and 
Type II diabetes were excluded. The methodology for data collection was based on Chapter 22 of the 
of the Cochrane Handbook of Systematic Reviews of Interventions (Becker 2011). Where appropriate 
the overview was prepared using the Review Manager Software (RevMan 2014). 
Selection of reviews   
Three overview authors independently assessed all potential Cochrane systematic reviews for inclusion 
identified through the search. We resolved any disagreements through discussions. 
Data extraction and management   
Two overview review authors, not involved in the included Cochrane systematic reviews, independently 
extracted data using a pre-defined data extraction form. We resolved any discrepancies through 
discussion. Where any information from the reviews were unclear or missing, we contacted the review 
authors (see under heading Methods page 54). 
Information from included reviews was extracted on the following: 
• Population demographics: We summarised participant's characteristics with inclusion and exclusion 
criteria as reported in the included reviews. 
• Review characteristics: We reported the number of included trials and trial countries, design and 
publication years, the number of participants (women, babies and children) in each review; the date 
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of search conducted for each review; up-to-date status (< two years was considered up-to-date); 
described the interventions and comparisons; included all pre-specified outcomes relevant to the 
overview and assessed and reported on the quality of the included Cochrane systematic reviews 
using the Cochrane risk of bias assessment as detailed in the included reviews. 
• Statistical summary: We reported the statistical summary by outcomes. 
Assessment of methodological quality of included reviews 
Quality of included trials within reviews 
We did not assess the quality of the trials within the included Cochrane systematic reviews but reported 
the trial quality according to the review authors assessments (Risk of bias assessments from included 
reviews). We also noted and reported for each included review the publication and search date (Table 
2.4). 
Quality of evidence in the included reviews 
Two overview review authors not listed as authors in the included Cochrane systematic reviews 
independently extracted outcomes that had been assessed in the individual reviews using the GRADE 
approach. Where the relevant outcomes had not been assessed using the GRADE approach, these 
were assessed independently by the two overview review authors using 'Grading of Recommendations 
Assessment, Development and Evaluation' (GRADE) (Balshem 2011; GRADEpro). 
GRADE Assessment 
GRADEpro uses five criteria: study limitations (risk of bias), consistency of effect, imprecision, 
indirectness and publication bias to assess the quality of the body of evidence for pre-specified 
outcomes, as described in Chapter 5 of the GRADE Handbook. It rates the quality of evidence as either: 
• high (further research is very unlikely to change confidence in the estimate of effect); 
• moderate (further research is likely to have an important impact on confidence in the estimate of 
effects and may change the estimate); 
• low (further research is very likely to have an important impact on confidence in the estimate of 
effect and is likely to change the estimate) or 
• very low (any estimate of effect is very uncertain). 
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We reported the quality of evidence as assessed by the Cochrane systematic review authors. 
Two overview review authors (RM, JB) generated 'Summary of findings tables' using GRADE for 
Cochrane systematic reviews included in the overview that did not produce a 'Summary of findings table' 
using GRADE. This applied for the reviews of Boulvain 2001 and Han 2012. 
The following seven maternal, seven child (as neonate, child, adult) and seven heath service costs 
outcomes for quality assessment were agreed by consensus between the overview review authors and 
all other review authors of Cochrane systematic reviews relating to GDM (Bain 2016). 
Maternal 
1. Hypertensive disorders of pregnancy (including pre-eclampsia, pregnancy-induced hypertension, 
eclampsia). 
2. Caesarean section. 
3. Development of type 2 diabetes. 
4. Perineal trauma. 
5. Return to pre-pregnancy weight. 
6. Postnatal depression. 
7. Induction of labour. 
Child (as neonate, child, adult) 
1. Large-for-gestational age. 
2. Perinatal mortality. 
3. Death or serious morbidity composite. 
4. Neonatal hypoglycaemia. 
5. Adiposity. 
6. Diabetes. 
7. Neurosensory disability. 
Health service use 
1. Number of antenatal visits or admissions. 
2. Length of postnatal stay (mother). 
3. Length of postnatal stay (baby) (including neonatal intensive care unit or special re baby unit). 
51 
4. Costs to families associated with the treatment. 
5. Costs associated with the treatment. 
6. Cost of maternal care. 
7. Cost of child (as neonate, child, adult) care. 
In order to provide a comprehensive judgement summary for outcomes, the overview review authors 
decided that all the overview secondary outcomes needed to be assessed for quality using the four 
GRADE quality ratings as above. This would provide a more accurate and comprehensive reporting of 
the evidence for a treatment intervention for women with GDM. These additional assessments were 
made by RM and JB. 
Overall quality of the included reviews  
We used two different quality measurement assessment tools for this overview in order to assess the 
overall quality of the included reviews: 'Assessment of Multiple Systematic Reviews’ (AMSTAR) (Shea 
2007; Shea 2009) and 'Risk of Bias in Systematic Reviews' (ROBIS) (Whiting 2016). 
AMSTAR Assessment 
Two overview authors not involved with the included Cochrane systematic reviews independently 
assessed the quality of the reviews using AMSTAR (A Measurement Tool to Assess Systematic 
Reviews). We resolved differences through discussion. The AMSTAR (Shea 2007; Shea 2009) tool is 
an instrument that measures 11 components to assess the methodological quality of a systematic 
review. Each AMSTAR domain is rated as: 
• 'yes' (Y) (clearly done), 
• 'no' (N) (clearly not done), 
• 'cannot answer' (CA) or 
• 'not applicable' (NA). 
High-quality reviews score eight or higher, moderate-quality reviews score between four and seven and 
low-quality systematic reviews score three or fewer ‘yes’ answers. 
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AMSTAR score (out of 11 criteria) Rating 
8 to 11 high quality 
4 to 7 moderate quality 
3 or lower low quality 
 
The included Cochrane systematic reviews were assessed using the following AMSTAR questions: 
1. Was an a priori design provided? 
2. Was there duplicate study selection and data extraction? 
3. Was a comprehensive literature search performed? 
4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? 
5. Was a list of studies (included and excluded) provided? 
6. Were the characteristics of the included studies provided? 
7. Was the scientific quality of the included studies assessed and documented? 
8. Was the scientific quality of the included studies used appropriately in formulating 
conclusions? 
9. Were the methods used to combine the findings of studies appropriate? 
10. Was the likelihood of publication bias assessed? 
11. Was the conflict of interest included? 
A score out of 11 is given regardless of any 'cannot answer' or 'not applicable' responses 
(https://amstar.ca/contact_us.php). 
ROBIS Assessment 
Two overview authors not involved with the included Cochrane systematic reviews independently 
assessed the quality of the reviews using ROBIS (Risk Of Bias In Systematic reviews) (Whiting 2016). 
We resolved differences through discussion. 
ROBIS considers risk of bias across four key domains. Each domain elicits information about possible 
limitations of the included Cochrane systematic review through a series of questions. Domain 1 - 3 have 
5 question each and Domain 4 has 6 questions. Questions are answered with either yes, no or unclear. 
The risk of bias for each domain is then judged and summarised as 'low, high or unclear concerns'. 
Once all four domains are assessed an overall judgement of risk of bias is made identified as 'low, high 
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or unclear risk' (Whiting 2016). The included Cochrane systematic reviews were assessed using the 
following ROBIS domains: 
Domain 1: Study eligibility criteria. 
Domain 2: Identification and selection of studies. 
Domain 3: Data collection and study appraisal. 
Domain 4: Synthesis and findings. 
Data synthesis   
A description of the characteristics of included Cochrane systematic reviews was undertaken (Table 
2.4). We did not examine indirect comparisons and did not conduct a network meta-analyses. We 
summarised the results of the included Cochrane systematic reviews by categorising their findings in 
the following framework organised by overview review outcomes: 
• Effective interventions: indicating that the review found high-quality evidence of effectiveness for an 
intervention. 
• Promising interventions (more evidence needed): indicating that the review found moderate-quality 
evidence of effectiveness for an intervention, but more evidence is needed. 
• Probably no difference between interventions: direction of effect suggests benefit/harm or 
ineffective, but more evidence is needed. 
• Ineffective interventions: indicating that the review found high-quality evidence of lack of 
effectiveness for an intervention. 
• Probably ineffective interventions (more evidence needed): indicating that the review found 
moderate-quality evidence suggesting lack of effectiveness for an intervention, but more evidence 
is needed. 
• No conclusions possible due to lack of evidence: indicating that the review found low- or very low-
quality evidence, or insufficient evidence to comment on the effectiveness of an intervention, more 
evidence needed. 
This approach to summarising the evidence was based on the publication of Effective Care in Pregnancy 
and Childbirth (Vol. 2: Materials and methods used in synthesizing evidence to evaluate the effects of 
care during pregnancy and childbirth) (Chalmers 1989) and a Cochrane Overview of pain management 
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in labour, which categorises interventions as “What works,” “What may work”, and “Insufficient evidence" 
to make a judgement (Jones 2012). 
2.2.4 Results 
Our search on 28 June 2017 of the Cochrane Database of Systematic Reviews identified 52 reviews 
and published protocols from 9706 records, four records from the Cochrane Pregnancy and Childbirth 
group's title registrations list, a total of 56 records (Figure 2.1). Following the screening of title and review 
abstracts we excluded 29 protocols and reviews as not eligible. The remaining 27 reviews, protocols 
and title registrations were assessed for eligibility. We excluded 15 publications which were either full-
text reviews, protocols, or title registrations (Figure 2.1). These included one protocol (Pelaez-Crisologo 
2015) that has been withdrawn, one report (Martis 2016b) was this overview protocol, two reviews were 
withdrawn as they were out-of-date (Walkinshaw 1996; Walkinshaw 2006), one review (Alwan 2009) 
has been superseded as it is now split into three new titles and published as one protocol (Brown 2016b) 
and two reviews (Brown 2017a; Brown 2017b), both reviews are included for assessment in this 
overview, one review (Ceysens 2006) has been superseded with a new title and is now published as a 
review (Brown 2017c), and is one of the included reviews for assessment and three reviews had no 
results for women with GDM for vitamins and other micronutrients (Vitamin D - DeRegil 2016; Vitamin 
A - McCauley 2015; Vitamin C - Rumbold 2015) (Table 2.2: Characteristics of excluded reviews). An 
additional three title registrations and three protocols, which indicated a treatment for women with GDM 
and have some or all pre-specified primary and secondary overview review outcomes were excluded at 
this stage and have been listed in Table 2.4 as Ongoing reviews. When they are published they will be 
considered for inclusion in future updates of this overview. 
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Figure 2.1: Search flow diagram 
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Table 2.2: Characteristics of excluded reviews 
Review ID and title Reason for exclusion 
Alwan 2009 
Treatments for gestational diabetes 
Most pre-specified overview outcomes included but this review was too large and has now been split into three reviews. 
Two reviews are currently published as ‘Oral anti-diabetic pharmacological therapies for the treatment of women with 
gestational diabetes’ Brown 2017a and ‘Lifestyle interventions for the treatment of women with gestational diabetes’ (Brown 2017b) and are 
included reviews in this overview (Table 2.4: Characteristics of included reviews). The other one is currently published as a protocol entitled 
'Insulin for the treatment of women with gestational diabetes' Brown 2016b (Table 2.2: Ongoing Cochrane systematic reviews). The reviews 
and the protocol include all overview pre-specified primary outcomes for maternal and neonatal outcomes and all overview pre-specified 
secondary outcomes for maternal, maternal long-term, fetal/neonatal, later infant/childhood, child as an adult and health services use. 
Ceysens 2006 
Exercise for diabetic pregnant women 
This review, which included some of the pre-specified overview primary and secondary outcomes, was not up-to-date and has now been 
superseded with a new title. It is now published as ‘Exercise for pregnant women with gestational diabetes for improving maternal and fetal 
outcomes’ (Brown 2017c) (Table 2.4: Characteristics of included reviews) and is an included review in this overview for assessment. 
DeRegil 2016 
Vitamin D supplementation for women 
during pregnancy 
Some primary and secondary overview review pre-specified outcomes included but not later infant/childhood, child as an adult and health 
service use outcomes. Pregnant women with pre-existing conditions (i.e. GDM) were excluded. 
McCauley 2015 
Vitamin A supplementation during 
pregnancy for maternal and  
newborn outcomes 
Some overview review pre-specified outcomes included. Neonatal primary outcome: perinatal mortality; Maternal secondary outcomes: 
Postpartum infection and maternal mortality. Fetal/neonatal secondary outcomes: Stillbirth, preterm birth (< 37 weeks’ gestation) and 
birthweight. No maternal long-term, later infant/childhood, child as an adult and health service use secondary outcomes. No outcome data for 
women with GDM separated out for the above outcomes. 
Rumbold 2015 
Vitamin C supplementation in 
pregnancy 
Some overview review pre-specified outcomes included. Maternal primary outcome: Hypertensive disorder of pregnancy and Caesarean. 
Neonatal primary outcome: Death or serious morbidity composite and neurosensory disability; Maternal secondary outcomes: Postpartum 
haemorrhage, maternal mortality, and women’s view of care. Fetal/neonatal secondary outcomes: Stillbirth, neonatal death, gestational age 
at birth, preterm birth (< 37 weeks’ gestation), five-minute Apgar < 7, birthweight, respiratory distress syndrome and neonatal jaundice. No 
later infant/childhood, child as an adult and health service use secondary outcomes. Of the 29 studies included in this review five studies 
excluded women with any diabetes in pregnancy. No outcome data for women with GDM separated out for the above outcomes. 
Walkinshaw 1996 
Dietary regulation for gestational 
diabetes 
Pre-specified outcomes not available as this review has been withdrawn and is now published as 'Different types of dietary advice for women 
with gestational diabetes mellitus' Han 2017, which is an included review in this overview review (Table 2.5: Characteristics of included 
reviews). 
Walkinshaw 2006 
Very tight versus tight control for 
diabetes in pregnancy 
Pre-specified outcomes not available as this review has been withdrawn because it is out-of-date. The review team were unable to prepare 
the up-date and it is now included in the review currently published as ‘different intensities of glycaemic control for women with gestational 
mellitus’ Martis 2016a 
57 
A further four Cochrane systematic reviews (Culliney 2016; East 2014; Farrar 2016 and Jefferys 2013) 
(Figure 2.1) have been listed as Cochrane systematic reviews awaiting further classification (Table 2.3). 
These reviews include some or all of the pre-specified primary and secondary overview outcomes but 
either had no studies that meet the inclusion criteria for that review or no outcome data were reported 
for women with GDM. These Cochrane systematic reviews will be considered for future up-dates of this 
overview.  
Therefore, we included eight Cochrane systematic reviews in this overview reporting on 62 RCTs (9133 
women, 8373 babies and 767 children) for assessment (Figure 2.1) See characteristics of included 
reviews (Table 2.5). 
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Table 2.3: Cochrane systematic reviews awaiting further classification 
Review citation 
Overview outcomes pre-specified in review with no  
outcome data 
Main conclusion(s) of the review 
Culliney KAT, Parry GK, Brown J, 
Crowther CA. Regimens of fetal 
surveillance of suspected large-for-
gestational-age fetuses for improving 
health outcomes. Cochrane Database of 
Systematic Reviews 2016, Issue 4. Art. 
No.: CD011739. DOI: 
10.1002/14651858.CD011739.pub2. 
Overview maternal primary outcomes pre-specified include: Mode of birth 
(caesarean section). 
Overview neonatal primary outcomes pre-specified include: Perinatal (fetal 
and neonatal death) but not later infant mortality and death or serious 
morbidity composite (as defined in reviews, e.g. perinatal or infant death, 
shoulder dystocia, bone fracture or nerve palsy). 
Overview secondary outcomes pre-specified for maternal include: Induction 
of labour, perineal trauma, post-partum haemorrhage, breastfeeding and 
women's view of care. 
No maternal long-term secondary outcomes pre-specified. 
Secondary pre-specified outcomes for fetal/neonatal, later infant/childhood, 
child as an adult include: gestational age at birth, birthweight, and z-score, 
LGA, Apgar < 7, neonatal hypoglycaemia, birth length and HC and 
adiposity. 
Health services use outcomes pre-specified include: admission to neonatal 
special care unit or NICU. 
No studies met the eligibility criteria for inclusion. Future review up-
dates may include women with GDM. 
"Most of the cases of LGA infants are associated with maternal 
factors including maternal height, weight, body mass index (BMI), 
gestational weight gain, ethnicity, parity and maternal age, as well 
as the presence of pre-gestational or gestational diabetes". "There 
is no evidence from randomised controlled trials to evaluate 
regimens of fetal surveillance for suspected large-for-gestational 
age (LGA) fetuses to improve health outcomes". 
East CE, Dolan WJ, Forster DA. 
Antenatal breastmilk expression by 
women with diabetes for improving 
infant outcomes. Cochrane Database of 
Systematic Reviews 2014, Issue 7. Art. 
No.: CD010408. DOI: 
10.1002/14651858.CD010408.pub2. 
No overview primary outcomes for maternal and neonatal outcomes pre-
specified.  
Overview secondary pre-specified outcomes for maternal includes: 
breastfeeding at six months. 
No maternal long-term secondary outcomes pre-specified. 
Secondary outcomes pre-specified for fetal/neonatal include: gestational 
age at birth and neonatal hypoglycaemia. 
No later infant/childhood, child as an adult secondary outcomes pre-
specified. 
Secondary outcomes pre-specified for health services use include: 
economic costs (as defined by trial authors) which may include some of the 
overview pre-specified outcomes 
No studies met the eligibility criteria for inclusion. Future review up-
dates may include women with GDM. 
"There were no published or unpublished randomised controlled 
trials comparing antenatal expressing with not expressing. One 
randomised trial is currently underway. There is no high level 
systematic evidence to inform the safety and efficacy of the 
practice of expressing and storing breast milk during pregnancy". 
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Review citation 
Overview outcomes pre-specified in review with no  
outcome data 
Main conclusion(s) of the review 
Farrar D, Tuffnell DJ, West J, West HM. 
Continuous subcutaneous insulin 
infusion versus multiple daily injections 
of insulin for pregnant women with 
diabetes. Cochrane Database of 
Systematic Reviews 2016, Issue 6. Art. 
No.: CD005542. DOI: 
10.1002/14651858.CD005542.pub3. 
All overview primary outcomes for maternal and neonatal outcomes pre-
specified.  
All overview secondary outcomes for maternal, maternal long-term, 
fetal/neonatal, later infant/childhood, child as an adult and health services 
use pre-specified. 
None of the included trials recruited women with GDM. Future 
review up-dates may include women with GDM. “There were no 
trials of appropriate methodological quality that assessed the use 
of MDI versus CSII for women with GDM” and suggest that as 
“prevalence of GDM is increasing and these women may require 
insulin; this is a group of women who should be included in future 
trials”. "Large multi-centre randomised, adequately powered trials 
are needed to assess the effectiveness of continuous 
subcutaneous insulin infusion compared with multiple daily 
injections for women with diabetes (GDM and pre-existing) in 
pregnancy who require insulin. It would be beneficial if outcomes 
were consistent across trials and included women’s preferences. 
Further trials to assess the effects of pumps on birthweight and 
macrosomia rates are needed. Future trials should undertake 
longer-term follow-up of participants (women and their infants) as 
well as assessment of associated costs". 
Jefferys AE, Siassakos D, Draycott T, 
Akande VA, Fox R. Deflation of gastric 
band balloon in pregnancy for improving 
outcomes. Cochrane Database of 
Systematic Reviews 2013, Issue 4. Art. 
No.: CD010048. DOI: 
10.1002/14651858.CD010048.pub2. 
Overview primary outcome for maternal pre-specified include: Hypertensive 
disorder in pregnancy. 
No overview primary outcomes for neonatal are pre-specified. 
Overview secondary outcomes pre-specified for maternal include: maternal 
weight gain in pregnancy, maternal hospital antenatal and postnatal 
admissions. 
No overview secondary outcomes pre-specified for maternal long-term.  
Overview secondary outcomes pre-specified for fetal/neonatal include: 
Apgar score < 7 at 5 minutes, preterm birth < 37 weeks and < 28 weeks, 
birthweight, macrosomia, SGA, stillbirth and early neonatal death. 
No overview secondary outcomes pre-specified for later infant/childhood, 
child as an adult and health services use. 
No studies met the eligibility criteria for inclusion. Future review up-
dates may include women with GDM and gastric balloons. "At 
present, there is no guidance on the best management of a gastric 
band during pregnancy and there is variation in care. Some 
clinicians advocate leaving the balloon filled (inflated) to limit food 
intake and limit weight gain during pregnancy. This strategy might 
reduce the likelihood of maternal high blood pressure or 
gestational diabetes and so improve the outcomes for mother and 
baby". 
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Table 2.4: Ongoing Cochrane systematic reviews (Protocol and Title registrations) 
Protocol ID and title 
registrations  
Reference Inclusion criteria for  
types of participants 
Comparison  
interventions 
Overview outcomes pre-specified  
in the protocols 
Brown 2016b Insulin for the 
treatment of women with 
gestational diabetes 
(Protocol) 
Brown J, Grzeskowiak L, Williamson 
K, Downie MR, Crowther CA. 
Insulin for the treatment of women with 
gestational diabetes. 
Cochrane Database of Systematic 
Reviews 2016, Issue 1. Art. No.: 
CD012037. 
DOI:10.1002/14651858.CD012037 
Women diagnosed with GDM. 
Pregnant women with type 1 or 
type 2 diabetes will be 
excluded 
Comparing any insulin with 
oral anti-diabetic agents or 
diet or exercise or diet plus 
exercise or other treatments 
not identified above or 
comparing one type of insulin 
with another type or one 
insulin regimen with another 
insulin regimen. 
All overview primary outcomes for maternal 
and neonatal outcomes pre-specified. 
All overview secondary outcomes for 
maternal, maternal long-term, 
fetal/neonatal, later infant/childhood, child 
as an adult and health services use pre-
specified. 
Gill 2014 
Home versus hospital glucose 
monitoring for gestational 
diabetes during pregnancy 
(Protocol) 
Gill MG, Nguyen TMN, Bain E, 
Crowther CA, Middleton P. 
Home versus hospital glucose 
monitoring for gestational diabetes 
during pregnancy. 
Cochrane Database of Systematic 
Reviews 2014, Issue 4. Art. No.: 
CD011069. 
DOI:10.1002/14651858.CD011069 
Women diagnosed with GDM 
and of any age, gestation and 
parity will be included. 
Pregnant women with type 1 or 
type 2 diabetes will be 
excluded. 
Comparing all home care in 
glucose monitoring with 
hospital care. 
Maternal primary outcome pre-specified 
include: Mode of birth (caesarean section)  
Neonatal primary outcomes pre-specified 
include: Perinatal (fetal and neonatal death) 
and late infant mortality and large for 
gestational age (as defined in reviews)  
Secondary outcomes pre-specified for 
maternal include: Use of additional 
pharmacotherapy, glycaemic control 
during/end of treatment (as defined in the 
reviews), weight gain in pregnancy, 
adherence to the intervention, induction of 
labour, placental abruption, postpartum 
haemorrhage (as defined in the reviews), 
postpartum infection, perineal 
trauma/tearing, maternal mortality, sense of 
well-being and quality of life. 
Secondary outcomes pre-specified for 
maternal long-term include: Body mass 
index (BMI), postnatal weight retention or 
return to pre-pregnancy weight, 
development of type 1 diabetes, 
development of type 2 diabetes, impaired 
glucose tolerance, subsequent gestational 
diabetes. 
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Protocol ID and title 
registrations  
Reference Inclusion criteria for  
types of participants 
Comparison  
interventions 
Overview outcomes pre-specified  
in the protocols 
Secondary outcomes pre-specified for 
fetal/neonatal include: Stillbirth, neonatal 
death, small-for-gestational age (as defined 
in the reviews), birth trauma (e.g. shoulder 
dystocia, bone fracture, nerve palsy), 
gestational age at birth, preterm birth (< 37 
weeks’ gestation and < 32 weeks’ 
gestation), five-minute Apgar < 7, 
birthweight and z score, ponderal index, 
neonatal hypoglycaemia (as defined in the 
reviews), respiratory distress syndrome, 
neonatal jaundice (hyperbilirubinaemia) (as 
defined in the reviews). 
Secondary outcomes pre-specified for later 
infant/childhood include: Weight and z 
scores, height and z scores, adiposity 
(including BMI, skinfold thickness, fat 
mass), development of type 1 diabetes, 
development of type 2 diabetes, impaired 
glucose tolerance, dyslipidaemia or 
metabolic syndrome. 
No secondary outcomes pre-specified for 
child as an adult. 
Secondary outcomes pre-specified for 
health service use include: Number of 
antenatal visits or admissions, admission to 
neonatal intensive care unit/nursery, length 
of stay in neonatal intensive care unit or 
special care baby unit, length of postnatal 
stay (maternal), length of postnatal stay 
(baby), cost of maternal care, cost of 
neonatal/child/adult care. 
Rao 2017  
Fetal biometry for guiding the 
medical management of women 
with gestational diabetes 
mellitus for improving maternal 
and perinatal health 
Rao U, de Vries B, Ross GP, Gordon 
A. Fetal biometry for guiding the 
medical management of women with 
gestational diabetes mellitus for 
improving maternal and perinatal 
health. Cochrane Database of 
Pregnant women with 
singleton pregnancies who 
have gestational diabetes 
mellitus (GDM), as defined by 
the authors. Women with 
multiple pregnancy are 
Comparing the use of medical 
therapy for GDM guided by 
maternal blood glucose 
values (glycaemic targets) 
only with medical therapy 
guided by fetal biometry on 
All overview primary outcomes for maternal 
and neonatal outcomes pre-specified, 
except neurosensory disability in later 
childhood (as defined in reviews) for 
neonatal outcomes pre-specified (listed as 
a pre-specified secondary outcome). 
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Protocol ID and title 
registrations  
Reference Inclusion criteria for  
types of participants 
Comparison  
interventions 
Overview outcomes pre-specified  
in the protocols 
(Protocol) Systematic Reviews 2017, Issue 2. 
Art. No.: CD012544. DOI: 
10.1002/14651858.CD012544 
excluded. Data from studies 
including women with single 
and multiple pregnancies will 
only be extracted and 
analysed for women with 
single pregnancy and where 
this is not possible the study 
will be only included if more 
than 95% of the participants 
have a singleton pregnancy. 
ultrasound, MRI or other 
imaging methods as well as 
maternal glycaemic targets. 
Where diet and exercise 
modifications are used, they 
should be consistent across 
the groups. 
All overview secondary outcomes for 
maternal, maternal long-term (except: 
development of type 2 diabetes), 
fetal/neonatal, later infant/childhood, child 
as an adult and health services use pre-
specified (except: length of stay in neonatal 
intensive care unit or special care baby 
unit). 
Dunn 2016 Planned elective 
birth for pregnant women with 
gestational diabetes 
(Title registration) 
Dunne F, Biesty LM, Egan A, Devane 
D, Dempsey E, Meskell P, Smith V. 
Awaiting protocol publication Awaiting protocol publication Awaiting protocol publication 
Okesene-Gafa 2016 
Probiotics for treating women 
with gestational diabetes for 
improving maternal and fetal 
health and well-being 
(Title registration) 
Okesene-Gafa KAM, Brown J, 
Crowther CA, McCowan L. 
Awaiting protocol publication Awaiting protocol publication Awaiting protocol publication 
Wang 2016 Chinese herbal 
medicines for treating 
gestational diabetes mellitus 
(Title registration) 
Wang CC, Li L, Li R, Tam WH,  
Dou L. 
Awaiting protocol publication Awaiting protocol publication Awaiting protocol publication 
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Table 2.5: Characteristics of included Cochrane systematic reviews 
Review ID and title Date of Search 
and date 
assessed as up 
to date 
No. included trials (countries, 
design and publication years) 
No. of 
participants 
in included 
trials 
Inclusion and exclusion  
criteria for types of  
participants 
Interventions and Comparisons  
Boulvain 2001 
Elective delivery in 
diabetic pregnant women 
Search: 24.07.09 
Up-to-date: 
05.07.04 
Not up-to-date 
Trials: 1 RCT 
Country: USA 
Published: 
1993: 1 RCT 
200 women 
200 babies  
no children 
Women diagnosed with pre-
gestational or gestational diabetes, 
treated with insulin or diet alone. 
Exclusion criteria not described. 
Comparing any dietary advice with each other; 
comparing two or more forms of the same type 
of dietary advice with each other and/or different 
intensities of dietary interventions with each 
other. 
Brown 2017a 
Oral anti-diabetic 
pharmacological 
therapies for the 
treatment of women with 
gestational diabetes. 
Search: 16.05.16 
(databases); 
14.05.16 (clinical 
trial registries) Up-
to-date: 14.05.16 
Up-to-date 
Trials: 11 RCTs Country: Brazil 
(3 RCTs); India (2 RCTs); Israel 
(1 RCT); UK (1 RCT); South 
Africa (1 RCT); USA (3 RCTs) 
Published: 
1971: 1 RCT 
2005: 1 RCT 
2006: 1 RCT 
2010: 1 RCT 
2012: 1 RCT 
2014: 1 RCT 
2015: 5 RCT 
1487 women 
1487 babies 
 no children 
Women diagnosed with GDM 
(diagnosis as defined by the 
individual trial). Women with type 1 
or type 2 diabetes diagnosed prior to 
pregnancy were excluded. 
Comparing oral pharmacological anti-diabetic 
agents used during pregnancy (including 
metformin, glibenclamide, acarbose, 
tolbutamide, chlorpropamide or combination of 
these therapies) with either placebo or no 
pharmacological treatment or one agent versus 
another agent or versus another intervention but 
not insulin. 
Brown 2017b 
Lifestyle interventions for 
the treatment of women 
with gestational diabetes 
Search: 14.05.16 
Up-to-date: 
14.05.16 
Up-to-date 
Trials: 15 RCTs 
Country: 
Australia (1 RCTs); Canada (1 
RCT); China (2 RCTs); Italy (1 
RCT); Iran (2 RCTs); Thailand 
(1 RCT); UK (1 RCT); United 
Arab Emirates (1 RCT); USA (4 
RCTs); multicentre (Australia 
and UK, 1 RCT) 
Published: 
1989: 1 RCT 
1997: 1 RCT 
2000: 1 RCT 
2003: 1 RCT 
2004: 1 RCT 
2005: 1 RCT 
 4501 women 
3768 babies 
767 children 
Women diagnosed with GDM 
(diagnosis as defined by the 
individual trial). Women with known 
type 1 or type 2 diabetes were 
excluded. 
Comparing lifestyle interventions (a combination 
of at least two or more, including standard 
dietary advice, with or without adjunctive 
pharmacotherapy (oral anti-diabetic 
pharmacological therapies or insulin)) versus 
standard care, expectant management or 
another lifestyle interventions or combination of 
lifestyle interventions. 
Intensive intervention were defined in included 
reviews as: standard dietary advice, glucose 
monitoring five days a week, HbA1c monthly, 
serial ultrasound, Doppler studies, 
cardiotocography (CTG monitoring) compared 
with usual care (dietary advice, HbA1c monthly); 
or individualised-dietary advice, advice on self-
monitoring of blood glucose) compared with 
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Review ID and title Date of Search 
and date 
assessed as up 
to date 
No. included trials (countries, 
design and publication years) 
No. of 
participants 
in included 
trials 
Inclusion and exclusion  
criteria for types of  
participants 
Interventions and Comparisons  
2008: 2 RCTs 
2009: 1 RCT 
2011: 1 RCT 
2014: 5 RCTs 
usual care; or structured pharmaceutical care, 
structured education, self-monitoring of blood 
glucose compared with usual care (no additional 
education or pharmacist counselling); or 
individualised advice on diet, exercise and 
breastfeeding compared with usual care (printed 
material only in prenatal and postnatal period; or 
dietary counselling, self-glucose monitoring, bi-
weekly review, monitoring of fetal growth, 
amniotic volume and cardiac size compared with 
usual care (no dietary counselling); or diet and 
exercise advice, self-monitoring of blood 
glucose, insulin if required, fortnightly specialist 
review) versus usual care (no details). Other 
interventions used were: Group session on 
education and diet followed by specific dietary 
advice compared with group session on 
education and diet followed by standard clinical 
care and advice; or diet alone compared with 
diet plus supervised exercise; or relaxation 
training (education, breathing, muscle relaxation, 
mental imagery, and contacted by telephone by 
the researcher three times per week) compared 
with usual care (no details); or nutritional 
counselling and diet therapy +/- insulin plus self-
monitoring of blood glucose compared with 
usual care +/- insulin plus self-monitoring of 
blood glucose; or intensive education and 
spiritual intervention compared with standard 
education; or face-to-face education (risks of 
GDM, training on glycaemic control, exercise, 
diet, medication and follow-up) compared with 
usual care (no details); or individualised and 
group dietary and physical activity counselling, 
self-monitoring blood glucose compared with 
usual care (group education on exercise and 
physical activity, not specifically taught blood 
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Review ID and title Date of Search 
and date 
assessed as up 
to date 
No. included trials (countries, 
design and publication years) 
No. of 
participants 
in included 
trials 
Inclusion and exclusion  
criteria for types of  
participants 
Interventions and Comparisons  
glucose self-monitoring); or mindfulness eating 
and yoga compared with standard diabetes care 
(no details); or combined behavioural and 
exercise compared with individualised-dietary 
advice alone. 
Brown 2017c 
Exercise for pregnant 
women with gestational 
diabetes for improving 
maternal and fetal 
outcomes 
 
Search:  
27.08.16 (and 
18.08.16 for trial 
registries) 
Up-to-date: 
18.08.16 
Up-to-date 
Trials: 11 RCTs 
Countries:  
USA (3 RCTs); Brazil (3 RCTs); 
Canada (2 RCTs); 
Italy (1 RCT); Australia(1RCT); 
Thailand (1 RCT) 
Published: 
1989: 1 RCT;  
1991: 1 RCT;  
1997: 1 RCT; 
2004: 1 RCT; 
2010: 1 RCT; 
2012: 1 RCT; 
2014: 4 RCTs; 
2015: 1 RCT 
638 women 
638 babies 
no children 
Pregnant women diagnosed with 
GDM (as defined by trialists). 
Women with known pre-gestational 
diabetes (type 1 or type 2 diabetes) 
were excluded. 
Comparing any type of exercise programme (+/- 
standard care) at any stage of pregnancy versus 
standard care or another intervention. 
Exercises summarised from reviews included 
individualised exercises follow-up by 
kinesiologist; timed exercises 2 - 4 times weekly 
with or without supervision and telephone 
counselling; brisk walking or resistance 
exercises: 30 minutes circuit workout with 
elastic-band exercises; exercises in lab 
conditions on cycles; home-based exercises; 
supervised arm ergometer training plus diet; low-
intensity aerobic training in cycle-ergometer and 
mindfulness eating and yoga exercise. 
Brown 2016a 
Dietary supplementation 
with myo-inositol in 
women during pregnancy 
for treating gestational 
diabetes. 
Search: 14.05.16 
Up-to-date: 
14.05.16 
Up-to-date 
Trials: 2 RCTs Country: 
Italy (2 RCTs) 
Published: 
2011: 1 RCT 
2013: 1 RCT 
159 women 
159 babies  
no children 
Pregnant women with a diagnosis of 
GDM (as defined by trialists). 
Women with pre-existing type 1 or 
type 2 diabetes were excluded. 
Comparing any dose of myo-inositol, alone or in 
a combination preparation for the treatment of 
women with GDM with women who received no 
treatment, placebo or another intervention. 
The two included trials assessed 4 g myo-
inositol + 400 mcg folic acid orally per day and 
exercise and dietary advice versus placebo 400 
mcg folic acid orally per day and exercise and 
dietary advice. 
Han 2017 
Different types of dietary 
advice for women with 
gestational diabetes 
mellitus. 
Search: 08.03.16 
Up-to-date: 
22.03.16 
Up-to-date 
Trials: 19 RCTs Countries: 
Australia (3 RCTs), Canada (2 
RCTs), China (2 RCTs), 
Denmark (1 RCT), 
Italy (2 RCTs); Iran (4 RCTs); 
Mexico (1 RCT); Poland (1 
1398 women 
1398 babies 
no children 
Women with GDM regardless of 
gestation, age, parity or plurality. 
Exclusion criteria not described. 
Comparing any dietary advice with each other; 
comparing two or more forms of the same type 
of dietary advice with each other and/or different 
intensities of dietary interventions with each 
other. These trials include: low-moderate GI diet 
versus moderate-high GI diet, energy-restricted 
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Review ID and title Date of Search 
and date 
assessed as up 
to date 
No. included trials (countries, 
design and publication years) 
No. of 
participants 
in included 
trials 
Inclusion and exclusion  
criteria for types of  
participants 
Interventions and Comparisons  
RCT); Spain (1 RCT); USA (2 
RCT) 
Published: 
1990: 1 RCT 
1995: 1 RCT 
1997: 1 RCT 
2000: 1 RCT 
2001: 1 RCT 
2007: 1 RCT 
2009: 1 RCT 
2010: 1 RCT 
2011: 2 RCTs 2012: 1 RCT 
2013: 3 RCTs 2014: 2 RCTs 
2015: 3 RCTs 
diet versus no energy-restricted diet, DASH 
(Dietary Approaches to Stop Hypertension) diet 
versus control diet with matching macronutrient 
contents, low-carbohydrate diet versus high-
carbohydrate diet, high unsaturated fat diet 
versus low unsaturated diet with matching 
calories, low-GI diet versus high-fibre moderate-
GI diet, diet recommendation and diet-related 
behavioural advice versus diet recommendation, 
soy protein-enriched diet versus no soy protein 
diet, high-fibre versus standard-fibre diet, ethnic-
specific diet versus standard healthy diet. 
Han 2012 
Interventions for 
pregnant women with 
hyperglycaemia not 
meeting gestational 
diabetes and type 2 
diabetes diagnostic 
criteria. 
Search: 30.09.11 
Up-to-date: 
21.11.11 
Not up-to-date 
Trials: 4 RCTs Country: 
Canada (1 RCT); Italy (1 RCT); 
USA (2 RCTs) 
Published: 
1989: 1 RCT 
1999: 1 RCT 
2005: 1 RCT 
2011: 1 RCT 
543 women 
543 babies  
no children 
Pregnant women with 
hyperglycaemia, regardless of 
gestation, age, parity or plurality, 
who do not meet the diagnostic 
criteria for GDM based on OGTT 
results defined by trialists. Women 
with pre-existing diabetes mellitus 
and previously treated GDM were 
not eligible. 
Comparing any form of management for women 
with pregnancy hyperglycaemia not meeting 
GDM criteria with standard antenatal care, 
included any type of dietary advice (standard or 
individualised), exercise and lifestyle advice 
(standard or individualised) and drug treatment 
including insulin and oral drugs with one type of 
intervention compared with standard antenatal 
care. 
Martis 2016a 
Different intensities of 
glycaemic control for 
women with gestational 
diabetes mellitus. 
Search: 31.01.16 
Up-to-date: 
31.01.16 
Up-to-date 
Trials: 1 RCT Country: Canada 
Published: 
1998: 1 RCT 
180 women 
180 babies  
no children 
 
All pregnant women diagnosed with 
GDM (screening and subsequent 
diagnosis and diagnostic criteria as 
identified in the individual trials). 
Women with known pre-existing type 
1 or type 2 diabetes are excluded. 
Comparing any glycaemic treatment targets 
used to guide treatment for women with GDM 
with another glycaemic target. 
Strict intensity of glycaemic control is defined in 
this one trial as: pre-prandial 5.0 mmol/L (90 
mg/dL) and at one-hour postprandial: 6.7 
mmol/L (120 mg/dL). Less strict glycaemic 
control is defined as: pre-prandial 5.8 mmol/L 
(104 mg/dL) and at one-hour postprandial 7.8 
mmol/L (140 mg/dL). 
RCT: Randomised Controlled Trial 
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Description of included reviews 
Population - 
Table 2.5 provides details of the characteristics of the included reviews including details of the inclusion 
and exclusion criteria of the participants. All of the included reviews included trials that recruited women 
with GDM. 
Settings - 
Table 2.5 provides details of the characteristics of the included reviews including details of the settings 
of the trials. There is a lack of trials from lower- and middle- income countries. 
Interventions and comparisons 
Of the eight Cochrane systematic reviews included (Table 2.5): 
• One review focused on any dietary modifications for women with GDM: 
o Different types of dietary advice for women with gestational diabetes mellitus (Han 2017) 
• One review focused on any exercise for women with GDM: 
o Exercise for pregnant women with gestational diabetes for improving maternal and fetal 
outcomes (Brown 2017c) 
• One review focused oral pharmacological interventions for treatment for women with GDM: 
o Oral anti-diabetic pharmacological therapies for the treatment of women with gestational 
diabetes (Brown 2017a) 
• One review assessed nutraceuticals or other dietary supplements for treatment for women with 
GDM: 
o Dietary supplementation with myo-inositol in women during pregnancy for treating gestational 
diabetes (Brown 2016a) 
• Two reviews assessed other management strategies for women with GDM: 
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o Elective delivery in diabetic pregnant women (Boulvain 2001). The results of this review are 
for women diagnosed with pre-gestational diabetes or GDM. The data could not be separated 
out for the two different groups. The overview review authors agreed to include this review as 
the results were based on 187 (93.5 %) women with GDM and 13 (6.5 %) women with pre-
gestational diabetes (defined as type 1 and type 2 diabetes). Furthermore, during email 
correspondence with the review author, it was confirmed that future up-dates of the review will 
separate the results for women with GDM and women with pre-gestational diabetes. 
o Different intensities of glycaemic control for women with gestational diabetes mellitus (Martis 
2016a) 
• One review assessed interventions for women with hyperglycaemia not meeting gestational 
diabetes and type 2 diagnostic criteria 
o Interventions for pregnant women with hyperglycaemia not meeting gestational diabetes and 
type 2 diagnostic criteria (Han 2012). The overview review authors agreed to include Han's 
2012 review into this overview, as different countries have different diagnostic levels for 
confirming that a pregnant woman has GDM. It is highly possible that women with 
hyperglycaemia identified in one country as not meeting the gestational diagnostic threshold 
for GDM would be diagnosed as having GDM in another country. 
• One review assessed lifestyle interventions for women with GDM 
o Lifestyle interventions for the treatment of women with GDM (Brown 2017b). Lifestyle 
interventions include at least two or more interventions such as dietary advice, self-monitoring 
blood glucose monitoring, education via group sessions or individual, mindfulness eating, 
yoga, relaxation, breathing, fetal growth monitoring and other antenatal tests.  
In total there were 62 RCTs in these eight Cochrane systematic reviews involving a total 9133 women, 
8373 babies and 767 children (Table 2.5). The eight reviews included between one RCT (Boulvain 2001; 
Martis 2016a) to 19 RCTs (Han 2017); and between 159 (Brown 2016a) to 4501 Brown 2017b women, 
with 159 (Brown 2016a) to 3768 babies (Brown 2017b); and data were reported for 767 children in one 
review (Brown 2017b). 
Six (75 %) of the included reviews had conducted searches in the last two years and were considered 
up-to-date (January 2016 - August 2016) (Brown 2017a; Brown 2017b; Brown 2017c; Brown 2016a; 
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Han 2017; Martis 2016a). The other two reviews had their last search date listed as 24.07.09 (Boulvain 
2001) and 30.09.11 (Han 2012) (Table 2.5). 
Table 2.5: Characteristics of included reviews describes the inclusion and exclusion criteria for the types 
of participants for each review and its intervention and comparison. 
Outcomes reported 
We listed the pre-specified overview outcomes and identified whether the included systematic review 
had included these outcomes or not (Table 2.6). 
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Table 2.6: Pre-specified overview outcomes in included reviews 
Included Review  
Author and Year → 
Boulvain  
2001 
Brown  
2017a 
Brown 
2017b 
Brown  
2017c 
Brown  
2016a 
Han  
2017 
Han 
2012 
Martis  
2016a 
Overview Primary Outcomes 
Maternal 
Hypertensive disorders of 
pregnancy (including 
preeclampsia, pregnancy-
induced hypertension, 
eclampsia as defined in 
reviews) 
x √ √ √ √ √ √ 
secondary outcome 
and pre-eclampsia 
only 
in this review 
√ 
Mode of birth (caesarean 
section) 
√ √ 
called 
'caesarean 
section' in the 
review 
√ √ √ 
called 'caesarean 
section' in the 
review 
√ √ 
includes also 
normal vaginal birth 
and operative 
vaginal birth 
√ 
secondary 
outcome called 
'caesarean 
section' in the 
review 
Development of 
type 2 diabetes 
x √ √ √ √ √ x √ 
Neonatal 
Perinatal (fetal and neonatal 
death) and later infant 
mortality 
√ √ √ √ 
does not 
include later 
infant mortality 
√ 
called 'perinatal 
mortality (stillbirth 
and neonatal 
mortality)' in review; 
does not include 
later infant mortality 
√ 
does not include 
later infant 
mortality 
√ 
does not include 
later infant mortality 
√ 
later infant 
mortality not 
stated 
Large-for-gestational age (as 
defined in reviews) 
x √ √ √ √ √ √ √ 
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Included Review  
Author and Year → 
Boulvain  
2001 
Brown  
2017a 
Brown 
2017b 
Brown  
2017c 
Brown  
2016a 
Han  
2017 
Han 
2012 
Martis  
2016a 
Death or serious morbidity 
composite (as defined in 
reviews, e.g. perinatal or 
infant death, shoulder 
dystocia, bone fracture or 
nerve palsy) 
√ 
called 'traumatic 
delivery (intracranial 
haemorrhage, fracture, 
brachial plexus injury)' 
in review, but does not 
include shoulder 
dystocia, listed under 
secondary outcomes 
in review 
√ √ √ √ √ x √ 
Neurosensory disability in 
later childhood (as defined in 
reviews) 
√ 
'long term disability in 
childhood' in this 
review 
√ √ √ √ 
'neurosensory 
disability' in this 
review 
√ x √ 
Overview Secondary Outcomes 
Maternal 
Use of additional 
pharmacotherapy 
x √ √ √ √ √ √ √ 
Maternal hypoglycaemia (as 
defined in the reviews) 
x √ √ √ √ √ x √ 
Glycaemic control during/end 
of treatment (as defined in 
the reviews) 
x √ √ √ √ √ x √ 
Weight gain in pregnancy x √ √ √ √ √ √ √ 
Adherence to the intervention x √ √ √ √ √ √ √ 
Induction of labour x √ √ √ √ √ √ √ 
Placental abruption x √ √ √ √ √ x √ 
Postpartum haemorrhage (as 
defined in the reviews) 
x √ √ √ √ √ √ √ 
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Included Review  
Author and Year → 
Boulvain  
2001 
Brown  
2017a 
Brown 
2017b 
Brown  
2017c 
Brown  
2016a 
Han  
2017 
Han 
2012 
Martis  
2016a 
Postpartum infection x √ √ √ √ √ √ √ 
Perineal trauma/tearing √ 
(third and fourth 
degree perineal tear, 
any perineal trauma)' 
in review 
√ √ √ √ √ √ √ 
Breastfeeding at discharge, 
six weeks postpartum, six 
months or longer 
x √ √ √ √ 
only states 'at 
discharge and six-
week post-partum' 
in review 
√ √ √ 
states only 
breastfeeding 
Maternal mortality x √ √ √ √ √ √ √ 
Sense of well-being and 
quality of life 
x √ √ √ √ √ √ √ 
Behavioural changes 
associated with the treatment 
x √ √ √ √ √ x √ 
Women’s view of the 
intervention 
√ 
(called 'women’s view 
of their care)' in review 
√ √ √ √ √ √ √ 
Relevant biomarker changes 
associated with the 
intervention (including 
adiponectin, free fatty acids, 
triglycerides, high-density 
lipoproteins, low-density 
lipoproteins, insulin) 
x √ √ √ √ x x √ 
Maternal long-term  
        
Postnatal depression x √ √ √ √ √ x √ 
Body mass index (BMI) x √ √ √ √ √ √ √ 
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Included Review  
Author and Year → 
Boulvain  
2001 
Brown  
2017a 
Brown 
2017b 
Brown  
2017c 
Brown  
2016a 
Han  
2017 
Han 
2012 
Martis  
2016a 
Postnatal weight retention or 
return to pre-pregnancy 
weight 
x √ √ √ √ √ √ √ 
Development of type 2 
diabetes 
x √ x √ x √ √ x 
Impaired glucose tolerance x √ √ √ √ √ √ √ 
Subsequent gestational 
diabetes 
x √ √ √ √ √ √ √ 
Cardiovascular health (as 
defined in the reviews 
including blood pressure, 
hypertension, cardiovascular 
disease, metabolic 
syndrome) 
x √ √ √ √ √ x √ 
Fetal/neonatal 
Stillbirth x √ √ √ √ √ x √ 
Neonatal death x √ √ √ √ √ x √ 
Macrosomia (>4000 g; or as 
defined in the reviews) 
x √ √ √ √ √ √ 
primary outcome; 
> 4000 g and 
> 4500 g 
√ 
Small-for-gestational age (as 
defined in the reviews) 
x √ √ √ √ √ √ √ 
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Included Review  
Author and Year → 
Boulvain  
2001 
Brown  
2017a 
Brown 
2017b 
Brown  
2017c 
Brown  
2016a 
Han  
2017 
Han 
2012 
Martis  
2016a 
Birth trauma (e.g. shoulder 
dystocia, bone fracture, 
nerve palsy) 
√ 
Shoulder dystocia only 
√ √ √ √ 
shoulder dystocia, 
bone fracture and 
nerve palsy, all 
separated out as 
secondary 
outcomes by 
themselves in this 
review 
√ 
shoulder dystocia, 
bone fracture and 
nerve palsy, all 
separated out as 
outcomes by 
themselves in this 
review 
√ 
shoulder dystocia, 
bone fracture and 
nerve palsy, all 
separated out as 
outcomes by 
themselves in this 
review 
√ 
shoulder dystocia, 
bone fracture and 
nerve palsy, all 
separated out as 
outcomes by 
themselves in this 
review 
Gestational age at birth x √ √ √ √ √ √ √ 
Preterm birth (< 37 weeks’ 
gestation and < 32 weeks’ 
gestation) 
x √ √ √ √ √ √ √ 
Five-minute 
Apgar < 7 
√ 
'low 5 minutes Apgar 
score, as defined by 
authors in the studies’ 
√ √ √ √ √ √ √ 
Birthweight and z score x √ √ √ √ √ √ 
birth weight only 
√ 
Head circumference and z 
score 
x √ √ √ √ √ x √ 
Length and z score x √ √ √ √ √ x √ 
Ponderal index x √ √ √ √ √ 
at birth only 
√ √ 
Adiposity (including skinfold 
thickness measurements 
(mm), fat mass) 
x √ √ √ √ √ √ √ 
Neonatal hypoglycaemia (as 
defined in the reviews) 
√ √ √ √ √ √ √ √ 
Respiratory distress 
syndrome 
x √ √ √ √ √ √ √ 
75 
Included Review  
Author and Year → 
Boulvain  
2001 
Brown  
2017a 
Brown 
2017b 
Brown  
2017c 
Brown  
2016a 
Han  
2017 
Han 
2012 
Martis  
2016a 
Neonatal jaundice 
(hyperbilirubinaemia) (as 
defined in the reviews) 
x √ √ √ √ √ √ √ 
Hypocalcaemia (as defined 
in the reviews) 
x √ √ √ √ √ x √ 
Polycythaemia (as defined in 
the reviews) 
x √ √ 
 
√ √ x √ 
Relevant biomarker changes 
associated with the treatment 
(including insulin, cord c-
peptide) 
x √ √ √ √ x x √ 
Later infant/childhood  
        
Weight and z scores x √ √ √ √ √ √ 
weight only 
√ 
Height and z scores x √ √ √ √ √ √ 
height only 
√ 
Head circumference and z 
scores 
x √ √ √ √ √ x √ 
Adiposity (including BMI, 
skinfold thickness, fat mass) 
x √ √ √ √ √ √ 
three separate 
outcomes: BMI, fat 
mass/fat-free mass, 
skinfold thickness 
measurements 
√ 
Educational attainment x √ √ √ √ √ 
only education 
achievement 
√ 
only education 
achievement 
√ 
Blood pressure x √ √ √ √ √ √ √ 
Development of type 1 
diabetes 
x √ √ √ √ √ √ √ 
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Included Review  
Author and Year → 
Boulvain  
2001 
Brown  
2017a 
Brown 
2017b 
Brown  
2017c 
Brown  
2016a 
Han  
2017 
Han 
2012 
Martis  
2016a 
Development of type 2 
diabetes 
x √ √ √ √ √ √ √ 
Impaired glucose tolerance x √ √ √ √ √ √ √ 
Dyslipidaemia or metabolic 
syndrome 
x √ √ √ √ √ √ √ 
Child as an adult 
Weight and z scores x √ 
weight only 
√ 
weight-
only 
√ √ 
weight only 
√ 
weight only 
√ 
weight only 
√ 
weight only 
Height and z scores x √ 
height only 
√ 
height 
only 
√ √ 
height only 
√ 
height only 
√ 
height only 
√ 
height only 
Adiposity (including BMI, 
skinfold thickness, fat mass) 
x √ √ √ √ √ √ 
as three separate 
outcomes: BMI, fat 
mass/fat-free mass, 
skinfold thickness 
measurements 
√ 
Cardiovascular health (as 
defined by trialists including 
blood pressure, 
hypertension, cardiovascular 
disease, metabolic 
syndrome) 
x √ √ √ √ √ √ 
blood pressure only 
√ 
Employment, education and 
social status/achievement 
x √ √ √ √ √ √ 
education 
achievements only 
√ 
Dyslipidaemia or metabolic 
syndrome 
x √ √ x √ √ √ √ 
Development of type 1 
diabetes 
x √ √ √ √ √ √ √ 
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Included Review  
Author and Year → 
Boulvain  
2001 
Brown  
2017a 
Brown 
2017b 
Brown  
2017c 
Brown  
2016a 
Han  
2017 
Han 
2012 
Martis  
2016a 
Development of type 2 
diabetes 
x √ √ √ √ √ √ √ 
Impaired glucose tolerance x √ √ √ √ √ √ √ 
Health service use 
Number of antenatal visits or 
admissions 
x √ √ √ √ √ √ 
visits only, not 
admissions 
√ 
Number of hospital or health 
professional visits (including 
midwife, obstetrician, 
physician, dietician, diabetic 
nurse) 
x √ √ √ √ √ √ 
dietician and 
medical physician 
visits only but each 
a separate outcome 
√ 
Admission to neonatal 
intensive care unit/nursery 
√ √ √ √ √ √ √ √ 
Length of stay in neonatal 
intensive care unit or special 
care baby unit 
x √ √ √ 
called 'duration' 
x x x x 
Length of antenatal stay x √ √ √ 
called 'duration 
of maternal and 
neonatal 
hospital stay 
(antenatal, 
neonatal, 
postnatal)' 
√ √ x √ 
Length of postnatal stay 
(maternal) 
x √ √ √ 
called 'duration 
of maternal and 
neonatal 
hospital stay 
(antenatal, 
neonatal, 
postnatal)' 
√ √ √ √ 
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Included Review  
Author and Year → 
Boulvain  
2001 
Brown  
2017a 
Brown 
2017b 
Brown  
2017c 
Brown  
2016a 
Han  
2017 
Han 
2012 
Martis  
2016a 
Length of postnatal stay 
(baby) 
x √ √ √ 
called 'duration 
of maternal and 
neonatal 
hospital stay 
(antenatal, 
neonatal, 
postnatal)' 
√ √ √ √ 
Cost of maternal care x √ √ √ √ √ √ √ 
Cost of neonatal/child/adult 
care 
x √ 
called 'cost of 
offspring care in 
this review' 
√ 
called 
'cost of 
offspring 
care in 
this 
review' 
√ 
called 'cost of 
offspring care in 
this review' 
√ 
called 'cost of 
offspring care in 
this review' 
√ 
called 'cost of 
offspring care in 
this review' 
√ 
called 'cost of 
offspring care in this 
review' 
√ 
called 'cost of 
offspring care in 
this review' 
Costs associated with the 
treatment 
x √ 
called 'costs 
associated with 
the intervention' 
√ √ 
called 'costs 
associated with 
the intervention' 
√ √ √ 
only 'costs for blood 
glucose monitoring 
during pregnancy' 
√ 
Costs to families associated 
with the treatment (e.g. 
change of diet, extra 
antenatal visits, etc) 
x √ 
called 'costs to 
families 
associated with 
the 
management 
provided' 
√ √ √ √ √ √ 
√ = pre-specified overview review outcome included in Cochrane systematic review                 x = pre-specified overview review outcome NOT included in Cochrane systematic review
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Description of excluded reviews 
We excluded 7 systematic reviews. Two reviews had been withdrawn as they were superseded 
(Walkinshaw 1996; Walkinshaw 2006); one review (Alwan 2009) has been split into three new titles, of 
which two have been published as reviews (Brown 2017a; Brown 2017b;) and another review (Ceysens 
2006) was not up-to-date and has been superseded with a new title and is now published as a review 
entitled ‘Exercise for pregnant women with gestational diabetes for improving maternal and fetal 
outcomes’ (Brown 2017c). Three reviews did not include GDM as an outcome (Vitamin D - DeRegil 
2016; Vitamin A - McCauley 2015; Vitamin C - Rumbold 2015) (Table 2.2). 
Methodological quality of included reviews 
Cochrane risk of bias assessments from included reviews 
All of the included reviews stated that the overall judgement for risk of bias for the trials included in 
their reviews was unclear due to lack of reporting of methodological details. Specific details of the 
assessment of risk of bias reported in the included reviews is summarised in Table 2.7.
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Table 2.7: Cochrane risk of bias assessments from included reviews 
Review ID and title Summary of trial limitations (risk of bias) Overall risk of bias 
Boulvain 2001 
Elective delivery in diabetic 
pregnant women 
Sequence generation: not reported 
Allocation concealment: 1 RCT unclear risk 
Blinding (participants and personnel): not reported 
Blinding (outcome assessors): not reported 
Incomplete outcome data: not reported 
Selective reporting: not reported 
Other: not reported 
"The method of randomizations and of concealment 
of the allocation was not reported" - unclear risk of 
bias 
Brown 2017a 
Oral anti-diabetic 
pharmacological therapies for 
the treatment of women with 
GDM 
Sequence generation: 5 RCTs low risk; 6 unclear risk 
Allocation concealment: 6 RCTs low risk; 5 RCTs unclear risk 
Blinding (participants and personnel): 2 RCTs low risk; 7 RCTs high risk;  
2 RCTs unclear risk 
Blinding (outcome assessors): 2 RCTs low risk; 9 RCTs unclear risk 
Incomplete outcome data: 7 RCT low risk; 2 RCTs high risk; 2 RCTs unclear risk 
Selective reporting: 3 RCTs low risk; 8 RCTs high risk 
Other: 3 RCT's low risk; 6 RCTs high risk; 2 RCTs unclear risk 
"The overall risk of bias was ’unclear’ due to 
inadequate reporting of methodology" 
Brown 2017b 
Lifestyle interventions for the 
treatment of women with GDM 
Sequence generation: 10 RCTs low risk; 5 RCTs unclear risk 
Allocation concealment: 5 RCTs low risk; 10 RCTs unclear risk 
Blinding (participants and personnel): 9 RCTs high risk; 4 RCTs low risk;  
2 RCTs unclear risk 
Blinding (outcome assessors): 6 RCTs low risk; 9 RCTs unclear risk 
Incomplete outcome data: 3 RCTs high risk; 10 RCTs low risk; 2 RCTs unclear risk 
Selective reporting: 11 RCTs high risk; 3 RCTs low risk; 1 RCT unclear risk 
Other: 2 RCTs high risk; 13 RCTs low risk 
“Overall the evidence was judged to be of unclear risk 
of bias due to inadequate reporting of allocation 
concealment and blinding of outcome assessors and 
selective outcome reporting. There is variation 
between the trials with regards to the content of the 
lifestyle interventions. The evidence is dominated by 
two large trials (Crowther 2005; Landon 2009) that 
included 1000 women and 958 women, respectively. 
Both of these trials were judged to be at low risk of 
bias” 
Brown 2017c 
Exercise for pregnant women 
with GDM for 
improving maternal and fetal 
outcomes 
Sequence generation: 4 RCTs low risk; 7 RCTs unclear risk 
Allocation concealment: 3 RCTs low risk; 8 RCTs unclear risk 
Blinding (participants and personnel): 3 RCTs high risk; 8 RCTs unclear risk 
Blinding (outcome assessors): 2 RCTs low risk; 9 RCTs unclear risk 
Incomplete outcome data: 2 RCTs high risk; 3 RCTs low risk; 6 RCTs unclear risk 
Selective reporting: 1 RCT low risk; 10 RCTs unclear risk 
Other: 3 RCTs low risk; 8 RCTs unclear risk 
“We judged the overall risk of bias of the 
included studies to be unclear due to lack of 
methodological details" 
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Review ID and title Summary of trial limitations (risk of bias) Overall risk of bias 
Brown 2016a 
Dietary supplementation with 
myo-inositol in women during 
pregnancy for treating GDM 
Sequence generation: 2 RCTs low risk 
Allocation concealment: 1 RCT low risk; 1 RCT unclear risk 
Blinding (participants and personnel): 1 RCT low risk; 1 RCT unclear risk 
Blinding (outcome assessors): 2 RCTs unclear risk 
Incomplete outcome data: 1 RCT low risk; 1 RCT unclear risk 
Selective reporting: 1 RCT high risk; 1 RCT unclear risk 
Other: 2 RCT's low risk 
"Overall, the risk of bias of the 
included studies was judged to be 
unclear due to the lack of key methodological 
information" 
Han 2017 
Different types of dietary 
advice for women with GDM 
Sequence generation: 11 RCTs low risk; 8 RCTs unclear risk 
Allocation concealment: 4 RCTs low risk; 14 RCTs unclear risk; 1 RCT high risk 
Blinding (participants and personnel): 4 RCTs low risk; 2 RCTs unclear risk;  
13 RCTs high risk 
Blinding (outcome assessors): 2 RCTs low risk, 16 RCTs unclear risk;  
1 RCT high risk 
Incomplete outcome data: 14 RCTs low risk; 3 RCTs unclear risk;  
2 RCTs high risk 
Selective reporting: 16 RCTs unclear risk; 3 RCTs high risk 
Other: 2 RCT's low risk 
"In this update, we included 19 trials 
randomising 1398 women with GDM, at 
an overall unclear to moderate 
risk of bias" 
Han 2012 
Interventions for pregnant 
women with hyperglycaemia 
not meeting GDM and type 2 
diabetes diagnostic criteria 
Sequence generation: 4 RCTs unclear risk 
Allocation concealment: 1 RCT low risk; 3 RCTs unclear risk 
Blinding (participants and personnel): 4 RCTs high risk 
Blinding (outcome assessors): 4 RCTs unclear risk 
Incomplete outcome data: 2 RCTs low risk; 2 RCTs high risk  
Selective reporting: 3 RCTs low risk; 1 RCT high risk 
Other: 4 RCTs low risk 
"Three included studies were at moderate 
to high risk of bias and one study 
was at low to moderate risk of bias" 
Martis 2016a 
Different intensities of 
glycaemic control for women 
with GDM 
Sequence generation: 1 RCT unclear risk 
Allocation concealment: 1 RCT unclear risk 
Blinding (participants and personnel): 1 RCT high risk 
Blinding (outcome assessors): 1 RCT unclear risk 
Incomplete outcome data: 1 RCT unclear risk 
Selective reporting: 1 RCT high risk 
Other: 1 RCT high risk 
"The overall quality of the included trial 
was judged to be unclear as conference abstract 
only" 
82 
GRADE Assessment 
The quality of the evidence reported for the eight included reviews as assessed by the Cochrane 
systematic review authors using the GRADE method varied widely ranging from very low- to high-quality, 
with the majority of studies being assessed as low- to very low-quality. See Table 2.8; Table 2.9; Table 
2.10 for details on the following pages. 
The quality of the evidence reported additionally for all overview review secondary outcomes using the 
four GRADE quality ratings varied widely ranging from very low- to high-quality. See Table 2.11; Table 
2.12; Table 2.13; Table 2.14; Table 2.15 for details on the following pages. 
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Table 2.8: GRADE Summary of findings table - Maternal 
Intervention and 
comparison 
Assumed risk 
with comparator 
Corresponding 
risk with 
intervention* 
Relative 
effect  
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments from included reviews in quotation marks 
Comments without quotation marks from overview review 
authors 
1.0 Hypertensive disorders of pregnancy (including pre-eclampsia, pregnancy-induced hypertension, eclampsia, as defined in reviews) 
Brown 2017a 
Oral anti-diabetic agents 
versus placebo 
(Glibenclamide versus 
placebo) 
Any hypertensive disorders 
of pregnancy, not defined 
167 per 1000 207 per 1000 
(135 to 317) 
RR 1.24 
(0.81 to 
1.90) 
375 (1 RCT)  
Very low 
"Evidence is based on one study and 93% were Hispanic women, 
results may not be generalisable to other populations. There is risk of 
bias, as we did not find a published protocol and there were more 
outcomes reported in the published paper than were listed in the trial 
registration document". 
Brown 2017a 
Metformin versus 
glibenclamide 
Any hypertensive disorders 
of pregnancy, not defined 
88 per 1000 62 per 1000 
(33 to 114) 
RR 0.70 
(0.38 to 
1.30) 
508 (3 
RCTs) 
Moderate "All studies were open label, some risk of bias". 
Brown 2017a 
Oral anti-diabetic agents 
versus placebo 
(Glibenclamide versus 
placebo) 
Pregnancy induced 
hypertension 
102 per 1000 127 per 1000 
(73 to 224) 
RR 1.24 
(0.71 to 
2.19) 
375 (1 RCT) Low Evidence is based on one study and imprecision as wide confidence 
interval crossing the line of no effect. 
Brown 2017a 
Metformin versus 
Glibenclamide 
Pregnancy induced 
hypertension 
108 per 1000 77 per 1000 
(40 to 148) 
RR 0.71 
(0.37 to 
1.37) 
359 (2 RCT) Moderate Risk of performance bias as study participants and care providers 
were not blinded in both trials and additionally one trial had reporting 
bias for not reporting pre-specified outcome for macrosomia. 
Han 2017 
Low carbohydrate diet versus 
high-carbohydrate diet 
Pregnancy induced 
hypertension 
133 per 1000 53 per 1000 
(17 to 163) 
RR 0.40 
(0.13 to 
1.22) 
150 (1 RCT) Very low Evidence is based on one study and imprecision as wide confidence 
interval crossing the line of no effect. Risk of performance bias as 
study participants and care providers were not blinded. 
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Intervention and 
comparison 
Assumed risk 
with comparator 
Corresponding 
risk with 
intervention* 
Relative 
effect  
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments from included reviews in quotation marks 
Comments without quotation marks from overview review 
authors 
Han 2017 
High unsaturated fat diet 
versus low unsaturated fat 
diet with matching calories 
Pregnancy induced 
hypertension 
143 per 1000 77 per 1000 
(9 to 751) 
RR 0.54 
(0.06 to 
5.26) 
27 (1 RCT) Very low Evidence is based on one study and imprecision as wide confidence 
interval crossing the line of no effect. Risk of performance bias as 
study participants and care providers were not blinded. 
Han 2017 
Ethnic specific diet versus 
standard healthy diet 
Pregnancy induced 
hypertension 
100 per 1000 33 per 1000 
(2 to 732) 
RR 0.33 
(0.02 to 
7.32) 
20 (1 RCT) Very low Evidence is based on one study and imprecision as wide confidence 
interval crossing the line of no effect. Risk of performance bias as 
study participants and care providers were not blinded and reporting 
bias as outcomes were reported in figures with no variance 
measures and no access to the study protocol. 
Brown 2017a 
Oral anti-diabetic agents 
versus placebo 
(Glibenclamide versus 
placebo) 
Severe hypertension or pre-
eclampsia 
65 per 1000 79 per 1000 
(38 to 165) 
RR 1.23 
(0.59 to 
2.56) 
375 (1 RCT) Low Evidence is based on one study and imprecision as wide confidence 
interval crossing the line of no effect. 
Han 2017 
Low-moderate GI diet versus 
moderate-high GI diet 
Severe hypertension or pre-
eclampsia 
21 per 1000 21 per 1000 
(2 to 333) 
RR 1.02 
(0.07 to 
15.86) 
95 (1 RCT) Very low "Evidence is based on one study in China. Study results may not be 
generalisable to other populations. Imprecision as wide confidence 
interval crossing the line of no effect with few events and small 
sample size". 
Brown 2017a 
Metformin versus 
Glibenclamide 
Pre-eclampsia 
41 per 1000 27 per 1000 
(4 to 155) 
RR 0.66 
(0.11 to 
3.82) 
149 (1 RCT) Very low Evidence is based on one study and imprecision as wide confidence 
interval crossing the line of no effect. Study participants and care 
providers were not blinded. 
Han 2017 
Energy restricted diet versus 
no energy-restricted diet 
Pre-eclampsia 
222 per 1000 222 per 1000 
(113 to 437) 
RR 1.00 
(0.51 to 
1.97) 
117 (1 RCT) Low "Evidence is based on one study. Imprecision as wide confidence 
interval crossing the line of no effect and small sample size". 
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Intervention and 
comparison 
Assumed risk 
with comparator 
Corresponding 
risk with 
intervention* 
Relative 
effect  
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments from included reviews in quotation marks 
Comments without quotation marks from overview review 
authors 
Han 2017 
DASH1 diet versus control 
diet with matching 
macronutrient contents 
Pre-eclampsia 
74 per 1000 74 per 1000 
(0.31 to 240) 
RR 1.00 
(0.31 to 
3.26) 
136 (3 
RCTs) 
Moderate Imprecision as wide confidence interval crossing the line of no effect. 
Han 2017 
High unsaturated fat diet 
versus low unsaturated fat 
diet with matching calories 
Pre-eclampsia 
0 per 1000 0 per 1000 
(0 to 0) 
RR not 
estimable 
27 (1 RCT) Low Evidence is based on one study. Risk of performance bias as study 
participants and care providers were not blinded. Further risk of bias 
as both groups of participants were unbalanced for BMI at baseline. 
There were no events in both groups. 
Han 2017 
Soy protein-enriched diet 
versus no soy protein diet 
Pre-eclampsia 
29 per 1000 59 per 1000 
(6 to 619) 
RR 2.00 
(0.19 to 
21.03) 
68 (1 RCT) Very low Evidence is based on one study. Imprecision as wide confidence 
interval crossing the line of no effect. Risk of performance bias, as 
participants and personnel were not blinded. 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone 
Pre-eclampsia 
129 per 1000 90 per 1000 
(51 to 157) 
RR 0.70 
(0.40 to 
1.22) 
2796 
(4 RCTs) 
Low "Evidence of inconsistency with I2 > 70% downgraded two levels". 
Brown 2017c 
Exercise versus control 
Pre-eclampsia 
43 per 1000 13 per 1000 
(0 to 308) 
RR 0.31 
(0.01 to 
7.09) 
48 (2 RCTs) Low "Wide confidence intervals crossing the line of no effect and low 
event rates with a small sample size are suggestive of imprecision 
and lack of clarity for most items related to risk of bias". 
Han 2012 
Intensive management versus 
routine care 
Pre-eclampsia 
21 per 1000 57 per 1000 
(5 to 619) 
RR 2.74 
(0.26 to 
29.07) 
83 (1 RCT) Low Evidence is based on one small study with few events and serious 
design limitations and imprecision with wide confidence intervals 
crossing the line of no effect. 
Han 2017 
Low-moderate GI diet versus 
moderate-high GI diet 
Eclampsia 
24 per 1000 8 per 1000 
(0 - 195) 
RR 0.34 
(0.01 to 
8.14) 
83 (1 RCT) Very low "Evidence is based on one study in China. Study results may not be 
generalisable to other populations. Imprecision as wide confidence 
interval crossing the line of no effect with few events and small 
sample size. 
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Intervention and 
comparison 
Assumed risk 
with comparator 
Corresponding 
risk with 
intervention* 
Relative 
effect  
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments from included reviews in quotation marks 
Comments without quotation marks from overview review 
authors 
2.0 Caesarean section 
Boulvain 2001 
Induction of labour versus 
expectant management 
310 per 1000 251 per 1000 
(161 to 391) 
RR 0.81 
(0.52 to 
1.26) 
200 (1 RCT) Low Evidence is based on one study with design limitations and 
imprecision with wide confidence intervals crossing the line of no 
effect. 
Brown 2017a 
Oral anti-diabetic agents 
versus placebo 
(Glibenclamide versus 
placebo) 
360 per 1000 371 per 1000 
(285 to 483) 
RR 1.03 
(0.79 to 
1.34) 
375 (1 RCT) Very low "Evidence is based on one study and 93% were Hispanic women, 
results may not be generalisable to other populations. There is risk of 
bias, as we did not find a published protocol and there were more 
outcomes reported in the published paper than were listed in the trial 
registration document". 
Brown 2017a 
Metformin versus 
glibenclamide 
392 per 1000 470 per 1000 
(325 to 674) 
RR 1.20 
(0.83 to 
1.72) 
554 (4 
RCTs) 
Low "Three of the four studies were open label and three of four studies 
were unclear for blinding of outcome assessors. Two studies 
reported additional outcomes that were not pre-specified, and 
heterogeneity was high". 
Brown 2017a 
Glibenclamide versus 
acarbose 
526 per 1000 500 per 1000 
(279 to 895) 
RR 0.95 
(0.53, 1.70) 
43 (1 RCT) Low "Evidence is based on one study. Method of randomisation was 
unclear, and the study was open-label". 
Han 2017 
Low-moderate GI diet versus 
moderate-high GI diet 
344 per 1000 277 per 1000 
(100 to 506) 
RR 0.66 
(0.29 to 
1.47) 
63 (1 RCT) Low "Evidence is based on one study with unclear risk of selection and 
detection bias and high risk of performance bias. Imprecision as wide 
confidence interval crossing the line of no effect and small sample 
size". 
Han 2017 
Energy restricted diet versus 
no energy restricted diet 
228 per 100 255 per 1000 
(182 to 356) 
RR 1.12 
(0.80 to 
1.56) 
420 (2 
RCTs) 
Low "Design limitations: two studies at unclear risk of selection bias; one 
study at high risk of performance bias and unclear risk of detection 
bias. Imprecision with wide confidence intervals crossing the line of 
no effect”. 
Han 2017 
DASH1 diet versus control 
diet with matching 
macronutrient contents 
837 per 1000 444 per 1000 
(310 to 636) 
RR 0.53 
(0.37 to 
0.76) 
86 (2 RCTs) Moderate Unclear risk of bias for allocation concealment and selective 
reporting in both trials and additionally in one trial risk of bias for 
blinding of participants, personnel and outcome assessors. 
Han 2017 
Low carbohydrate diet versus 
high-carbohydrate diet 
278 per 1000 358 per 1000 
(233 to 553) 
RR 1.29 
(0.84 to 
1.99) 
179 (2 
RCTs) 
Low Risk of performance bias as study participants and care providers 
were not blinded. Additionally, one study had a high risk of bias for 
selective reporting as limited data was reported and no access to 
study protocol. 
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Intervention and 
comparison 
Assumed risk 
with comparator 
Corresponding 
risk with 
intervention* 
Relative 
effect  
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments from included reviews in quotation marks 
Comments without quotation marks from overview review 
authors 
Han 2017 
High unsaturated fat diet 
versus low unsaturated fat 
diet with matching calories 
71 per 1000 77 per 1000 
(5 to 1000) 
RR 1.08 
(0.07 to 
15.50) 
179 (2 
RCTs) 
Very low Evidence is based on one study and imprecision as wide confidence 
interval crossing the line of no effect. Risk of performance bias as 
study participants and care providers were not blinded. Further risk 
of bias as both groups of participants were unbalanced for BMI at 
baseline. 
Han 2017 
Low-GI diet versus high-fibre 
moderate-GI diet 
178 per 1000 340 per 1000 
(162 to 716) 
RR 1.91 
(0.91 to 4.03 
92 (1 RCT) Very low Evidence is based on one study and imprecision as wide confidence 
interval crossing the line of no effect. Risk of detection and attrition 
bias as study outcome assessors were not blinded and incomplete 
data reported. Baseline for blood glucose concentration were 
unbalanced between groups. 
Han 2017 
Diet recommendation + diet-
related behavioural advice 
versus diet recommendation 
only 
260 per 1000 203 per 1000 
(99 to 421) 
RR 0.78 
(0.38 to 
1.62) 
99 (1 RCT) Low Evidence is based on one study and risk of performance bias as 
study participants and care providers were not blinded. 
Han 2017 
Soy protein-enriched diet 
versus no soy protein diet 
412 per 1000 412 per 1000 
(235 to 729) 
RR 1.00 
(0.57 to 
1.77) 
68 (1 RCT) Low Evidence is based on one study and risk of performance bias as 
study participants and care providers were not blinded. 
Han 2017 
Ethnic specific diet versus 
standard healthy diet 
500 per 1000 600 per 1000 
(270 to 1000) 
RR 1.20 
(0.54 to 
2.67) 
20 (1 RCT) Very low Evidence is based on one study and imprecision as wide confidence 
interval crossing the line of no effect. Risk of performance bias as 
study participants and care providers were not blinded and reporting 
bias as outcomes were reported in figures with no variance 
measures and no access to the study protocol. 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone 
380 per 1000 342 per 1000 
(296 to 399) 
RR 0.90 
(0.78 to 
1.05) 
3545 
(10 RCTs) 
Low "Evidence of selective reporting in more than half of the trials 
reporting this outcome and evidence of inconsistency with I2 = > 50% 
but < 70%. There is some suggestion of asymmetry observed in the 
funnel plot". 
Brown 2017c 
Exercise versus control 
319 per 1000 274 per 1000 
(201 to 370) 
RR 0.86 
(0.63 to 
1.16) 
316 (5 
RCTs) 
Moderate "Lack of clarity for most items related to risk of bias". 
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Intervention and 
comparison 
Assumed risk 
with comparator 
Corresponding 
risk with 
intervention* 
Relative 
effect  
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments from included reviews in quotation marks 
Comments without quotation marks from overview review 
authors 
Han 2012 
Intensive management versus 
routine care 
249 per 1000 232 per 1000 
(169 to 316) 
RR 0.93 
(0.68 to 
1.27) 
509 (3 
RCTs) 
Very low Evidence based on three RCTs with serious/very serious design 
limitations and imprecision with wide confidence intervals crossing 
the line of no effect. 
Martis 2016a 
Strict intensity2 of glycaemic 
control 
versus less strict glycaemic 
control 
244 per 1000 330 per 1000 
(203 to 532) 
RR 1.35 
(0.83 to 
2.18) 
171 (1 RCT) Very low "Evidence based on one trial that was only published in conference 
abstract form. 
Lack of detail to make a judgement about random sequence 
generation, allocation concealment, attrition bias and reporting 
bias. Open label study and no details regarding blinding of outcome 
assessors was reported. Wide confidence intervals that cross the 
line of no effect". 
3.0 Development of Type 2 diabetes 
Han 2017 
High unsaturated fat diet 
versus low unsaturated fat diet 
with matching calories 
OGTT3 for diagnosis of type 
2 diabetes at one to two 
weeks post-partum  
167 per 1000 333 per 1000 
(75 to 1000) 
RR 2.00 
(0.45 to 
8.94) 
24 (1 RCT) Very low Evidence is based on one study and imprecision as wide confidence 
interval crossing the line of no effect. Risk of performance bias as 
study participants and care providers were not blinded. Further risk 
of bias as both groups of participants were unbalanced for BMI at 
baseline. 
Han 2017 
Low-GI diet versus high fibre 
moderate-GI diet 
OGTT3 for diagnosis of type 
2 diabetes at three months 
post-partum 
80 per 1000 61 per 1000 
(9 to 401) 
RR 0.76 
(0.11 to 
5.01) 
58 (1 RCT) Very low Imprecision - evidence is based on one study and wide confidence 
interval crossing the line of no effect. Risk of detection and attrition 
bias as study outcome assessors were not blinded and incomplete 
data reported. Baseline for blood glucose concentration were 
unbalanced between groups. 
Han 2017 
High unsaturated fat diet 
versus low unsaturated fat diet 
with matching calories 
OGTT3 for diagnosis of type 
2 diabetes at four to 13 
months post-partum  
333 per 1000 333 per 1000 
(33 to 1000) 
RR 1.00 
(0.10 to 
9.61) 
6 (1 RCT) Very low Evidence is based on one study and imprecision as wide confidence 
interval crossing the line of no effect. Risk of performance bias as 
study participants and care providers were not blinded. Further risk 
of bias as both groups of participants were unbalanced for BMI at 
baseline. 
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Intervention and 
comparison 
Assumed risk 
with comparator 
Corresponding 
risk with 
intervention* 
Relative 
effect  
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments from included reviews in quotation marks 
Comments without quotation marks from overview review 
authors 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone 
Test and time frame not 
defined 
83 per 1000 81 per 1000 
(45 to 146) 
RR 0.98 
(0.54 to 
1.76) 
486 (2 
RCTs) 
Low "Evidence of risk of bias with one of the two studies not blinding 
participants/researcher and evidence of risk of bias for attrition" 
18.0. Perineal trauma 
Brown 2017a 
Oral anti-diabetic agents 
versus placebo 
(Glibenclamide versus 
placebo) 
5 per 1000 5 per 1000 
(0 to 84) 
RR 0.98 
(0.06 to 
15.62) 
375 
(1 RCT) 
 
Very low 
"Evidence is based on one study and 93% were Hispanic women, 
results may not be generalisable to other populations. We did not find 
a published protocol and there were more outcomes reported in the 
published paper than were listed in the trial registration document". 
"There are wide confidence intervals crossing the line of no effect 
and low event rates suggestive of imprecision. Event rates were low 
1/189 for anti-diabetic pharmacological therapy and 1/186 in the 
control (placebo) group". 
Brown 2017a 
Metformin versus 
glibenclamide 
6 per 1000 11 per 1000 
(1 to 81) 
RR 1.67 
(0.22 to 
12.52) 
308 (2 
RCTs) 
Low "All studies were open label and wide confidence intervals along with 
low event rates suggest imprecision. Low event rates (2/154 for 
metformin and 1/154 for glibenclamide". 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone 
498 per 1000 518 per 1000 
(463 to 588) 
RR 1.04 
(0.93 to 
1.18) 
1000 
(1 RCT) 
Moderate "Imprecision - evidence is based on a single trial" 
27.0. Return to pre-pregnancy weight 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone 
At six weeks post-partum 
173 per 1000 208 per 1000 
(116 to 376) 
RR 1.20 
(0.67 to 
2.17) 
189 (1 RCT) Low Imprecision - evidence based on one trial. Evidence of risk of bias as 
participants and researchers were not blinded and selective 
reporting. Wide confidence interval crossing the line of no effect. 
Han 2017 
Low-GI diet versus high fibre 
moderate-GI diet 
At three months post-
partum 
217 per 1000 250 per 1000 
(93 to 667) 
RR 1.15 
(0.43 to 
3.07) 
555 (1 RCT) Very low Imprecision - evidence based on one trial. Evidence of risk of bias as 
participants and researchers were not blinded and attrition bias for 
incomplete data. Wide confidence interval crossing the line of no 
effect. 
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Intervention and 
comparison 
Assumed risk 
with comparator 
Corresponding 
risk with 
intervention* 
Relative 
effect  
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments from included reviews in quotation marks 
Comments without quotation marks from overview review 
authors 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone 
At seven months post-
partum 
239 per 1000 379 per 1000 
(236 to 613) 
RR 1.59 
(0.99 to 
2.57) 
159 (1 RCT) Very low Imprecision - evidence based on one trial. Evidence of risk of bias as 
participants and researchers were not blinded and selective 
reporting evident. Wide confidence interval crossing the line of no 
effect. 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone 
At 12 months post-partum 
214 per 1000 375 per 1000 
(225 to 621) 
RR 1.75 
(1.05 to 
2.90) 
156 (1 RCT) Low "Imprecision - evidence is based on a single trial. Evidence of risk of 
bias as unclear allocation concealment and no blinding of 
participants and researchers" 
Brown 2017c 
Exercise versus control 
At follow-up (timing not 
defined) 
The maternal 
BMI (follow-up) 
kg/m2 was 0 
MD 0.11 higher 
(-1.04 lower to 1.26 
higher) 
- 254 (3 
RCTs) 
High 
 
25.0 Post-natal depression 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone 
169 per 1000 83 per 1000 
(53 to 132) 
RR 0.49 
(0.31 to 
0.78) 
573 (1 RCT Low "Imprecision - evidence is based on a single trial and evidence of risk 
of attrition bias" 
14.0. Induction of labour 
Brown 2017a 
Oral anti-diabetic agents 
versus placebo 
(Glibenclamide versus 
placebo) 
188 per 1000 222 per 1000 
(149 to 331) 
RR 1.18 
(0.79 to 
1.76) 
375 (1 RCT)  
Very low 
"Evidence is based on one study and 93% were Hispanic women, 
results may not be generalisable to other populations. We did not 
find a published protocol and there were more outcomes reported in 
the published paper than were listed in the trial registration 
document". 
Brown 2017a 
Metformin versus 
glibenclamide 
613 per 1000 496 per 1000 
(374 to 655) 
RR 0.81 
(0.61, 1.07) 
159 (1 RCT) Low "Evidence is based on one study. Method of randomisation was 
unclear, and the study was open-label". 
Han 2017 
Low-moderate GI diet versus 
moderate-high GI diet 
219 per 1000 193 per 1000 
(72 to 512) 
RR 0.88 
(0.33 to 
2.34) 
63 (1 RCT) Low "One small study at unclear risk of selection and detection bias and 
high risk of performance bias. Wide confidence interval crossing the 
line of no effect". 
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Intervention and 
comparison 
Assumed risk 
with comparator 
Corresponding 
risk with 
intervention* 
Relative 
effect  
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments from included reviews in quotation marks 
Comments without quotation marks from overview review 
authors 
Han 2017 
Energy restricted diet versus 
no energy restricted diet 
451 per 1000 460 per 1000 
(307 to 690) 
RR 1.02 
(0.68 to 
1.53) 
114 (1 RCT) Low "One small study at unclear risk of selection and detection bias and 
wide confidence interval crossing the line of no effect". 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone 
211 per 1000 252 per 1000 
(220 to 285) 
RR 1.20 
(0.99 to 
1.46) 
2699 
(4 RCTs) 
High 
 
Brown 2017c 
Exercise versus control 
400 per 1000 552 per 1000 
(284 to 1000) 
RR 1.38 
(0.71 to 
2.68) 
40 (1 RCT) Low "Imprecision - low event rates and small sample size. Lack of clarity 
for most items related to risk of bias". 
Han 2012 
Intensive management versus 
routine care 
0 per 1000 0 per 1000 
(0 to 0) 
RR 17.69 
(1.03 to 
304.09) 
83 (1 RCT) Very low Evidence is based on one small study with few events and serious 
design limitations and imprecision with wide confidence intervals 
crossing the line of no effect. 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% 
CI). 
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio; MD: mean difference 
 
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially 
different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
1 DASH is an acronym for Dietary Approaches to Stop Hypertension 
2Strict intensity of glycaemic control (stricter) defined in review as: pre-prandial 5.0 mmol/L (90 mg/dL) and one hour post-prandial 6.7 mmol/L (120 mg/dL) and less 
 strict glycaemic control (liberal) defined in review as: pre-prandial 5.8 mmol/L (104 mg/dL) and one hour post-prandial 7.8 mmol/L (140 mg/dL) 
3OGTT is an acronym for Oral Glucose Tolerance Test 
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Table 2.9: GRADE Summary of findings table - Child (as neonate, child, adult) 
Intervention and comparison  
and outcome 
Assumed risk 
with 
comparator 
Corresponding  
risk with intervention* 
Relative effect  
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality 
(GRADE)* 
Comments from included reviews in quotation marks. 
Comments without quotation marks from overview review 
authors 
5.0 Large-for-gestational age (LGA) (as defined in reviews) 
Boulvain 2001 
Induction of labour versus 
expectant management 
LGA defined as > 90th 
percentile 
230 per 1000 99 per 1000 
(51 to 200) 
RR 0.43 
(0.22 to 0.87) 
200 (1 RCT) Low Evidence is based on one small study with design limitations. 
Brown 2017a 
Oral anti-diabetic agents 
versus placebo: 
(Glibenclamide versus 
placebo) 
LGA defined > 90th 
percentile 
118 per 1000 105 per 1000 
(60 to 187) 
RR 0.89 
(0.51 to 1.58) 
375 (1 RCT) Very low "Evidence is based on one study and 93% were Hispanic women, 
results may not be generalisable to other populations. There is risk 
of bias, as we did not find a published protocol and there were 
more outcomes reported in the published paper than were listed in 
the trial registration document". 
Brown 2017a 
Metformin versus 
glibenclamide 
LGA defined as > 90th 
percentile 
193 per 1000 129 per 1000 
(46 to 354) 
RR 0.67 
(0.24 to 1.83) 
246 
(2 RCTs) 
Low "Allocation concealment was unclear in one study and one study 
was open label. Inconsistent as heterogeneity was I2= 54%, which 
could not be explained by the diagnostic criteria used". 
Brown 2017a 
Glibenclamide versus 
acarbose 
LGA defined as > 90th 
percentile 
105 per 1000 251 per 1000 
(57 to 1000) 
RR 2.38 
(0.54 to 10.46) 
43 (1 RCT) Low "Evidence is based on one small study with wide confidence 
intervals and evidence of selective reporting". 
Brown 2016a 
Myo-inositol versus placebo2 
LGA defined as > 90th 
centile 
26 per 1000 9 per 1000 
(1 to 226) 
RR 0.36 (0.02 
to 8.58) 
73 (1 RCT) Low "Evidence is based on one small study with low event rates - 0/35 
events in myo-inositol group and 1/38 events 
in the placebo group". 
Han 2017 
Low-moderate GI diet versus 
moderate-high GI diet 
LGA defined as ≥ 90th 
percentile for gestational 
age 
146 per 1000 104 per 1000 
(32 to 342) 
RR 0.71 (0.22 
to 2.34) 
89 (2 RCTs) Low "One study at unclear risk of selection bias and two studies at risk 
of performance bias and unclear risk of detection bias. Wide 
confidence intervals crossing the line of no effect and small 
sample size". 
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Intervention and comparison  
and outcome 
Assumed risk 
with 
comparator 
Corresponding  
risk with intervention* 
Relative effect  
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality 
(GRADE)* 
Comments from included reviews in quotation marks. 
Comments without quotation marks from overview review 
authors 
Han 2017 
Energy restricted diet versus 
no energy-restricted diet 
LGA defined as ≥ 90th 
percentile for gestational 
age 
246 per 1000 288 per 1000 
(160 to 522) 
RR 1.17 (0.65 
to 2.12) 
123 (1 RCT) Low "One study at unclear risk of selection and detection bias and wide 
confidence interval crossing the line of no effect and small sample 
size". 
Han 2017 
Low carbohydrate diet versus 
high-carbohydrate diet 
LGA defined as ≥ 90th 
percentile for gestational 
age 
80 per 1000 41 per 1000 
(10 to 156) 
RR 0.51 (0.13 
to 1.95) 
149 (1 RCT) Very low Imprecision - evidence is based on one study and wide confidence 
interval crossing the line of no effect. Risk of performance bias as 
participants and researchers were not blinded. 
Han 2017 
High unsaturated fat diet 
versus low unsaturated fat diet 
with matching calories 
LGA defined as ≥ 90th 
percentile for gestational 
age 
571 per 1000 309 per 1000 
(120 to 783) 
RR 0.54 (0.21 
to 1.37) 
27 (1 RCT) Very low Imprecision - evidence is based on one study and wide confidence 
interval crossing the line of no effect. Risk of performance bias as 
participants and researchers were not blinded. Baseline for BMI 
were unbalanced between groups. 
Han 2017 
Low-GI diet versus high-fibre 
moderate-GI diet 
LGA defined as ≥ 90th 
percentile for gestational 
age 
44 per 1000 128 per 1000 
(27 to 600) 
RR 2.87 (0.61 
to 13.50) 
92 (1 RCT) Very low Imprecision - evidence is based on one study and wide confidence 
interval crossing the line of no effect. Risk of detection bias as 
outcome assessors were not blinded. Incomplete data reported 
(attrition bias) and blood glucose concentration unbalanced at 
baseline. 
Han 2017 
Diet recommendation + diet-
related behavioural advice 
versus diet recommendation 
only 
LGA defined as ≥ 90th 
percentile for gestational 
age 
140 per 1000 102 per 1000 
(35 to 300) 
RR 0.73 (0.25 
to 2.14) 
99 (1 RCT) Very low Imprecision - evidence is based on one study and wide confidence 
interval crossing the line of no effect. Risk of performance bias as 
participants and personnel were not blinded. 
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Intervention and comparison  
and outcome 
Assumed risk 
with 
comparator 
Corresponding  
risk with intervention* 
Relative effect  
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality 
(GRADE)* 
Comments from included reviews in quotation marks. 
Comments without quotation marks from overview review 
authors 
Han 2017 
Ethnic specific diet versus 
standard healthy diet 
LGA defined as ≥ 90th 
percentile for gestational 
age 
300 per 1000 42 per 1000 
(3 to 735) 
RR 0.14 (0.01 
to 2.45) 
20 (1 RCT) Very low Imprecision - evidence is based on one study and wide confidence 
interval crossing the line of no effect. Risk of performance bias as 
participants and personnel were not blinded and selective 
reporting (reporting bias). Low event rates, as there were no 
events in the intervention group and three events in the control 
group. 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone 
LGA not defined 
189 per 1000 113 per 1000 
(95 to 134) 
RR 0.60 (0.50 
to 0.71) 
2994 
(6 RCTs) 
Moderate "Several included studies had high risk of bias for lack of blinding, 
incomplete outcome data and selective reporting. Allocation 
concealment was in unclear in two of the six studies". 
Han 2012 
Intensive management versus 
routine care 
LGA defined as ≥ 90th 
percentile for gestational 
age 
171 per 1000 63 per 1000 
(34 to 113) 
RR 0.37 (0.20 
to 0.66) 
438 
(3 RCTs) 
Low Evidence based on three studies with serious/very serious design 
limitations. 
4.0 Perinatal mortality (fetal and neonatal death) and later infant mortality 
Boulvain 2001 
Induction of labour versus 
expectant management 
Perinatal death 
0 per 1000 0 per 1000 
(0 to 0) 
RR not 
estimable 
200 (1 RCT) Very low Evidence is based on one small study with no events and design 
limitations. 
Brown 2017a 
Metformin versus 
glibenclamide 
Perinatal death 
6 per 1000 5 per 1000 
(0 to 83) 
RR 0.92 (0.06 
to 14.55) 
359 
(2 RCTs) 
Very low "Open label studies with no evidence of blinding of participants or 
researchers. Event rates were very low. One study had no event of 
perinatal death in either the metformin nor the glibenclamide 
group. The second study had one death in each group". 
Brown 2017a 
Glibenclamide versus 
acarbose 
Perinatal death 
0 per 1000 0 per 1000 
(0 to 0) 
RR not 
estimable 
43 (1 RCT) Low "Evidence based on a single small study with wide confidence 
intervals. No events were reported in either group. There is 
evidence of selective reporting". 
Han 2017 
Energy restricted diet versus 
no energy restricted diet 
Perinatal death 
0 per 1000 0 per 1000 
(0 to 0) 
RR not 
estimable 
423 
(2 RCTs) 
Low "Two studies at unclear risk of selection bias. One study at high 
risk of performance bias and unclear risk of detection bias. There 
were no events in either group and relatively small sample sizes". 
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Intervention and comparison  
and outcome 
Assumed risk 
with 
comparator 
Corresponding  
risk with intervention* 
Relative effect  
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality 
(GRADE)* 
Comments from included reviews in quotation marks. 
Comments without quotation marks from overview review 
authors 
Han 2017 
Low-carbohydrate diet versus 
high-carbohydrate diet 
Perinatal death 
0 per 1000 0 per 1000 
(0 to 0) 
RR 3.00 (0.12 
to 72.49) 
150 (1 RCT) Very low Evidence is based on one study and imprecision as wide 
confidence interval crossing the line of no effect. Risk of 
performance bias as study participants and care providers were 
not blinded. Low event rates (one event in the control group). 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone 
Perinatal death 
5 per 1000 0 per 1000 
(0 to 9) 
RR 0.09 (0.01 
to 1.70) 
1988 
(2 RCTs) 
Low "There is evidence of imprecision with wide confidence intervals 
and low events rates (5 perinatal deaths in one trail's control 
group) and one of the two trials did not blind 
participants/researchers". 
Brown 2017c 
Exercise versus control 
Perinatal death 
0 per 1000 0 per 1000 
(0 to 0) 
RR not 
estimable 
19 (1 RCT) Low Imprecision - There are no events in either group and the sample 
size is only 19 infants. 
There is a lack of clarity for most items associated with risk of 
bias". 
6.0 Death or serious morbidity composite (as defined in reviews) 
Brown 2017a 
Metformin versus 
glibenclamide 
Defined as composite of 
neonatal outcomes including 
hypoglycaemia, 
hyperbilirubinaemia, 
macrosomia, respiratory 
illness, birth injury, stillbirth 
or neonatal death 
350 per 1000 189 per 1000 
(109 to 329) 
RR 0.54 (0.31 
to 0.94) 
159 (1 RCT) Low "Evidence is based on one small study". 
Risk of performance bias as participants and personnel were not 
blinded. 
Han 2017 
Ethnic specific diet versus 
standard healthy diet 
Defined as composite of 
neonatal outcomes that 
included hypoglycaemia, 
neonatal asphyxia, 
respiratory distress 
syndrome (RDS), 
hyperbilirubinaemia and 
hypocalcaemia 
0 per 1000 0 per 1000 
(0 to 0) 
RR not 
estimable 
20 (1 RCT) Very low Imprecision - evidence is based on one study. Risk of performance 
bias as participants and personnel were not blinded and selective 
reporting (reporting bias). No events in either group. 
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Intervention and comparison  
and outcome 
Assumed risk 
with 
comparator 
Corresponding  
risk with intervention* 
Relative effect  
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality 
(GRADE)* 
Comments from included reviews in quotation marks. 
Comments without quotation marks from overview review 
authors 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone 
Defined as composite of 
death, shoulder dystocia, 
bone fracture and nerve 
palsy in one trial and still 
birth, neonatal death, 
hypoglycaemia, 
hyperbilirubinaemia, 
elevated cord-blood C-
peptide and birth trauma in 
the other trial 
193 per 1000 110 per 1000 
(41 to 299) 
Average RR 
0.57 (0.21 to 
1.55) 
1930 
(2 RCTs) 
Very low "Evidence of inconsistency with I2 > 70%. One of the two trials did 
not blind participants/researchers and evidence of imprecision with 
wide confidence intervals crossing the line of no effect". 
Brown 2017c 
Exercise versus control 
Defined as mortality and 
morbidity composite 
65 per 1000 36 per 1000 
(8 to 169) 
RR 0.56 (0.12 
to 2.61) 
169 
(2 RCTs) 
Moderate Imprecision - wide confidence intervals and low event rates. 
44.0 Neonatal hypoglycaemia (as defined in the reviews) 
Boulvain 2001 
Induction of labour versus 
expectant management 
Not defined 
0 per 1000 0 per 1000 
(0 to 0) 
not estimable 200 (1 RCT) Very low Evidence is based on one small study with no events and serious 
design limitations and imprecision with wide confidence intervals 
crossing the line of no effect. 
Brown 2017a 
Oral anti-diabetic agents 
versus placebo: 
(Glibenclamide versus 
placebo) 
Not defined 
11 per 1000 21 per 1000 
(4 to 114) 
RR 1.97 (0.36 
to 10.62) 
375 (1 RCT) Very low "Evidence is based on one study and 93% were Hispanic women, 
results may not be generalisable to other populations. There is risk 
of bias, as we did not find a published protocol and there were 
more outcomes reported in the published paper than were listed in 
the trial registration document. Event rates were low with 4/189 for 
oral antidiabetic pharmacological therapy (Glibenclamide) and 
2/186 for placebo group with wide confidence intervals crossing 
the line of no effect". 
Brown 2017a 
Metformin versus 
glibenclamide 
Defined as 
< 2.2 mmol/L (< 40mg/dL) 
48 per 1000 41 per 1000 
(20 to 84) 
RR 0.86 
(0.42 to 1.77) 
554 
(4 RCTs) 
Low "Allocation concealment was unclear in one study and one other 
study was open label. Event rates were low (< 30), 12/281 for the 
Metformin group and 13/273 for the Glibenclamide group". 
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Intervention and comparison  
and outcome 
Assumed risk 
with 
comparator 
Corresponding  
risk with intervention* 
Relative effect  
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality 
(GRADE)* 
Comments from included reviews in quotation marks. 
Comments without quotation marks from overview review 
authors 
Brown 2017a 
Glibenclamide versus 
acarbose 
Defined as 
< 2.2 mmol/L (< 40 mg/dL) 
53 per 1000 333 per 1000 
(46 to 1000) 
RR 6.33 (0.87 
to 46.32) 
43 (1 RCT) Low "There is evidence of selective reporting. Evidence based on one 
small study with wide confidence intervals. Low event rates and 
sample size with 8/24 in Glibenclamide group and 1/19 in 
acarbose group". 
Brown 2016a 
Myo-inositol versus placebo2 
Not defined 
263 per 1000 13 per 1000 
(0 to 224) 
RR 0.05 (0.00 
to 0.85) 
73 (1 RCT) Low "Evidence is based on one small study with low event rates - 0/35 
events in myo-inositol group and 10/38 events 
in the placebo group". 
Han 2017 
Energy restricted diet versus 
no energy restricted diet 
Not defined 
190 per 1000 201 per 1000 
(91 to 441) 
RR 1.06 (0.48 
to 2.32) 
408 
(2 RCTs) 
Very low "Evidence is based on two small studies at unclear risk of 
selection bias; one study at high risk of performance bias and 
unclear risk of 
detection bias. Wide confidence intervals crossing the line of no 
effect and substantial heterogeneity: I² = 75% present". 
Han 2017 
Low-carbohydrate diet versus 
high-carbohydrate diet 
Not defined 
133 per 1000 121 per 1000 
(52 to 283) 
RR 0.91 (0.39 
to 2.12) 
149 (1 RCT) Very low Imprecision - evidence is based on one study and wide confidence 
interval crossing the line of no effect. Risk of performance bias as 
participants and researchers were not blinded. 
Han 2017 
Soy protein-enriched diet 
versus no soy protein diet 
Defined as BGL < 1.7 mmol/L 
(< 30.6 mg/dL) 
29 per 1000 88 per 1000 
(10 to 806) 
RR 3.00 (0.33 
to 27.42) 
68 (1 RCT) Very low Imprecision - evidence is based on one study and wide confidence 
interval crossing the line of no effect. Risk of performance bias as 
participants and personnel were not blinded. 
Han 2017 
Ethnic specific diet versus 
standard healthy diet 
Not defined 
0 per 1000 0 per 1000 
(0 to 0) 
RR not 
estimable 
20 (1 RCT) Very low Imprecision - evidence is based on one study. Risk of performance 
bias as participants and personnel were not blinded and selective 
reporting (reporting bias). There were no neonatal hypoglycaemic 
events in either group. 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone 
Not defined 
75 per 1000 74 per 1000 
(49 to 114) 
RR 0.99 (0.65 
to 1.52) 
3000 
(6 RCTs) 
Moderate "Allocation concealment was unclear in two trials and blinding was 
not undertaken in two other trials". 
Brown 2017c 
Exercise versus control 
Not defined 
59 per 1000 118 per 1000 
(12 to 1000) 
RR 2.00 (0.20 
to 20.04) 
34 (1 RCT) Low "Imprecision - wide confidence intervals and low event rates. 
There is a lack of clarity for most items associated with risk of 
bias". 
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Intervention and comparison  
and outcome 
Assumed risk 
with 
comparator 
Corresponding  
risk with intervention* 
Relative effect  
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality 
(GRADE)* 
Comments from included reviews in quotation marks. 
Comments without quotation marks from overview review 
authors 
Han 2012 
Intensive management versus 
routine care 
Defined as: 
2 studies: < 1.7 mmol/L (< 
30.6 mg/dL) in any two 
consecutive measurements 
1 study: < 1.94 mmol/L (< 35 
mg/dL) 
66 per 1000 26 per 1000 
(4 to 167) 
RR 0.39 (0.06 
to 2.54) 
426 
(2 RCTs) 
Very low Evidence is based on two studies with few events and serious/very 
serious design limitations. Wide confidence intervals crossing the 
line of no effect and substantial heterogeneity: I² = 62% 
43.0. Adiposity - neonate 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone 
Defined as: neonatal fat 
mass (estimated from 
skinfold thickness) 
Mean Mass: 
427 g 
Mean Mass: 
37.80 g fewer 
(63.97 g fewer to 10.63 
g fewer) 
MD -37.30 g 
(63.97 to -
10.63) 
958 (1 RCT) Low "Imprecision. Evidence is based on a single trial and there was no 
blinding of participants/researchers". 
51.0 Adiposity - child 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone 
Defined as: Childhood BMI1 
> 85th percentile kg/m2 
350 per 1000 318 per 1000 
(262 to 388) 
RR 0.91 (0.75 
to 1.11) 
767 
(3 RCTs) 
Moderate "Allocation concealment and randomisation were unclear in 1/3 
trials and 1/3 trials did not blind participants/researchers" 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone 
Defined as: Childhood BMI1 z 
score 
The mean 
childhood BMI z 
score was 0.49 
lower 
The childhood BMI z 
score in the 
intervention group was 
0.08 lower (0.28 lower 
to 10.63 lower) 
MD 0.08 
(-0.28 to 0.44) 
199 (1 RCT) Very low Imprecision - evidence is based on one study and wide confidence 
interval crossing the line of no effect. Only reports on 199 children 
of the original trial of 1000 participants. 
55.0 Diabetes 
- - - - - - Either no data were reported for this outcome in any of the 
included Cochrane systematic reviews or none of the included 
studies in the review pre-specified this outcome. 
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Intervention and comparison  
and outcome 
Assumed risk 
with 
comparator 
Corresponding  
risk with intervention* 
Relative effect  
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality 
(GRADE)* 
Comments from included reviews in quotation marks. 
Comments without quotation marks from overview review 
authors 
7.0 Neurosensory disability 
- - - - - - Either no data were reported for this outcome in any of the 
included Cochrane systematic reviews or none of the included 
studies in the review pre-specified this outcome. 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention  
(and its 95% CI).  
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio; MD: mean difference 
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially 
different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
1BMI is an acronym for Body Mass Index 
24 g myo-inositol + 400 mcg folic acid orally per day and exercise and dietary advice versus placebo 400 mcg folic acid orally per day and exercise and dietary advice 
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Table 2.10: GRADE Summary of findings table - Health service use 
Intervention and comparison 
and outcome 
Assumed  
risk with 
comparator 
Corresponding 
risk with 
intervention* 
Relative 
effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments 
from overview review authors 
56.0 Number of antenatal visits or admissions 
Han 2017 
Soy protein-enriched diet 
versus no soy protein diet 
Defined as maternal 
hospitalisation  
118 per 1000 88 per 1000 
(21 to 365) 
RR 0.75 
(18 to 3.10) 
68 (1 RCT) Very low Imprecision - evidence based on one trial. Evidence of risk of bias as 
participants and researchers were not blinded. Wide confidence interval 
crossing the line of no effect. 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone.    
Not defined 
273 per 1000 289 per 1000 
(237 to 352) 
RR 1.06 
(0.87 to 
1.29) 
1000  
(1 RCT) 
Moderate Imprecision, evidence is based on a single trial. 
61.0 Length of postnatal stay (mother) 
- - - - - - Either no data were reported for this outcome in any of the included 
Cochrane systematic reviews or none of the included studies in the 
review pre-specified this outcome. 
59.0. Length of postnatal stay (baby) including NICU1 or SCBU2 
Han 2017 
Diet recommendation + diet-
related behavioural advice 
versus diet recommendation 
only. Defined as >4 days 
260 per 1000 346 per 1000 
(190 to 634) 
RR 1.33 
(0.73 to 
2.44) 
99 (1 RCT) Very low Imprecision - evidence based on one small trial. Evidence of risk of bias 
as participants and researchers were not blinded. Wide confidence 
interval crossing the line of no effect. 
61.0 Costs to families associated with the treatment 
- - - - - - Either no data were reported for this outcome in any of the included 
Cochrane systematic reviews or none of the included studies in the 
review pre-specified this outcome. 
60.0 Costs associated with the treatment 
Brown 2017b 
Lifestyle intervention versus 
usual care or diet alone 
see comment see comment see 
comment 
1000  
(1 RCT) 
Moderate One trial in this review included costs associated with the treatment for 
mild GDM versus usual care and showed costs were higher in the 
lifestyle intervention group compared to the control group which is mainly 
due to increased surveillance and increased contact with health 
professionals. However, the data was not in a suitable format for 
inclusion in a meta-analysis and therefore summarised in Table 2.20. 
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Intervention and comparison 
and outcome 
Assumed  
risk with 
comparator 
Corresponding 
risk with 
intervention* 
Relative 
effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments 
from overview review authors 
61.0 Cost of maternal care 
- - - - - - Either no data were reported for this outcome in any of the included 
Cochrane systematic reviews or none of the included studies in the 
review pre-specified this outcome. 
61.0 Cost of child (as neonate, child, adult) care 
- - - - - - Either no data were reported for this outcome in any of the included 
Cochrane systematic reviews or none of the included studies in the 
review pre-specified this outcome. 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention  
(and its 95% CI).  
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio 
 
 
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially 
different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
1NICU - Neonatal Intensive Care Unit 2SCBU - Special Care Baby Unit 
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Table 2.11: Quality assessment table – Maternal – secondary outcomes 
Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
8.0 Use of additional pharmacotherapy 
Brown 2017a 
Oral antidiabetic agents versus placebo 
(Glibenclamide versus placebo) 
Defined as Insulin 
RR 0.68 
(0.42 to 1.11) 
434 
(2 RCTs) 
Low Risk of reporting bias for selective reporting. One trial has 
been registered twice and the population was 93% 
Hispanic, results may not be generalisable. One trial is 
only a conference abstract. 
Brown 2017a 
Metformin versus glibenclamide 
Defined as Insulin 
RR 0.66 
(0.28 to 1.57) 
660 
(5 RCTs) 
Very low Risk of performance bias for not blinding participants and 
personnel in four trials. Risk of reporting bias for selective 
reporting in three trials. Substantial heterogeneity: I² = 72% 
Brown 2017a 
Glibenclamide versus acarbose 
Defined as Insulin 
RR 0.49 
(0.19 to 1.27) 
43 (1 RCT) Low Imprecision - one trial. Evidence of risk of performance 
bias for not blinding participants and researchers. 
Brown 2016a 
Myo-inositol versus placebo5 
Defined as Insulin 
average 
RR 0.37 
(0.08 to 1.73) 
157 
(2 RCTs) 
Low Wide confidence intervals and risk of reporting bias for 
selective reporting in one trial and unclear risk of bias for 
most other areas in the same trial. 
Han 2017 
Low-moderate GI diet versus moderate-high GI diet 
Not defined 
RR 0.82 
(0.39 to 1.74) 
221 
(4 RCTs) 
Low Evidence of risk of performance bias for not blinding 
participants and researchers in all trials. One trial had a 
risk of selection bias for no allocation concealment and 
one trial had risk of attrition bias for incomplete outcome 
data. 
Han 2017 
Energy restricted diet versus no energy restricted diet 
Defined as Insulin 
RR 1.05 
(0.47 to 2.34) 
117 (1 RCT) Very low Imprecision - one trial with wide confidence interval. Risk 
of reporting bias for selective reporting. The control group 
had a higher proportion of women with a history of preterm 
labour. 
Han 2017 
DASH1 diet versus control diet with matching 
macronutrient contents 
Not defined 
RR 0.28 
(0.14 to 0.53) 
86 (2 RCTs) Moderate Imprecision- small sample size 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
Han 2017 
Low carbohydrate diet versus high-carbohydrate diet 
Not defined 
RR 1.02 
(0.77 to 1.37) 
180 
(2 RCTs) 
Low Risk of performance bias for not blinding participants and 
personnel in both trials and risk of reporting bias for 
selective reporting in one trial. 
Han 2017 
High unsaturated fat diet versus low unsaturated fat 
diet with matching calories 
Not defined 
RR not estimable 111 
(2 RCTs) 
Low Risk of performance bias for not blinding participants and 
personnel. Unbalanced groups at baseline for BMI. There 
was no use of additional pharmacotherapy in either group. 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet 
Not defined 
RR 0.83 
(0.58 to 1.17) 
92 (1 RCT) Low Imprecision - one trial. Risk of detection bias for not 
blinding of outcome assessment, risk of attrition bias for 
incomplete outcome data and unbalanced groups at 
baseline for blood glucose concentration. 
Han 2017 
Diet recommendation + diet-related behavioural 
advice versus diet recommendation only  
Not defined 
RR 0.61 
(0.15 to 2.42) 
99 (1 RCT) Very low Imprecision - one trial with wide confidence interval. 
Evidence of risk of performance bias for not blinding 
participants and personnel. 
Han 2017 
Soy protein-enriched diet versus no soy protein diet 
Not defined 
RR 1.00 
(0.15 to 6.70) 
68 (1 RCT) Very low Imprecision - one trial with wide confidence interval. Risk 
of performance bias for not blinding participants and 
personnel. 
Han 2017 
High-fibre diet versus standard-fibre diet 
Not defined 
not estimable 22 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. There were no events 
in both groups. 
Han 2017 
Ethnic specific diet versus standard healthy diet 
Not defined 
RR 2.00 
(0.21 to 18.69) 
20 (1 RCT) Very low Imprecision - one trial. Risk of performance bias for not 
blinding of participants and personnel and risk of reporting 
bias for selective reporting. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
Defined as oral antidiabetic agents 
average 
RR 0.79 
(0.52 to 1.19) 
197 (1 RCT) Moderate Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel and risk of reporting 
bias for selective reporting. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
Defined as Insulin 
average 
RR 2.54 
(1.19 to 5.42) 
3254 
(9 RCTs) 
Very low Imprecision - wide confidence intervals. Risk of 
performance bias for not blinding participants and 
personnel in four trials. Reporting bias for selective 
reporting in five trials and substantial heterogeneity: I² = 
80%. 
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Brown 2017c 
Exercise versus control 
Not defined (insulin in one trial) 
RR 0.76 
(0.54 to 1.08) 
413 (7 
RCTs) 
Moderate Risk of performance bias for not blinding participants and 
personnel for three trials and mostly unclear risk of bias 
assessment for the rest of the trials. 
Han 2012 
Intensive management versus routine care 
Defined as Insulin or oral hypoglycaemic agents 
RR 1.00 
(0.30 to 3.32) 
12 (1 RCT) Very low Imprecision - one trial with wide confidence interval. Risk 
of performance bias for not blinding participants and 
personnel. 
Martis 2016a 
Strict intensity2 of glycaemic control versus less strict glycaemic control 
Defined as Insulin 
RR 1.85 
(1.14 to 3.03) 
171 (1 RCT) Very low Imprecision - one trial with wide confidence interval. Risk 
of performance bias for not blinding participants and 
personnel, risk of reporting bias for selective reporting. 
Other bias includes no sample size calculation reported, 
ITT unclear and no protocol has been identified for this 
trial. 
9.0 Maternal hypoglycaemia (as defined in the reviews) 
Brown 2017a 
Metformin versus glibenclamide  
Not defined in two trials 
Third trial defined as < 3.3 mmol/L (60 mg/dL) 
RR 0.89 
(0.36 to 2.19) 
354 (3 
RCTs) 
Low Imprecision - wide confidence interval. Risk of 
performance bias for not blinding participants and 
personnel in two trials. 
Brown 2017a 
Glibenclamide versus acarbose 
Not defined 
RR not estimable 43 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. There were no events 
for maternal hypoglycaemia in either group. 
Han 2017 
High-fibre diet versus standard-fibre diet  
Not defined 
MD -1.00 
(-2.08 to 0.08) 
22 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of performance bias for 
not blinding participants and personnel. 
(Recorded as mean numbers of events).  
Brown 2017b 
Lifestyle intervention versus usual care or diet alone  
Not defined 
RR not estimable 19 (1 RCT) Very low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel and risk of reporting 
bias for selective reporting. Unbalanced groups at baseline 
for 1-hour plasma glucose in diagnostic test. There were 
no events for maternal hypoglycaemia in either group. 
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Brown 2017c 
Exercise versus control 
Not defined 
 
 
 
 
RR not estimable 34 (1 RCT) Low Imprecision - one trial with small number. There were no 
events for maternal hypoglycaemia in either group. 
10.1 Glycaemic control: timing not defined 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet 
Timing or test not defined 
MD -0.10 mmol/L 
(-0.38 to 0.18) 
74 (1 RCT) Very low Imprecision - one trial. Risk of detection bias for not 
blinding of outcome assessment, risk of attrition bias for 
incomplete outcome data and unbalanced groups at 
baseline for blood glucose concentration. 
10.2 Glycaemic control during the treatment: pre-prandial/fasting 
Han 2017 
Energy restricted diet versus no energy restricted diet 
During not defined 
MD 0.21 mmol/L 
(-0.58 to -0.99) 
311 
(2 RCTs) 
Low Imprecision - wide confidence interval. Risk of 
performance bias for not blinding participants and 
personnel in one trial and unclear risk of bias for five out of 
seven risk of bias assessments in one trial. 
Han 2017 
High unsaturated fat diet versus low unsaturated fat diet with matching 
calories 
During defined as at 38 weeks gestation 
MD 0.50 mmol/L 
(0.30 to 0.70) 
24 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. Unbalanced groups at 
baseline for BMI. 
10.3 Glycaemic control during the treatment: post-prandial 
Han 2017 
Energy restricted diet versus no energy restricted diet 
During not defined but at one hour post-prandial 
MD -0.25 mmol/L 
(-0.68 to -0.18) 
299 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. 
Han 2017 
High unsaturated fat diet versus low unsaturated fat diet with matching 
calories 
During defined as at 38 weeks gestation 
and post-prandial time not defined 
MD 0.90 mmol/L 
(0.58 to 1.22) 
25 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. Unbalanced at 
baseline for BMI. 
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10.4 Glycaemic control during treatment: HbA1c (haemoglobin A1c or glycated haemoglobin) 
Brown 2017a 
Metformin versus glibenclamide 
During defined as third trimester 
SMD -0.12 
(-0.39 to 0.16) 
200 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. 
Han 2017 
High unsaturated fat diet versus low unsaturated fat diet with matching 
calories 
At 38 weeks gestation 
MD 0.40 % 
(0.32 to 0.48) 
25 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. Unbalanced groups at 
baseline for BMI. 
10.5 Glycaemic control during the treatment: 24 hour mean plasma glucose 
Han 2017 
Energy restricted diet versus no energy restricted diet 
During not defined 
MD 0.10 mmol/L 
(-0.82 to 1.02) 
12 (1 RCT) Low Imprecision - one trial. Unclear risk of bias for five out of 
seven risk of bias assessments. 
10.6 Glycaemic control at the end of treatment: Fasting 
Brown 2017a 
Oral antidiabetic agents versus placebo 
(Glibenclamide versus placebo) 
Blood glucose concentration taken at the last three antenatal 
visits 
MD -3.0 mg/dL 
(-5.13 to -0.87) 
375 (1 RCT) Low Imprecision - one trial with wide confidence interval. Risk 
of reporting bias for selective reporting. 
Brown 2017a 
Metformin versus glibenclamide 
Defined as blood glucose concentration 
SMD 0.19 mmol/L 
(0.02 to 0.37) 
508 
(3 RCTs) 
Low Imprecision - wide confidence intervals. Risk of 
performance bias for not blinding participants and 
personnel. 
Brown 2016a 
Myo-inositol versus placebo5 
Tested with OGGT4 
MD -0.47 mmol/L 
(-0.59 to -0.35) 
142 
(2 RCTs) 
Moderate Risk of reporting bias for selective reporting in one trial and 
unclear risk of bias in four assessments in the same trial. 
Han 2017 
Low-moderate GI diet versus moderate-high GI diet 
Defined as blood glucose concentration 
MD -0.15 mmol/L 
(-0.55 to 0.25) 
83 (1 RCT) Very low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel and risk of selection 
bias for no allocation concealment. 
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Han 2017 
Energy restricted diet versus no energy restricted diet 
Defined as blood glucose concentration 
MD -0.23 mmol/L 
(-0.44 to -0.03) 
311 
(2 RCTs) 
Low Imprecision - wide confidence intervals. Risk of 
performance bias for not blinding participants and 
personnel in one trial and unclear risk of bias for five out of 
seven risk of bias assessments in one trial. 
Han 2017 
DASH1 diet versus control diet with matching macronutrient contents 
Defined as blood glucose concentration 
MD -0.42 mmol/L 
(-0.53 to -0.32) 
66 (2 RCTs) Moderate Imprecision due to small sample size 
Han 2017 
Low carbohydrate diet versus high-carbohydrate diet 
Defined as blood glucose concentration 
MD 5.00 mg/dL (-
0.01 to 10.01) 
30 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of performance bias for 
not blinding participants and personnel. 
Han 2017 
High unsaturated fat diet versus low unsaturated fat diet with matching 
calories 
Defined as blood glucose concentration 
MD 0.18 mmol/L 
(-0.17 to 0.53) 
84 (1 RCT) Low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of performance bias for 
not blinding participants and personnel. 
Han 2017 
Diet recommendation + diet-related behavioural advice versus diet  
Defined as blood glucose concentration 
MD 0.0 mg/dL (-
4.25 to 4.25) 
99 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of performance bias for 
not blinding participants and personnel. 
Han 2017 
Soy protein-enriched diet versus no soy protein diet 
Defined as blood glucose concentration 
MD -10.60 mg/dL 
(-15.37 to -5.83) 
68 (1 RCT) Very low Imprecision - one trial with wide confidence interval. Risk 
of performance bias for not blinding participants and 
personnel. 
Brown 2017c 
Exercise versus control 
SMD -0.59 
(-1.07 to -0.11) 
363 (4 
RCTs) 
Low Heterogeneity: I² = 73% and the risk of bias assessment 
for most trials are mainly unclear. 
10.7 Glycaemic control at the end of treatment: One hour post-prandial 
Brown 2016a 
Myo-inositol versus placebo5 
Tested with OGGT4 
MD -0.90 mmol/L 
(-1.73 to -0.07) 
73 (1 RCT) Moderate Imprecision - one trial with small numbers. 
Han 2017 
Energy restricted diet versus no energy restricted diet 
Blood glucose concentration 
MD -0.51 mmol/L 
(-0.89 to -0.13) 
299 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. 
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Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
Blood glucose concentration: 
One hour post-prandial in two trials; 
Two hours post-prandial in two trials; 
One trial timing not defined 
average 
MD -27.11 mg/dL 
(-44.62 to -9.61) 
588 
(4 RCTs) 
Very low Imprecision - wide confidence intervals. Risk of 
performance bias for not blinding participants and 
personnel and risk of reporting bias for selective reporting. 
10.8 Glycaemic control at the end of treatment: Two hours post-prandial 
Brown 2017a 
Metformin versus glibenclamide 
Blood glucose concentration: after dinner where specified 
SMD 0.16 mmol/L 
and mg/dL (-0.01 
to 0.34) 
508 
(3 RCTs) 
Low Imprecision - wide confidence intervals crossing the line of 
no effect. Risk of performance bias for not blinding 
participants and personnel. 
Brown 2016a 
Myo-inositol versus placebo5 
Tested with OGTT4 
MD -0.70 mmol/L 
(-1.46 to 0.06) 
73 (1 RCT) Low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. 
Han 2017 
Low-moderate GI diet versus moderate-high GI diet 
Blood glucose concentration  
MD -0.71 mmol/L 
(-1.21 to -0.21) 
83 (1 RCT) Very low Imprecision - one trial with small numbers. Risk of 
performance bias for not blinding participants and 
personnel and risk of selection bias for no allocation 
concealment. 
Han 2017 
Low carbohydrate diet versus high-carbohydrate diet 
Blood glucose concentration after breakfast 
MD 6.00 mg/dL (-
1.47 to 13.47) 
30 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
Low carbohydrate diet versus high-carbohydrate diet 
Blood glucose concentration after lunch 
MD 3.00 mg/dL (-
2.77 to 8.77) 
30 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
Low carbohydrate diet versus high-carbohydrate diet 
Blood glucose concentration after dinner 
MD 6.00 mg/dL (-
1.47 to 13.47) 
30 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
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Han 2017 
High unsaturated fat diet versus low unsaturated fat diet with matching 
calories 
Blood glucose concentration 
MD -0.02 mmol/L 
(-0.29 to 0.25) 
84 (1 RCT) Low Imprecision - one trial with small numbers. Risk of 
performance bias for not blinding participants and 
personnel. 
10.9 Glycaemic control at the end of treatment: Post-prandial timing not defined 
Han 2017 
Diet recommendation + diet-related behavioural advice versus diet 
recommendation only 
Blood glucose concentration 
MD -9.30 mg/dL (-
15.58 to -3.02) 
99 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval. Risk of performance bias for not 
blinding participants and personnel. 
Brown 2017c 
Exercise versus control 
Blood glucose concentration 
SMD -0.85 
(-1.15, -0.55) 
344 (3 
RCTs) 
Moderate Most of the risk of bias assessments in the trials unclear 
and one trial had risk of performance bias for not blinding 
participants and personnel. 
Brown 2017c 
Exercise versus control 
OGTT4 
MD -81.60 mg/dL 
(-96.03 to -67.17) 
19 (1 RCT) Low Imprecision - one trial with small numbers. Six out of seven 
risk of bias assessments in the trial are unclear. 
10.10 Glycaemic control at the end of treatment: mean plasma glucose 
Han 2017 
Energy restricted diet versus no energy restricted diet 
in 24 hours  
MD -1.30 mmol/L 
(-2.25 to -0.35) 
12 (1 RCT) Low Imprecision - one trial with small numbers and wide 
confidence interval. Risk of bias unclear for five risk of bias 
assessments. 
Brown 2017c 
Exercise versus control 
MD 0.28 mmol/L 
(0.04 to 0.52) 
34 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval and small numbers. Risk of attrition 
bias for incomplete outcome data and unclear for the other 
risk of bias assessments. 
10.11 Glycaemic control at the end of treatment: HbA1c (haemoglobin A1c or glycated haemoglobin) 
Han 2017 
Low-moderate GI diet versus moderate-high GI diet 
MD 0.01 % 
(-0.18 to 0.20) 
83 (1 RCT) Very low Imprecision - one trial with small numbers. Risk of 
selection bias for no allocation concealment and risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
DASH1 diet versus control diet with matching macronutrient contents 
MD -0.25 % 
(-0.76 to 0.26) 
34 (1 RCT) Moderate Imprecision - one trial with small numbers. 
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Han 2017 
Diet recommendation + diet-related behavioural advice versus diet 
recommendation only 
MD -0.10 % 
(-0.28 to 0.08) 
99 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
average 
MD -0.33 
mmol/mol 
(-0.47 to -0.19) 
532 
(6 RCTs) 
Very low Imprecision - wide confidence intervals crossing the line of 
no effect. Risk of performance bias for not blinding 
participants and personnel in 3 trials and risk of reporting 
bias for selective reporting in 4 trials. Substantial 
heterogeneity: I² = 92% 
Brown 2017c 
Exercise versus control 
MD -0.43 
mmol/mol 
(-0.51 to -0.35) 
320 (2 
RCTs) 
High All risk of bias assessments unclear in one trial. 
10.12 Glycaemic control during/at the end of treatment: Fasting 
Han 2017 
Energy restricted diet versus no energy restricted diet 
MD 0.10 mmol/L 
(-0.18 to -0.38) 
117 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of reporting bias for 
selective reporting. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
average 
MD -3.10 mg/dL 
(-7.01 to 0.81) 
853 (6 
RCTs) 
Very low Imprecision - wide confidence intervals crossing the line of 
no effect. Risk of performance bias for not blinding 
participants and personnel risk of reporting bias for 
selective reporting for most trails. Substantial 
heterogeneity: I² = 92% 
10.13 Glycaemic control during/at the end of treatment: Mean plasma glucose 
Han 2017 
Energy restricted diet versus no energy restricted diet 
MD 0.10 mmol/L 
(-0.34 to -0.54) 
117 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of reporting bias for 
selective reporting. 
Han 2017 
High-fibre diet versus standard-fibre diet 
MD 0.0 mmol/L 
(-8.26 to 8.26) 
22 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
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10.14 Glycaemic control during/at the end of treatment: Mean HbA1c 
Han 2017 
Energy restricted diet versus no energy restricted diet 
MD -0.20 % 
(-0.64 to -0.24) 
117 (1 RCT) Low Imprecision - one trial. Risk of reporting bias for selective 
reporting. 
11.0 Weight gain in pregnancy 
Brown 2017a 
Oral antidiabetic agents versus placebo 
(Glibenclamide versus placebo) 
MD 0.0 kg 
(-0.96 to 0.96) 
375 (1 RCT) Low Imprecision - one trial. Risk of reporting bias for selective 
reporting. 
Brown 2017a 
Metformin versus glibenclamide 
MD -2.06 kg 
(-3.98 to -0.14) 
200 (1 RCT) Very low Imprecision - one trial with wide confidence interval. Risk 
of reporting bias for selective reporting. 
Brown 2017a 
Glibenclamide versus acarbose 
MD -0.60 kg 
(-3.13 to -1.93) 
43 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval. Risk of performance bias for not 
blinding participants and personnel. 
Brown 2016a 
Myo-inositol versus placebo5 
MD -0.50 kg 
(-3.35 to 2.25) 
69 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
reporting bias for selective reporting and unclear risk of 
bias for four other risk assessments. 
Han 2017 
Low-moderate GI diet versus moderate-high GI diet 
MD -0.47 kg 
(-2.18 to 1.24) 
83 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
selection bias for no allocation concealment and risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
Energy restricted diet versus no energy restricted diet 
MD 1.88 kg 
(-1.96 to 5.72) 
117 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of reporting bias for 
selective reporting. 
Han 2017 
DASH1 diet versus control diet with matching macronutrient contents 
MD -2.88 kg 
(-8.48 to 2.71) 
66 (2 RCTs) Moderate Imprecision - wide confidence interval crossing the line of 
no effect. 
Han 2017 
Low-carbohydrate diet versus high-carbohydrate diet 
MD -0.90 kg 
(-1.60 to -0.20) 
145 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. 
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Han 2017 
High unsaturated fat diet versus low unsaturated fat diet with matching 
calories 
MD -1.98 kg 
(-4.32 to 0.36) 
84 (1 RCT) Low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet 
MD -1.20 kg 
(-3.43 to 1.03) 
87 (1 RCT) Very low Imprecision - one trial. Risk of detection bias for not 
blinding of outcome assessment, risk of attrition bias for 
incomplete outcome data and unbalanced groups at 
baseline for blood glucose concentration. 
Han 2017 
Diet recommendation + diet-related behavioural advice versus diet 
recommendation only 
MD -0.10 kg 
(-4.91 to 4.71) 
99 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
Soy protein-enriched diet versus no soy protein diet 
MD 3.50 kg 
(-1.47 to 8.47) 
68 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
High-fibre diet versus standard-fibre diet 
MD 2.40 kg 
(-2.20 to 7.00) 
22 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
Ethnic specific diet versus standard healthy diet 
MD -2.20 kg 
(-7.24 to 2.84) 
20 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel and risk of attrition bias for incomplete outcome 
data. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
average 
MD -1.30 kg 
(-2.26 to -0.35) 
2930 
(4 RCTs) 
Moderate Substantial heterogeneity: I² = 80% 
Brown 2017c 
Exercise versus control 
MD -0.34 
(-1.25 to 0.58) 
104 (2 
RCTs) 
Low Imprecision - wide confidence intervals crossing the line of 
no effect. Risk of performance bias for not blinding 
participants and personnel in one trial and unclear risk of 
bias assessments in five out of seven for second trial. 
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Han 2012 
Intensive management versus routine care 
MD -0.63 kg 
(-3.07 to 1.81) 
426 
(2 RCTs) 
Very low Imprecision - wide confidence intervals crossing the line of 
no effect. Risk of performance bias for not blinding 
participants and personnel and risk of attrition bias for 
incomplete outcome data. 
12.0 Other measures of weight gain in pregnancy (not prespecified for this overview) 
Brown 2016a 
Myo-inositol versus placebo5 
BMI during pregnancy 
MD -1.50 kg/m2 
(-2.35 to -0.65) 
73 (1 RCT) Moderate Imprecision - one trial. 
Han 2017 
DASH1 diet versus control diet with matching macronutrient contents 
BMI at the end of the pregnancy 
MD -0.83 kg/m2 
(-3.76 to 2.11) 
66 (2 RCTs) Moderate Imprecision - wide confidence interval crossing the line of 
no effect. 
Han 2017 
Diet recommendation + diet-related behavioural advice versus diet 
recommendation only 
BMI at the end of the pregnancy 
MD -0.0 kg/m2 (-
1.75 to 1.75) 
99 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
Soy protein-enriched diet versus no soy protein diet 
BMI at the end of the pregnancy 
MD 0.60 kg/m2 (-
1.43 to 2.63) 
68 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Brown 2017c 
Exercise versus control 
Excessive weight gain in pregnancy 
RR 0.90 
(0.47, 1.72) 
79 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval. All risk of bias assessments are 
unclear. 
13.0 Adherence to the intervention 
Han 2017 
Low-carbohydrate diet versus high-carbohydrate diet 
Adherence not defined 
RR 1.09 
(0.73 to 1.62) 
30 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel and risk of reporting 
bias for selective reporting. 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet 
Assessed by a 24-hour recall when women were attending their 
dietitian appointment 
RR 0.84 
(0.64 to 1.11) 
92 (1 RCT) Very low Imprecision - one trial. Risk of detection bias no blinding of 
outcome assessment and risk of attrition bias for 
incomplete outcome data. Unbalanced groups at baseline 
for blood glucose concentration at diagnosis of GDM. 
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Han 2017 
Ethnic specific diet versus standard healthy diet 
Assessed using a 24-hour food intake recall method; women with 
an intake of more than 20% higher than prescribed received a score of 
0; those with an intake of 10% to 20% higher received a score of 1; and 
women with intake consistent with the plan or up to 10% lower received 
a score of 2. ’Good adherence’ was defined as women being scored a 1 
or 2 
RR 3.50 
(0.95 to 12.90) 
20 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval. Risk of performance bias for not 
blinding participants and personnel and risk of reporting 
bias for selective reporting. 
Brown 2017c 
Exercise versus control 
RR 1.00 
(0.83 to 1.21) 
19 (1 RCT) Low Imprecision - one trial with small numbers. Six out of seven 
risk of bias assessments are unclear. 
 
15.0 Placental abruption 
Han 2017 
DASH1 diet versus control diet with matching macronutrient contents 
RR 3.00 
(0.13 to 70.73) 
58 (1 RCT) Low Imprecision - one trial with small numbers and wide 
confidence interval. Unclear risk of selection bias, 
performance bias, detection bias and reporting bias. 
 
Han 2017 
High unsaturated fat diet versus low unsaturated fat diet with matching 
calories 
RR not estimable 27 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. There were no events 
in either group. Unbalanced groups at baseline for BMI. 
 
16.0 Postpartum haemorrhage (PPH) (as defined in the reviews) 
Han 2017 
Low-moderate GI diet versus moderate-high GI diet 
PPH not defined 
RR 1.02 
(0.15 to 6.93) 
83 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval. Risk of performance bias for not 
blinding participants and personnel and risk of selection 
bias for no allocation concealment. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
PPH not defined 
average 
RR 0.61 
(0.20 to 1.89) 
1165 
(2 RCTs) 
Low Risk of performance bias for not blinding participants and 
personnel. 
Heterogeneity: I² = 64% 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
17.0 Postpartum infection 
Han 2017 
Low-moderate GI diet versus moderate-high GI diet 
RR 0.34 
(0.01 to 8.14) 
83 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval. Risk of performance bias for not 
blinding participants and personnel and risk of selection 
bias for no allocation concealment. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
RR 0.61 
(0.34 to 1.10) 
1000 
(1 RCT) 
Moderate Imprecision - one trial. 
19.1 Breastfeeding at discharge 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
RR 1.04 
(0.99 to 1.10) 
1000 
(1 RCT) 
Moderate Imprecision - one trial. 
19.1.2 Breastfeeding at six weeks postpartum 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
RR 0.97 
(0.87 to 1.07) 
188 (1 RCT) Very low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel and risk of reporting 
bias for selective reporting. 
19.1.3 Breastfeeding at six months postpartum or longer 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
RR 1.31 
(0.99 to 1.74) 
161 (1 RCT) Very low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel and risk of reporting 
bias for selective reporting. 
20.0 Maternal mortality 
Brown 2017c 
Exercise versus control 
RR not estimable 48 (2 RCTs) Very low Risk of performance bias for not blinding participants and 
personnel and risk of attrition bias for incomplete data 
outcome in one trial and unclear risk of bias for most of the 
assessments in both trials. There were no events in either 
group. 
21.1 Sense of well-being and quality of life during treatment: Overall physical component 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
Short Form Health Survey (SF-36) 
MD 1.5 
(0.12 to 2.88) 
682 (1 RCT) Low Imprecision - one trial with wide confidence interval. 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
21.2 Sense of well-being and quality of life during treatment: Overall mental component 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
Short Form Health Survey (SF-36) 
MD 1.30 
(-0.17 to 2.77) 
682 (1 RCT) Low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. 
21.3 Sense of well-being and quality of life during treatment: Anxiety 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
Short Form Health Survey (SF-36) 
MD -0.30 
(-0.88 to 0.28) 
682 (1 RCT) Moderate Imprecision - one trial. 
21.4 Sense of well-being and quality of life at three months post-partum: Overall physical component 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
Short Form Health Survey (SF-36) 
 
MD 1.20 
(-0.19 to 2.59) 
573 (1 RCT) Low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. 
21.5 Sense of well-being and quality of life at three months post-partum: Overall mental component 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
Short Form Health Survey (SF-36) 
 
MD 0.20 
(-1.51 to 1.91) 
573 (1 RCT) Low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. 
21.6 Sense of well-being and quality of life at three months post-partum: Anxiety 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
Short Form Health Survey (SF-36) 
MD -0.20 
(-0.83 to 0.43) 
573 (1 RCT) Low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. 
22.0 Women's view of the intervention 
Brown 2017c 
Exercise versus control 
Women reported 
favourable views 
but 
MD SD not 
estimable 
40 (1 RCT) Low Imprecision - one trial with small numbers. Five out of 
seven risk of bias assessments are unclear. 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
23.1 Homeostasis Model Assessment Insulin Resistance (HOMA-IR) and (HOMA2-IR up-dated version) 
Han 2017 
DASH1 diet versus control diet with matching macronutrient contents 
Measured with HOMA-IR at the end of the intervention 
MD -1.00 % 
(-1.34 to -0.66) 
32 (1 RCT) Moderate Imprecision - one trial. 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet 
Measured with HOMA2-IR at the end of the intervention 
MD -0.10 % 
(-0.38 to 0.18) 
77 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence intervals crossing the line of no effect. Risk of 
detection bias for no blinding of outcome assessment and 
risk of attrition bias for incomplete outcome data. 
Hans 2017 
Low-GI diet versus high-fibre moderate-GI diet 
Measured with HOMA-IR at three months postpartum 
MD -0.30 % 
(-0.66 to 0.06) 
53 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence intervals crossing the line of no effect. Risk of 
detection bias for no blinding of outcome assessment and 
risk of attrition bias for incomplete outcome data. 
Han 2017 
Diet recommendation + diet-related behavioural advice versus diet 
recommendation only 
Measured with HOMA-IR at the end of the intervention 
MD -0.30 % 
(-0.77 to 0.17) 
99 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
Soy protein-enriched diet versus no soy protein diet 
Measured with HOMA-IR at the end of the intervention 
MD -1.60 % 
(-2.20 to 0.20) 
68 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
23.2 Quantitative Insulin Sensitivity Check Index (QUICKI) 
Han 2017 
Soy protein-enriched diet versus no soy protein diet 
Measured at the end of the intervention 
MD 0.0 
(-0.01 to 0.01) 
68 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence intervals crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
 
23.3 Fasting plasma insulin during the intervention 
Han 2017 
Energy restricted diet versus no energy restricted diet 
During (gestation) not defined 
MD 100.00 pM3 
(-26.02 to 226.02) 
12 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence intervals crossing the line of no effect. Risk of 
bias unclear for five risk of bias assessments. 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
Han 2017 
High unsaturated fat diet versus low unsaturated fat diet with matching 
calories 
Measured at 38 weeks gestation 
MD 4.40 mU/L 
(2.59 to 6.21) 
24 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence intervals. Risk of performance bias for not 
blinding participants and personnel. Unbalanced groups at 
baseline for BMI. 
Han 2017 
High unsaturated fat diet versus low unsaturated fat diet with matching 
calories 
Measured in 10−5 min−1 per mU/L min at 38 weeks gestation 
MD -0.08 mU/L 
min (-0.21 to 0.05) 
24 (1 RCT) Very low Imprecision - one trial with small numbers. Risk of 
performance bias for not blinding participants and 
personnel. Unbalanced groups at baseline for BMI. 
23.4 Fasting plasma insulin end of intervention 
Han 2017 
Energy restricted diet versus no energy restricted diet 
MD -20.00 pM3 
(-127.70 to 87.70) 
12 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence intervals. Risk of bias unclear for five risk of 
bias assessments. 
Han 2017 
DASH1 diet versus control diet with matching macronutrient contents 
MD -3.26 µIU/mL 
(-4.42 to -2.10) 
32 (1 RCT) Low Imprecision - one trial with small numbers and wide 
confidence interval. 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet 
MD 10.80 pmol/L 
(-22.36 to 43.96) 
70 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence intervals. Risk of detection bias for not blinding 
outcome assessment and risk of attrition bias for selective 
reporting. 
Han 2017 
Diet recommendation + diet-related behavioural advice versus diet 
recommendation only 
MD -0.50 µIU/mL 
(-2.69 to 1.69) 
99 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
Soy protein-enriched diet versus no soy protein diet 
MD -2.60 µIU/mL 
(-8.03 to 2.83) 
68 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
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CI: confidence interval; MD: mean difference; RCT: randomised controlled trial; RR: risk ratio  
 
 
*GRADE ratings of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially 
different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
1 DASH is an acronym for Dietary Approaches to Stop Hypertension 
2Strict intensity of glycaemic control (stricter) defined in review as: pre-prandial 5.0 mmol/L (90 mg/dL) and one hour post-prandial 6.7 mmol/L (120 mg/dL) and less strict glycaemic 
 control (liberal) defined in review as: pre-prandial 5.8 mmol/L (104 mg/dL) and one hour post-prandial 7.8 mmol/L (140 mg/dL) 
3pM is the same as pmol/L 
4OGTT is an acronym for Oral Glucose Tolerance Test 
54 g myo-inositol + 400 mcg folic acid orally per day and exercise and dietary advice versus placebo 400 mcg folic acid orally per day and exercise and dietary advice 
 
 
Table 2.12: Quality assessment table - Maternal long term - secondary outcomes 
Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments 
from overview review authors 
26.0 Body Mass Index (BMI) 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet 
BMI at three months 
MD -0.50 
kg/m2 
(-2.79 to 1.79) 
52 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
detection bias for not blinding of outcome assessment and 
risk of attrition bias for incomplete outcome data. Unbalanced 
groups at baseline for blood glucose concentration at 
diagnosis of GDM. 
Han 2017 
High unsaturated fat diet versus low unsaturated fat diet with 
matching calories 
BMI at five to nine months 
MD 4.10 kg/m2 
(2.34 to 5.86) 
27 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval. Risk of performance bias for not blinding 
participants and personnel. Unbalanced groups at baseline 
for BMI. 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments 
from overview review authors 
28.0 Impaired glucose tolerance 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
Test and timing not defined 
RR 0.67 
(0.12 to 3.69) 
56 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval. 
Risk of reporting bias for selective reporting. 
Han 2017 
High unsaturated fat diet versus low unsaturated fat diet with 
matching calories 
Borderline OGTT1 one to two weeks postpartum 
RR 1.50 
(0.30 to 7.43) 
24 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval. Risk of performance bias for not blinding 
participants and personnel. Unbalanced groups at baseline 
for BMI. 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet 
At three months post-partum, test not defined 
RR 1.33 
(0.44 to 4.04) 
58 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval. Risk of detection bias not blinding of 
outcome assessment and risk of attrition bias for incomplete 
outcome data. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
Fasting plasma glucose at three months post-partum 
MD -0.08 
mmol/L (-0.16 
to 0.00) 
165 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
Fasting plasma glucose at six months post-partum 
MD -0.14 
mmol/L 
(-0.22 to -0.06) 
165 (1 RCT) Low Imprecision - one trial. Risk of performance bias as no 
blinding of participants and personnel. 
Han 2017 
High unsaturated fat diet versus low unsaturated fat diet with 
matching calories 
Borderline OGTT1 four to 13 months post-partum 
RR 0.27 
(0.01 to 4.93) 
7 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval. Risk of performance bias for not blinding 
participants and personnel. Unbalanced groups at baseline 
for BMI. 
29.0 Cardiovascular health (as defined in the reviews including blood pressure, hypertension, cardiovascular disease, metabolic syndrome) 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
Defined as metabolic syndrome at 4.5 to 10 years follow-up 
RR 0.93 
(0.71 to 1.22) 
430 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. 
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CI: confidence interval; MD: mean difference; RCT: randomised controlled trial; RR: risk ratio 
 
 
*GRADE ratings of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially 
different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
1OGTT is an acronym for Oral Glucose Tolerance Test 
Table 2.13: Quality assessment table - Fetal/neonatal - secondary outcomes 
Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
31.0 Stillbirth 
Brown 2017a 
Oral antidiabetic agents versus placebo 
(Glibenclamide versus placebo) 
RR 0.49 
(0.05 to 5.38) 
375 (1 RCT) Very low Imprecision- one trial with wide confidence interval 
crossing the line of no effect. Low event rates. Risk of 
reporting bias for selective reporting. The population was 
93% Hispanic, results may not be generalisable. No 
published protocol was found. 
Brown 2017a 
Metformin versus glibenclamide 
RR 0.92 
(0.06 to 14.55) 
200 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of performance bias 
for not blinding participants and personnel and risk of 
reporting bias for selective reporting. 
Han 2017 
Energy restricted diet versus no energy restricted diet 
RR not 
estimable 
423 (2 RCTs) Low Risk of performance bias for not blinding participants and 
personnel and risk of reporting bias for selective 
reporting. There were no events in either group. 
Han 2017 
Low-carbohydrate diet versus high-carbohydrate diet 
RR 3.00 
(0.12 to 72.49) 
150 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of performance bias 
for not blinding participants and personnel. 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
RR 0.15 
(0.01 to 2.86) 
2355 
(4 RCTs) 
Very low Imprecision - wide confidence intervals crossing the line 
of no effect. Risk of performance bias for not blinding 
participants and personnel in one trial and risk of 
reporting bias for selective reporting in two trials. 
Brown 2017c 
Exercise versus control 
RR not 
estimable 
29 (1 RCT) Very low Imprecision - one trial with low numbers. Risk of 
performance bias as no blinding of participants and risk 
of attrition bias for incomplete outcome data. There were 
no events in either group. 
32.0 Neonatal death 
Brown 2017a 
Oral antidiabetic agents versus placebo 
(Glibenclamide versus placebo) 
RR not 
estimable 
375 (1 RCT) Very low Imprecision - one trial. The population was 93% 
Hispanic, results may not be generalisable. Risk of 
reporting bias for selective reporting, no published 
protocol was found. The trial appears to be registered 
twice with the same outcomes. There were no events of 
neonatal deaths reported in either group. 
Han 2017 
Energy restricted diet versus no energy restricted diet 
RR not 
estimable 
423 (2 RCTs) Low Risk of performance bias for not blinding participants and 
personnel. There were no events of stillbirths reported in 
either group. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
RR 0.73 
(0.22 to 2.42) 
3055 
(5 RCTs) 
Low Imprecision - wide confidence intervals crossing the line 
of no effect. Risk of performance bias for not blinding 
participants and personnel in one trial, risk of reporting 
bias for selective reporting in four trials and risk of 
attrition bias for incomplete outcome data in one trial. 
33.0 Macrosomia (> 4000 g; or as defined in the reviews) 
Boulvain 2001 
Induction of labour versus expectant management       > 4000 g 
RR 0.56 
(0.32 to 0.98) 
200 (1 RCT) Very low Imprecision - one trial. Unclear risk of bias for all 
assessments. 
Brown 2017a 
Glibenclamide versus placebo                                       ≥ 4000 g 
RR 0.71 
(0.36 to 1.41) 
375 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of reporting bias for 
selective reporting, no published protocol was found. The 
population was 93% Hispanic, results may not be 
generalisable. The trial appears to be registered twice 
with the same outcomes. 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
Brown 2017a 
Metformin versus glibenclamide 
                                        ≥ 4000 g (one trial) ≥ 3700 g (one trial) 
RR 0.72 
(0.23 to 2.21) 
308 (2 RCTs) Low Imprecision - wide confidence intervals crossing the line 
of no effect. Risk of performance bias for not blinding 
participants and personnel. 
Brown 2017a 
Glibenclamide versus acarbose                                    > 4000 g 
RR 7.20 
(0.41 to 
125.97) 
43 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval. Risk of performance bias for not 
blinding participants and personnel. 
Han 2017 
Low-moderate GI diet versus moderate-high GI diet    > 4000 g 
RR 0.59 
(0.16 to 2.26) 
172 (3 RCTs) Very low Imprecision - one trial with wide confidence intervals 
crossing the line of no effect. Risk of performance bias 
for not blinding participants and personnel and risk of 
selection bias for no allocation concealment. 
Han 2017 
Energy restricted diet versus no energy restricted diet > 4000 g 
RR 0.99 
(0.64 to 1.53) 
421 (2 RCTs) Very low Wide confidence interval crossing the line of no effect. 
Risk of performance bias for not blinding participants and 
personnel and risk of reporting bias for selective 
reporting. 
Han 2017 
Energy restricted diet versus no energy restricted diet > 4500 g 
RR 1.01 
(0.33 to 3.05) 
299 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of performance bias 
for not blinding participants and personnel. 
Han 2017 
DASH1 diet versus control diet with matching macronutrient  
contents                                                                        ≥ 4000 g 
RR 0.10 
(0.01 to 0.73) 
52 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Unclear 
risk of bias for four assessments. 
Han 2017 
Low-carbohydrate diet versus high-carbohydrate diet  > 4000 g 
RR 0.20 
(0.02 to 1.69) 
179 (2 RCTs) Low Imprecision - one trial with wide confidence intervals 
crossing the line of no effect. Risk of performance bias 
for not blinding participants and personnel and risk of 
reporting bias for selective reporting. 
Han 2017 
High unsaturated fat diet versus low unsaturated fat diet with matching 
calories                                                                          > 4000 g 
RR 0.53 
(0.18 to 1.56) 
111 (2 RCTs) Low Imprecision - one trial with wide confidence intervals 
crossing the line of no effect. Risk of performance bias 
for no blinding of participants and personnel. Unbalanced 
groups at baseline for BMI. 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet            > 4000 g 
RR 0.32 
(0.03 to 2.96) 
92 (1 RCT) Very low Imprecision - one trial wide confidence intervals. Risk of 
detection bias for not blinding outcome assessment and 
risk of attrition bias for incomplete data. 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
Han 2017 
Soy protein-enriched diet versus no soy protein diet    > 4000 g 
RR 0.60 
(0.16 to 2.31) 
68 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
Ethnic specific diet versus standard healthy diet          > 4000 g 
RR 0.20 
(0.01 to 3.70) 
20 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel and risk of attrition bias for incomplete data. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
                                                                        > 4 kg (five trials) 
                                                                        ≥ 4 kg (two trials) 
average 
RR 0.64 
(0.48 to 0.87) 
3422 
(7 RCTs) 
Low Risk of performance bias for not blinding participants and 
personnel in three trials. Risk of reporting bias for 
selective reporting in three trials. Risk of attrition bias for 
incomplete data in one trial. 
Heterogeneity: I2= 65% 
Brown 2017c 
Exercise versus control                                             not defined 
RR 0.69 
(0.35 to 1.35) 
296 (5 RCTs) Moderate Risk of performance bias for not blinding participants and 
personnel in two trials and risk of attrition bias for 
incomplete data in two trials. 
Han 2012 
Intensive management versus routine care                  ≥ 4000 g 
RR 0.38 
(0.19 to 0.74) 
438 (3 trials) Moderate Risk of performance bias for not blinding participants and 
personnel and risk of attrition bias for incomplete data. 
Martis 2016a 
Strict intensity of glycaemic control2 versus less strict glycaemic control                                                                            
> 4000 g 
RR 1.35 
(0.31 to 5.85) 
171 (1 RCT) Very low Imprecision - one trial with wide confidence intervals. 
Risk of performance bias for not blinding participants and 
personnel and risk of reporting bias for selective 
reporting. 
34.0 Small-for-gestational age (SGA) (as defined in the reviews) 
Brown 2017a 
Oral antidiabetic agents versus placebo 
(Glibenclamide versus placebo) 
not defined 
RR 1.11 
(0.58 to 2.10) 
375 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of reporting bias for 
selective reporting, no published protocol was found. The 
population was 93% Hispanic, results may not be 
generalisable. The trial appears to be registered twice 
with the same outcomes. 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
Brown 2017a 
Glibenclamide versus acarbose 
not defined 
RR not 
estimable 
43 (1 RCT) Low Imprecision - one trial with small numbers. Risk of 
performance bias for not blinding participants and 
personnel. There were no events reported in either 
group. 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet 
not defined 
RR 5.16 
(0.26 to 
103.27) 
63 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
Low-carbohydrate diet versus high-carbohydrate diet 
not defined 
RR 0.68 
(0.29 to 1.56) 
149 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet 
not defined 
RR 1.20 
(0.34 to 4.18) 
92 (1 RCT) Very low Imprecision - one trial with wide confidence intervals 
crossing the line of no effect. Risk of detection bias for no 
blinding of outcome assessments and risk of attrition bias 
for incomplete outcome data. 
Han 2017 
Ethnic specific diet versus standard healthy diet 
not defined 
RR 0.33 
(0.02 to 7.32) 
20 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of performance bias 
for not blinding participants and personnel and risk of 
attrition bias for incomplete data. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
not defined 
RR 0.98 
(0.73 to 1.32) 
2324 
(4 RCTs) 
Moderate Risk of performance bias for not blinding participants and 
personnel and risk of reporting bias for selective 
reporting. 
 
Han 2012 
Intensive management versus routine care 
not defined 
RR 1.53 
(0.81 to 2.88) 
509 (3 RCTs) Very low Imprecision - one trial with wide confidence intervals 
crossing the line of no effect. Risk of performance bias 
for not blinding participants and personnel and risk of 
attrition bias for incomplete data. 
Martis 2016a 
Strict intensity of glycaemic control2 versus less strict glycaemic control 
not defined 
RR 1.12 
(0.48 to 2.63) 
171 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of performance bias 
for not blinding participants and personnel and risk of 
reporting bias for selective reporting. 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
35.1 Birth trauma not defined 
Brown 2017a 
Metformin versus glibenclamide 
RR not 
estimable 
159 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. There were no 
events either group. 
Brown 2017a 
Glibenclamide versus acarbose 
RR not 
estimable 
43 (1 RCT) Low Imprecision - one trial with small numbers. Risk of 
performance bias for not blinding participants and 
personnel. There were no events reported in either 
group. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
RR 0.48 
(0.12 to 1.90) 
1930 
(3 RCTs) 
Low Risk of performance bias for not blinding participants and 
personnel in one trial. Risk of reporting bias for selective 
reporting in two trials and risk of attrition bias for 
incomplete outcome data. 
35.2 Birth trauma: Shoulder dystocia 
Boulvain 2001 
Induction of labour versus expectant management 
Induction at 38 completed weeks for all women 
RR 0.14 
(0.01 to 2.73) 
200 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Rik of bias for all 
assessments unclear, as not reported in the review. 
There were three babies with shoulder dystocia in the 
expectant management group and none in the 
intervention group. 
Brown 2017a 
Oral antidiabetic agents versus placebo 
(Glibenclamide versus placebo) 
RR 0.33 
(0.01 to 8.00) 
375 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of reporting bias for 
selective reporting, no published protocol was found. The 
population was 93% Hispanic, results may not be 
generalisable. The trial appears to be registered twice 
with the same outcomes. 
Brown 2017a 
Metformin versus glibenclamide 
RR 0.99 
(0.14 to 6.89) 
195 (2 RCTs) Low Imprecision - wide confidence intervals crossing the line 
of no effect. Risk of performance bias for not blinding 
participants and personnel in one trial and risk of 
reporting bias for selective reporting in one trial. 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
Han 2017 
Energy restricted diet versus no energy restricted diet 
RR 0.12 
(0.01 to 2.26) 
418 (2 RCTs) Very low Imprecision - wide confidence intervals crossing the line 
of no effect. Risk of performance bias for not blinding 
participants and personnel and risk of reporting bias for 
selective reporting. 
Han 2012 
Intensive management versus routine care 
RR 0.69 
(0.06 to 7.27) 
83 (1 RCT) Very low Imprecision - one trial with wide confidence intervals 
crossing the line of no effect. Risk of performance bias 
for not blinding participants and personnel, risk of attrition 
bias for incomplete data and risk of reporting bias for 
selective reporting. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
RR 0.38 
(0.21 to 0.66) 
2894 
(5 RCTs) 
Low Risk of attrition bias for incomplete outcome data in one 
trial, risk of performance bias for not blinding participants 
and personnel in two trials and risk of reporting bias for 
selective reporting in two trials 
35.3 Birth trauma: Bone fracture 
Boulvain 2001 
Induction of labour versus expectant management 
RR not 
estimable 
200 (1 RCT) Very low Imprecision - one trial. Risk of bias for all assessments 
unclear, as not reported in the review. There were no 
events reported in either group. 
Brown 2017a 
Oral antidiabetic agents versus placebo 
(Glibenclamide versus placebo) 
RR 0.74 
(0.17 to 3.25) 
375 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of reporting bias for 
selective reporting, no published protocol was found. The 
population was 93% Hispanic, results may not be 
generalisable. The trial appears to be registered twice 
with the same outcomes. 
Han 2017 
Energy restricted diet versus no energy restricted diet 
RR not 
estimable 
299 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. There were no 
events reported in either group. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
RR 0.35 
(0.01 to 8.45) 
1730 
(2 RCTs) 
Low Imprecision - wide confidence intervals crossing the line 
of no effect. Risk of attrition bias for incomplete outcome 
data in one trial and risk of reporting bias for selective 
reporting in one trial. Event rates were very low with only 
one bone fracture reported in the control group. 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
35.4 Birth trauma: Nerve palsy (brachial plexus) 
Boulvain 2001 
Induction of labour versus expectant management 
RR not 
estimable 
200 (1 RCT) Very low Imprecision - one trial. Risk of bias for all assessments 
unclear, as not reported in the review. There were no 
events reported in either group. 
Brown 2017a 
Oral antidiabetic agents versus placebo 
(Glibenclamide versus placebo) 
RR 0.33 
(0.01 to 8.00) 
375 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of reporting bias for 
selective reporting, no published protocol was found. The 
population was 93% Hispanic, results may not be 
generalisable. The trial appears to be registered twice 
with the same outcomes. 
Han 2017 
Energy restricted diet versus no energy restricted diet 
RR not 
estimable 
299 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. There were no 
events reported in either group. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
RR 0.15 
(0.01 to 2.86) 
1030 (1 RCT) Low Imprecision - one trial with wide confidence intervals 
crossing the line of no effect. Three babies reported with 
nerve palsy in the control group. 
36.0 Gestational age at birth 
Brown 2017a 
Oral antidiabetic agents versus placebo 
(Glibenclamide versus placebo) 
MD 0.0 weeks 
(-0.32 to 0.32) 
375 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of reporting bias for 
selective reporting, no published protocol was found. The 
population was 93% Hispanic, results may not be 
generalisable. The trial appears to be registered twice 
with the same outcomes. 
Brown 2017a 
Metformin versus glibenclamide 
MD 0.03 weeks 
(-0.22 to 0.28) 
508 (3 RCTs) Very low Imprecision - wide confidence intervals crossing the line 
of no effect. Risk of performance bias for not blinding 
participants and personnel and risk of reporting bias for 
selective reporting. 
Brown 2017a 
Glibenclamide versus acarbose 
MD -0.10 
weeks 
(-0.82 to 0.62) 
43 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
Brown 2016a 
Myo-inositol3 versus placebo 
MD 2.1 weeks 
(1.27 to 2.93) 
73 (1 RCT) Moderate Imprecision - one trial. 
Han 2017 
Low-moderate GI diet versus moderate-high GI diet 
MD 0.30 weeks 
(-0.30 to 0.90) 
62 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence intervals crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
Energy restricted diet versus no energy restricted diet 
MD -0.16 
weeks 
(-0.67 to 0.36) 
423 (2 RCTs) Moderate Risk of performance bias for not blinding participants and 
personnel and risk of reporting bias for selective 
reporting. 
Han 2017 
DASH1 diet versus control diet with matching macronutrient contents 
MD 0.20 weeks 
(-0.45 to 0.85) 
52 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Unclear 
risk of bias for four other risk of bias assessments. 
Han 2017 
Low-carbohydrate diet versus high-carbohydrate diet 
MD 0.10 weeks 
(-0.42 to 0.62) 
180 (2 RCTs) Low Imprecision - wide confidence intervals crossing the line 
of no effect. Risk of performance bias for not blinding 
participants and personnel and risk of reporting bias for 
selective reporting. 
Han 2017 
High unsaturated fat diet versus low unsaturated fat diet with matching 
calories 
MD 0.25 weeks 
(-0.51 to 1.01) 
111 (2 RCTs) Low Imprecision - wide confidence intervals crossing the line 
of no effect. Risk of performance bias for not blinding 
participants and personnel. Unbalanced groups at 
baseline for BMI. 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet 
MD -0.10 
(-0.39 to 0.19) 
92 (1 RCT) Low Imprecision - one trial with small numbers. Risk of 
detection bias for not blinding outcome assessments and 
risk of attrition bias for incomplete outcome data. 
Han 2017 
Soy protein-enriched diet versus no soy protein diet 
MD 0.40 weeks 
(-0.23 to 1.03) 
68 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
High-fibre diet versus standard-fibre diet 
MD 0.0 weeks 
(-1.30 to 1.30) 
22 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
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(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
Han 2017 
Ethnic specific diet versus standard healthy diet 
MD -0.40 
weeks 
(-1.15 to 0.35) 
20 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel and risk of attrition bias for incomplete data. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
MD 0.04 weeks 
(-0.13 to 0.20) 
2057 
(5 RCTs) 
Low Imprecision - wide confidence intervals crossing the line 
of no effect. Risk of performance bias for not blinding 
participants and personnel in one trial, risk of attrition 
bias for incomplete data in one trial and risk of reporting 
bias for selective reporting in four trials. 
Brown 2017c 
Exercise versus control 
MD -0.01 
weeks 
(-0.40 to 0.38) 
167 (4 RCTs) Low Risk of performance bias for not blinding participants and 
personnel in two trials and risk of attrition bias for 
incomplete data in two trials. Unclear risk of bias 
assessment in most trials for all other risk of bias 
assessments. 
Han 2012 
Intensive management versus routine care 
MD -0.18 
weeks 
(-0.43 to 0.07) 
521 (4 RCTs) Very low Imprecision - one trial with wide confidence intervals 
crossing the line of no effect. Risk of performance bias 
for not blinding participants and personnel and risk of 
attrition bias for incomplete data. 
Martis 2016a 
Strict intensity of glycaemic control2 versus less strict glycaemic control 
MD -0.30 
weeks 
(-0.73 to 0.13) 
171 (1 RCT) Very low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel and risk of reporting 
bias for selective reporting. 
37.0 Preterm birth (< 37 weeks’ gestation and < 32 weeks’ gestation) 
Brown 2017a 
Metformin versus glibenclamide 
< 37 weeks gestation 
RR 1.59 
(0.59 to 4.29) 
508 (3 RCTs) Very low Imprecision - wide confidence intervals. Risk of 
performance bias for not blinding participants and 
personnel and risk of reporting bias for selective 
reporting. 
Brown 2017a 
Glibenclamide versus acarbose 
< 37 weeks gestation 
RR not 
estimable 
43 (1 RCT) Low Imprecision - one trial with small numbers. Risk of 
performance bias for not blinding participants and 
personnel. There were no events reported in either 
group. 
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(95% CI) 
№ of 
participants 
(studies) 
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Quality  
(GRADE)* 
Comments  
from overview review authors 
Brown 2016a 
Myo-inositol versus placebo3 
< 37 weeks gestation 
RR 1.00 
(0.09 to 10.56) 
84 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
reporting bias for selective reporting and four other risk of 
bias assessments unclear. 
Han 2017 
Low-moderate GI diet versus moderate-high GI diet 
< 37 weeks gestation 
RR 0.64 
(0.22 to 1.85) 
146 (2 RCTs) Low Risk of performance bias for not blinding participants and 
personnel and risk of selection bias for no allocation 
concealment. 
Han 2017 
High unsaturated fat diet versus low unsaturated fat diet with matching 
calories    < 37 weeks gestation 
RR not 
estimable 
84 (1 RCT) Low Imprecision - one trial with small numbers. Risk of 
performance bias for not blinding participants and 
personnel. There were no events reported in either group 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet 
< 37 weeks gestation 
RR 0.96 
(0.14 to 6.53) 
96 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
detection bias for not blinding outcome assessments and 
risk of attrition bias for incomplete data. 
Han 2017 
Diet recommendation + diet-related behavioural advice versus diet 
recommendation only 
< 37 weeks gestation 
RR 0.51 
(0.10 to 2.66) 
99 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
Soy protein-enriched diet versus no soy protein diet 
< 37 weeks gestation 
RR 2.00 
(0.19 to 21.03) 
68 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
< 37 weeks gestation 
RR 0.71 
(0.53 to 0.96) 
1797 
(3 RCTs) 
Moderate Risk of performance bias for not blinding participants and 
personnel in two trials, risk of attrition bias for incomplete 
data in one trial and risk of reporting bias for selective 
reporting in one trial. 
Brown 2017c 
Exercise versus control 
Weeks not defined 
RR 0.95 
(0.39 to 2.36) 
302 (5 RCTs) Low Wide confidence interval crossing the line of no effect. 
Risk of performance bias for not blinding participants and 
personnel in two trials and risk of attrition bias for 
incomplete data in one trial. 
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(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
Han 2012 
Intensive management versus routine care 
< 37 weeks gestation 
RR 1.00 
(0.26 to 3.82) 
138 (2 RCTs) Low Imprecision - wide confidence intervals crossing the line 
of now effect. Risk of performance bias for not blinding 
participants and personnel. 
 
 
 
38.0 Five-minute Apgar < 7 
Brown 2017a 
Metformin versus glibenclamide 
RR not 
estimable 
149 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel. There were no 
events reported in either group. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
RR 0.56 
(0.21 to 1.52) 
1030 (1 RCT) Moderate Imprecision - one trail with low events rates. 
Brown 2017c 
Exercise versus control 
RR 0.33 
(0.01 to 7.65) 
343 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of attrition bias for 
incomplete outcome data and all other risk of bias 
assessments are unclear. 
39.0 Birthweight and z score (included reviews did not report z-scores) 
Brown 2017a 
Oral antidiabetic agents versus placebo 
(Glibenclamide versus placebo) 
MD -33.0 g 
(-134.53 to 
68.53) 
375 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of reporting bias for 
selective reporting, no published protocol was found. The 
population was 93% Hispanic, results may not be 
generalisable. The trial appears to be registered twice 
with the same outcomes. 
Brown 2017a 
Metformin versus glibenclamide 
MD -209.13 g 
(-314.53 to 
103.73) 
349 (2 RCTs) Very low Imprecision - wide confidence interval crossing the line of 
no effect. Risk of performance bias for not blinding of 
participants and personnel and risk of reporting bias for 
selective reporting. 
Brown 2017a 
Glibenclamide versus acarbose 
MD 153.0 g 
(-123.52 to 
429.52) 
43 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
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(95% CI) 
№ of 
participants 
(studies) 
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Quality  
(GRADE)* 
Comments  
from overview review authors 
Brown 2016a 
Myo-inositol versus placebo3 
MD 16.00 g 
(-209.72 to 
241.72) 
73 (1 RCT) Low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. 
Han 2017 
Low-moderate GI diet versus moderate-high GI diet 
MD -55.98 g 
(-201.90 to 
89.95) 
145 (2 RCTs) Very low Imprecision - wide confidence intervals crossing the line 
of no effect. Risk of performance bias for not blinding 
participants and personnel and risk of selection bias for 
no allocation concealment. 
Han 2017 
Energy restricted diet versus no energy restricted diet 
MD -107.00 g 
(-240.32 to 
26.32) 
299 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of performance bias 
for not blinding participants and personnel. 
Han 2017 
DASH1 diet versus control diet with matching macronutrient contents 
MD -.581.27 g 
(-790.32 to -
372.22) 
86 (2 RCT) Moderate Imprecision - wide confidence intervals. Unclear risk of 
bias for four assessments. 
Han 2017 
Low-carbohydrate diet versus high-carbohydrate diet 
MD 22.00 g 
(-241.06 to 
285.06) 
30 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence intervals crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel and risk of reporting bias for selective 
reporting. 
Han 2017 
High unsaturated fat diet versus low unsaturated fat diet with matching 
calories 
MD -138.19 g 
(-292.59 to 
16.21) 
111 (2 RCTs) Low Imprecision - wide confidence intervals crossing the line 
of no effect. Risk of performance bias for not blinding 
participants and personnel. Unbalanced groups at 
baseline for BMI. 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet 
MD 0.0 g 
(-277.18 to 
277.18) 
92 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
detection bias for not blinding outcome assessments and 
risk of attrition bias for incomplete outcome data. 
Han 2017 
Soy protein-enriched diet versus no soy protein diet 
MD -142.60 g 
(-360.40 to 
75.20) 
68 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
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from overview review authors 
Han 2017 
High-fibre diet versus standard-fibre diet 
MD -94.00 g 
(-446.71 to 
258.71) 
22 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
Ethnic specific diet versus standard healthy diet 
MD -370.00 g 
(-928.87 to 
188.87) 
20 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel and risk of attrition bias for incomplete data. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
MD -109.64 g 
(-149.77 to -
69.51) 
3074 
(6 RCT) 
Moderate Risk of performance bias for not blinding participants and 
personnel in two trials, risk of attrition bias for incomplete 
data in one trial and risk of reporting bias for selective 
reporting in four trials. 
Brown 2017c 
Exercise versus control 
MD -61.50 g 
(-195.21 to 
72.20) 
192 (6 RCTs) Very low Imprecision - with wide confidence intervals crossing the 
line of no effect. Risk of performance bias for not blinding 
participants and personnel in two trials and risk of 
attrition bias for incomplete data in one trial. For most 
trials unclear risk of bias assessments. 
Han 2012 
Intensive management versus routine care 
MD -117.33 g 
(-198.72 to -
35.94) 
521 (4 RCTs) Very low Imprecision - wide confidence intervals. Risk of 
performance bias for not blinding participants and 
personnel (four trials), risk of attrition bias for incomplete 
data (two trials) and reporting bias for selective reporting 
(1 trial). 
Martis 2016a 
Strict intensity of glycaemic control2 versus less strict glycaemic control 
MD -0.92 g 
(-241.97 to 
57.97) 
171 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of performance bias 
for not blinding participants and personnel and risk of 
reporting bias for selective reporting. 
40.0 Head circumference and z score at birth (included reviews did not report z-scores) 
Han 2017 
Low-moderate GI diet versus moderate-high GI diet 
MD 0.40 cm 
(-0.58 to 1.38) 
59 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
135 
Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
Han 2017 
DASH1 diet versus control diet with matching macronutrient contents 
MD -0.90 cm (-
1.44 to -0.36) 
52 (1 RCT) Moderate Imprecision - one trial with small numbers and unclear 
risk of bias for three bias assessments. 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet 
MD -0.20 cm (-
0.91 to 0.51) 
82 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
detection bias for not blinding outcome assessments and 
risk of attrition bias for incomplete outcome data. 
Han 2017 
Soy protein-enriched diet versus no soy protein diet 
MD -0.20 cm (-
1.01 to 0.61) 
68 (1 RCT) Very low Imprecision - one trial small numbers and with wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
41.0 Length and z score at birth (included reviews did not report z-scores) 
Han 2017 
Low-moderate GI diet versus moderate-high GI diet 
MD -0.50 cm (-
1.54 to 0.54) 
60 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Han 2017 
DASH1 diet versus control diet with matching macronutrient contents 
MD -0.50 cm (-
1.59 to 0.59) 
52 (1 RCT) Low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Unclear 
risk of bias for three bias assessments. 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet 
MD 0.0 cm 
(-0.83 to 0.83) 
92 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
detection bias for not blinding outcome assessments and 
risk of attrition bias for incomplete outcome data. 
Han 2017 
Soy protein-enriched diet versus no soy protein diet 
MD -0.10 cm (-
1.07 to 0.87) 
68 (1 RCT) Very low Imprecision - one trial with small numbers and with wide 
confidence interval crossing the line of no effect. Risk of 
performance bias for not blinding participants and 
personnel. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
MD -0.10 cm (-
0.37 to 0.17) 
700 (1 RCT) Low Imprecision - one trial. Risk of attrition bias for 
incomplete data and risk of reporting bias for selective 
reporting. 
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Brown 2017c 
Exercise versus control 
MD -1.70 cm (-
3.41 to 0.01) 
34 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval. Risk of attrition bias for incomplete 
outcome data and unclear risk of bias for all other risk of 
bias assessments. 
42.0 Ponderal index 
Brown 2017a 
Metformin versus glibenclamide 
MD -0.09 units 
(-0.17 to -0.01) 
200 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel and risk of reporting 
bias for selective reporting. 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet 
MD -0.10 
kg/m3 
(-0.03 to 0.23) 
60 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval. Risk of performance bias for not 
blinding participants and personnel. 
Han 2017 
DASH1 diet versus control diet with matching macronutrient contents 
MD -0.37 
kg/m3 
(-0.54 to -0.20) 
52 (1 RCT) Moderate Imprecision - one trial with small numbers and unclear 
risk of bias for three bias assessments. 
Han 2017 
Low-GI diet versus high-fibre moderate-GI diet 
MD 0.20 kg/m3 
(-0.79 to 1.19) 
92 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
detection bias for not blinding outcome assessments and 
risk of attrition bias for incomplete outcome data. 
Han 2012 
Intensive management versus routine care 
MD -0.09 g x 
100 m3 
(-0.16 to -0.02) 
300 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel and risk of attrition 
bias for incomplete data. 
45.0 Respiratory distress syndrome (RDS) 
Boulvain 2001 
Induction of labour versus expectant management 
RR not 
estimable 
200 (1 RCT) Very low Imprecision - one trial. Risk of bias for all assessments 
unclear, as not reported in the review. There were no 
events reported in either group. 
Brown 2017a 
Metformin versus glibenclamide 
RR 0.51 
(0.10 to 2.69) 
159 (1 RCT) Very low Imprecision - one trial with wide confidence interval. Risk 
of performance bias for not blinding participants and 
personnel. 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
Brown 2017a 
Glibenclamide versus acarbose 
RR not 
estimable 
43 (1 RCT) Low Imprecision - one trial with small numbers. Risk of 
performance bias for not blinding participants and 
personnel. There were no events reported in either 
group. 
Han 2017 
Ethnic specific diet versus standard healthy diet 
RR not 
estimable 
20 (1 RCT) Low Imprecision - one trial with small numbers. Risk of 
performance bias for not blinding participants and 
personnel and risk of attrition bias for incomplete data. 
There were no events reported in either group. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
average 
RR 0.79 
(0.34 to 1.85) 
2195 
(4 RCTs) 
Moderate Risk of performance bias for not blinding participants and 
personnel in two trials and risk of reporting bias for 
selective reporting in one trial. 
Brown 2017c 
Exercise versus control 
RR not 
estimable 
34 (1 RCT) Very low Imprecision - one study with small numbers. Risk of 
attrition bias for incomplete data. Unclear for all other risk 
of bias assessments. There were no events reported in 
either group. 
46.0 Neonatal jaundice (hyperbilirubinaemia) (as defined in the reviews) (defined in one review only) 
Brown 2017a 
Oral antidiabetic agents versus placebo 
(Glibenclamide versus placebo) 
RR 1.97 
(0.50 to 7.75) 
375 (1 RCT) Very low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of reporting bias for 
selective reporting, no published protocol was found. The 
population was 93% Hispanic, results may not be 
generalisable. The trial appears to be registered twice 
with the same outcomes. 
Brown 2017a 
Metformin versus glibenclamide 
RR 0.68 
(0.37 to 1.25) 
1205 
(2 RCTs) 
Moderate Risk of performance bias for not blinding participants and 
personnel and risk of reporting bias for selective 
reporting. 
Han 2017 
Energy restricted diet versus no energy restricted diet 
RR 0.81 
(0.33 to 1.98) 
299 (1 RCT) Low Imprecision - one trial with wide confidence interval. Risk 
of performance bias for not blinding participants and 
personnel. 
Han 2017 
Soy protein-enriched diet versus no soy protein diet 
RR 0.27 
(0.08 to 0.89) 
68 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval. Risk of performance bias for not 
blinding participants and personnel. 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
Han 2017 
Ethnic specific diet versus standard healthy diet 
RR not 
estimable 
20 (1 RCT) Low Imprecision - one trial with small numbers. Risk of 
performance bias for not blinding participants and 
personnel and risk of attrition bias for incomplete data. 
There were no events reported in either group. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
average 
RR 0.76 
(0.50 to 1.16) 
2362 
(4 RCT's) 
Moderate Risk of performance bias for not blinding of participants 
and personnel in two trials and risk of attrition bias for 
incomplete data in one trial. 
Brown 2017c 
Exercise versus control 
RR 0.33 
(0.01 to 7.65) 
34 (1 RCT) Very low Imprecision - one study with small numbers and wide 
confidence interval. Risk of attrition bias for incomplete 
data. Unclear for all other risk of bias assessments. 
There was no event reported in the treatment group and 
one event reported in the control group. 
Han 2012 
Intensive management versus routine care. Defined as: 
One trial: plasma bilirubin at least 205 μmol/l  
One trial: plasma bilirubin at least 670 μmol/l  
RR 0.79 
(0.24 to 2.60) 
426 (2 RCTs) Low Imprecision - wide confidence intervals. Risk of 
performance bias for not blinding participants and 
personnel and risk of attrition bias for incomplete data. 
Heterogeneity: I2 = 50%. 
47.0 Hypocalcaemia (as defined in the reviews) (not defined in the included reviews) 
Han 2017 
Energy restricted diet versus no energy restricted diet 
RR 1.36 
(1.00 to 1.86) 
299 (1 RCT) Low Imprecision - one trial with wide confidence intervals. 
Risk of performance bias for not blinding participants and 
personnel. 
Han 2017 
Ethnic specific diet versus standard healthy diet 
RR not 
estimable 
20 (1 RCT) Low Imprecision - one trial. Risk of performance bias for not 
blinding participants and personnel and risk of attrition 
bias for incomplete data. There were no events reported 
in either group. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
RR 1.38 
(1.01 to 1.88) 
462 (2 RCTs) Moderate Risk of performance bias for not blinding participants and 
personnel and risk of detection bias for not blinding 
outcome assessments. 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
Brown 2017c 
Exercise versus control 
RR not 
estimable 
34 (1 RCT) Very low Imprecision - one study with small numbers. Risk of 
attrition bias for incomplete data. Unclear for all other risk 
of bias assessments. There were no events reported in 
either group. 
 
 
 
 
 
48.0 Polycythaemia (as defined in the reviews) (not defined in the review) 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
RR 0.22 
(0.01 to 5.40) 
165 (1 RCT) Low Imprecision - one trial with wide confidence interval. Risk 
of performance bias for not blinding participants and 
personnel. There was event of polycythaemia reported in 
the control group. 
CI: confidence interval; MD: mean difference; RCT: randomised controlled trial; RR: risk ratio 
 
 
*GRADE ratings of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially 
different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
1DASH is an acronym for Dietary Approaches to Stop Hypertension 
2Strict intensity of glycaemic control: pre-prandial 5.0 mmol/L (90 mg/d) and at one-hour post-prandial: 6.7 mmol/L (120 mg/d). Less strict glycaemic control: pre-prandial 5.8 mmol/L 
(104 mg/d) and at one-hour post-prandial 7.8 mmol/L (140 mg/d) 
34 g myo-inositol + 400 mcg folic acid orally per day and exercise and dietary advice versus placebo 400 mcg folic acid orally per day and exercise and dietary advice 
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Table 2.14: Quality assessment table - Later infant/childhood - secondary outcomes 
Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
49.0 Weight and z scores (included review reported no z scores) 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
Weight at four to five years of age  
MD -0.30 kg 
(-1.29 to 0.69) 
199 (1 RCT) Low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of attrition bias as it only 
reports on 199 children of original trial of 1000 participants. 
50.0 Height and z scores (included review reported no z scores) 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
Height at four to five years of age 
MD -0.60 cm (-
2.05 to 0.85) 
199 (1 RCT) Low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of attrition bias as it only 
reports on 199 children of original trial of 1000 participants. 
53.1 Impaired glucose tolerance: fasting blood glucose 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
At seven to 11 years of age 
MD 0.10 
mmol/L 
(-0.10 to 0.30) 
68 (1 RCT) Low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
reporting bias for selective reporting. 
53.2 Impaired glucose tolerance: post-prandial blood glucose 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
Two hours post-prandial at seven to 11 years of age 
MD 0.00 
mmol/L 
(-0.48 to 0.48) 
68 (1 RCT) Low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
reporting bias for selective reporting. 
54.0 Dyslipidaemia or metabolic syndrome (as defined in the reviews) 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
Total cholesterol at seven to 11 years of age 
MD -0.20 
mg/dL 
(-0.55 to 0.15) 
68 (1 RCT) Low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
reporting bias for selective reporting. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
LDL1 cholesterol at seven to 11 years of age 
MD -0.12 
mg/dL 
(-0.50 to 0.26) 
68 (1 RCT) Low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
reporting bias for selective reporting. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
HDL2 cholesterol at seven to 11 years of age 
MD 0.10 mg/dL 
(-0.05 to 0.25) 
68 (1 RCT) Low Imprecision - one trial with small numbers and wide 
confidence interval crossing the line of no effect. Risk of 
reporting bias for selective reporting. 
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CI: confidence interval; MD: mean difference; RCT: randomised controlled trial; RR: risk ratio 
 
 
*GRADE ratings of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially 
different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
1LDL is an acronym for Low Density Lipoprotein cholesterol 
2HDL is an acronym for High-Density Lipoprotein cholesterol 
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Table 2.15: Quality assessment table - Health service use - secondary outcomes 
Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
57.1 Visits with dietitian 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
RR 9.24 
(7.12 to 12.01) 
1000 
(1 RCT) 
Moderate 
Imprecision - one trial with wide confidence interval. 
57.2 Visits with diabetes educator 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
RR 8.55 
(6.67 to 10.96) 
1000 
(1 RCT) 
Moderate 
Imprecision - one trial with wide confidence interval. 
57.3. Visits with obstetrician 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
MD 0.20 visits 
(-0.21 to 0.61) 
700 (1 RCT) Low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of attrition bias for 
incomplete outcome data and risk of reporting bias for 
selective reporting. 
57.4 Visits with healthcare provider (not specified) 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
MD 0.10 visits 
(-1.58 to 1.78) 
197 (1 RCT) Low Imprecision - one trial with wide confidence interval 
crossing the line of no effect. Risk of reporting bias for 
selective reporting and risk of performance bias for not 
blinding participants and personnel. 
58.0 Admission to neonatal intensive care unit/nursery 
Han 2017 
Soy protein-enriched diet versus no soy protein diet 
Admission was defined as "hypoxia, low-risk Apgar scores 6-7 (at 5 
or 15 min of age), high-risk Apgar scores at 1 minute 0-5 and at 5 or 
15 minutes less than 6, hyperbilirubinaemia, birth weight less than 
2500 g, and/or gestational age less than 32 weeks, sepsis, 
pneumonia, or meningitis, hypoglycaemia  
(blood glucose < 1.7mmol/L)" 
RR 0.14 
(0.02 to 1.10) 
68 (1 RCT) Very low Imprecision - one trial with small numbers and wide 
confidence interval. Risk of performance bias for not 
blinding participants and personnel. 
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Intervention and comparison and outcome Relative effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments  
from overview review authors 
Brown 2017a 
Oral antidiabetic agents versus placebo 
(Glibenclamide versus placebo) 
RR 1.16 
(0.53 to 2.53) 
375 (1 RCT) Very low 
Imprecision - one trial with wide confidence interval. Risk of 
reporting bias for selective reporting. 
Brown 2017a 
Metformin versus glibenclamide 
RR 1.52 
(0.65 to 3.56) 
349 
(2 RCTs) 
Low Imprecision - wide confidence interval. Risk of reporting 
bias for selective reporting and risk of performance bias not 
blinding participants and personnel. 
Han 2012 
Intensive management versus routine care 
RR 0.64 
(0.29 to 1.45) 
426 
(2 RCTs) 
Moderate Risk of attrition bias for incomplete outcome data in one 
trial and risk of performance bias for not blinding 
participants and personnel in both trials. 
Brown 2017b 
Lifestyle intervention versus usual care or diet alone 
average 
RR 0.91 
(0.59 to 1.40) 
2030 
(3 RCTs) 
Low Heterogeneity: I² = 80%. 
Risk of reporting bias for selective reporting in one trial and 
risk of performance bias for not blinding participants and 
personnel in one trial. 
CI: confidence interval; MD: mean difference; RCT: randomised controlled trial; RR: risk ratio 
 
 
*GRADE ratings of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially 
different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
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AMSTAR assessment 
Using the AMSTAR tool, seven included reviews assessed were of high methodological quality scoring 
between 9 and 11 points (Brown 2017a; Brown 2017b; Brown 2017c; Brown 2016a; Han 2017; Han 
2012; Martis 2016a). One review assessed was of moderate methodological quality scoring 7 points 
due to no recent up-date and lack of information about the methodological quality assessment (Boulvain 
2001) (Table 2.16). 
The assessment for each of the 11 items of the AMSTAR tool are as follows: 
1. All reviews provided a priori design. 
2. All reviews reported duplicate study selection and data extraction. 
3. All reviews performed a comprehensive literature search. 
4. All reviews included searches of grey literature. 
5. All reviews provided a list of included and excluded studies. 
6. All reviews described the characteristics of the included studies. 
7. All reviews assessed and documented the scientific quality of the included studies. 
8. Seven reviews assessed the scientific quality of the included studies appropriately in formulating 
conclusion. One review did not assess the scientific quality. 
9. Six reviews combined the findings of studies using appropriate methods. For two reviews this was 
not applicable as both included only one RCT. 
10. Four reviews assessed the likelihood of publication bias. The other four reviews did not mention 
that publication bias could not be assessed because there were fewer than 10 included studies 
but included test values or funnel plots. 
11. Six reviews clearly reported conflict of interest. 
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Table 2.16: AMSTAR assessments for included reviews 
Review ID Boulvain  
2001 
Brown 
2017a 
Brown 
2017b 
Brown 
2017c 
Brown 
2016a 
Han  
2017 
Han  
2012 
Martis 
2016a 
AMSTAR Domains 
Answer code:   √ = Yes;   x = No;   ? = Unclear;  
NA = Not applicable 
        
1. Was an a priori design provided? √ √ √ √ √ √ √ √ 
2. Was there duplicate study selection and data extraction? √ √ √ √ √ √ √ √ 
3. Was a comprehensive literature search performed? √ √ √ √ √ √ √ √ 
4. Was the status of publication (i.e. grey literature) used as an 
inclusion criterion? 
√ √ √ √ √ √ √ √ 
5. Was a list of studies (included and excluded) provided? √ √ √ √ √ √ √ √ 
6. Were the characteristics of the included studies provided? √ √ √ √ √ √ √ √ 
7. Was the scientific quality of the included studies assessed and 
documented? 
√ √ √ √ √ √ √ √ 
8. Was the scientific quality of the included studies used appropriately 
in formulating conclusions? 
x √ √ √ √ √ √ √ 
9. Were the methods used to combine the findings of studies 
appropriate? 
NA √ √ √ √ √ √ NA 
10. Was the likelihood of publication bias assessed? * x √ √ √ x √ x x 
11. Was the conflict of interest included? x √ √ √ √ √ x √ 
Total Score (out of 11): 
Score interpretation: √ 
8-11 = High quality 
4-7 = Moderate quality 
≤3 = Low quality 
7/11 
Moderate 
quality 
11/11 
High 
quality 
11/11 
High 
quality 
11/11 
High 
quality 
10/11 
High 
quality 
11/11 
High 
quality 
9/11 
High 
quality 
9/11 
High 
quality 
*We judged publication bias assessed as a 'yes' when a funnel plot and at least 10 studies were included in the review
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ROBIS assessment 
Overall the risk of bias for the included reviews using the ROBIS tool were judged as low risk for seven 
reviews (Brown 2017a; Brown 2017b; Brown 2017c; Brown 2016a; Han 2017; Han 2012; Martis 2016a) 
and as unclear risk for one review due to lack of evidence to minimise error in risk of bias assessment 
in that review. (Boulvain 2001) (Table 2.17). 
The assessment for each of the four domains of the ROBIS tool are as follows: 
Domain 1: All reviews were considered of low concern for specification of study eligibility criteria. 
Domain 2: All reviews were considered of low concern regarding methods used to identify and/or select 
studies. 
Domain 3: Seven reviews were considered of low concern regarding methods used to collect data and 
appraise studies. One study was of unclear concern as there was no evidence of risk of bias 
assessment. 
Domain 4: All reviews were considered of low concern regarding synthesis and findings, although one 
study did not include a funnel plot or sensitivity analysis. 
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Table 2.17: ROBIS assessment for included reviews 
Review ID  Boulvain 
2001 
Brown 
2017a 
Brown 
2017b 
Brown 
2017c 
Brown 
2016a 
Han 
2017 
Han 
2012 
Martis 
2016a 
ROBIS DOMAINS 
Answer Code:    √ = Yes;    x = No;    ? = unclear 
        
Domain 1: Study eligibility criteria 
Did the review adhere to pre-defined objectives and eligibility criteria? √ √ √ √ √ √ √ √ 
Were the eligibility criteria appropriate for the review question? √ √ √ √ √ √ √ √ 
Were eligibility criteria unambiguous? √ √ √ √ √ √ √ √ 
Were all restrictions in eligibility criteria based on study characteristics appropriate (e.g. date, 
sample size, study quality, outcomes measured)? 
√ √ √ √ √ √ √ √ 
Were any restrictions in eligibility criteria based on sources of information appropriate 
(publication status or format, language, availability of data)? 
√ √ √ √ √ √ √ √ 
Concerns regarding specification of study eligibility criteria  
LOW, HIGH, UNCLEAR 
Low Low Low Low Low Low Low Low 
Domain 2: Identification and selection of studies 
Did the search include an appropriate range of databases/electronic sources for published 
and unpublished reports? 
√ √ √ √ √ √ √ √ 
Were methods additional to database searching used to identify relevant reports? √ √ √ √ √ √ √ √ 
Were the terms and structure of the search strategy likely to retrieve as many eligible studies 
as possible? 
√ √ √ √ √ √ √ √ 
Were restrictions based on date, publication format, or language appropriate? √ √ √ √ √ √ √ √ 
Were efforts made to minimise error in selection of studies? √ √ √ √ √ √ √ √ 
Concerns regarding methods used to identify and/or select studies: LOW, HIGH, 
UNCLEAR 
Low Low Low Low Low Low Low Low 
Domain 3: Data collection and study appraisal 
Were efforts made to minimise error in data collection? √ √ √ √ √ √ √ √ 
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Review ID  Boulvain 
2001 
Brown 
2017a 
Brown 
2017b 
Brown 
2017c 
Brown 
2016a 
Han 
2017 
Han 
2012 
Martis 
2016a 
Were sufficient study characteristics available for both review authors and readers to be able 
to interpret the results? 
√ √ √ √ √ √ √ √ 
Were all relevant study results collected for use in the synthesis? √ √ √ √ √ √ √ √ 
Was risk of bias (or methodological quality) formally assessed using appropriate criteria? x √ √ √ √ √ √ √ 
Were efforts made to minimise error in risk of bias assessment? x √ √ √ √ √ √ √ 
Concerns regarding methods used to collect data and appraise studies: LOW, HIGH, 
UNCLEAR 
Unclear Low Low Low Low Low Low Low 
Domain 4: Synthesis and findings 
Did the synthesis include all studies that it should? √ √ √ √ √ √ √ √ 
Were all pre-defined analyses reported or departures explained? √ √ √ √ √ √ √ √ 
Was the synthesis appropriate given the nature and similarity in the research questions, study 
designs and outcomes across included studies? 
√ √ √ √ √ √ √ √ 
Was between-study variation (heterogeneity) minimal or 
addressed in the synthesis? 
√ √ √ √ √ √ √ √ 
Were the findings robust, e.g. as demonstrated through funnel plot or sensitivity analyses? x √ √ √ √ √ √ √ 
Were biases in primary studies minimal or addressed in the synthesis? √ √ √ √ √ √ √ √ 
Concerns regarding the synthesis and finding:  
LOW, HIGH, UNCLEAR 
Low Low Low Low Low Low Low Low 
Risk of bias in the review 
        
Did the interpretation of findings address all concerns identified in Domains 1-4? x √ √ √ √ √ √ √ 
Was the relevance of identified studies to the review's research question appropriately 
considered? 
√ √ √ √ √ √ √ √ 
Did the reviewers avoid emphasising results on the basis of their statistical significance? √ √ √ √ √ √ √ √ 
Overall Risk of Bias 
(According to Whiting 2016) 
Unclear 
Risk 
Low Risk Low Risk Low Risk Low Risk Low 
Risk 
Low 
Risk 
Low Risk 
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Effects of interventions   
We summarised the results of the included reviews by categorising their findings using the following 
framework organised by the overview review outcomes: 
• Effective interventions: indicating that the review found high-quality evidence of effectiveness for an 
intervention. 
• Promising interventions (more evidence needed): indicating that the review found moderate-quality 
evidence of effectiveness for an intervention, but more evidence is needed. 
• Probably no difference between interventions: direction of effect suggests benefit/harm or 
ineffective, but more evidence is needed. 
• Ineffective interventions: indicating that the review found high-quality evidence of lack of 
effectiveness for an intervention. 
• Probably ineffective interventions (more evidence needed): indicating that the review found 
moderate-quality evidence suggesting lack of effectiveness for an intervention, but more evidence 
is needed. 
• No conclusions possible due to lack of evidence: indicating that the review found low- or very low-
quality evidence, or insufficient evidence to comment on the effectiveness of an intervention, more 
evidence needed. 
For further details see Characteristics of included reviews (Table 2.5). For the pre-specified GRADE 
outcomes see Summary of findings tables for maternal (Table 2.8), child (as neonate, child, adult) (Table 
2.9) and health service use (Table 2.10). 
Additional quality assessments for non-GRADE maternal secondary outcomes; maternal long term 
secondary outcomes; fetal/neonatal secondary outcomes; later infant/childhood secondary outcomes 
and health service use have been summarised in Table 2.11, Table 2.12, Table 2.13, Table 2.14, and 
Table 2.15 respectively. 
For the assessment summary of interventions for all overview review outcomes see Table 2.18 for 
primary outcomes and Table 2.19 for secondary outcomes. 
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Table 2.18: Summary of main results - all primary outcomes (maternal and neonatal) 
Primary Outcomes – Maternal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
1.1 Any hypertensive disorders 
of pregnancy, not defined 
 Metformin versus glibenclamide 
(Brown 2017a) 
Glibenclamide versus placebo (Brown 2017a) 
1.2 Pregnancy induced 
hypertension 
 Metformin versus glibenclamide 
(Brown 2017a) 
Glibenclamide versus placebo (Brown 2017a) 
   Low carbohydrate diet versus high carbohydrate diet  
(Han 2017) 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (Han 2017) 
   Ethnic specific diet versus standard healthy diet (Han 2017) 
1.3 Severe hypertension or pre-
eclampsia 
  Glibenclamide versus placebo (Brown 2017a) 
   Low-moderate GI diet versus moderate-high GI diet 
(Han 2017) 
1.4 Pre-eclampsia (not defined)  DASH1 diet versus control diet with 
matching macronutrient contents (Han 
2017) 
Metformin versus glibenclamide (Brown 2017a) 
 
   Energy restricted diet versus no energy restricted diet 
(Han 2017) 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (Han 2017) 
   Soy protein-enriched diet versus no soy protein diet 
(Han 2017) 
   Lifestyle intervention versus usual care or diet alone  
(Brown 2017b) 
   Exercise versus control (Brown 2017c) 
   Intensive management versus routine care (Han 2012) 
1.5 Eclampsia (not defined)   Low-moderate GI diet versus moderate-high GI die 
(Han 2017) 
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Primary Outcomes – Maternal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
2.0 Caesarean section  DASH1 diet versus control diet with 
matching macronutrient contents (Han 
2017) 
Induction of labour versus expectant management 
(Boulvain 2001) 
  Exercise versus control 
(Brown 2017c) 
Glibenclamide versus placebo (Brown 2017a) 
   Metformin versus glibenclamide (Brown 2017a) 
   Glibenclamide versus acarbose (Brown 2017a) 
   Low-moderate GI diet versus moderate-high GI diet 
(Han 2017) 
   Energy restricted diet versus no energy restricted diet 
(Han 2017) 
   Low carbohydrate diet versus high-carbohydrate diet 
(Han 2017) 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (Han 2017) 
   Low-GI diet versus high-fibre moderate-GI diet (Han 2017) 
   Diet recommendation + diet-related behavioural advice versus diet 
recommendation only (Han 2017) 
   Soy protein-enriched diet versus no soy protein diet 
(Han 2017) 
   Ethnic specific diet versus standard healthy diet (Han 2017) 
   Lifestyle intervention versus usual care or diet alone 
(Brown 2017b) 
   Intensive management versus routine care (Han 2012) 
   Strict intensity of glycaemic control2 versus less strict glycaemic 
control (Martis 2016a) 
3.1 OGTT (Oral Glucose 
Tolerance Test) for diagnosis of 
type 2 diabetes 
  High unsaturated fat diet versus low unsaturated fat diet with 
matching calories at one to two weeks post-partum 
(Han 2017) 
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Primary Outcomes – Maternal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
   Low-GI diet versus high fibre moderate-GI diet at three months post-
partum (Han 2017) 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories at four to 13 months post-partum 
(Han 2017) 
   Lifestyle intervention versus usual care or diet alone (test and time 
frame not defined (Brown 2017b) 
 
Primary Outcomes - Neonatal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
4.0 Perinatal (fetal and neonatal 
death) and later infant mortality 
All included reviews reported 
on perinatal mortality only  
  Induction of labour versus expectant management 
(Boulvain 2001) 
   Metformin versus glibenclamide (Brown 2017a) 
   Glibenclamide versus acarbose (Brown 2017a) 
   Energy restricted diet versus no energy restricted diet (Han 2017) 
   Low carbohydrate diet versus high-carbohydrate diet (Han 2017) 
   Lifestyle intervention versus usual care or diet alone   
(Brown 2017b) 
   Exercise versus control (Brown 2017c) 
5.0 Large-for-gestational age 
(LGA) (defined as > 90th 
percentile in all included 
reviews) 
 Lifestyle intervention versus usual care 
or diet alone (Brown 2017b) 
Induction of labour versus expectant management 
(Boulvain 2001) 
   Glibenclamide versus placebo (Brown 2017a) 
   Metformin versus glibenclamide (Brown 2017a) 
   Glibenclamide versus acarbose (Brown 2017a) 
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Primary Outcomes - Neonatal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
   4 g myo-inositol + 400 mcg folic acid orally per day and exercise 
and dietary advice versus placebo 400 mcg folic acid orally per day 
and exercise and dietary advice (Brown 2016a) 
   Low-moderate GI diet versus moderate-high GI diet  
(Han 2017) 
   Energy restricted diet versus no energy restricted diet 
(Han 2017) 
   Low carbohydrate diet versus high-carbohydrate diet 
(Han 2017) 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (Han 2017) 
   Low-GI diet versus high-fibre moderate-GI diet (Han 2017) 
   Diet recommendation + diet-related behavioural advice versus diet 
recommendation only (Han 2017) 
   Ethnic specific diet versus standard healthy diet (Han 2017) 
   Intensive management versus routine care (Han 2012) 
6.0 Death or serious morbidity 
composite (as defined in 
reviews, e.g. perinatal or infant 
death, shoulder dystocia, bone 
fracture or nerve palsy) 
 Exercise versus control 
(Brown 2017c) 
Metformin versus glibenclamide. The morbidity composite included 
hypoglycaemia, hyperbilirubinaemia, macrosomia, respiratory 
illness, birth injury, stillbirth or neonatal death. 
(Brown 2017a) 
   Ethnic specific diet versus standard healthy diet. The morbidity 
composite included hypoglycaemia, neonatal asphyxia, respiratory 
distress syndrome, hyperbilirubinaemia and hypocalcaemia (Han 
2017) 
   Lifestyle intervention versus usual care or diet alone.  The death or 
serious morbidity composite included death, shoulder dystocia, bone 
fracture and nerve palsy in one trial and in the other trial included 
stillbirth, neonatal death, hypoglycaemia, hyperbilirubinaemia, 
elevated cord-blood C-peptide and birth trauma (Brown 2017b) 
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Table 2.19: Summary of main results -  all secondary outcomes (maternal, neonatal, later infant/childhood/adult and health service use) 
Secondary Outcomes - Maternal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
8.0 Use of additional 
pharmacotherapy 
 DASH1 diet versus control diet with 
matching macronutrient contents 
(Han 2017) 
Glibenclamide versus placebo (insulin) (Brown 2017a) 
 
  Lifestyle intervention versus usual care 
or diet alone (oral antidiabetic agents) 
(Brown 2017b) 
Acarbose versus placebo (insulin) (Brown 2017a) 
   Metformin versus glibenclamide (insulin) (Brown 2017a) 
   Glibenclamide versus acarbose (insulin) (Brown 2017a) 
   4 g myo-inositol + 400 mcg folic acid orally per day and exercise 
and dietary advice versus placebo 400 mcg folic acid orally per day 
and exercise and dietary advice (insulin) (Brown 2016a) 
   Low-moderate GI diet versus moderate-high GI diet (not defined) 
(Han 2017) 
   Energy restricted diet versus no energy restricted diet (insulin) 
(Han 2017) 
   Low carbohydrate diet versus high-carbohydrate diet (not defined) 
(Han 2017) 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (not defined) (Han 2017) 
   Low-GI diet versus high-fibre moderate-GI diet (not defined)  
(Han 2017) 
   Diet recommendation + diet-related behavioural advice versus diet 
recommendation only (not defined) (Han 2017) 
   Soy protein-enriched diet versus no soy protein diet (not defined) 
(Han 2017) 
   High-fibre diet versus standard-fibre diet (not defined) (Han 2017) 
   Ethnic specific diet versus standard healthy diet (not defined) 
(Han 2017) 
   Lifestyle intervention versus usual care or diet alone (insulin) 
(Brown 2017b) 
   Exercise versus control (Brown 2017c) 
   Intensive management versus routine care (insulin or oral 
hypoglycaemics) (Han 2012) 
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Secondary Outcomes - Maternal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
   Strict intensity of glycaemic control2 versus less strict glycaemic 
control (insulin) (Martis 2016a) 
9.0 Maternal hypoglycaemia (as 
defined in the reviews) 
  Metformin versus glibenclamide maternal hypoglycaemia as < 3.3 
mmol/L (60 mg/dL) (one trial) (Brown 2017a) 
   Glibenclamide versus acarbose (not defined) (Brown 2017a) 
   High-fibre diet versus standard-fibre diet (not defined) (Han 2017) 
   Lifestyle intervention versus usual care or diet alone (not defined) 
(Brown 2017b) 
   Exercise versus control (Brown 2017c) 
10.1 Glycaemic control: timing 
not defined 
  Low-GI diet versus high-fibre moderate-GI diet (not defined) 
(Han 2017) 
10.2 Glycaemic control during 
the treatment: pre-
prandial/fasting 
  Energy restricted diet versus no energy restricted diet (during not 
defined) (Han 2017) 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (at 38 weeks gestation) (Han 2017) 
10.3 Glycaemic control during 
the treatment: post-prandial 
  Energy restricted diet versus no energy restricted diet (at one hour) 
(Han 2017) 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (no post-prandial time given) (at 38 weeks 
gestation) (Han 2017) 
10.4 Glycaemic control during 
treatment: HbA1c 
  Metformin versus glibenclamide (Brown 2017a) 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (at 38 weeks gestation) (Han 2017) 
10.5 Glycaemic control during 
the treatment: 24 hours mean 
plasma glucose 
  Energy restricted diet versus no energy restricted diet (Han 2017) 
10.6 Glycaemic control at the 
end of treatment: Fasting 
 4 g myo-inositol + 400 mcg folic acid 
orally per day and exercise and dietary 
advice versus placebo 400 mcg folic 
acid orally per day and exercise and 
dietary advice (with OGTT) (Brown 
2016a) 
Glibenclamide versus placebo (taken at the last three antenatal 
visits) (Brown 2017a) 
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Secondary Outcomes - Maternal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
  DASH1 diet versus control diet with 
matching macronutrient contents (Han 
2017) 
Metformin versus glibenclamide (Brown 2017a) 
   Low-moderate GI diet versus moderate-high GI diet (Han 2017) 
   Energy restricted diet versus no energy restricted diet (Han 2017) 
   Low carbohydrate diet versus high-carbohydrate diet (Han 2017) 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (Han 2017) 
   Diet recommendation + diet-related behavioural advice versus diet 
recommendation only (Han 2017) 
   Soy protein-enriched diet versus no soy protein diet (Han 2017) 
   Exercise versus control (Brown 2017c) 
10.7 Glycaemic control at the 
end of treatment: One hour 
post-prandial 
 4 g myo-inositol + 400 mcg folic acid 
orally per day and exercise and dietary 
advice versus placebo 400 mcg folic 
acid orally per day and exercise and 
dietary advice (with OGTT) (Brown 
2016a) 
Energy restricted diet versus no energy restricted diet  
(Han 2017) 
 
   Lifestyle intervention versus usual care or diet alone  
(Brown 2017b) 
10.8 Glycaemic control at the 
end of treatment: Two hours 
post-prandial 
  Metformin versus glibenclamide (After DINNER where specified) 
(Brown 2017a)  
   4 g myo-inositol + 400 mcg folic acid orally per day and exercise 
and dietary advice versus placebo 400 mcg folic acid orally per day 
and exercise and dietary advice (with OGTT) (Brown 2016a)  
   Low-moderate GI diet versus moderate-high GI diet (Han 2017) 
   Low carbohydrate diet versus high-carbohydrate diet (after 
BREAKFAST) (Han 2017)  
   Low carbohydrate diet versus high-carbohydrate diet (after LUNCH) 
(Han 2017)  
   Low carbohydrate diet versus high-carbohydrate diet (after 
DINNER) (Han 2017)  
High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (Han 2017) 
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Secondary Outcomes - Maternal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
10.9 Glycaemic control at the 
end of treatment: Post-prandial 
timing not defined 
 Exercise versus control  
(Brown 2017c) 
Diet recommendation + diet-related behavioural advice versus diet 
recommendation only (Han 2017) 
   Exercise versus control (with OGTT) (Brown 2017c) 
 
10.10 Glycaemic control at the 
end of treatment: mean plasma 
glucose 
  Energy restricted diet versus no energy restricted diet (24 hours 
mean) (Han 2017) 
 
   Exercise versus control (Brown 2017c) 
10.11 Glycaemic control at the 
end of treatment: HbA1c 
Exercise versus control 
(Brown 2017c) 
DASH1 diet versus control diet with 
matching macronutrient contents (Han 
2017) 
Low-moderate GI diet versus moderate-high GI diet (Han 2017) 
 
   Diet recommendation + diet-related behavioural advice versus diet 
recommendation only (Han 2017) 
   Lifestyle intervention versus usual care or diet alone  
(Brown 2017b) 
10.12 Glycaemic control 
during/at the end of treatment: 
Fasting 
  Energy restricted diet versus no energy restricted diet (Han 2017) 
   Lifestyle intervention versus usual care or diet alone  
(Brown 2017b) 
10.13 Glycaemic control 
during/at the end of treatment: 
Mean plasma glucose 
  Energy restricted diet versus no energy restricted diet (Han 2017) 
 
   High-fibre diet versus standard-fibre diet (Han 2017) 
10.14 Glycaemic control 
during/at the end of treatment: 
Mean HbA1c 
  Energy restricted diet versus no energy restricted diet (Han 2017) 
 
11.0 Weight gain in pregnancy  DASH1 diet versus control diet with 
matching macronutrient contents 
(Han 2017) 
Glibenclamide versus placebo (Brown 2017a) 
  Lifestyle intervention versus usual care 
or diet alone (Brown 2017b) 
Metformin versus glibenclamide (Brown 2017a) 
   Glibenclamide versus acarbose (Brown 2017a) 
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Secondary Outcomes - Maternal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
   4 g myo-inositol + 400 mcg folic acid orally per day and exercise 
and dietary advice versus placebo 400 mcg folic acid orally per day 
and exercise and dietary advice (Brown 2016a) 
   Low-moderate GI diet versus moderate-high GI diet (Han 2017) 
   Energy restricted diet versus no energy restricted diet (Han 2017) 
   Low-carbohydrate diet versus high-carbohydrate diet (Han 2017) 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (Han 2017) 
   Low-GI diet versus high-fibre moderate-GI diet (Han 2017) 
   Diet recommendation + diet-related behavioural advice versus diet 
recommendation only (Han 2017) 
   Soy protein-enriched diet versus no soy protein diet (Han 2017) 
   High-fibre diet versus standard-fibre diet (Han 2017) 
   Ethnic specific diet versus standard healthy diet (Han 2017) 
   Exercise versus control (Brown 2017c) 
   Intensive management versus routine care (Han 2012) 
12.0 Other measures of weight 
gain in pregnancy (not pre-
specified for this overview) 
- BMI during the pregnancy 
- BMI at the end of the 
  Pregnancy 
- Excessive weight gain in 
pregnancy 
 4 g myo-inositol + 400 mcg folic acid 
orally per day and exercise and dietary 
advice versus placebo 400 mcg folic 
acid orally per day and exercise and 
dietary advice (BMI during) (Brown 
2016a) 
Diet recommendation + diet-related behavioural advice versus diet 
recommendation only (BMI at end) (Han 2017) 
 
  DASH1 diet versus control diet with 
matching macronutrient contents (BMI at 
end) (Han 2017) 
Soy protein-enriched diet versus no soy protein diet (BMI at end) 
(Han 2017) 
 
   Exercise versus control (excessive weight gain in pregnancy) 
(Brown 2017c) 
13.0 Adherence to the 
intervention 
  Low-carbohydrate diet versus high-carbohydrate diet (Han 2017) 
   Low-GI diet versus high-fibre moderate-GI diet (Han 2017) 
   Ethnic specific diet versus standard healthy diet (Han 2017) 
   Exercise versus control (Brown 2017c) 
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Secondary Outcomes - Maternal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
14.0 Induction of labour Lifestyle intervention 
versus usual care or diet 
alone (Brown 2017b) 
 Glibenclamide versus placebo (Brown 2017a) 
   Metformin versus glibenclamide (Brown 2017a) 
   Low-moderate GI diet versus moderate-high GI diet (Han 2017) 
   Energy restricted diet versus no energy restricted diet (Han 2017) 
   Exercise versus control (Brown 2017c) 
   Intensive management versus routine care (Han 2012) 
15. Placental abruption   DASH1 diet versus control diet with matching macronutrient 
contents (Han 2017) 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (Han 2017) 
16.0 Postpartum haemorrhage 
(as defined in the reviews) 
  Low-moderate GI diet versus moderate-high GI diet (PPH not 
defined) (Han 2017) 
   Lifestyle intervention versus usual care or diet alone (PPH not 
defined) (Brown 2017b) 
17.0 Postpartum infection  Lifestyle intervention versus usual care 
or diet alone (Brown 2017b) 
Low-moderate GI diet versus moderate-high GI diet (Han 2017) 
18.0 Perineal trauma/tearing  Lifestyle intervention versus usual care 
or diet alone (Brown 2017b) 
Glibenclamide versus placebo (Brown 2017a) 
   Metformin versus glibenclamide (Brown 2017a) 
19.1 Breastfeeding at discharge  Lifestyle intervention versus usual care 
or diet alone (Brown 2017b) 
 
19.1.2 Breastfeeding at six 
weeks postpartum 
  Lifestyle intervention versus usual care or diet alone  
(Brown 2017b) 
19.1.3 Breastfeeding at six 
months post-partum or longer 
  Lifestyle intervention versus usual care or diet alone  
(Brown 2017b) 
20.0 Maternal mortality   Exercise versus control (Brown 2017c) 
21.1 Sense of well-being and 
quality of life during treatment: 
Overall physical component 
  Lifestyle intervention versus usual care or diet alone (SF-36) 
(Brown 2017b) 
21.2 Sense of well-being and 
quality of life during treatment: 
Overall mental component 
  Lifestyle intervention versus usual care or diet alone (SF-36) 
(Brown 2017b) 
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Secondary Outcomes - Maternal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
21.3 Sense of well-being and 
quality of life during treatment: 
Anxiety 
 Lifestyle intervention versus usual care 
or diet alone (SF-36)  
(Brown 2017b) 
 
21.4 Sense of well-being and 
quality of life at three months 
post-partum: Overall physical 
component 
  Lifestyle intervention versus usual care or diet alone (SF-36) 
(Brown 2017b) 
21.5 Sense of well-being and 
quality of life at three months 
post-partum: Overall mental 
component 
  Lifestyle intervention versus usual care or diet alone (SF-36) 
(Brown 2017b) 
21.6 Sense of well-being and 
quality of life at three months 
post-partum: Anxiety 
  Lifestyle intervention versus usual care or diet alone (SF-36) 
(Brown 2017b) 
22.0 Women's view of the 
intervention 
  Exercise versus control (Brown 2017c) 
23.1 Relevant biomarker 
changes: Homeostasis Model 
Assessment Insulin Resistance 
(HOMA-IR) and HOMA2-IR 
 DASH1 diet versus control diet with 
matching macronutrient contents 
(HOMA-IR at end) (Han 2017)  
Low-GI diet versus high-fibre moderate-GI diet (HOMA2-IR at end) 
(Han 2017) 
   Low-GI diet versus high-fibre moderate-GI diet (HOMA2-IR at 3 
months) (Han 2017) 
   Diet recommendation + diet-related behavioural advice versus diet 
recommendation only (HOMA-IR at end) (Han 2017) 
   Soy protein-enriched diet versus no soy protein diet (HOMA-IR at 
end) (Han 2017) 
23.2 Relevant biomarker 
changes: Quantitative Insulin 
Sensitivity Check Index 
(QUICKI) 
  Soy protein-enriched diet versus no soy protein diet (QUICKI at the 
end of the intervention) (Han 2017) 
23.3 Relevant biomarker 
changes: Fasting plasma insulin 
during the intervention 
  Energy restricted diet versus no energy restricted diet (Han 2017) 
   High unsaturated fat diet group compared to low unsaturated fat 
diet with matching calories (at 38 weeks gestation) (Han 2017) 
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Secondary Outcomes - Maternal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
23.4 Relevant biomarker 
changes: Fasting plasma insulin 
at end of treatment 
  Energy restricted diet versus no energy restricted diet (Han 2017) 
 
   DASH1 diet versus control diet with matching macronutrient 
contents (Han 2017) 
   Low-GI diet versus high-fibre moderate-GI diet (Han 2017) 
   Diet recommendation + diet-related behavioural advice versus diet 
recommendation only (Han 2017) 
   Soy protein-enriched diet versus no soy protein diet (Han 2017) 
 
Secondary Outcomes – Maternal long-term Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
25.0 Postnatal depression   Lifestyle intervention versus usual care or diet alone (defined as 
Edinburgh Postnatal Depression Score (EPDS) >12) 
(Brown 2017b) 
26.0 Body Mass Index (BMI)   Low-GI diet versus high-fibre moderate-GI diet (BMI at 3 months) 
(Han 2017) 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (at 5 to 9 months) (Han 2017) 
27.0 Postnatal weight retention 
or return to pre-pregnancy 
weight 
Exercise versus control 
(timing not defined) 
(Brown 2017c) 
 Lifestyle intervention versus usual care or diet alone (at 6 weeks 
post-partum) (Brown 2017b) 
   Low-GI diet versus high-fibre moderate-GI diet (at 3 months post-
partum) (Han 2017) 
   Lifestyle intervention versus usual care or diet alone (at 7 months 
post-partum) (Brown 2017b) 
   Lifestyle intervention versus usual care or diet alone (at 12 months 
post-partum) (Brown 2017b) 
28.0 Impaired glucose tolerance   Lifestyle intervention versus usual care or diet alone (test and timing 
not defined) (Brown 2017b) 
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Secondary Outcomes – Maternal long-term Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (borderline OGTT at one to two weeks post-
partum) (Han 2017) 
   Low-GI diet versus high-fibre moderate-GI diet (at three months 
post-partum, measure not defined) (Han 2017) 
   Lifestyle intervention versus usual care or diet alone (fasting plasma 
glucose at three months post-partum) (Brown 2017b) 
   Lifestyle intervention versus usual care or diet alone (fasting blood 
glucose concentration at 6 months post-partum)  
(Brown 2017b) 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (borderline OGTT at four to 13 months post-
partum) (Han 2017) 
29.0 Cardiovascular health (as 
defined in the reviews including 
blood pressure, hypertension, 
cardiovascular disease, 
metabolic syndrome) 
  Lifestyle intervention versus usual care or diet alone (metabolic 
syndrome) (Brown 2017b) 
 
 
Secondary Outcomes - Fetal/neonatal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
31.0 Stillbirth   Glibenclamide versus placebo (Brown 2017a) 
   Metformin versus glibenclamide (Brown 2017a) 
   Energy restricted diet versus no energy restricted diet (Han 2017) 
   Low-carbohydrate diet versus high-carbohydrate diet (Han 2017) 
   Lifestyle intervention versus usual care or diet alone  
(Brown 2017b) 
   Exercise versus control (Brown 2017c) 
32.0 Neonatal death   Glibenclamide versus placebo (Brown 2017a) 
   Energy restricted diet versus no energy restricted diet (Han 2017) 
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Secondary Outcomes - Fetal/neonatal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
   Lifestyle intervention versus usual care or diet alone (Brown 2017b) 
33.0 Macrosomia (> 4000 g; or 
as defined in the reviews) 
 Exercise versus control (not defined) 
(Brown 2017c) 
Induction of labour versus expectant management (> 4000 g) 
(Boulvain 2001) 
  Intensive management versus routine 
care (≥ 4000 g) (Han 2012) 
Glibenclamide versus placebo (≥ 4000 g) (Brown 2017a) 
 
   Metformin versus glibenclamide (≥ 4000 g (1 trial) (≥ 3700 g (1 trial) 
(Brown 2017a) 
   Glibenclamide versus acarbose (> 4000 g) (Brown 2017a) 
   Low-moderate GI diet versus moderate-high GI diet (> 4000 g) (Han 
2017) 
   Energy restricted diet versus no energy restricted diet (> 4000 g) 
(Han 2017) 
   Energy restricted diet versus no energy restricted diet (> 4500 g) 
(Han 2017) 
   DASH1 diet versus control diet with matching macronutrient contents 
(≥ 4000 g) (Han 2017) 
   Low-carbohydrate diet versus high-carbohydrate diet (> 4000 g) 
(Han 2017) 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (> 4000 g) (Han 2017) 
   Low-GI diet versus high-fibre moderate-GI diet (> 4000 g)  
(Han 2017) 
   Soy protein-enriched diet versus no soy protein diet (> 4000 g)  
(Han 2017) 
   Ethnic specific diet versus standard healthy diet (> 4000 g)  
(Han 2017) 
   Lifestyle intervention versus usual care or diet alone (> 4 kg (5 trials) 
(≥ 4 kg (2 trials) (Han 2017) 
   Strict intensity of glycaemic control2 versus less strict glycaemic 
control (> 4000 g) (Martis 2016a) 
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Secondary Outcomes - Fetal/neonatal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
34.0 Small-for-gestational age 
(SGA) (not defined in the 
reviews) 
 Lifestyle intervention versus usual care 
or diet alone (Brown 2017b) 
Glibenclamide versus placebo (Brown 2017a) 
   Glibenclamide versus acarbose (Brown 2017a) 
   Low-moderate GI diet versus moderate-high GI diet (Han 2017) 
   Low-carbohydrate diet versus high-carbohydrate diet (Han 2017) 
   Low-GI diet versus high-fibre moderate-GI diet (Han 2017) 
   Ethnic specific diet versus standard healthy diet (Han 2017) 
   Intensive management versus routine care (Han 2012) 
   Strict intensity of glycaemic control versus less strict glycaemic 
control (Martis 2016a) 
35.1 Birth trauma not defined   Metformin versus glibenclamide (Brown 2017a) 
   Glibenclamide versus acarbose (Brown 2017a) 
   Lifestyle intervention versus usual care or diet alone (Brown 2017a) 
35.2 Birth trauma: Shoulder 
dystocia 
  Induction of labour versus expectant management  
(Boulvain 2001) 
   Glibenclamide versus placebo (Brown 2017a) 
   Metformin versus glibenclamide (Brown 2017a) 
   Energy restricted diet versus no energy restricted diet (Han 2017) 
   Intensive management versus routine care (Han 2012) 
   Lifestyle intervention versus usual care or diet alone 
(Brown 2017b) 
35.3 Birth trauma: Bone fracture   Induction of labour versus expectant management  
(Boulvain 2001) 
   Glibenclamide versus placebo (Brown 2017a) 
   Energy restricted diet versus no energy restricted diet (Han 2012) 
   Lifestyle intervention versus usual care or diet alone (Brown 2017b) 
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Secondary Outcomes - Fetal/neonatal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
35.4 Birth trauma: Nerve palsy 
(brachial plexus) 
  Induction of labour versus expectant management  
(Boulvain 2001) 
   Glibenclamide versus placebo (Brown 2017a) 
   Energy restricted diet versus no energy restricted diet (Han 2012) 
   Lifestyle intervention versus usual care or diet alone (Brown 2017b) 
36.0 Gestational age at birth  4 g myo-inositol + 400 mcg folic acid 
orally per day and exercise and dietary 
advice versus placebo 400 mcg folic 
acid orally per day and exercise and 
dietary advice 
(Brown 2016a) 
Glibenclamide versus placebo (Brown 2017a) 
  Energy restricted diet versus no energy 
restricted diet (Han 2017) 
Metformin versus glibenclamide (Brown 2017a) 
   Glibenclamide versus acarbose (Brown 2017a) 
   Low-GI diet versus high-fibre moderate-GI diet (Han 2017) 
   DASH1 diet versus control diet with matching macronutrient contents 
(Han 2017) 
   Low-carbohydrate diet versus high-carbohydrate diet (Han 2017)  
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (Han 2017) 
   Low-GI diet versus high-fibre moderate-GI diet (Han 2017) 
   Soy protein-enriched diet versus no soy protein diet (Han 2017) 
   High-fibre diet versus standard-fibre diet (Han 2017) 
   Ethnic specific diet versus standard healthy diet (Han 2017)  
   Lifestyle intervention versus usual care or diet alone  
(Brown 2017b) 
   Exercise versus control (Brown 2017c) 
   Intensive management versus routine care (Han 2012) 
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Secondary Outcomes - Fetal/neonatal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
   Strict intensity of glycaemic control2 versus less strict glycaemic 
control (Martis 2016a) 
37.0 Preterm birth (< 37 weeks’ 
gestation and < 32 weeks’ 
gestation) 
 Lifestyle intervention versus usual care 
or diet alone (Brown 2017b) 
Metformin versus glibenclamide (Brown 2017a) 
   Glibenclamide versus acarbose (Brown 2017a) 
   4 g myo-inositol + 400 mcg folic acid orally per day and exercise 
and dietary advice versus placebo 400 mcg folic acid orally per day 
and exercise and dietary advice (Brown 2016a) 
   Low-moderate GI diet versus moderate-high GI diet (Han 2017) 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (Han 2017) 
   Low-GI diet versus high-fibre moderate-GI diet (Han 2017) 
   Diet recommendation + diet-related behavioural advice versus diet 
recommendation only (Han 2017) 
   Soy protein-enriched diet versus no soy protein diet (Han 2017) 
   Exercise versus control (Brown 2017c) 
   Intensive management versus routine care (Han 2012) 
38.0 Five-minute Apgar < 7  Lifestyle intervention versus usual care 
or diet alone (Brown 2017b) 
Metformin versus glibenclamide (Brown 2017a) 
   Exercise versus control (Brown 2017c) 
39.0 Birthweight and z score 
(None of the included reviews 
reported data for birthweight z 
scores) 
 DASH1 diet versus control diet with 
matching macronutrient contents (Han 
2017) 
Glibenclamide versus placebo (Brown 2017b) 
  Lifestyle intervention versus usual care 
or diet alone (Brown 2017b) 
Metformin versus glibenclamide (Brown 2017a) 
   Glibenclamide versus acarbose (Brown 2017a) 
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Secondary Outcomes - Fetal/neonatal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
   4 g myo-inositol + 400 mcg folic acid orally per day and exercise 
and dietary advice versus placebo 400 mcg folic acid orally per day 
and exercise and dietary advice (Brown 2016a) 
   Low-moderate GI diet versus moderate-high GI diet (Han 2017) 
   Energy restricted diet versus no energy restricted diet (Han 2017) 
   Low-carbohydrate diet versus high-carbohydrate diet (Han 2017) 
   High unsaturated fat diet versus low unsaturated fat diet with 
matching calories (Han 2017) 
   Low-GI diet versus high-fibre moderate-GI diet (Han 2017) 
   Soy protein-enriched diet versus no soy protein diet (Han 2017) 
   High-fibre diet versus standard-fibre diet (Han 2017) 
   Ethnic specific diet versus standard healthy diet (Han 2017) 
   Exercise versus control (Brown 2017c) 
   Intensive management versus routine care (Han 2012) 
   Strict intensity of glycaemic control2 versus less strict glycaemic 
control (Martis 2016a) 
40.0 Head circumference and z 
score 
(The included review did not 
reported data for head 
circumference z scores) 
 
 DASH1 diet versus control diet with 
matching macronutrient contents 
evidence (Han 2017) 
Low-moderate GI diet versus moderate-high GI diet (Han 2017) 
   Low-GI diet versus high-fibre moderate-GI diet (Han 2017) 
   Soy protein-enriched diet versus no soy protein diet (Han 2017) 
41.0 Length and z score 
(None of the included reviews 
reported data for length z 
scores) 
  Low-moderate GI diet versus moderate-high GI diet (Han 2017) 
   DASH1 diet versus control diet with matching macronutrient contents 
(Han 2017) 
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Secondary Outcomes - Fetal/neonatal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
   Low-GI diet versus high-fibre moderate-GI diet (Han 2017) 
   Soy protein-enriched diet versus no soy protein diet (Han 2017) 
   Lifestyle intervention versus usual care or diet alone  
(Brown 2017b) 
   Exercise versus control (Brown 2017c) 
42.0 Ponderal index  DASH1 diet versus control diet with 
matching macronutrient contents (Han 
2017) 
Metformin versus glibenclamide evidence (Brown 2017a) 
   Low-moderate GI diet versus moderate-high GI diet (Han 2017) 
   Low-GI diet versus high-fibre moderate-GI diet (Han 2017) 
   Intensive management versus routine care (Han 2012) 
43.0 Adiposity (including 
skinfold thickness 
measurements (mm), fat mass) 
  Lifestyle intervention versus usual care or diet alone (whole-body 
neonatal fat mass) (Brown 2017b) 
44.1 Neonatal hypoglycaemia 
(not defined in the reviews) 
 Lifestyle intervention versus usual care 
or diet alone (Brown 2017b) 
Induction of labour versus expectant management 
(Boulvain 2001) 
   Glibenclamide versus placebo (Brown 2017a) 
   4 g myo-inositol + 400 mcg folic acid orally per day and exercise 
and dietary advice versus placebo 400 mcg folic acid orally per day 
and exercise and dietary advice (Brown 2016a) 
   Energy restricted diet versus no energy restricted diet (Han 2017)  
   Low-carbohydrate diet versus high-carbohydrate diet (Han 2017)  
   Ethnic specific diet versus standard healthy diet (Han 2017) 
   Exercise versus control (Brown 2017c) 
44.2 Neonatal hypoglycaemia 
(defined) 
  Metformin versus glibenclamide (BGL < 2.2 mmol/L; < 40 mg/dL) 
(Brown 2017a) 
   Glibenclamide versus acarbose (BGL < 2.2 mmol/L; < 40 mg/dL) 
(Brown 2017a) 
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Secondary Outcomes - Fetal/neonatal Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
   Soy protein-enriched diet versus no soy protein diet (BGL < 1.7 
mmol/L (< 30.6 mg/dL) (Han 2017) 
   Intensive management versus routine care evidence (BGL < 1.7 
mmol/L in two consecutive measurements (one trial) and as BGL < 
1.94 mmol/L (one trial)) (Han 2012) 
45.0 Respiratory distress 
syndrome (RDS) 
 Lifestyle intervention versus usual care 
or diet alone (Brown 2017b) 
Induction of labour versus expectant management  
(Boulvain 2001) 
   Metformin versus glibenclamide (Brown 2017a) 
   Glibenclamide versus acarbose (Brown 2017a) 
   Ethnic specific diet versus standard healthy diet (Han 2017) 
   Exercise versus control (Brown 2017c) 
46.0 Neonatal jaundice 
(hyperbilirubinaemia) (as 
defined in the reviews) 
 Metformin versus glibenclamide 
(Brown 2017a) 
Glibenclamide versus placebo (Brown 2017a) 
  Lifestyle intervention versus usual care 
or diet alone (Brown 2017b) 
Energy restricted diet versus no energy restricted diet (Han 2017) 
   Soy protein-enriched diet versus no soy protein diet (Han 2017) 
   Ethnic specific diet versus standard healthy diet (Han 2017) 
   Exercise versus control (Brown 2017c) 
   Intensive management versus routine care (plasma bilirubin at least 
205 μmol/l (one trial) and plasma bilirubin at least 670 μmol/l (one 
trial)) (Han 2012) 
 
47.0 Hypocalcaemia  Lifestyle intervention versus usual care 
or diet alone (Brown 2017b) 
Energy restricted diet versus no energy restricted diet (Han 2017) 
   Ethnic specific diet versus standard healthy diet (Han 2017) 
   Exercise versus control (Brown 2017c) 
 
48.0 Polycythaemia   Lifestyle intervention versus usual care or diet alone  
(Brown 2017b) 
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Secondary Outcomes - Later infant/childhood Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
49.0 Weight and z scores 
(The included review did not 
reported data for weight z 
scores) 
  Lifestyle intervention versus usual care or diet alone (at 4 to 5 years 
of age) (Brown 2017b) 
50.0 Height and z scores 
(The included review did not 
reported data for height z 
scores) 
  Lifestyle intervention versus usual care or diet alone (at 4 to 5 years 
of age) (Brown 2017b) 
51.1 Adiposity: Childhood BMI  Lifestyle intervention versus usual care 
or diet alone (at 4 to 5 years of age (one 
trial); 7 to 11 years of age (one trial; 5 to 
10 years of age (one trial)) (Brown 
2017b) 
 
51.1.2 Adiposity: Childhood BMI 
z score 
  Lifestyle intervention versus usual care or diet alone (at 4 to 5 years 
of age) (Brown 2017b) 
 
53.1 Impaired glucose 
tolerance: fasting blood 
glucose 
  Lifestyle intervention versus usual care or diet alone (at 7 to 11 
years of age) (Brown 2017b) 
53.2 Impaired glucose 
tolerance: two-hour post-
prandial blood glucose 
  Lifestyle intervention versus usual care or diet alone (2 hours post 
prandial) (7 to 11 years of age) (Brown 2017b) 
54.1 1 Dyslipidaemia or 
metabolic syndrome: Total 
cholesterol 
  Lifestyle intervention versus usual care or diet alone (at 7 to 11 
years of age) (Brown 2017b) 
54.2 Dyslipidaemia or metabolic 
syndrome: LDL1 cholesterol 
 
  Lifestyle intervention versus usual care or diet alone (at 7 to 11 
years of age) (Brown 2017b) 
54.3 Dyslipidaemia or metabolic 
syndrome: HDL2 cholesterol 
 
  Lifestyle intervention versus usual care or diet alone (at 7 to 11 
years of age) (Brown 2017b) 
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Secondary Outcomes - Health service use Benefit No clear difference Harm  
Overview Review Outcomes High Quality Evidence Moderate Quality Evidence Low or Very Low-Quality Evidence 
56.0 Number of antenatal visits 
or admissions 
 Lifestyle intervention versus usual care 
or diet alone (Brown 2017b) 
Soy protein-enriched diet versus no soy protein diet (Han 2017) 
57.1 Visits with dietitian nurse)  Lifestyle intervention versus usual care 
or diet alone (Brown 2017b) 
 
57.2 Visits with diabetes 
educator 
 Lifestyle intervention versus usual care 
or diet alone (Brown 2017b) 
 
57.3 Visits with obstetrician   Lifestyle intervention versus usual care or diet alone  
(Brown 2017b) 
57.4 Visits with healthcare 
provider (not specified) 
  Lifestyle intervention versus usual care or diet alone  
(Brown 2017b) 
58.0 Admission to neonatal 
intensive care unit/nursery 
  Glibenclamide versus placebo (Brown 2017a) 
   Metformin versus glibenclamide (Brown 2017a) 
   Soy protein-enriched diet versus no soy protein diet (Han 2017) 
  Intensive management versus routine 
care (Han 2012) 
Lifestyle intervention versus usual care or diet alone  
(Brown 2017b) 
59.0 Length of postnatal stay 
(baby) 
  Diet recommendation + diet-related behavioural advice versus diet 
recommendation only (Han 2017) 
1LDL is an acronym for Low Density Lipoprotein cholesterol 
2HDL is an acronym for High-Density Lipoprotein cholesterol 
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Primary outcomes - Maternal 
1.0 Hypertensive disorders of pregnancy (including pre-eclampsia, pregnancy-induced 
hypertension, eclampsia as defined in reviews) 
Hypertensive disorders of pregnancy were reported using various outcomes (any hypertensive disorder, 
not defined; pregnancy induced hypertension; severe pregnancy-induced hypertension or pre-
eclampsia; pre-eclampsia; eclampsia) at the end of pregnancy by five reviews (Brown 2017a; Brown 
2017b; Brown 2017c; Han 2012; Han 2017) (Table 2.8; Table 2.18). The quality of the evidence ranged 
from moderate- to very low-quality. There was no clear evidence of a difference between groups 
reported for any comparison for any hypertensive disorders of pregnancy; not defined; pregnancy-
induced hypertension; severe pregnancy-induced hypertension or pre-eclampsia; pre-eclampsia or 
eclampsia. 
1.1 Any hypertensive disorders of pregnancy (not defined) 
1.1.1 Oral antidiabetic agents versus placebo: There was no clear difference for the risk of any 
hypertensive disorder of pregnancy for women with GDM between the glibenclamide and the placebo 
group (RR 1.24; 95% CI 0.81 to 1.90; one trial, 375 women; very low-quality evidence) (Brown 2017a). 
1.1.2 Metformin versus glibenclamide: There was no clear difference for the risk of any hypertensive 
disorder of pregnancy for women with GDM between metformin and glibenclamide group (RR 0.70; 95% 
CI 0.38 to 1.30; three trials, 508 women; moderate-quality evidence) (Brown 2017a). 
Summary 
Probably no difference between interventions: direction of effect suggest benefit, but more 
evidence is needed 
• Moderate-quality evidence showed no clear difference for women with GDM for the 
treatment with metformin versus glibenclamide for the risk of any hypertensive disorders of 
pregnancy. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to 
comment on the effectiveness, more evidence needed 
• Very low-quality evidence showed no clear difference for the treatment with glibenclamide 
versus placebo for women with GDM for the risk of any hypertensive disorder of pregnancy. 
1.2 Pregnancy induced hypertension 
1.2.1 Oral antidiabetic agents versus placebo: There was no clear difference for the risk of pregnancy 
induced hypertension for women with GDM between the glibenclamide and the placebo group (RR 1.24, 
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95% CI 0.71 to 2.19; one trial, 375 women; low-quality evidence) (Brown 2017a). Pregnancy induced 
hypertension was defined as persistent systolic blood pressure ≥ 140 mmHg or diastolic blood pressure 
≥ 90 mmHg. 
1.2.2 Metformin versus glibenclamide: There was no clear difference for the risk of pregnancy 
induced hypertension (not defined) for women with GDM between the metformin and glibenclamide 
group (RR 0.71, 95 % CI 0.37 to 1.37; two trials, 359 women; moderate-quality evidence) (Brown 
2017a). 
1.2.3 Low carbohydrate diet versus high carbohydrate diet: There was no clear difference for the 
risk of maternal hypertension in pregnancy (not defined) for women with GDM between the low 
carbohydrate diet and high carbohydrate diet group (RR 0.40, 95 % CI 0.13 to 1.22; one trial, 150 
women; very low-quality evidence) (Han 2017). 
1.2.4 High unsaturated fat diet versus low unsaturated fat diet with matching calories: There was 
no clear difference for the risk of maternal hypertension in pregnancy (not defined) for women with GDM 
between the high unsaturated fat diet versus low unsaturated fat diet with matching calories group (RR 
0.54, 95 % CI 0.06 to 5.26; one trial, 27 women; very low-quality evidence) (Han 2017). 
1.2.5 Ethnic specific diet versus standard healthy diet: There was no clear difference for the risk of 
maternal hypertension in pregnancy (not defined) for women with GDM between the ethnic specific diet 
and standard healthy diet group (RR 0.33, 95 % CI 0.02 to 7.32; one trial, 20 women; very low-quality 
evidence) (Han 2017). 
Summary 
Probably no difference between interventions: direction of effect suggest benefit, but more 
evidence is needed 
• Moderate-quality evidence showed no clear difference for women with GDM for the treatment 
with metformin versus glibenclamide for the risk of pregnancy induced hypertension. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for the treatment with glibenclamide versus 
placebo for women with GDM for the risk of pregnancy induced hypertension. 
• Very low-quality evidence showed no clear difference for the treatment with low carbohydrate 
diet versus high carbohydrate diet; high unsaturated fat diet versus low unsaturated fat diet 
with matching calories; and ethnic specific diet versus standard healthy diet for women with 
GDM for the risk of pregnancy induced hypertension. 
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1.3 Severe pregnancy-induced hypertension or pre-eclampsia 
1.3.1 Oral antidiabetic agents versus placebo: There was no clear difference for the risk of severe 
pregnancy induced hypertension or pre-eclampsia for women with GDM between glibenclamide and the 
placebo group (1.23, 95% CI 0.59 to 2.56; one trial, 375 women; low-quality evidence) (Brown 2017a). 
Severe pregnancy induced hypertension or pre-eclampsia was defined as proteinuria ≥ 2 g in 24 hours, 
or ≥ 2+ on dipstick, blood pressure ≥ 160 mmHg or diastolic pressure ≥ 110 mmHg, serum creatinine > 
1.0 mg/dL, platelets < 100,000 mm3, asparate aminotransferase > 90 units/L, or symptoms such as 
persistent headache, scotomata or epigastric pain. 
1.3.2 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference for the risk 
of severe hypertension (not defined) or pre-eclampsia for women with GDM between the low-moderate 
GI diet and the moderate-high GI diet group (RR 1.02; 95% CI 0.07 to 15.86; one trial, 95 women; very 
low-quality evidence) (Han 2017). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for the treatment with glibenclamide versus 
placebo for women with GDM for the risk of severe hypertension or pre-eclampsia combined. 
• Very low-quality evidence showed no clear difference for the treatment with low-moderate GI 
diet versus moderate-high GI diet for women with GDM for the risk of severe hypertension or 
pre-eclampsia combined. 
1.4 Pre-eclampsia (not defined) 
1.4.1 Metformin versus Glibenclamide: There was no clear difference for the risk of pre-eclampsia for 
women with GDM between metformin and glibenclamide group (RR 0.66, 95 % CI 0.11 to 3.82; one 
trial, 149 women; very low-quality evidence) (Brown 2017a). 
1.4.2 Energy restricted diet versus no energy restricted diet: There was no clear difference for the 
risk of pre-eclampsia for women with GDM between the energy restricted diet and no energy restricted 
diet group (RR 1.00; 95% CI 0.51 to 1.97; one trial, 117 women; low quality evidence) (Han 2017). 
1.4.3 DASH diet versus control diet with matching macronutrient contents: There was no clear 
difference for the risk of pre-eclampsia for women with GDM between the DASH and the control diet 
with matching macronutrient contents group (RR 1.00, 95% CI 0.31 to 3.26; three trials, 136 women; 
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moderate-quality evidence) (Han 2017). (DASH is an acronym for Dietary Approaches to Stop 
Hypertension). 
1.4.4 High unsaturated fat diet versus low unsaturated fat diet with matching calories: There was 
no events of pre-eclampsia for women with GDM in either the high unsaturated fat or the low unsaturated 
fat diet with matching calories group (RR not estimable; one trial, 27 women; low-quality evidence) (Han 
2017). 
1.4.5 Soy protein-enriched diet versus no soy protein diet: There was no clear difference for the 
risk of pre-eclampsia for women with GDM between the soy protein-enriched and the no soy protein diet 
group (RR 2.00, 95 % CI 0.19 to 21.03; one trial, 68 women; very low-quality evidence) (Han 2017). 
1.4.6 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the 
risk of pre-eclampsia for women with GDM between the lifestyle intervention and usual care or diet alone 
group (RR 0.70, 95% CI 0.40 to 1.22; four trials, 2796 women; low-quality evidence) (Brown 2017b). 
1.4.7 Exercise versus control: There was no clear difference for the risk of pre-eclampsia for women 
with GDM between the exercise and control group (RR 0.31, 95% CI 0.01 to 7.09; two trials, 48 women; 
low-quality evidence) (Brown 2017c). 
1.4.8 Intensive management versus routine care: There was no clear difference for the risk of pre-
eclampsia for women with GDM between the intensive management and routine care group (RR 2.74; 
95% CI 0.26 to 29.07; one trial, 83 women; low-quality evidence) (Han 2012). 
Summary 
Probably ineffective interventions (more evidence needed): indicating that the review found 
moderate-quality evidence suggesting lack of effectiveness for an intervention, more evidence 
needed 
• Moderate-quality evidence showed no clear difference for women with GDM for the treatment 
with the DASH diet versus control diet with matching macronutrient contents for the risk of pre-
eclampsia. Insufficient evidence available. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for the treatment with energy restricted diet 
versus no energy restricted diet; high unsaturated fat diet versus low unsaturated fat diet with 
matching calories; lifestyle intervention versus usual care or diet alone; exercise versus control; 
and intensive management versus routine care for women with GDM for the risk of pre-
eclampsia.  
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Summary 
• Very low-quality evidence showed no clear difference for the treatment with metformin versus 
glibenclamide; or soy protein-enriched diet versus no soy protein diet for women with GDM for 
the risk of pre-eclampsia. 
1.5 Eclampsia (not defined) 
1.5.1 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference for the risk 
of eclampsia for women with GDM between a low-moderate GI diet and moderate-high GI diet group 
(RR 0.34; 95% CI 0.01 to 8.14, one trial 83 women; very low-quality evidence) (Han 2017). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Very low-quality evidence showed no clear difference for the risk of eclampsia with the 
treatment with low-moderate GI diet versus moderate-high GI diet. 
2.0 Caesarean section 
Caesarean section was reported as an outcome in seven reviews (Boulvain 2001; Brown 2017a; Brown 
2017b; Brown 2017c; Han 2012; Han 2017; Martis 2016a) (Table 2.8; Table 2.18). The quality of the 
evidence ranged from moderate- to very low-quality. 
2.1 Induction of labour versus expectant management: There was no clear difference for the risk of 
birth by caesarean section for women with GDM between induction of labour and expectant 
management group (RR 0.81, 95% CI 0.52 to 1.26; one trial, 200 women; low-quality evidence) 
(Boulvain 2001). 
2.2 Oral antidiabetic agents versus placebo: There was no clear difference for the risk of birth by 
caesarean section for women with GDM between the glibenclamide and placebo group (RR 1.03, 95% 
CI 0.79 to 1.34; one trial, 375 women; very low-quality evidence) (Brown 2017a). 
2.3 Metformin versus glibenclamide: There was no clear difference for the risk of birth by caesarean 
section for women with GDM between the metformin and glibenclamide group (average RR 1.20, 95% 
CI 0.83 to 1.72; four trials, 554 women; low-quality evidence) (Brown 2017a). 
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2.4 Glibenclamide versus acarbose: There was no clear difference for the risk of birth by caesarean 
section for women with GDM between the glibenclamide and acarbose group (RR 0.95, 95% CI 0.53 to 
1.70; one trial, 43 women; low-quality evidence) (Brown 2017a). 
2.5 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference for the risk 
of birth by caesarean section for women with GDM between the low-moderate GI diet and moderate-
high GI diet group (RR 0.66, 95% CI 0.29 to 1.47; one trial, 63 women; very low-quality evidence) (Han 
2017). 
2.6 Energy restricted diet versus no energy restricted diet: There was no clear difference for the 
risk of birth by caesarean section for women with GDM between the energy restricted diet and no energy 
restricted diet group (RR 1.12, 95% CI 0.80 to 1.56; two trials, 420 women; low-quality evidence) (Han 
2017). 
2.7 DASH diet versus control diet with matching macronutrient contents: There was evidence for 
a reduction for the risk of birth by caesarean section for women with GDM in the DASH diet group 
compared to the control diet with matching macronutrient contents group (RR 0.53, 95% CI 0.37 to 0.76; 
two trials, 86 women; moderate-quality evidence) (Han 2017). 
2.8 Low carbohydrate diet versus high-carbohydrate diet: There was no clear difference for the risk 
of birth by caesarean section for women with GDM between the low carbohydrate diet and high-
carbohydrate diet group (RR 1.29, 95% CI 0.84 to 1.99; two trials, 179 women; low-quality evidence) 
(Han 2017). 
2.9 High unsaturated fat diet versus low unsaturated fat diet with matching calories: There was 
no clear difference for the risk of birth by caesarean section for women with GDM between the high 
unsaturated fat diet and low unsaturated fat diet with matching calories group (RR 1.08, 95% CI 0.07 to 
15.50; one trial, 27 women; very low-quality evidence) (Han 2017). 
2.10 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference for the risk of 
birth by caesarean section for women with GDM between the low-GI diet and high-fibre moderate-GI 
diet group (RR 1.91, 95% CI 0.91 to 4.03; one trial, 92 women; low-quality evidence) (Han 2017). 
2.11 Diet recommendation + diet-related behavioural advice versus diet recommendation only: 
There was no clear difference for the risk of birth by caesarean section for women with GDM between 
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the diet recommendation + diet-related behavioural advice and diet recommendation only group (RR 
0.78, 95% CI 0.38 to 1.62; one trial, 99 women; low-quality evidence) (Han 2017). 
2.12 Soy protein-enriched diet versus no soy protein diet: There was no clear difference for the risk 
of birth by caesarean section for women with GDM between the soy protein-enriched diet and no soy 
protein diet group (RR 1.00, 95% CI 0.57 to 1.77; one trial 68 women; low-quality evidence) (Han 2017). 
2.13 Ethnic specific diet versus standard healthy diet: There was no clear difference for the risk of 
birth by caesarean section for women with GDM between the ethnic specific diet and standard healthy 
diet group (RR 1.20, 95% CI 0.54 to 2.67; one trial, 20 women; very low-quality evidence) (Han 2017). 
2.14 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the risk 
of birth by caesarean section for women with GDM between the lifestyle intervention and usual care or 
diet alone group (RR 0.90, 95% CI 0.78 to 1.05; 10 trials, 3545 women; low-quality evidence) (Brown 
2017b). 
2.15 Exercise versus control: There was no clear difference for the risk of birth by caesarean section 
for women with GDM between the exercise and control group (RR 0.86, 95% CI 0.63 to 1.16; five trials, 
316 women; moderate-quality evidence) (Brown 2017c). 
2.16 Intensive management versus routine care: There was no clear difference for the risk of birth 
by caesarean section for women with GDM between the intensive management and routine care group 
(RR 0.93, 95% CI 0.68 to 1.27; three trials, 509 women; very low-quality evidence) (Han 2012). 
2.17 Strict intensity of glycaemic control versus less strict glycaemic control: There was no clear 
difference for the risk of birth by caesarean section for women with GDM between the strict intensity of 
glycaemic control and less strict glycaemic control group (RR 1.35, 95% CI 0.83 to 2.18; one trial, 171 
women; very low-quality evidence) (Martis 2016a). 
Summary  
Promising interventions: moderate quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence of benefit suggested a benefit by a reduction for the risk of birth by 
caesarean section for women with GDM who were treated with the DASH diet compared to the 
control diet with matching macronutrient contents group. 
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Summary  
• Moderate-quality evidence showed no clear difference (the direction of the effect suggested 
benefit) for the treatment with exercise versus control for women with GDM for the risk of birth 
by caesarean section. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for the treatment with induction of labour 
versus expectant management; metformin versus glibenclamide; glibenclamide versus 
acarbose; energy restricted diet versus no energy restricted diet; low carbohydrate diet versus 
high-carbohydrate diet; low-GI diet versus high-fibre moderate-GI diet; diet recommendation + 
diet-related behavioural advice versus diet recommendation only; soy protein-enriched diet 
versus no soy protein diet; and lifestyle intervention versus usual care or diet alone for women 
with GDM for the risk of birth by caesarean section. 
• Very low-quality evidence showed no clear difference for the treatment with glibenclamide 
versus placebo; low-moderate GI diet versus moderate-high GI diet; high unsaturated fat diet 
versus low unsaturated fat diet with matching calories; ethnic specific diet versus standard 
healthy diet; intensive management versus routine care; and strict intensity of glycaemic 
control versus less strict glycaemic control for women with GDM for the risk of birth by 
caesarean section. 
3.0 Development of type 2 diabetes 
Development of type 2 diabetes was reported as an outcome by two reviews (Brown 2017b; Han 2017) 
(Table 2.8; Table 2.18). Time points for testing for type two diabetes ranged from one to two weeks 
postpartum (Han 2017) up to 13 months post-partum (Han 2017). The Brown 2017b review did not 
define the test or the time point. The quality of the evidence ranged from low- to very low-quality. There 
was no clear evidence of a difference for the risk of development of type 2 diabetes for any of the 
comparisons reporting this outcome. 
3.1 OGTT (Oral Glucose Tolerance Test) for diagnosis of type 2 diabetes 
3.1.1 High unsaturated fat diet versus low unsaturated fat diet with matching calories: There was 
no clear difference for the risk of developing type 2 diabetes at one to two weeks postpartum, (RR 2.00, 
95% CI 0.45 to 8.94; one trial, 24 women; very low-quality evidence) or at four to 13 months postpartum 
(RR 1.00, 95% CI 0.10 to 9.61; one trial, 6 women; very low-quality evidence) for women with GDM 
between the high unsaturated fat diet and low unsaturated fat diet with matching calories group (Han 
2017). 
3.1.2 Low-GI diet versus high fibre moderate-GI diet: There was no clear difference for the risk of 
developing type 2 diabetes at three months postpartum, for women with GDM between the low-GI diet 
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versus high fibre moderate-GI diet group (RR 0.76, 95% CI 0.11 to 5.01; one trial, 58 women; very low-
quality evidence) (Han 2017). 
3.1.3 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the 
risk of developing type 2 diabetes (test and time frame not defined in the review) for women with GDM 
between the lifestyle intervention and usual care or diet alone group (RR 0.98, 95% CI 0.54 to 1.76; two 
trials, 486 women; low-quality evidence) (Brown 2017b). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for the treatment with lifestyle intervention 
versus usual care or diet alone for women with GDM for the risk of developing type 2 diabetes 
(diagnostic test or timeframe not defined). 
• Very low-quality evidence showed no clear difference for the treatment with high unsaturated 
fat diet versus low unsaturated fat diet with matching calories for women with GDM or the risk 
of developing type 2 diabetes using the OGTT (Oral Glucose Tolerance Test) for diagnosis of 
type 2 diabetes at one- to two-weeks post-partum or at four to 13 months post-partum. There 
was no clear difference for the treatment with low-GI diet versus high fibre moderate-GI diet 
for women with GDM for the risk of developing type 2 diabetes using the OGTT at three months 
post-partum. 
Primary outcomes - Neonatal 
4.0 Perinatal (fetal and neonatal death) and later infant mortality 
Perinatal (fetal and neonatal death) and later infant mortality was an outcome that was reported by five 
reviews (Boulvain 2001; Brown 2017a; Brown 2017b; Brown 2017c; Han 2017) (Table 2.9; Table 2.18). 
All five reviews reported perinatal mortality. None reported on later infant mortality. The quality of the 
evidence ranged from low- to very low-quality. There was no clear evidence of a difference for the risk 
of perinatal mortality for any of the comparisons reporting this outcome. 
4.1 Induction of labour versus expectant management: There were no events of perinatal mortality 
recorded for babies born to mothers with GDM in either the induction of labour or the expectant 
management group (RR not estimable; one trial, 200 babies; very low-quality evidence) (Boulvain 2001). 
4.2 Metformin versus glibenclamide: There was no clear difference for the risk of perinatal mortality 
for babies born to mothers with GDM between the metformin and glibenclamide group (average RR 
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0.92, 95% CI 0.06 to 14.55; two trials, 359 babies; very low-quality evidence) (Brown 2017a). There 
were no deaths in each group in one trial and one death in each group for the second trial. 
4.3 Glibenclamide versus acarbose: There were no perinatal deaths for babies whose mothers were 
treated with either glibenclamide or acarbose (RR not estimable; one trial, 43 babies; low-quality 
evidence) (Brown 2017a). 
4.4 Energy restricted diet versus no energy restricted diet: There were no perinatal deaths reported 
for babies born to mothers with GDM who were treated with the energy restricted diet or the no energy 
restricted diet group (RR not estimable; two trials, 423 babies; low-quality evidence) (Han 2017). 
4.5 Low carbohydrate diet versus high-carbohydrate diet: There was no clear difference for the risk 
of perinatal mortality for babies born to mothers with GDM between the low carbohydrate diet and high-
carbohydrate diet group (RR 3.00, 95% CI 0.12 to 72.49; one trial, 150 babies; very low-quality evidence) 
(Han 2017). There was one event in the control group. 
4.6 Lifestyle intervention versus usual care or diet alone: There was no clear difference and 
substantial uncertainty about the size and the direction of effect for perinatal mortality for babies born to 
mothers with GDM between the lifestyle intervention and usual care or diet alone group (RR 0.09, 95% 
CI 0.01 to 1.70; two trials, 1988 babies; low-quality evidence) (Brown 2017b). One trial had no events 
and one trial had 5 events in the control group. 
4.7 Exercise versus control: There were no events of perinatal deaths reported for babies born to 
mothers with GDM who were treated either in the exercise or the control group (RR not estimable; one 
trial, 19 babies; low-quality evidence) (Brown 2017c). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for the risk of perinatal mortality for babies 
born to mothers with GDM who were treated with glibenclamide versus acarbose; energy 
restricted diet versus no energy restricted diet; lifestyle intervention versus usual care; or diet 
alone or exercise versus control. 
• Very low-quality evidence showed no clear difference for the risk of perinatal mortality for 
babies born to mothers with GDM who were treated with induction of labour versus expectant 
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management; metformin versus glibenclamide; or low carbohydrate diet versus high-
carbohydrate diet for women with GDM for the risk of perinatal mortality. 
5.0 Large-for-gestational age (LGA) (defined as > 90th percentile in all included reviews) 
Large-for-gestational age (LGA) was reported as an outcome by six reviews (Boulvain 2001; Brown 
2016a; Brown 2017a; Brown 2017b; Han 2012; Han 2017) (Table 2.9; Table 2.18). The quality of the 
evidence ranged from low- to very low-quality. 
5.1 Induction of labour versus expectant management: The evidence suggested a reduction in the 
risk of LGA for babies whose mothers were induced at 38 completed weeks of gestation compared to 
the expectant management group (RR 0.43, 95% CI 0.22 to 0.87; one trial, 200 babies; low-quality 
evidence) (Boulvain 2001). 
5.2 Oral antidiabetic agents versus placebo: There was no clear difference in the risk of LGA for 
babies born to mothers with GDM between the glibenclamide and placebo group (RR 0.89, 95% CI 0.51 
to 1.58; one trial, 375 babies; very low-quality evidence) (Brown 2017a). 
5.3 Metformin versus glibenclamide: There was no clear difference in the risk of LGA for babies born 
to mothers with GDM between the metformin and glibenclamide group (RR 0.67, 95% CI 0.24 to 1.83; 
two trials, 246 babies; low-quality evidence) (Brown 2017a). 
5.4 Glibenclamide versus acarbose: There was no clear difference in the risk of LGA for babies born 
to mothers with GDM between the glibenclamide and acarbose group (RR 2.38, 95% CI 0.54 to 10.46; 
one trial, 43 babies; low-quality evidence) (Brown 2017a). 
5.5 Myo-inositol versus placebo: There was no clear difference in the risk of LGA for babies born to 
mothers with GDM between the myo-inositol and the placebo group (RR 0.36, 95 % CI 0.02 to 8.58; one 
trial, 73 babies; low-quality evidence) (Brown 2016a). 
5.6 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference for the risk 
of LGA for babies born to mothers with GDM between the low-moderate GI diet and moderate-high GI 
diet group (RR 0.71, 95% CI 0.22 to 2.34; two trials, 89 babies; low-quality evidence) (Han 2017). 
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5.7 Energy restricted diet versus no energy restricted diet: There was no clear difference for the 
risk of LGA for babies born to mothers with GDM between the energy restricted diet and no energy 
restricted diet group (RR 1.17, 95% CI 0.65 to 2.12; one trial, 123 babies; low-quality evidence) (Han 
2017). 
5.8 Low carbohydrate diet versus high-carbohydrate diet: There was no clear difference for the risk 
of LGA for babies born to mothers with GDM between the low carbohydrate diet and high-carbohydrate 
diet group (RR 0.51, 95% CI 0.13 to 1.95; one trial, 149 babies; very low-quality evidence) (Han 2017). 
5.9 High unsaturated fat diet versus low unsaturated fat diet with matching calories: There was 
no clear difference for the risk of LGA for babies born to mothers with GDM between the high 
unsaturated fat diet and low unsaturated fat diet with matching calories group (RR 0.54, 95% CI 0.21 to 
1.37; one trial, 27 women; very low-quality evidence) (Han 2017). 
5.10 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference for the risk of 
LGA for babies born to mothers with GDM between the low-GI diet and high-fibre moderate-GI diet 
group (RR 2.87, 95% CI 0.61 to 13.50; one trial, 92 babies; very low-quality evidence) (Han 2017). 
5.11 Diet recommendation + diet-related behavioural advice versus diet recommendation only: 
There was no clear difference for the risk of LGA for babies born to mothers with GDM between the diet 
recommendation + diet-related behavioural advice and diet recommendation only group (RR 0.73, 95% 
CI 0.25 to 2.14; one trial, 99 babies; very low-quality evidence) (Han 2017). 
5.12 Ethnic specific diet versus standard healthy diet: There was no clear difference for the risk of 
LGA for babies born to mothers with GDM between the ethnic specific diet and standard healthy diet 
group (RR 0.14, 95% CI 0.01 to 2.45; one trial, 20 women; very low-quality evidence) (Han 2017). 
5.13 Lifestyle intervention versus usual care or diet alone: The evidence suggested a reduction in 
the risk of LGA for babies born to mothers with GDM in the lifestyle intervention compared to the usual 
care or diet alone group (RR 0.60, 95% CI 0.50 to 0.71; six trials, 2994 babies; moderate-quality 
evidence) (Brown 2017b). 
5.14 Intensive management versus routine care: The evidence suggested a reduction in the risk of 
LGA for babies born to mothers with GDM in the intensive management group compared to the routine 
care group (RR 0.37, 95% CI 0.20 to 0.66; three trials, 438 babies; low-quality evidence) (Han 2012). 
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Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence suggested a benefit by a reduction in the risk of LGA for babies 
born to mothers who were treated with lifestyle intervention compared to the usual care or diet 
alone. 
No conclusions possible: low to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence suggested a benefit by a reduction in the risk of LGA for babies born to 
mothers who were treated with induction of labour compared to expectant management at 38 
weeks' complete gestation; or with intensive management compared to routine care. There 
was no clear evidence of a difference for the risk of being born LGA for babies born to mothers 
with GDM who were treated with metformin versus glibenclamide; glibenclamide versus 
acarbose; myo-inositol versus placebo; low-moderate GI diet versus moderate-high GI diet or 
energy restricted diet versus no energy restricted diet. 
• Very low-quality evidence showed no clear difference in the risk of LGA for babies born to 
mothers with GDM who were treated with glibenclamide versus placebo; low carbohydrate diet 
versus high-carbohydrate diet; high unsaturated fat diet versus low unsaturated fat diet with 
matching calories; low-GI diet versus high-fibre moderate-GI diet; Diet recommendation + diet-
related behavioural advice versus diet recommendation only; or ethnic specific diet versus 
standard healthy diet for the risk of LGA for the babies. 
6.0 Death or serious morbidity composite (as defined in reviews, e.g. perinatal or infant death, 
shoulder dystocia, bone fracture or nerve palsy) 
Death or serious morbidity composite (as defined in reviews, e.g. perinatal or infant death, shoulder 
dystocia, bone fracture or nerve palsy) was reported as an outcome in four reviews (Brown 2017a; Han 
2017; Brown 2017b; Brown 2017c) (Table 2.9; Table 2.18). The components of the composite differed 
between trials. The quality of the evidence ranged from moderate- to very low-quality.  
6.1 Metformin versus glibenclamide: The evidence suggested a reduction in the risk of a death or 
serious morbidity composite outcome for babies born to mothers with GDM in the metformin group 
compared to the glibenclamide group (RR 0.54, 95% CI 0.31 to 0.94; one trial, 159 babies; low-quality 
evidence) (Brown 2017a). The morbidity composite included hypoglycaemia, hyperbilirubinaemia, 
macrosomia, respiratory illness, birth injury, stillbirth or neonatal death. 
6.2 Ethnic specific diet versus standard healthy diet: There were no babies in either group that 
experienced morbidity composite outcomes whose mothers were treated with the ethnic specific diet or 
the standard healthy diet group (RR not estimable; one trial, 20 babies; very low-quality evidence) (Han 
2017). The morbidity composite included hypoglycaemia, neonatal asphyxia, respiratory distress 
syndrome, hyperbilirubinaemia and hypocalcaemia.  
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6.3 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the risk 
of a death or serious morbidity composite outcome for babies born to mothers with GDM between the 
lifestyle intervention and usual care or diet alone group (average RR 0.57, 95% CI 0.21 to 1.55; two 
trials, 1930 babies; very low-quality evidence) (Brown 2017b). The death or serious morbidity composite 
included death, shoulder dystocia, bone fracture and nerve palsy in one trial and in the other trial 
included stillbirth, neonatal death, hypoglycaemia, hyperbilirubinaemia, elevated cord-blood C-peptide 
and birth trauma. The authors of the review decided to include both trials in the meta-analysis as the 
direction of the treatment effect is the same for both trials. 
6.4 Exercise versus control: There was no clear difference for the risk of a death or serious morbidity 
composite outcome for babies born to mothers with GDM between the exercise and control group (RR 
0.56, 95% CI 0.12 to 2.61; two trials, 169 babies; moderate-quality evidence) (Brown 2017c). 
Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence showed no clear difference in the risk of death or serious morbidity 
composite outcomes for babies born to mothers with GDM who were treated with exercise 
versus control. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed  
• Low-quality evidence suggested a benefit by a reduction in the risk of death or serious morbidity 
composite outcomes for babies born to mothers with GDM who were treated with metformin 
compared to glibenclamide. 
• Very low-quality evidence showed no clear difference in the risk of death or serious morbidity 
composite outcomes for babies born to mothers with GDM who were treated with ethnic 
specific diet versus standard healthy diet or with lifestyle intervention versus usual care or diet 
alone. 
7.0 Neurosensory disability in later childhood (as defined in reviews) 
None of the included reviews reported data for neurosensory disability in later childhood as either a 
primary or a secondary outcome. 
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Secondary outcomes - Maternal 
8.0 Use of additional pharmacotherapy 
The use of additional pharmacotherapy was reported as an outcome by seven reviews (Brown 2016a; 
Brown 2017a; Han 2017; Brown 2017b; Brown 2017c; Han 2012; Martis 2016a) (Table 2.11; Table 
2.19). The quality of the evidence ranged from high- to very low-quality.  
8.1 Oral antidiabetic agents versus placebo: There was no clear difference for the risk of requiring 
additional pharmacotherapy (insulin) for women with GDM between the oral antidiabetic agent 
(glibenclamide or acarbose) and placebo group (RR 0.68, 95% CI 0.42 to 1.11; two trials, 434 women; 
low-quality evidence) (Brown 2017a). A further included trial in the review reported that "15/19 women 
in the standard care group were prescribed metformin and two women required insulin. However, it is 
not clear if any women in the metformin group required supplementary insulin". 
8.2 Metformin versus glibenclamide: There was no difference for the risk of requiring additional 
pharmacotherapy (insulin) for women with GDM between the metformin and glibenclamide group (RR 
0.66; 95% CI 0.28 to 1.57; five trials, 660 women; very low-quality evidence) (Brown 2017a). 
8.3 Glibenclamide versus acarbose: There was no clear difference for the risk of requiring additional 
pharmacotherapy (insulin) for women with GDM between the glibenclamide and acarbose group (RR 
0.49, 95% CI 0.19 to 1.27; one trial, 43 women; low-quality evidence) (Brown 2017a). 
8.4 Myo-inositol versus placebo: There was no clear difference for the risk of requiring additional 
pharmacotherapy (insulin) for women with GDM between the myo-inositol and the placebo group 
(average RR 0.37, 95 % CI 0.08 to 1.73; two trials, 157 women; low-quality evidence) (Brown 2016a). 
8.5 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference for the use 
of additional pharmacotherapy (not defined) for women with GDM between the low-moderate GI diet 
and moderate-high GI diet group (RR 0.82, 95% CI 0.39 to 1.74; four trials, 221 women; low-quality 
evidence) (Han 2017). 
8.6 Energy restricted diet versus no energy restricted diet: Meta-analysis was not possible for this 
outcome due to substantial heterogeneity (I² = 94%). One trial was judged to be of very low-quality 
evidence (Han 2017) and showed no clear difference for the use of additional pharmacotherapy (insulin) 
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for women with GDM between the energy restricted diet and no energy restricted diet group (RR 1.05, 
95% CI 0.47 to 2.34; one trial, 117 women). 
The use of insulin in the second trial was only part of the protocol for the energy-restricted diet 
intervention group, and thus accordingly there were more cases of additional pharmacotherapy use in 
this group (36/149 versus 0/150 in the energy-restricted diet and no energy-restricted diet groups, 
respectively) (RR 73.49, 95% CI 4.55 to 1186.39; one trial, 299 women; very low-quality). 
8.7 DASH diet versus control diet with matching macronutrient contents: The evidence suggested 
a reduced use of additional pharmacotherapy (not defined) for women with GDM in the DASH diet group 
compared to the control diet with matching macronutrient contents group (RR 0.28, 95% CI 0.14 to 0.53; 
two trials, 86 women; moderate-quality evidence) (Han 2017). 
8.8 Low carbohydrate diet versus high-carbohydrate diet: There was no clear difference for the use 
of additional pharmacotherapy (not defined) for women with GDM between the low carbohydrate diet 
and high-carbohydrate diet group (RR 1.02, 95% CI 0.77 to 1.37; two trials, 180 women; low-quality 
evidence) (Han 2017). 
8.9 High unsaturated fat diet versus low unsaturated fat diet with matching calories: There were 
no events of the use of additional pharmacotherapy (not defined) for women with GDM in either the high 
unsaturated fat diet or the low unsaturated fat diet with matching calories group (RR not estimable; two 
trials, 111 women; low-quality evidence) (Han 2017). 
8.10 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference for the use of 
additional pharmacotherapy (not defined) for women with GDM between the low-GI diet and high-fibre 
moderate-GI diet group (RR 0.83, 95% CI 0.58 to 1.17; one trial, 92 women; low-quality evidence) (Han 
2017). 
8.11 Diet recommendation + diet-related behavioural advice versus diet recommendation only: 
There was no clear difference for the use of additional pharmacotherapy (not defined) for women with 
GDM between the diet recommendation + diet-related behavioural advice and diet recommendation 
only group (RR 0.61, 95% CI 0.15 to 2.42; one trial, 99 women; very low-quality evidence) (Han 2017). 
8.12 Soy protein-enriched diet versus no soy protein diet: There was no clear difference for the use 
of additional pharmacotherapy (not defined) for women with GDM between the soy protein-enriched diet 
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and the no soy protein diet group (RR 1.00, 95 % CI 0.15 to 6.70; one trial, 68 women; very low-quality 
evidence) (Han 2017). 
8.13 High-fibre diet versus standard-fibre diet: There were no events of the use of additional 
pharmacotherapy (not defined) for women with GDM in either the high-fibre diet or the standard-fibre 
diet (RR not estimable; one trial, 22 women; low-quality evidence) (Han 2017). 
8.14 Ethnic specific diet versus standard healthy diet: There was no clear difference for the use of 
additional pharmacotherapy (not defined) for women with GDM between the ethnic specific diet and 
standard healthy diet group (RR 2.00, 95% CI 0.21 to 18.69; one trial, 20 women; very low-quality 
evidence) (Han 2017). 
8.15 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the 
use of additional pharmacotherapy (oral antidiabetic agents) for women with GDM between the lifestyle 
intervention and usual care or diet alone group (average RR 0.79, 95% CI 0.52 to 1.19; one trial, 197 
women; moderate-quality evidence) (Brown 2017b). 
8.16 Lifestyle intervention versus usual care or diet alone: The evidence suggested an increased 
risk of needing additional pharmacotherapy (insulin) for women with GDM in the lifestyle intervention 
group compared to the usual care or diet alone group (average RR 2.54, 95% CI 1.19 to 5.42; nine trials, 
3254 women; very low-quality evidence) (Brown 2017b). 
8.17 Exercise versus control: There was no clear difference in the risk of needing additional 
pharmacotherapy (one trial defined as insulin, others not defined) for women with GDM between the 
exercise and control group (RR 0.76, 95% CI 0.54 to 1.08; seven trials, 413 women; moderate-quality 
evidence) (Brown 2017c). 
8.18 Intensive management versus routine care: There was no clear difference in the risk of needing 
additional pharmacotherapy (defined as insulin or oral hypoglycaemic agents in the review) for women 
with GDM between the intensive management and routine care group (RR 1.00, 95% CI 0.30 to 3.32; 
one trial, 12 women; very low-quality evidence) (Han 2012). 
8.19 Strict intensity of glycaemic control versus less strict glycaemic control: The evidence 
suggested an increased risk of needing additional pharmacotherapy (insulin) for women with GDM in 
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the strict intensity of glycaemic control group compared to the less strict glycaemic control group (RR 
1.85, 95% CI 1.14 to 3.03; one trial, 171 women; very low-quality evidence) (Martis 2016a). 
Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence showed no clear difference for the use of additional 
pharmacotherapy for women with GDM who were treated with lifestyle interventions versus 
usual care or diet alone (the additional pharmacotherapy being the oral antidiabetic agents 
glibenclamide and acarbose); the DASH diet compared to the control diet with matching 
macronutrient contents (additional pharmacotherapy not defined in the review) or exercise 
versus control (the additional pharmacotherapy being insulin one trial, others not defined). 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for the use of additional pharmacotherapy for 
women who were treated with glibenclamide versus placebo; acarbose versus placebo; 
glibenclamide versus acarbose; myo-inositol versus placebo; low-moderate GI diet versus 
moderate-high GI diet; low carbohydrate diet versus high-carbohydrate diet or low-GI diet 
versus high-fibre moderate-GI diet. There were no events reported in either group for high 
unsaturated fat diet versus low unsaturated fat diet with matching calories or high-fibre diet 
versus standard-fibre diet. 
• Very low-quality evidence suggested an increase in the use of insulin for women who were 
treated with lifestyle interventions compared to usual care or diet alone; or strict intensity of 
glycaemic control compared to less strict glycaemic control. 
• Very low-quality evidence showed no clear difference for the use of additional 
pharmacotherapy for women who were treated with metformin versus glibenclamide; or energy 
restricted diet versus no energy restricted diet; diet recommendation + diet-related behavioural 
advice versus diet recommendation only; soy protein-enriched diet versus no soy protein diet; 
or ethnic specific diet versus standard healthy diet or intensive management versus routine 
care. 
9.0 Maternal hypoglycaemia (as defined in the reviews) 
Maternal hypoglycaemia was reported as an outcome by four reviews (Brown 2017a; Brown 2017b; 
Brown 2017c; Han 2017). Maternal hypoglycaemia was only defined in one of three trials within the 
Brown 2017a review. None of the remaining reviews included definitions of maternal hypoglycaemia 
(Table 2.11; Table 2.19). The quality of the evidence ranged from low- to very low-quality. There was 
no clear evidence of a difference for the risk of maternal hypoglycaemia for any of the comparisons 
reporting this outcome. 
9.1 Metformin versus glibenclamide: There was no clear difference for the risk of maternal 
hypoglycaemia for women with GDM between the metformin and glibenclamide group (RR 0.89; 95% 
CI 0.36 to 2.19; three trials, 354 women; low-quality evidence) (Brown 2017a). One of the three trials 
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defined maternal hypoglycaemia as < 3.3 mmol/L (60 mg/dL). One further trial was excluded from this 
analysis, "currently published as a conference abstract, reported data for women who dropped out of 
the study with hypoglycaemia. 39% of women in the glibenclamide group (17/45) and 3% of women in 
the metformin group (1/36) “dropped out” of the study due to maternal hypoglycaemia. It is unclear 
whether they withdrew from the study due to treatment side effects or were lost to follow-up". 
9.2 Glibenclamide versus acarbose: There were no events for maternal hypoglycaemia in either the 
glibenclamide or acarbose treated group (RR not estimable; one trial, 43 women; low-quality evidence) 
(Brown 2017a). 
9.3 High-fibre diet versus standard-fibre diet: There was no clear difference for the risk of maternal 
hypoglycaemia for women with GDM between the high-fibre diet and standard-fibre diet (recorded as 
mean numbers of events) (MD -1.00; -2.08 to 0.08; one trial, 22 women; very low-quality evidence) (Han 
2017). 
9.4 Lifestyle intervention versus usual care or diet alone: There were no events for maternal 
hypoglycaemia in either the lifestyle intervention or usual care or diet group (RR not estimable; one trial, 
19 women; very low-quality evidence) (Brown 2017b). 
9.5 Exercise versus control: There were no events for maternal hypoglycaemia in either the exercise 
or the control group (RR not estimable; one trial, 34 women; low-quality evidence) (Brown 2017c). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for the risk of maternal hypoglycaemia for 
women with GDM who were treated with Metformin versus glibenclamide (defined as < 3.3 
mmol/L (60 mg/dL)); or glibenclamide versus acarbose (not defined); or exercise versus 
control. 
• Very low-quality evidence showed no clear difference for the risk of maternal hypoglycaemia 
for women with GDM who were treated with high-fibre diet versus standard-fibre diet (not 
defined); or lifestyle intervention versus usual care or diet alone (not defined). 
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10.0 Glycaemic control during/ end of treatment (as defined in the reviews) 
Glycaemic control during/end of treatment was reported as an outcome by five reviews (Brown 2016a; 
Brown 2017a; Brown 2017b; Brown 2017c; Han 2017) (Table 2.11; Table 2.19). The outcome was 
reported at different time points during or at the end of treatment using the following measures: 
Glycaemic control (timing not defined); Glycaemic control during the treatment: pre-prandial/fasting, 
post-prandial; HbA1c, 24 hour mean plasma glucose; Glycaemic control at the end of treatment: Fasting, 
one-hour post-prandial, two-hours postprandial, post-prandial timing not defined, mean plasma glucose, 
HbA1c; Glycaemic control during/at the end of treatment: Fasting, mean plasma glucose, HbA1c. 
The time of day for the recording of one-hour and two-hour post-prandial blood glucose measurements 
also varied with some being recorded after breakfast, and others after lunch or dinner. 
The quality of the evidence ranged from moderate- to very low-quality.  
10.1 Glycaemic control: timing not defined 
10.1.1 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference in blood 
glucose concentration (timing and testing not defined in the review) for women with GDM between the 
low-GI diet and high-fibre moderate-GI diet group (MD -0.10 mmol/L, 95% CI -0.38 to 0.18; one trial, 74 
women; very low-quality evidence) (Han 2017). 
10.2 Glycaemic control during the treatment: pre-prandial/fasting 
10.2.1 Energy restricted diet versus no energy restricted diet: There was no clear difference in pre-
prandial/fasting blood glucose concentration during the intervention (timing not defined) for women with 
GDM between the energy restricted diet and no energy restricted diet group (MD 0.21 mmol/L, 95% CI 
-0.58 to -0.99; two trials, 311 women; low-quality evidence) (Han 2017). 
10.2.2 High unsaturated fat diet versus low unsaturated fat diet with matching calories: The 
evidence suggested a small but elevated fasting glucose concentration during the intervention at 38 
weeks' gestation for women with GDM in the high unsaturated fat diet group compared to the low 
unsaturated fat diet with matching calories group (MD 0.50 mmol/L, 95% CI 0.30 to 0.70; one trial, 24 
women; low-quality evidence) (Han 2017). 
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10.3 Glycaemic control during the treatment: post-prandial 
10.3.1 Energy restricted diet versus no energy restricted diet: There was no clear difference in one-
hour post-prandial glucose concentration for women with GDM between the energy restricted diet and 
no energy restricted diet group (MD -0.25 mmol/L, 95% CI -0.68 to -0.18; one trial, 299 women; low-
quality evidence) (Han 2017). 
10.3.2 High unsaturated fat diet versus low unsaturated fat diet with matching calories: The 
evidence suggested higher post-prandial glucose concentration (no post-prandial time given) during the 
intervention at 38 weeks' gestation for women with GDM in the high unsaturated fat diet group compared 
to the low unsaturated fat diet with matching calories group (MD 0.90 mmol/L, 95% CI 0.58 to 1.22; one 
trial, 25 women; low-quality evidence) (Han 2017). 
10.4 Glycaemic control during treatment: HbA1c 
10.4.1 Metformin versus glibenclamide: There was no clear difference in HbA1c in the third trimester 
of the pregnancy for women with GDM between the metformin and glibenclamide group (SMD -0.12, 
95% CI -0.39 to 0.16; one trial, 200 women; low-quality evidence) (Brown 2017a). 
10.4.2 High unsaturated fat diet versus low unsaturated fat diet with matching calories: The 
evidence suggested higher HbA1c results during the intervention at 38 weeks' gestation for women with 
GDM in the high unsaturated fat diet group compared to the low unsaturated fat diet with matching 
calories group (MD 0.40 %, 95% CI 0.32 to 0.48; one trial, 25 women; low-quality evidence) (Han 2017). 
10.5 Glycaemic control during the treatment: 24 hour mean plasma glucose 
10.5.1 Energy restricted diet versus no energy restricted diet: There was no clear difference in the 
24 hour mean plasma glucose concentration during the intervention for women with GDM between the 
energy restricted diet and no energy restricted diet group (MD 0.10 mmol/L, 95% CI -0.82 to 1.02; one 
trial, 12 women; low-quality evidence) (Han 2017). 
10.6 Glycaemic control at the end of treatment: Fasting 
10.6.1 Oral antidiabetic agents versus placebo: The evidence suggested a reduction in fasting 
capillary glucose concentration (taken at the last three antenatal visits) for women with GDM in the oral 
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antidiabetic drug glibenclamide group compared to the placebo group (MD -3.0 mg/dL, 95% CI -5.13 to 
-0.87; one trial, 375 women; low-quality evidence) (Brown 2017a). 
10.6.2 Metformin versus glibenclamide: The evidence suggested an increase in fasting blood glucose 
concentration at the end of treatment for women with GDM in the metformin group compared to the 
glibenclamide group (SMD 0.19 mmol/L, 95% CI 0.02 to 0.37; three trials, 508 women; low-quality 
evidence) (Brown 2017a). 
10.6.3 Myo-inositol versus placebo: The evidence suggested a reduction in fasting blood glucose 
concentration at the end of treatment (with OGTT) for women with GDM in the myo-inositol group 
compared to the placebo 400 mcg folic acid orally per day and exercise and dietary advice group (MD -
0.47 mmol/L, 95% CI -0.59 to -0.35; two trials, 142 women; moderate-quality evidence) (Brown 2016a). 
10.6.4 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference in fasting 
plasma glucose concentration at the end of treatment for women with GDM between the low-moderate 
GI diet and moderate-high GI diet group (MD -0.15 mmol/L, 95% CI -0.55 to 0.25; one trial, 83 women; 
very low-quality evidence) (Han 2017). 
10.6.5 Energy restricted diet versus no energy restricted diet: The evidence suggested a reduction 
in fasting blood glucose concentration at the end of treatment for women with GDM in the energy 
restricted diet group compared to the no energy restricted diet group (MD -0.23 mmol/L, 95% CI -0.44 
to -0.03; two trials, 311 women; low-quality evidence) (Han 2017). 
10.6.6 DASH diet versus control diet with matching macronutrient contents: The evidence 
suggested a reduction in fasting blood glucose concentration at the end of treatment for women with 
GDM in the DASH diet group compared to the diet with matching macronutrient contents group (MD -
0.42 mmol/L, 95% CI -0.53 to -0.32; two trials, 66 women; moderate-quality evidence) (Han 2017). 
10.6.7 Low carbohydrate diet versus high-carbohydrate diet: There was no clear difference in 
fasting blood glucose concentration at the end of treatment for women with GDM between the low 
carbohydrate diet and high-carbohydrate diet group (MD 5.00 mg/dL, 95% CI -0.01 to 10.01; one trial, 
30 women; very low-quality evidence) (Han 2017). 
10.6.8 High unsaturated fat diet versus low unsaturated fat diet with matching calories: There 
was no clear difference in fasting blood glucose concentration at the end of treatment for women with 
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GDM between the high unsaturated fat diet and low unsaturated fat diet with matching calories group 
(MD 0.18 mmol/L, 95% CI -0.17 to 0.53; one trial, 84 women; low-quality evidence) (Han 2017). 
10.6.9 Diet recommendation + diet-related behavioural advice versus diet recommendation only: 
There was no clear difference in fasting blood glucose concentration at the end of treatment for women 
with GDM between the diet recommendation + diet-related behavioural advice and diet recommendation 
only group (MD 0.0 mg/dL, 95% CI -4.25 to 4.25; one trial, 99 women; very low-quality evidence) (Han 
2017). 
10.6.10 Soy protein-enriched diet versus no soy protein diet: The evidence suggested a reduction 
in fasting plasma glucose concentration at the end of treatment for women with GDM in the soy protein-
enriched diet group compared to the no soy protein diet group (MD -10.60 mg/dL, 95% CI -15.37 to -
5.83; one trial, 68 women; very low-quality evidence) (Han 2017). 
10.6.11 Exercise versus control: The evidence suggested a reduction in fasting plasma glucose 
concentration at the end of treatment for women with GDM in the exercise group compared to the control 
group (average SMD -0.59, 95% CI -1.07 to -0.11; four trials, 363 women; I2 = 73%; low-quality evidence) 
(Brown 2017c). 
10.7 Glycaemic control at the end of treatment: One-hour post-prandial 
10.7.1 Myo-inositol versus placebo: The evidence suggested a reduction in one-hour post-prandial 
blood glucose concentration (with OGTT) at the end of treatment for women with GDM in the myo-
inositol group compared to the placebo group (MD -0.90 mmol/L, 95% CI -1.73 to -0.07; one trial, 73 
women; moderate-quality of evidence) (Brown 2016a). 
10.7.2 Energy restricted diet versus no energy restricted diet: The evidence suggested a reduction 
in one-hour post-prandial blood glucose concentration at the end of treatment for women with GDM in 
the energy restricted diet group compared to the no energy restricted diet group (MD -0.51 mmol/L, 95% 
CI -0.89 to -0.13; one trial, 299 women; low quality evidence) (Han 2017). 
10.7.3 Lifestyle intervention versus usual care or diet alone: The evidence suggested a reduction 
post-prandial blood glucose concentration at the end of treatment (timing reported as one-hour post-
prandial in two trials; two-hours in two trials and one trial did not define the timing) for women with GDM 
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in the lifestyle intervention group compared to the usual care or diet alone group (average MD -27.11 
mg/dL, 95% CI -44.62 to -9.61; four trials, 588 women; very low-quality evidence) (Brown 2017b). 
10.8 Glycaemic control at the end of treatment: Two-hours post-prandial 
10.8.1 Metformin versus glibenclamide: There was no clear difference in the two-hour post-prandial 
blood glucose concentration (measured after dinner, where specified) for women with GDM between 
the metformin and glibenclamide group (SMD 0.16, 95% CI -0.01 to 0.34; three trials, 508 women; low-
quality evidence) (Brown 2017a). 
10.8.2 Myo-inositol versus placebo: There was no clear difference in two-hour post-prandial blood 
glucose concentration at the end of treatment (with OGTT) for women with GDM between the myo-
inositol and the placebo group (MD -0.70 mmol/L, 95% CI -1.46 to 0.06; one trial, 73 women; low-quality 
evidence) (Brown 2016a). 
10.8.3 Low-moderate GI diet versus moderate-high GI diet: The evidence suggested a reduction in 
two-hour post-prandial blood glucose concentration at the end of treatment for women with GDM in the 
low-moderate GI diet group compared to the moderate-high GI diet group (MD -0.71 mmol/L, 95% CI -
1.21 to -0.21; one trial, 83 women; very low-quality evidence) (Han 2017). 
10.8.4 Low carbohydrate diet versus high-carbohydrate diet: There was no clear difference in two-
hour post-prandial blood glucose concentration (measured after breakfast) at the end of treatment for 
women with GDM between the low carbohydrate diet and high-carbohydrate diet group (MD 6.00 mg/dL, 
95% CI -1.47 to 13.47; one trial, 30 women; very low-quality evidence) (Han 2017). 
10.8.5 Low carbohydrate diet versus high-carbohydrate diet: There was no clear difference in two-
hour post-prandial blood glucose concentration (measured after lunch) at the end of treatment for 
women with GDM between the low carbohydrate diet and high-carbohydrate diet group (MD 3.00 mg/dL, 
95% CI -2.77 to 8.77; one trial, 30 women; very low-quality evidence) (Han 2017). 
10.8.6 Low carbohydrate diet versus high-carbohydrate diet: There was no clear difference in two 
hours post-prandial blood glucose concentration (measured after dinner) at the end of treatment for 
women with GDM between the low carbohydrate diet and high-carbohydrate diet group (MD 6.00 mg/dL, 
95% CI -1.47 to 13.47; one trial, 30 women; very low-quality evidence) (Han 2017). 
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10.8.7 High unsaturated fat diet versus low unsaturated fat diet with matching calories: There 
was no clear difference in the two-hour post-prandial blood glucose concentration at the end of treatment 
for women with GDM between the high unsaturated fat diet and low unsaturated fat diet with matching 
calories group (MD -0.02 mmol/L, 95% CI -0.29 to 0.25; one trial, 84 women; low-quality evidence) (Han 
2017). 
10.9 Glycaemic control at the end of treatment: Post-prandial timing not defined 
10.9.1 Diet recommendation + diet-related behavioural advice versus diet recommendation only: 
The evidence suggested a reduction in post-prandial blood glucose concentration at the end of treatment 
(timing not defined) for women with GDM in the diet recommendation + diet-related behavioural advice 
compared to the diet recommendation only group (MD -9.30 mg/dL, 95% CI -15.58 to -3.02; one trial, 
99 women; very low-quality evidence) (Han 2017). 
10.9.2 Exercise versus control: The evidence suggested a reduction in post- prandial blood glucose 
concentration at the end of treatment (timing not defined) for women with GDM in the exercise group 
compared to the control group (average SMD -0.85, 95% CI -1.15 to -0.55; three trials, 344 women; 
moderate-quality evidence) (Brown 2017c). 
10.9.3 Exercise versus control: The evidence suggested a reduction in the OGTT result for women 
with GDM at the end of treatment in the exercise group compared with the control group (MD -81.60 
mg/dl, 95% CI -96.03 to -67.17; one trial, 19 women; low-quality evidence) (Brown 2017c). 
10.10 Glycaemic control at the end of treatment: mean plasma glucose 
10.10.1 Energy restricted diet versus no energy restricted diet: The evidence suggested a reduction 
in 24-hour mean plasma glucose concentration for women with GDM in the energy restricted diet group 
compared to the no energy restricted diet group (MD -1.30 mmol/L, 95% CI -2.25 to -0.35; one trial, 12 
women; low-quality evidence) (Han 2017). 
10.10.2 Exercise versus control: The evidence suggested a higher mean plasma glucose 
concentration for women with GDM in the exercise group compared to the control group (MD 0.28 
mmol/L, 95% CI 0.04 to 0.52; one trial, 34 women; very low-quality evidence) (Brown 2017c). It is unclear 
if a difference of 0.28 mmol/L is of clinical significance. 
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10.11 Glycaemic control at the end of treatment: HbA1c 
10.11.1 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference for 
HbA1c concentration for women with GDM between the low-moderate GI diet and moderate-high GI 
diet group (MD 0.01 %, 95% CI -0.18 to 0.20; one trial, 83 women; very low-quality evidence) (Han 
2017). 
10.11.2 DASH diet versus control diet with matching macronutrient contents: The evidence 
suggested a reduction in HbA1c concentration at the end of treatment for women with GDM in the DASH 
diet group compared to the control diet with matching macronutrient contents group (MD -0.25 %, 95% 
CI -0.76 to 0.26; one trial, 34 women; moderate-quality evidence) (Han 2017). 
10.11.3 Diet recommendation + diet-related behavioural advice versus diet recommendation 
only: There was no clear difference in HbA1c concentration at the end of treatment for women with 
GDM between the diet recommendation + diet-related behavioural advice and diet recommendation 
only group (MD -0.10 %, 95% CI -0.28 to 0.08; one trial, 99 women; very low-quality evidence) (Han 
2017). 
10.11.4 Lifestyle intervention versus usual care or diet alone: The evidence suggested a reduction 
in HbA1c concentration at the end of treatment for women with GDM in the lifestyle intervention group 
compared to the usual care or diet alone group (average MD -0.33 mmol/mol, 95% CI -0.47 to -0.19; six 
trials, 532 women; very low-quality evidence) (Brown 2017b). 
10.11.5 Exercise versus control: There was no clear difference in HbA1c concentration at the end of 
treatment for women with GDM between the exercise and control group (MD -0.43 mmol/mol, 95% CI -
0.51 to -0.35; two trials, 320 women; high-quality evidence) (Brown 2017c). 
10.12 Glycaemic control during/at the end of treatment: Fasting 
10.12.1 Energy restricted diet versus no energy restricted diet: There was no clear difference in the 
fasting blood glucose concentration at the end of treatment for women with GDM between the energy 
restricted diet and no energy restricted diet group (MD 0.10 mmol/L, 95% CI -0.18 to -0.38; one trial, 
117 women; very low-quality evidence) (Han 2017). 
10.12.2 Lifestyle intervention versus usual care or diet alone: There was no clear difference in the 
fasting blood glucose concentration during/at the end of treatment for women with GDM between the 
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lifestyle intervention and usual care or diet alone group (average MD -3.10 mg/dL, 95% CI -7.01 to 0.81; 
six trials, 853 women; very low-quality evidence). Data from one trial reported on median and range for 
postnatal fasting blood glucose concentration, which could not be included in the meta-analysis, 
however there was no clear evidence of a difference between the intervention and control group (Brown 
2017b). 
10.13 Glycaemic control during/at the end of treatment: Mean plasma glucose 
10.13.1 Energy restricted diet versus no energy restricted diet: There was no clear difference in the 
mean plasma glucose concentration during/at the end of treatment for women with GDM between the 
energy restricted diet and no energy restricted diet group (MD 0.10 mmol/L, 95% CI -0.34 to -0.54; one 
trial, 117 women; very low-quality evidence) (Han 2017). 
10.13.2 High-fibre diet versus standard-fibre diet: There was no clear difference in the mean plasma 
glucose concentration during/at the end of treatment for women with GDM between high-fibre diet and 
standard-fibre diet (MD 0.0 mmol/L, 95% CI -8.26 to 8.26; one trial, 22 women; very low-quality 
evidence) (Han 2017). 
10.14 Glycaemic control during/at the end of treatment: HbA1c 
10.14.1 Energy restricted diet versus no energy restricted diet: There was no clear difference in 
mean HbA1c at the end of treatment for women with GDM between the energy restricted diet and no 
energy restricted diet group (MD -0.20 %, 95% CI -0.64 to -0.24; one trial, 117 women; low-quality 
evidence) (Han 2017). 
Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence suggested a benefit by a reduction in fasting blood glucose 
concentration and one-hour post-prandial blood glucose concentration at the end of treatment 
for women with GDM who were treated with myo-inositol compared to placebo; a reduction in 
post-prandial (timing not defined) blood glucose concentration at the end of treatment for 
women with GDM who were treated with exercise compared to control or a reduction in fasting 
blood glucose and mean HbA1c at the end of treatment for women with GDM who were treated 
with the DASH diet compared to the control diet with matching macronutrient contents. 
Ineffective interventions: high-quality evidence of lack of effectiveness  
• High-quality evidence showed no clear difference for HbA1c at the end treatment for women 
with GDM who were treated with exercise versus control. 
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Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence suggested a benefit by a reduction in fasting blood glucose concentration 
at the end of treatment for women with GDM who were treated with glibenclamide compared 
to placebo; energy restricted diet compared to the no energy restricted diet; or exercise 
compared to control; a reduction in one-hour post-prandial blood glucose concentration and 
24-hour mean plasma glucose concentration at the end of treatment for women with GDM who 
were treated with the energy restricted diet compared to no energy restricted diet or a reduction 
in OGTT at the end of treatment for women with GDM who were treated with exercise 
compared to control. 
• Very low-quality suggested a benefit by a reduction in fasting blood glucose concentration at 
the end of treatment for women with GDM who were treated with soy protein-enriched diet 
compared to no soy protein diet ; a reduction in one-hour post-prandial blood glucose 
concentration at the end of treatment for women with GDM who were treated with lifestyle 
interventions compared to usual care or diet alone; a reduction in two-hour post-prandial blood 
glucose concentration at the end of treatment for women with GDM who were treated with the 
low-moderate GI diet compared to moderate-high GI diet; a reduction in post-prandial 
(undefined) blood glucose concentration at the end of treatment for women with GDM who 
were treated with diet recommendation + diet-related behavioural advice compared to diet 
recommendation only or a reduction in mean HbA1c at the end of treatment for women with 
GDM who were treated with lifestyle interventions compared usual care or diet alone. 
• Low-quality evidence suggested harm by an increased fasting and post-prandial (undefined) 
blood glucose concentration and HbA1c during treatment at 38 weeks' gestation for women 
with GDM who were treated with a high unsaturated fat diet compared to a low unsaturated fat 
diet with matching calories or an increase in fasting blood glucose concentration at the end of 
treatment for women with GDM who were treated with metformin compared to glibenclamide. 
Very low-quality evidence suggested harm by an increased mean plasma glucose 
concentration at the end of treatment for women with GDM who were treated with exercise 
compared to control. 
• Low-quality evidence showed no clear difference in fasting, one-hour post-prandial blood 
glucose concentration and 24-hour mean plasma glucose concentration during (not defined) 
treatment and mean HbA1c during/at the end of treatment for women with GDM who were 
treated with the energy restricted diet versus no energy restricted diet ; no clear difference for 
HbA1c during treatment (not defined) for women with GDM who were treated with metformin 
versus glibenclamide; no clear difference in fasting blood glucose concentration at the end of 
treatment for women with GDM who were treated with high unsaturated fat diet versus low 
unsaturated fat diet with matching calories or no clear difference in two hours post-prandial 
blood glucose concentration at the end of treatment for women with GDM who were treated 
with metformin versus glibenclamide (after dinner); or with myo-inositol versus placebo. 
• Very low-quality evidence showed no clear difference for glycaemic control (not defined) for 
women with GDM who were treated with a low-GI diet versus high-fibre moderate-GI diet; no 
clear difference in fasting blood glucose concentration at the end of treatment for women with 
GDM who were treated with low-moderate GI diet compared to moderate-high GI diet; or low 
carbohydrate diet compared to high-carbohydrate diet; or Diet recommendation + diet-related 
behavioural advice compared to diet recommendation only; no clear difference in two hours 
post-prandial blood glucose concentration at the end of treatment for women with GDM who 
were treated with a high unsaturated fat diet versus low unsaturated fat diet with matching 
calories; or low carbohydrate diet compared to a high-carbohydrate diet after breakfast, lunch 
or dinner; no clear difference for mean HbA1 at the end of treatment for women with GDM who 
were treated with a low-moderate GI diet compared to a moderate-high GI diet; or Diet 
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recommendation + diet-related behavioural advice compared to diet recommendation only; no 
clear difference in fasting blood glucose concentration at the during/at the end of treatment for 
women with GDM who were treated with an energy restricted diet compared to a no energy 
restricted diet; or lifestyle intervention compared usual care or diet alone or no clear difference 
for mean plasma glucose during/at the end of treatment for women with GDM who were treated 
with an energy restricted diet compared to no energy restricted diet; or with a high-fibre diet 
compared to a standard-fibre diet. 
11.0 Weight gain in pregnancy 
Weight gain in pregnancy was reported as an outcome in six reviews (Brown 2016a; Brown 2017a; 
Brown 2017b; Brown 2017c; Han 2012; Han 2017) (Table 2.11; Table 2.19). It was not clear from the 
reviews regarding the timing of weight gain in pregnancy. The quality of the evidence ranged from 
moderate- to very low-quality. 
11.1 Oral antidiabetic agents versus placebo: There was no difference in weight gain in pregnancy 
for women with GDM between glibenclamide and placebo group (MD 0.0 kg, 95% CI -0.96 to 0.96; one 
trial, 375 women; low-quality evidence) (Brown 2017a). 
11.2 Metformin versus glibenclamide: The evidence suggested reduced weight gain in pregnancy for 
women with GDM in the metformin group compared to the glibenclamide group (MD -2.06 kg, 95% CI -
3.98 to -0.14; one trial, 200 women; very low-quality evidence) (Brown 2017a). 
11.3 Glibenclamide versus acarbose: There was no clear difference in weight gain in pregnancy for 
women with GDM between the glibenclamide and acarbose group (MD -0.60 kg, 95% CI -3.13 to -1.93; 
one trial, 43 women; very low-quality evidence) (Brown 2017a). 
11.4 Myo-inositol versus placebo: There was no clear difference for the risk of weight gain in 
pregnancy for women with GDM between the myo-inositol and the placebo group (MD -0.50 kg, 95% CI 
-3.35 to 2.25; one trial, 69 women; very low-quality evidence) (Brown 2016a). 
11.5 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference in weight 
gain in pregnancy for women between the low-moderate GI diet and moderate-high GI diet group (MD 
-0.47 kg, 95% CI -2.18 to 1.24; one trial, 83 women; very low-quality evidence) (Han 2017). 
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11.6 Energy restricted diet versus no energy restricted diet: There was no clear difference in weight 
gain in pregnancy for women between the energy restricted diet and no energy restricted diet group 
(MD 1.88 kg, 95% CI -1.96 to 5.72; one trial, 117 women; very low-quality evidence) (Han 2017). 
11.7 DASH diet versus control diet with matching macronutrient contents: There was showed no 
clear difference in weight gain in pregnancy for women with GDM between the DASH diet and control 
diet with matching macronutrient contents group (MD -2.88 kg, 95% CI -8.48 to 2.71; two trials, 66 
women; moderate-quality evidence) (Han 2017). 
11.8 Low-carbohydrate diet versus high-carbohydrate diet: The evidence suggested less weight 
gain in pregnancy for women with GDM in the low-carbohydrate diet group compared to the high-
carbohydrate diet group (MD -0.90 kg, 95% CI -1.60 to -0.20; one trial, 145 women; low-quality evidence) 
(Han 2017). 
11.9 High unsaturated fat diet versus low unsaturated fat diet with matching calories: There was 
no clear difference in weight gain in pregnancy for women with GDM between the high unsaturated fat 
diet and low unsaturated fat diet with matching calories group (MD -1.98 kg, 95% CI -4.32 to 0.36; one 
trial, 84 women; low-quality evidence) (Han 2017). 
11.10 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference in weight gain 
in pregnancy for women with GDM between the low-GI diet and high-fibre moderate-GI diet group (MD 
-1.20 kg, 95% CI -3.43 to 1.03; one trial, 87 women; very low-quality evidence) (Han 2017). 
11.11 Diet recommendation + diet-related behavioural advice versus diet recommendation only: 
There was no clear difference in weight gain in pregnancy for women with GDM between the diet 
recommendation + diet-related behavioural advice and diet recommendation only group (MD -0.10 kg, 
95% CI -4.91 to 4.71; one trial, 99 women; very low-quality evidence) (Han 2017). 
11.12 Soy protein-enriched diet versus no soy protein diet: There was no clear difference in weight 
gain in pregnancy for women with GDM between the soy protein-enriched diet and no soy protein diet 
group (MD 3.50 kg, 95% CI -1.47 to 8.47; one trial, 68 women; very low-quality evidence) (Han 2017). 
11.13 High-fibre diet versus standard-fibre diet: There was no clear difference in weight gain in 
pregnancy for women with GDM between high-fibre diet and standard-fibre diet (MD 2.40 kg, 95% CI -
2.20 to 7.00; one trial, 22 women; very low-quality evidence) (Han 2017). 
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11.14 Ethnic specific diet versus standard healthy diet: There was no clear difference in weight gain 
in pregnancy for women with GDM between the ethnic specific diet and standard healthy diet group (MD 
-2.20 kg, 95% CI -7.24 to 2.84; one trial, 20 women; very low-quality evidence) (Han 2017). 
11.15 Lifestyle intervention versus usual care or diet alone: The evidence suggested less weight 
gain in pregnancy at the end of the intervention for women with GDM in the lifestyle intervention group 
compared to the usual care or diet alone group (average MD -1.30 kg, 95% CI -2.26 to -0.35; four trials, 
2930 women; moderate-quality evidence) (Brown 2017b). 
11.16 Exercise versus control: There was no clear difference in weight gain in pregnancy for women 
with GDM between the exercise and control group (MD -0.34 kg, 95% CI -1.25 to 0.58; two trials, 104 
women; low-quality evidence) (Brown 2017c). The increase in weight differs substantially between the 
two trials. There was no clear explanation for this. 
11.17 Intensive management versus routine care: There was no clear difference in weight gain in 
pregnancy for women with GDM between the intensive management and routine care group (MD -0.63 
kg, 95% CI -3.07 to 1.81; two trials, 426 women; very low-quality evidence) (Han 2012). 
Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence suggested a benefit by reduced weight gain in pregnancy for 
women who were treated with lifestyle intervention compared to usual care or diet alone. 
Probably no difference between interventions: direction of effect suggests benefit, but more 
evidence needed 
• Moderate-quality evidence showed no clear difference for weight gain in pregnancy for women 
with GDM who were treated DASH diet and control diet with matching macronutrient contents, 
suggesting a similar risk for both diet interventions for weight gain in pregnancy. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence suggested a benefit by reduced weight gain in pregnancy for women with 
GDM who were treated with the low-carbohydrate diet compared to high-carbohydrate diet. 
• Low-quality evidence showed no clear difference in weight gain in pregnancy for women with 
GDM who were treated with glibenclamide versus placebo; with a high unsaturated fat diet 
versus low unsaturated fat diet with matching calories; or exercise versus control. 
• Very low-quality evidence suggested a benefit by reduced weight gain in pregnancy for women 
with GDM who were treated with metformin compared to glibenclamide. 
• Very low-quality evidence showed no clear difference in weight gain in pregnancy for women 
with GDM who were treated with glibenclamide versus acarbose; myo-inositol versus placebo; 
low-moderate GI diet versus moderate-high GI diet; energy restricted diet versus no energy 
restricted diet; low-GI diet versus high-fibre moderate-GI diet; diet recommendation + diet-
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related behavioural advice versus diet recommendation only; soy protein-enriched diet versus 
no soy protein diet; with high-fibre diet versus standard-fibre diet; with ethnic specific diet 
versus standard healthy diet; or intensive management versus routine care. 
12.0 Other measures of weight gain in pregnancy (not pre-specified for this overview) 
Three reviews (Brown 2016a; Brown 2017c; Han 2017) reported on the outcome of BMI during or at the 
end of treatment. One review reported on excessive weight gain in pregnancy (Brown 2017c) (Table 
2.11; Table 2.19). We considered these as alternate measures for weight gain in pregnancy although 
we had not pre-specified them as outcomes in our protocol. The quality of the evidence ranged from 
moderate- to very low-quality. There was no clear evidence of a difference for other measures of weight 
gain in pregnancy for any of the comparisons reporting this outcome. 
12.1 Myo-inositol versus placebo: The evidence suggested a reduction of BMI during pregnancy for 
women with GDM in the myo-inositol group compared to the placebo 400 mcg folic acid orally per day 
and exercise and dietary advice group (MD -1.50 kg/m2, 95% CI -2.35 to -0.65; one trial, 73 women; 
moderate-quality evidence) (Brown 2016a). 
12.2 DASH diet versus control diet with matching macronutrient contents: There was no clear 
difference of BMI at the end of the pregnancy for women with GDM between the DASH diet and control 
diet with matching macronutrient contents group (MD -0.83 in kg/m2, 95% CI -3.76 to 2.11; two trials, 66 
women; moderate-quality evidence) (Han 2017). 
12.3 Diet recommendation + diet-related behavioural advice versus diet recommendation only: 
There was no clear difference of BMI at the end of the pregnancy for women with GDM between the 
diet recommendation + diet-related behavioural advice and diet recommendation only group (MD -0.0 
kg/m2, 95% CI -1.75 to 1.75; one trial, 99 women; very low-quality evidence) (Han 2017). 
12.4 Soy protein-enriched diet versus no soy protein diet: There was no clear difference of BMI at 
the end of the pregnancy for women with GDM in the soy protein-enriched diet and no soy protein diet 
group (MD 0.60 kg/m2, 95% CI -1.43 to 2.63; one trial, 68 women; very low-quality evidence) (Han 2017). 
12.5 Exercise versus control: There was no clear difference for excessive weight gain in pregnancy 
for women with GDM between the exercise and control group (RR 0.90, 95% CI 0.47 to 1.72; one trial, 
79 women; very low-quality evidence) (Brown 2017c). 
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Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence suggested a benefit by a reduction of BMI during pregnancy for 
women with GDM who were treated with myo-inositol compared to placebo. 
Probably no difference between interventions: direction of effect suggests benefit, but more 
evidence needed 
• Moderate-quality evidence showed no clear difference for BMI at the end of the pregnancy for 
women with GDM who were treated DASH diet and control diet with matching macronutrient 
contents, suggesting a similar risk for both diet interventions for weight gain in pregnancy. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Very low-quality evidence showed no clear difference in excessive weight gain in pregnancy 
for women with GDM who were treated with exercise versus control and no clear evidence of 
a difference in BMI at the end of the pregnancy for women with GDM who were treated with 
diet recommendation + diet-related behavioural advice versus diet recommendation only; or 
soy protein-enriched diet versus no soy protein. 
13.0 Adherence to the intervention 
Adherence to the intervention was reported as an outcome by two reviews (Han 2017; Brown 2017c) 
(Table 2.11; Table 2.19). The quality of the evidence ranged from low- to very low-quality. There was 
no clear evidence of a difference for adherence to the intervention for any of the comparisons reporting 
this outcome. 
13.1 Low-carbohydrate diet versus high-carbohydrate diet: There was no clear difference for 
women with GDM who fully adhered to the intervention (adherence not defined) between the low-
carbohydrate and high-carbohydrate diet group (RR 1.09, 95% CI 0.73 to 1.62; one trial, 30 women; 
low-quality evidence) (Han 2017). 
13.2 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference for women with 
GDM who fully adhered to the intervention (assessed by a 24-hour recall when women were attending 
their dietitian appointment) between the low-GI diet and high-fibre moderate-GI diet group (RR 0.84, 
95% CI 0.64 to 1.11; one trial, 92 women; very low-quality evidence) (Han 2017). 
13.3 Ethnic specific diet versus standard healthy diet: There was no clear difference for women with 
GDM who fully adhered to the intervention between the ethnic specific diet and standard healthy diet 
group (RR 3.50, 95% CI 0.95 to 12.90; one trial, 20 women; very low-quality evidence) (Han 2017). 
Adherence to the intervention was defined in the review as: " adherence to the dietary intervention was 
measured using a 24-hour food intake recall method; women with an intake of more than 20% higher 
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than prescribed received a score of 0; those with an intake of 10% to 20% higher received a score of 1; 
and women with intake consistent with the plan or up to 10% lower received a score of 2. 'Good 
adherence' was defined as women being scored a 1 or 2. 
13.4 Exercise versus control: There was no clear difference for women with GDM who fully adhered 
to the intervention between the exercise and the control group (RR 1.00, 95% CI 0.83 to 1.21; one trial, 
19 women; low-quality evidence) (Brown 2017c). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for adherence to the intervention for women 
with GDM who were treated with a low-carbohydrate diet versus high-carbohydrate diet; or 
exercise versus control. 
• Very low-quality evidence showed no clear difference for adherence to the intervention for 
women with GDM who were treated with a low-GI diet versus high-fibre moderate-GI diet; or 
with an ethnic specific diet versus standard healthy diet for adherence to the intervention. 
14.0. Induction of labour 
Induction of labour was reported as an outcome by five reviews (Brown 2017a; Han 2017; Brown 2017b; 
Brown 2017c; Han 2012) (Table 2.; Table 2.18). The quality of the evidence ranged from high- to very 
low-quality. 
14.1 Oral antidiabetic agents versus placebo: There was no clear difference for the risk of induction 
of labour for women with GDM between the glibenclamide and placebo group (RR 1.18, 95% CI 0.79 to 
1.76; one trial, 375 women; very low-quality evidence) (Brown 2017a). 
14.2 Metformin versus glibenclamide: There was no clear difference for the risk of induction of labour 
for women with GDM between the metformin and glibenclamide group (RR 0.81, 95% CI 0.61 to 1.07; 
one trial, 159 women; low-quality evidence) (Brown 2017a). 
14.3 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference for the risk 
of induction of labour for women with GDM between the low-moderate GI diet and moderate-high GI 
diet group (RR 0.88, 95% CI 0.33 to 2.34; one trial, 63 women; low-quality evidence) (Han 2017). 
14.4 Energy restricted diet versus no energy restricted diet: There was no clear difference for the 
risk of induction of labour for women with GDM between the energy restricted diet and no energy 
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restricted diet group (RR 1.02, 95% CI 0.68 to 1.53; one trial, 114 women; low-quality evidence) (Han 
2017). 
14.5 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the risk 
of induction of labour for women with GDM between the lifestyle intervention and usual care or diet 
alone group (average RR 1.20, 95% CI 0.99 to 1.46; four trials, 2699 women; high-quality evidence) 
(Brown 2017b). 
14.6 Exercise versus control: There was no clear difference for the risk of induction of labour for 
women with GDM (RR 1.38, 95% CI 0.71 to 2.68; one trial, 40 women; low quality evidence) (Brown 
2017c). 
14.7 Intensive management versus routine care: The evidence suggested an increased risk of 
induction of labour for women with GDM in the intensive management group compared to the routine 
care group (RR 17.69, 95% CI 1.03 to 304.09; one trial, 83 women; very low-quality evidence) (Han 
2012). There were six events of induction of labour for women with GDM in the intensive management 
group but no events in the control group. 
Summary 
Ineffective interventions: high-quality evidence of lack of effectiveness 
• High-quality evidence showed no clear difference for the risk of induction of labour for women 
with GDM who were treated with lifestyle intervention versus usual care or diet alone. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Very low-quality evidence suggested harm by an increased risk of induction in labour for 
women with GDM who were treated with intensive management compared to the routine care. 
• Low-quality evidence showed no clear difference for the risk of induction of labour for women 
with GDM who were treated with metformin versus glibenclamide; low-moderate GI diet versus 
moderate-high GI diet; energy restricted diet versus no energy restricted diet; or exercise 
versus control. 
• Very low-quality evidence showed no clear difference for the risk of induction of labour for 
women with GDM who were treated with glibenclamide versus placebo. 
15.0 Placental abruption 
Placental abruption was reported as an outcome in one review (Han 2017) (Table 2.11; Table 2.19). 
The quality of the evidence was low-quality. There was no clear evidence of a difference for the risk of 
placental abruption for either of the comparisons reporting this outcome. 
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15.1 DASH diet versus control diet with matching macronutrient contents: There was no clear 
difference for the risk of placental abruption for women with GDM between the DASH diet and control 
diet with matching macronutrient contents group (RR 3.00, 95% CI 0.13 to 70.73; one trial, 58 women; 
low-quality evidence) (Han 2017). 
15.2 High unsaturated fat diet versus low unsaturated fat diet with matching calories: There was 
no clear difference for the risk of placental abruption for women with GDM between the high unsaturated 
fat diet and low unsaturated fat diet with matching calories group (RR not estimable; one trial, 27 women; 
low-quality evidence) (Han 2017). There were no events of placental abruption in either group. 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for the risk of placental abruption for women 
with GDM who were treated with the DASH diet versus control diet with matching macronutrient 
contents; or high unsaturated fat diet versus low unsaturated fat diet with matching calories. 
16.0 Postpartum haemorrhage (as defined in the reviews) 
Postpartum haemorrhage was reported as an outcome by two reviews (Brown 2017b; Han 2017) (Table 
2.11; Table 2.19). Neither review defined postpartum haemorrhage. The quality of the evidence ranged 
from low- to very low- quality. There was no clear evidence of a difference for the risk of postpartum 
haemorrhage for either of the comparisons reporting this outcome. 
16.1 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference for the risk 
of postpartum haemorrhage for women with GDM between the low-moderate GI diet and moderate-high 
GI diet group (RR 1.02, 95% CI 0.15 to 6.93; one trial, 83 women; very low-quality evidence) (Han 2017). 
16.2 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the risk 
of postpartum haemorrhage for women with GDM between the lifestyle intervention and usual care or 
diet alone group (average RR 0.61, 95% CI 0.20 to 1.89; two trials, 1165 women; low-quality evidence) 
(Brown 2017b). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
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Summary 
• Low-quality evidence showed no clear difference for the risk of postpartum haemorrhage (not 
defined) for women with GDM who were treated with lifestyle intervention versus usual care or 
diet alone. 
• Very low-quality evidence showed no clear difference for the risk of postpartum haemorrhage 
(not defined) for women with GDM who were treated with low-moderate GI diet versus 
moderate-high GI diet. 
17.0 Postpartum infection 
Postpartum infection was reported as an outcome by two reviews (Brown 2017b; Han 2017) (Table 2.11; 
Table 2.19). The quality of the evidence ranged from moderate- to very low- quality. There was no clear 
evidence of a difference for the risk of postpartum infection for either of the comparisons reporting this 
outcome. 
Low-moderate GI diet versus moderate-high GI diet: There was no clear difference for the risk of 
postpartum infection for women with GDM between the low-moderate GI diet and moderate-high GI diet 
group (RR 0.34, 95% CI 0.01 to 8.14; one trial, 83 women; very low-quality evidence) (Han 2017). 
Lifestyle intervention versus usual care or diet alone: There was no clear difference for the risk of 
postpartum infection for women between the lifestyle intervention and usual care or diet alone group 
(RR 0.61, 95% CI 0.34 to 1.10; one trial, 1000 women; moderate-quality evidence) (Brown 2017b). 
Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence showed no clear difference for the risk of postpartum infection for 
women with GDM who were treated with lifestyle intervention versus usual care or diet alone. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Very low-quality evidence showed no clear difference for the risk of postpartum infection for 
women with GDM who were treated with low-moderate GI diet versus moderate-high GI diet. 
18.0 Perineal trauma/tearing 
Perineal trauma/tearing was reported as an outcome by two reviews (Brown 2017a; Brown 2017b) 
(Table 2.8; Table 2.19). The quality of the evidence ranged from moderate- to very low- quality. There 
was no clear evidence of a difference for the risk of perineal trauma/tearing for any of the comparisons 
reporting this outcome. 
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18.1 Oral antidiabetic agents versus placebo: There was no clear difference for the risk of perineal 
trauma/tearing (defined as third to fourth degree tear) for women with GDM between glibenclamide and 
placebo group (RR 0.98, 95% CI 0.06 to 15.62; one trial, 375 women; very low-quality evidence) (Brown 
2017a). 
18.2 Metformin versus glibenclamide: There was no clear difference for the risk of perineal 
trauma/tearing (defined as third and fourth degree perineal tearing) for women with GDM between the 
metformin and glibenclamide group (RR 1.67, 95% CI 0.22 to 12.52; two trials, 308 women; low-quality 
evidence) (Brown 2017a). 
18.3 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the risk 
of perineal trauma/tearing (not defined) for women with GDM between the lifestyle intervention and 
usual care or diet alone group (RR 1.04, 95% CI 0.93 to 1.18; one trial, 1000 women; moderate-quality 
evidence) (Brown 2017b). 
Summary 
Probably no difference between interventions: Direction of the effect suggested ineffective 
intervention: moderate quality evidence. 
• Moderate-quality evidence showed no clear difference for the risk of perineal trauma/tearing 
for women with GDM who were treated with lifestyle intervention versus usual care or diet 
alone. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for the risk of perineal trauma/tearing for 
women with GDM who were treated with metformin versus glibenclamide. 
• Very low-quality evidence showed no clear difference for the risk of perineal trauma/tearing for 
women with GDM who were treated with glibenclamide versus placebo. 
19.0 Breastfeeding at discharge, six weeks postpartum, six months or longer 
Breastfeeding was reported as an outcome by one review (Brown 2017b). Data were reported at 
discharge, at six weeks postpartum and six months postpartum. The quality of the evidence ranged from 
moderate - to very low- quality. There was no clear evidence of a difference between groups for 
breastfeeding at any of the time points reported for this comparison. 
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19.1 Breastfeeding at discharge 
19.1.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for 
breastfeeding at discharge for women with GDM between the lifestyle intervention and usual care or 
diet alone group (RR 1.04, 95% CI 0.99 to 1.10; one trial, 1000 women; moderate-quality evidence) 
(Brown 2017b). 
19.1.2 Breastfeeding at six weeks post-partum 
Lifestyle intervention versus usual care or diet alone: There was no clear difference for 
breastfeeding at six weeks post-partum for women with GDM between the lifestyle intervention and 
usual care or diet alone group (RR 0.97, 95% CI 0.87 to 1.07; one trial, 188 women; very low-quality 
evidence) (Brown 2017b). 
19.1.3 Breastfeeding at six months postpartum or longer 
Lifestyle intervention versus usual care or diet alone: There was no clear difference for 
breastfeeding at six months post-partum for women with GDM between the lifestyle intervention and 
usual care or diet alone group (RR 1.31, 95% CI 0.99 to 1.74; one trial, 161 women; very low-quality 
evidence) (Brown 2017b). 
Summary 
Probably no difference between interventions: moderate-quality evidence. 
• Moderate-quality evidence showed no clear difference for the breastfeeding at discharge for 
women with GDM who were treated with lifestyle intervention versus usual care or diet alone. 
No conclusions possible: low to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Very low-quality evidence showed no clear difference for the breastfeeding at six weeks and 
six months or longer postpartum for women with GDM who were treated with lifestyle 
intervention versus usual care or diet alone. 
20.0 Maternal mortality 
Maternal mortality was reported as an outcome by one review (Brown 2017c) (Table 2.11; Table 2.19). 
The quality of the evidence was very low- quality. 
Exercise versus control: There were no events of maternal mortality in either the exercise or the 
control group (RR not estimable; two trials, 48 women; very low-quality evidence) (Brown 2017c). 
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Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Very low-quality evidence showed no clear difference for the risk of maternal mortality for 
women with GDM who were treated with exercise versus control. 
21.0 Sense of well-being and quality of life 
Sense of well-being and quality of life of reported as an outcome by one review (Brown 2017b) (Table 
2.11; Table 2.19). The outcome was reported during treatment and at three months postpartum using 
the Short Form Health Survey SF-36 (overall physical component, overall mental component and 
anxiety). The quality of the evidence ranged from moderate- to low- quality.  
21.1 Sense of well-being and quality of life during treatment: Overall physical component 
21.1.1 Lifestyle intervention versus usual care or diet alone: The evidence suggested an 
improvement for the overall physical component for sense of well-being and quality of life from the Short 
Form Health Survey (SF-36) during treatment for women with GDM in the lifestyle intervention group 
compared to usual care or diet alone group (MD 1.5, 95% CI 0.12 to 2.88; one trial, 682 women; low-
quality evidence) (Brown 2017b). 
21.2 Sense of well-being and quality of life during treatment: Overall mental component 
21.2.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the 
overall mental component for sense of well-being and quality of life from the Short Form Health Survey 
(SF-36) during treatment for women with GDM between the lifestyle intervention and usual care or diet 
alone group (MD 1.30, 95% CI -0.17 to 2.77; one trial, 682 women; low-quality evidence) (Brown 2017b). 
21.3 Sense of well-being and quality of life during treatment: Anxiety 
21.3.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the 
anxiety component for sense of well-being and quality of life from the Short Form Health Survey (SF-
36) during treatment for women with GDM between the lifestyle intervention and usual care or diet alone 
group (MD -0.30, 95% CI -0.88 to 0.28; one trial, 682 women; moderate-quality evidence) (Brown 
2017b). 
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21.4 Sense of well-being and quality of life at three months post-partum: Overall physical 
component 
21.4.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the 
overall physical component for sense of well-being and quality of life from the Short Form Health Survey 
(SF-36) at three months post-partum for women with GDM between the lifestyle intervention and usual 
care or diet alone group (MD 1.20, 95% CI -0.19 to 2.59; one trial, 573 women; low quality evidence) 
(Brown 2017b). 
21.5 Sense of well-being and quality of life at three months post-partum: Overall mental 
component 
21.5.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the 
overall mental component for sense of well-being and quality of life from the Short Form Health Survey 
(SF-36) at three months post-partum for women with GDM between the lifestyle intervention and usual 
care or diet alone group (MD 0.20, 95% CI -1.51 to 1.91; one trial, 573 women; low-quality evidence) 
(Brown 2017b). 
21.6 Sense of well-being and quality of life at three months post-partum: Anxiety 
21.6.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the 
anxiety component for sense of well-being and quality of life from the Short Form Health Survey (SF-
36) at three months post-partum for women between the lifestyle intervention and usual care or diet 
alone group (MD -0.20, 95% CI -0.83 to 0.43; one trial, 573 women; low-quality evidence) (Brown 
2017b). 
Summary 
Probably no difference between interventions: moderate-quality evidence  
• Moderate-quality evidence showed no clear difference during treatment for the anxiety for 
sense of well-being and quality of life for women with GDM who were treated with lifestyle 
intervention versus usual care or diet alone. 
No conclusions possible: low to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence of benefit suggested an improvement during treatment for the overall 
physical component and the overall mental component for sense of well-being and quality of 
life for women with GDM who were treated with lifestyle intervention compared to usual care 
or diet alone, but no clear difference at three months postpartum. 
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Summary 
• Low-quality evidence showed no clear difference for anxiety at three months postpartum for 
women with GDM who were treated with lifestyle intervention compared to usual care or diet 
alone. 
22.0 Women's view of the intervention 
Women's views of the interventions were reported as an outcome by one review (Brown 2017c) (Table 
2.11; Table 2.19). The quality of the evidence was low-quality.  
22.1 Exercise versus control: The evidence suggested favourable views of the intervention for women 
with GDM, however the MD and SD were not estimable; one trial, 40 women; low-quality evidence) 
(Brown 2017c). 
Summary 
No conclusions possible: low to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence suggested favourable views of the intervention for women with GDM 
treated with exercise compared with control. 
 
23.0 Relevant biomarker changes associated with the intervention (including adiponectin, free 
fatty acids, triglycerides, high-density lipoproteins, low-density lipoproteins, insulin) 
Relevant biomarker changes associated with the intervention were reported as an outcome by one 
review (Han 2017). The measures reported were Homeostasis Model Assessment Insulin Resistance 
(HOMA-IR), Quantitative Insulin Sensitivity Check Index (QUICKI) and fasting plasma insulin. The timing 
of the measures varied and included during treatment, at the end of treatment. three months postpartum 
and 38 weeks' gestation (Table 2.11; Table 2.19). The quality of the evidence ranged from moderate- 
to very low- quality.  
23.1 Homeostasis Model Assessment Insulin Resistance (HOMA-IR) and HOMA2-IR 
23.1.1 DASH diet versus control diet with matching macronutrient contents: The evidence 
suggested lower insulin resistance measured with HOMA-IR at the end of treatment for women with 
GDM in the DASH diet group compared to the control diet with matching macronutrient contents group 
(MD -1.00 %, 95% CI -1.34 to -0.66; one trial, 32 women; moderate-quality evidence) (Han 2017). 
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23.1.2 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference for insulin 
sensitivity measured with HOMA2-IR at the end of treatment for women with GDM between the low-GI 
diet and high-fibre moderate-GI diet group (MD -0.10 %, 95% CI -0.38 to 0.18; one trial, 77 women; very 
low-quality evidence) (Han 2017). 
23.1.3 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference for insulin 
sensitivity measured with HOMA-IR at three months postpartum for women with GDM between the low-
GI diet and high-fibre moderate-GI diet group (MD -0.30 %, 95% CI -0.66 to 0.06; one trial, 53 women; 
very low-quality evidence) (Han 2017). 
23.1.4 Diet recommendation + diet-related behavioural advice versus diet recommendation only: 
There was no clear difference for insulin sensitivity measured with HOMA-IR at the end of treatment for 
women with GDM between the diet recommendation + diet-related behavioural advice and diet 
recommendation only group (MD -0.30 %, 95% CI -0.77 to 0.17; one trial, 99 women; very low-quality 
evidence) (Han 2017). 
23.1.5 Soy protein-enriched diet versus no soy protein diet: There was no clear difference for insulin 
sensitivity measured with HOMA-IR at the end of the intervention for women with GDM in the soy protein-
enriched diet and no soy protein diet group (MD -1.60 %, 95% CI -2.20 to 0.20; one trial, 68 women; 
very low-quality evidence) (Han 2017). 
23.2 Quantitative Insulin Sensitivity Check Index (QUICKI) 
23.2.1 Soy protein-enriched diet versus no soy protein diet: There was no clear difference for insulin 
sensitivity measured with QUICKI at the end of the intervention for women with GDM in the soy protein-
enriched diet and no soy protein diet group (MD 0.0, 95% CI -0.01 to 0.01; one trial, 68 women; very 
low-quality evidence) (Han 2017). 
23.3 Fasting plasma insulin during the intervention 
23.3.1 Energy restricted diet versus no energy restricted diet: There was no clear difference for 
insulin sensitivity (fasting plasma insulin) (during (gestation) not defined) for women with GDM between 
the energy restricted diet versus no energy restricted diet group (MD 100.00 pM, 95% CI -26.02 to 
226.02; one trial, 12 women; very low-quality evidence) (Han 2017). 
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23.3.2 High unsaturated fat diet versus low unsaturated fat diet with matching calories: The 
evidence suggested higher fasting plasma insulin at 38 weeks' gestation for women with GDM in the 
high unsaturated fat diet group (MD 4.40 mU/L, 95% CI 2.59 to 6.21; one trial, 24 women; very low-
quality evidence) (Han 2017). 
23.3.3 High unsaturated fat diet versus low unsaturated fat diet with matching calories: There 
was no clear difference for insulin sensitivity measured in 10−5 min−1 per mU/L min at 38 weeks' gestation 
for women with GDM in the high unsaturated fat diet group (MD -0.08 mU/L min, 95% CI -0.21 to 0.05; 
one trial, 24 women; very low-quality evidence) (Han 2017). 
23.4 Fasting plasma insulin at end of treatment 
23.4.1 Energy restricted diet versus no energy restricted diet: There was no clear difference for 
fasting plasma insulin for women with GDM between the energy restricted diet and no energy restricted 
diet group (MD -20.00 pM, 95% CI -127.70 to 87.70; one trial, 12 women; very low-quality evidence) 
(Han 2017). 
23.4.2 DASH diet versus control diet with matching macronutrient contents: The evidence 
suggested lower fasting plasma insulin for women with GDM in the DASH diet group compared to the 
control diet with matching macronutrient contents group (MD -3.26 µIU/mL, 95% CI -4.42 to -2.10; one 
trial, 32 women; low-quality evidence) (Han 2017). 
23.4.3 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference for insulin 
sensitivity - fasting plasma insulin for women with GDM between the low-GI diet and high-fibre 
moderate-GI diet group (MD 10.80 pmol/L, 95% CI -22.36 to 43.96; one trial, 70 women; very low-quality 
evidence) (Han 2017). 
23.4.4 Diet recommendation + diet-related behavioural advice versus diet recommendation only: 
There was no clear difference for fasting plasma insulin for women with GDM between the diet 
recommendation + diet-related behavioural advice and diet recommendation only group (MD -0.50 
µIU/mL, 95% CI -2.69 to 1.69; one trial, 99 women; very low-quality evidence) (Han 2017). 
23.4.5 Soy protein-enriched diet versus no soy protein diet: There was no clear difference for fasting 
insulin for women with GDM in the soy protein-enriched diet and no soy protein diet group (MD -2.60 
µIU/mL, 95% CI -8.03 to 2.83; one trial, 68 women; very low-quality evidence) (Han 2017). 
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Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence of benefit showed lower insulin resistance (measured with HOMA-
IR) at the end of the intervention for women with GDM who were treated with the DASH diet 
compared to the control diet with matching macronutrient contents. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence suggested a benefit by a reduced fasting plasma insulin for women with 
GDM who were treated with the DASH diet versus compared to a diet with matching 
macronutrient contents. 
• Very low-quality evidence showed no clear difference for insulin resistance (measured with 
HOMA-IR or HOMA2-IR) for women with GDM who were treated with low-GI diet versus high-
fibre moderate-GI diet; diet recommendation + diet-related behavioural advice versus diet 
recommendation only; soy protein-enriched diet versus no soy protein diet; or treated at three 
months postpartum with low-GI diet versus high-fibre moderate-GI diet. There was no evidence 
of a clear difference for insulin sensitivity for women with GDM who were treated with soy 
protein-enriched diet versus no soy protein diet (end with Quantitative Insulin Sensitivity Check 
Index (QUICKI); or high unsaturated fat diet versus low unsaturated fat diet with matching 
calories (during treatment; at 38 weeks' gestation). There was no clear evidence of a difference 
for fasting plasma insulin for women with GDM who were treated with energy restricted diet 
versus no energy restricted diet and no clear evidence of a difference for fasting plasma insulin 
at the end of the intervention for women with GDM who were treated with an energy restricted 
diet versus no energy restricted diet; low-GI diet versus high-fibre moderate-GI diet; diet 
recommendation + diet-related behavioural advice versus diet recommendation only; or soy 
protein-enriched diet versus no soy protein diet. 
• Very low-quality evidence suggested harm by an increase for fasting plasma insulin (at 38 
weeks' gestation) for women with GDM who were treated with high unsaturated fat diet group 
compared to low unsaturated fat diet with matching calories. 
24.0 Pre-specified overview maternal secondary outcomes not reported in the included reviews 
None of the included reviews reported data for behavioural changes associated with the treatment. 
Secondary outcomes - Maternal long-term 
25.0 Postnatal depression 
Postnatal depression was reported as an outcome by one review (Brown 2017b) (Table 2.8; Table 2.19). 
The quality of the evidence was low-quality. 
25.1 Lifestyle intervention versus usual care or diet alone: The evidence suggested a decrease for 
the risk of developing postnatal depression (defined as Edinburgh Postnatal Depression Score (EPDS) 
>12) for women who had GDM in the lifestyle intervention group compared to the usual care or diet 
alone group (RR 0.49, 95% CI 0.31 to 0.78; one trial, 573 women; low-quality evidence) (Brown 2017b). 
217 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence suggested a benefit by a decrease for the risk of developing postnatal 
depression for women with GDM who were treated with lifestyle intervention compared to usual 
care or diet alone. 
26.0 Body Mass Index (BMI) 
BMI was reported as an outcome by two reviews (Brown 2017b; Han 2017) (Table 2.12; Table 2.19). 
See Table 10. The timing of the assessment of BMI varied from three months (Han 2017) to 11 years 
(Brown 2017b). The quality of the evidence was very low-quality. 
26.1 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference in BMI at three 
months postpartum for women who had GDM between the low-GI diet and high-fibre moderate-GI diet 
group (MD -0.50 kg/m2, 95% CI -2.79 to 1.79; one trial, 52 women; very low-quality evidence) (Han 
2017). 
26.2 High unsaturated fat diet versus low unsaturated fat diet with matching calories: The 
evidence suggested a higher BMI at five to nine months postpartum for women who had GDM in the 
high unsaturated fat diet group compared to the low unsaturated fat diet with matching calories group 
(MD 4.10 kg/m2, 95% CI 2.34 to 5.86; one trial, 27 women; very low-quality evidence) (Han 2017). 
26.3 Lifestyle intervention versus usual care or diet alone: Evidence from two trials in the Brown 
(2017b) review showed no clear difference in BMI for women who had GDM between the lifestyle 
intervention and usual care or diet alone group (at 4.5 to 10 years follow-up in one trial (moderate-quality 
evidence) and 9 to 11 years follow-up in the other trial (moderate-quality evidence). The data in both 
trials were not in a format suitable for inclusion in a meta-analysis. 
Summary 
Probably no difference between interventions: Direction of effect suggested no difference. 
• Moderate-quality evidence showed no clear difference for BMI at a maximum follow-up of 11 
years for women with GDM who were treated with a lifestyle intervention versus usual care or 
diet alone. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to 
comment on the effectiveness, more evidence needed 
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Summary 
• Very low-quality suggested evidence of harm by a higher BMI at five to nine months for women 
with GDM who were treated with high unsaturated fat diet compared to low unsaturated fat 
diet with matching calories. 
• Very low-quality evidence showed no clear difference for BMI at three months for women with 
GDM who were treated with low-GI diet versus high-fibre moderate-GI diet. 
27.0 Postnatal weight retention or return to pre-pregnancy weight 
Postnatal weight retention or return to pre-pregnancy weight was reported as an outcome by three 
reviews (Brown 2017b; Brown 2017c; Han 2017) (Table 2.8; Table 2.19). The timing of the measurement 
of the outcome varied between reviews and was reported at six weeks, three months, seven months 
and twelve months. One review did not report the timing. The quality of the evidence ranged from high- 
to very low-quality. 
27.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for return 
to pre-pregnancy weight (defined as the ability to meet postpartum weight goals at six weeks 
postpartum) for women who had GDM between the lifestyle intervention and usual care or diet alone 
group (RR 1.20, 95% CI 0.67 to 2.17; one trial, 189 women; low-quality evidence) (Brown 2017b). 
27.2 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference for return to pre-
pregnancy weight (defined as returned to within one kg of their pre-pregnancy weight at three months 
postpartum) for women who had GDM between the low-GI diet and high-fibre moderate-GI diet group 
(RR 1.15, 95% CI 0.43 to 3.07; one trial, 55 women; very low-quality evidence) (Han 2017). 
27.3 Lifestyle intervention versus usual care or diet alone: There was no clear difference for return 
to pre-pregnancy weight (defined as the ability to meet postpartum weight goals at seven months 
postpartum) for women who had GDM between the lifestyle intervention and usual care or diet alone 
group (RR 1.59, 95% CI 0.99 to 2.57; one trial, 159 women; very low-quality evidence) (Brown 2017b). 
27.4 Lifestyle intervention versus usual care or diet alone: The evidence suggested that more 
women who had GDM met postpartum weight goals by returning to their pre-pregnancy weight (at twelve 
months postpartum) in the lifestyle intervention group compared to the usual care or diet alone group 
(RR 1.75, 95% CI 1.05 to 2.90; one trial, 156 women; low-quality evidence) (Brown 2017b). 
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27.5 Exercise versus control: There was no clear difference for return to pre-pregnancy BMI (at follow-
up, timing not defined) for women who had GDM between the exercise and control group (MD 0.11 
kg/m2, 95% CI -1.04 to 1.26; three trials, 254 women; high-quality evidence) (Brown 2017c). 
Summary 
Effective interventions: high-quality evidence of effectiveness 
• High-quality evidence showed no clear difference for the return to pre-pregnancy BMI (at 
follow-up, timing not defined) for women with GDM who were treated with exercise versus 
control. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence suggested benefit by an increased number of women meeting 
postpartum weight goals, that is returning to their pre-pregnancy weight at twelve months 
postpartum for women with GDM who were treated with lifestyle intervention compared to usual 
care or diet alone. 
• Low-quality evidence showed no clear difference for postnatal weight retention or return to pre-
pregnancy weight at six weeks postpartum for women with GDM who were treated with lifestyle 
intervention versus usual care or diet alone. 
• Very low-quality evidence showed no clear difference for postnatal weight retention or return 
to pre-pregnancy weight at three months postpartum for women with GDM who were treated 
with low-GI diet versus high-fibre moderate-GI diet; or lifestyle intervention versus usual care 
or diet alone at eight months postpartum. 
 
28.0 Impaired glucose tolerance 
Impaired glucose tolerance was reported as an outcome by two reviews (Brown 2017b; Han 2017) 
(Table 2.12; Table 2.19). The timing for the reporting of this outcome varied between reviews and 
included up to 2 weeks postpartum, three months postpartum, six months postpartum, four to 13 months 
postpartum and not defined. The measures used to determine impaired glucose tolerance also varied 
between reviews and included OGTT, fasting blood glucose and test was not defined. The quality of the 
evidence ranged from low- to very low-quality. 
28.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the risk 
of impaired glucose tolerance (test and timing not defined) for women who had GDM between the 
lifestyle intervention and usual care or diet alone group (RR 0.67, 95% CI 0.12 to 3.69; one trial, 56 
women; very low-quality evidence) (Brown 2017b). 
28.2 High unsaturated fat diet versus low unsaturated fat diet with matching calories: There was 
no clear difference for the risk of impaired glucose tolerance (defined as borderline OGTT at one to two 
220 
weeks postpartum) for women who had GDM between the high unsaturated fat diet and low unsaturated 
fat diet with matching calories group (RR 1.50, 95% CI 0.30 to 7.43; one trial, 24 women; very low-
quality evidence) (Han 2017). 
28.3 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference for the risk of 
impaired glucose tolerance (measure not defined at three months postpartum) for women who had GDM 
between the low-GI diet and high-fibre moderate-GI diet group (RR 1.33, 95% CI 0.44 to 4.04; one trial, 
58 women; very low-quality evidence) (Han 2017). 
28.4 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the risk 
of impaired glucose tolerance (fasting plasma glucose at three months postpartum) but a non-significant 
trend towards lower fasting glucose concentration for the women who had GDM in the lifestyle 
intervention group compared to the usual care or diet alone group (MD -0.08 mmol/L, 95% CI -0.16 to 
0.00; one trial, 165 women; low-quality evidence) (Brown 2017b). 
28.5 Lifestyle intervention versus usual care or diet alone: The evidence suggested fewer women 
had impaired glucose tolerance (defined as fasting blood glucose concentration at six months 
postpartum) for the women who had GDM in the lifestyle intervention group compared to the usual care 
or diet alone group (MD -0.14 mmol/L, 95% CI -0.22 to -0.06; one trial, 165 women; low-quality evidence) 
(Brown 2017b). 
28.6 High unsaturated fat diet versus low unsaturated fat diet with matching calories: There was 
no clear difference for the risk of impaired glucose tolerance (defined as borderline OGTT at four to 13 
months post-partum) for women who had GDM between the high unsaturated fat diet and low 
unsaturated fat diet with matching calories group (RR 0.27, 95% CI 0.01 to 4.93; one trial, 7 women; 
very low-quality evidence) (Han 2017). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence suggested a benefit by a reduced impaired glucose tolerance at six 
months postpartum for women with GDM who were treated with lifestyle intervention compared 
to usual care or diet alone. 
• Low-quality evidence showed no clear difference for the risk of impaired glucose tolerance for 
women with GDM who were treated with lifestyle intervention versus usual care or diet alone 
at three months postpartum. 
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Summary 
• Very low-quality evidence showed no clear difference for the risk of impaired glucose tolerance 
for women with GDM who were treated with lifestyle intervention versus usual care or diet 
alone (timing not defined); high unsaturated fat diet versus low unsaturated fat diet with 
matching calories (at one to two weeks postpartum); low-GI diet versus high-fibre moderate-
GI diet (at three months postpartum); or high unsaturated fat diet versus low unsaturated fat 
diet with matching calories (at 13 months postpartum. 
29.0 Cardiovascular health (as defined in the reviews including blood pressure, hypertension, 
cardiovascular disease, metabolic syndrome) 
Cardiovascular health reported as metabolic syndrome was reported by one review (Brown 2017b) 
(Table 2.12; Table 2.19). The quality of the evidence was low-quality. 
29.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the risk 
of cardiovascular health at follow-up between 4.5 to 10 years after diagnosis of GDM for the women 
between the lifestyle intervention and usual care or diet alone group (RR 0.93, 95% CI 0.71 to 1.22; one 
trial, 430 women; low-quality evidence) (Brown 2017b). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for the risk of metabolic syndrome for women 
with GDM who were treated lifestyle intervention versus usual care or diet alone. 
30.0 Pre-specified overview maternal long-term secondary outcomes not reported in the 
included reviews 
None of the included reviews reported data for the development of type 2 diabetes and subsequent 
gestational diabetes. 
Secondary outcomes - Fetal/neonatal 
31.0 Stillbirth 
Stillbirth was reported as an outcome by four reviews (Brown 2017a; Brown 2017b; Brown 2017c; Han 
2017) (Table 2.13; Table 2.19). There was no clear evidence of a difference for the risk of stillbirth for 
any of the comparisons reporting this outcome. The quality of the evidence ranged from low- to very 
low-quality. 
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31.1 Oral antidiabetic agents versus placebo: There was no clear difference for the risk of stillbirth 
for babies born to mothers with GDM between the glibenclamide and placebo group (RR 0.49, 95% CI 
0.05 to 5.38; one trial, 375 babies; very low-quality evidence) (Brown 2017a). 
31.2 Metformin versus glibenclamide: There was no clear difference for the risk of stillbirth for babies 
born to mothers with GDM between the metformin and glibenclamide group (RR 0.92, 95% CI 0.06 to 
14.55; one trial, 200 babies; very low-quality evidence) (Brown 2017a). 
31.3 Energy restricted diet versus no energy restricted diet: There was no clear difference for the 
risk of stillbirth for babies born to mothers with GDM between the energy restricted diet and no energy 
restricted diet group (RR not estimable; two trials, 423 babies; low-quality evidence) (Han 2017). There 
were no events of stillbirths reported in either group. 
31.4 Low-carbohydrate diet versus high-carbohydrate diet: There was no clear difference for the 
risk of stillbirth for babies born to mothers with GDM between the low-carbohydrate and high-
carbohydrate diet group (RR 3.00, 95% CI 0.12 to 72.49; one trial, 150 babies; very low-quality evidence) 
(Han 2017). 
31.5 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the risk 
of stillbirth for babies born to mothers with GDM between the lifestyle intervention and usual care or diet 
alone group (RR 0.15, 95% CI 0.01 to 2.86; four trials, 2355 babies; very low-quality evidence) (Brown 
2017b). 
31.6 Exercise versus control: There were no events of stillbirth reported for babies born to mothers 
with GDM in either the exercise or the control groups (RR not estimable; one trial, 29 babies; very low-
quality evidence) (Brown 2017c). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence reported no events for stillbirth for babies born to mothers with GDM who 
were treated with either energy restricted diet or no energy restricted diet. 
• Very low-quality evidence showed no clear difference for the risk of stillbirth for babies born to 
mothers with GDM who were treated with glibenclamide versus placebo; metformin versus 
glibenclamide; low-carbohydrate diet versus high-carbohydrate diet; lifestyle intervention 
versus usual care or diet alone; or exercise versus control (no events). 
223 
32.0 Neonatal death 
Neonatal death was reported as an outcome by three reviews (Brown 2017a; Brown 2017b; Han 2017) 
(Table 2.13; Table 2.19). There was no clear evidence of a difference for the risk of neonatal death for 
any of the comparisons reporting this outcome. The quality of the evidence ranged from low- to very 
low-quality. 
32.1 Oral antidiabetic agents versus placebo: There were no events of neonatal death reported for 
babies born to mothers with GDM in either the glibenclamide or the placebo groups (RR not estimable; 
one trial, 375 babies; very low-quality evidence) (Brown 2017a). 
32.2 Energy restricted diet versus no energy restricted diet: There were no events of neonatal death 
reported for babies born to mothers with GDM in either the energy restricted diet or the no energy 
restricted diet groups (RR not estimable; two trials, 423 babies; low-quality evidence) (Han 2017). 
32.3 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the risk 
of neonatal death for babies born to mothers with GDM between the lifestyle intervention and usual care 
or diet alone group (RR 0.73, 95% CI 0.22 to 2.42; five trials, 3055 babies; low-quality evidence) (Brown 
2017b). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for the risk of neonatal death for babies born 
to mothers with GDM who were treated with energy restricted diet versus no energy restricted 
diet (no events); or lifestyle intervention versus usual care or diet alone. 
• Very low-quality evidence reported no events of neonatal death for babies born to mothers with 
GDM who were treated either with glibenclamide or placebo. 
33.0 Macrosomia (> 4000 g; or as defined in the reviews) 
Macrosomia was reported as an outcome by seven reviews (Boulvain 2001; Brown 2017a; Brown 
2017b; Brown 2017c; Han 2012; Han 2017; Martis 2016a) (Table 2.13; Table 2.19). Definitions of 
macrosomia varied between reviews and included ≥ 3700 g; >4000 g; ≥ 4000 g; > 4500 g or not defined. 
The quality of the evidence ranged from moderate- to very low-quality. 
33.1 Induction of labour versus expectant management: The evidence suggested a reduction for 
the risk of macrosomia (> 4000 g) for babies born to mothers with GDM in the induction of labour group 
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compared to the expectant management group (RR 0.56, 95% CI 0.32 to 0.98; one trial, 200 babies; 
very low-quality evidence) (Boulvain 2001). 
33.2 Oral antidiabetic agents versus placebo: There was no difference for the risk of macrosomia (≥ 
4000 g) for babies born to mothers with GDM between the glibenclamide and placebo group (RR 0.71, 
95% CI 0.36 to 1.41; one trial, 375 babies; very low-quality evidence) (Brown 2017a). 
33.3 Metformin versus glibenclamide: There was no clear difference for the risk of macrosomia (≥ 
4000 g in one trial and ≥ 3700 g in one trial) for babies born to mothers with GDM between the metformin 
and glibenclamide group (RR 0.72, 95% CI 0.23 to 2.21; two trials, 308 babies; low-quality evidence) 
(Brown 2017a). 
33.4 Glibenclamide versus acarbose: There was no clear difference for the risk of macrosomia (> 
4000 g) for babies born to mothers with GDM between the glibenclamide and acarbose group (RR 7.20, 
95% CI 0.41 to 125.97; one trial, 43 babies; very low-quality evidence) (Brown 2017a). 
33.5 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference for the risk 
of macrosomia (> 4000 g) for babies born to mothers with GDM between the low-moderate GI diet and 
moderate-high GI diet group (RR 0.59, 95% CI 0.16 to 2.26; three trials, 172 babies; very low-quality 
evidence) (Han 2017). 
33.6 Energy restricted diet versus no energy restricted diet: There was no clear difference for the 
risk of macrosomia (> 4000 g) for babies born to mothers with GDM between the energy restricted diet 
and no energy restricted diet group (RR 0.99, 95% CI 0.64 to 1.53; two trials, 421 babies; very low-
quality evidence) (Han 2017). 
33.7 Energy restricted diet versus no energy restricted diet: There was no clear difference for the 
risk of macrosomia (> 4500 g) for babies born to mothers with GDM between the energy restricted diet 
and no energy restricted diet group (RR 1.01, 95% CI 0.33 to 3.05; one trial, 299 babies; very low-quality 
evidence) (Han 2017). 
33.8 DASH diet versus control diet with matching macronutrient contents: The evidence 
suggested a reduced risk of macrosomia (≥ 4000 g) for babies born to mothers with GDM in the DASH 
diet group compared to the control diet with matching macronutrient contents (RR 0.10, 95% CI 0.01 to 
0.73; one trial, 52 babies; very low-quality evidence) (Han 2017). 
225 
33.9 Low-carbohydrate diet versus high-carbohydrate diet: There was no clear difference for the 
risk of macrosomia (> 4000 g) for babies born to mothers with GDM between the low-carbohydrate and 
high-carbohydrate diet group (RR 0.20, 95% CI 0.02 to 1.69; two trials, 179 babies; low-quality evidence) 
(Han 2017). 
33.10 High unsaturated fat diet versus low unsaturated fat diet with matching calories: There was 
no clear difference for the risk of macrosomia (> 4000 g) for babies born to mothers with GDM between 
the high unsaturated fat diet and low unsaturated fat diet with matching calories group (RR 0.53, 95% 
CI 0.18 to 1.56; two trials, 111 babies; low-quality evidence) (Han 2017). 
33.11 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference for the risk of 
macrosomia (> 4000 g) for babies born to mothers with GDM between the low-GI diet and high-fibre 
moderate-GI diet group (RR 0.32, 95% CI 0.03 to 2.96; one trial, 92 babies; very low-quality evidence) 
(Han 2017). 
33.12 Soy protein-enriched diet versus no soy protein diet: There was no clear difference for the 
risk of macrosomia (> 4000 g) for babies born to mothers with GDM between the soy protein-enriched 
diet and no soy protein diet group (RR 0.60, 95% CI 0.16 to 2.31; one trial, 68 babies; very low-quality 
evidence) (Han 2017). 
33.13 Ethnic specific diet versus standard healthy diet: There was no clear difference for the risk of 
macrosomia (> 4000 g) for babies born to mothers with GDM between the ethnic specific diet and 
standard healthy diet group (RR 0.20 g, 95% CI 0.01 to 3.70; one trial, 20 women; very low-quality 
evidence) (Han 2017). 
33.14 Lifestyle intervention versus usual care or diet alone: The evidence suggested a reduced risk 
of macrosomia (> 4 kg in five trials and ≥ 4 kg in two trials) for babies born to mothers with GDM in the 
lifestyle intervention group compared to the usual care or diet alone (average RR 0.64, 95% CI 0.48 to 
0.87; seven trials, 3422 babies; low-quality evidence) (Brown 2017b). 
33.15 Exercise versus control: There was no clear difference for the risk of macrosomia (not defined 
in the review) for babies born to mothers with GDM between the exercise and control group (RR 0.69, 
95% CI 0.35 to 1.35; five trials, 296 babies; moderate-quality evidence) (Brown 2017c). 
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33.16 Intensive management versus routine care: The evidence suggested a reduced risk of 
macrosomia (≥ 4000 g) for babies born to mothers with GDM in the intensive management group 
compared to the routine care group (RR 0.38, 95% CI 0.19 to 0.74; three trials, 438 babies; moderate-
quality evidence) (Han 2012). 
33.17 Strict intensity of glycaemic control versus less strict glycaemic control: There was no clear 
difference for the risk of macrosomia (> 4000 g) for babies born to mothers with GDM between the strict 
intensity of glycaemic control and less strict glycaemic control group (RR 1.35, 95% CI 0.31 to 5.85; one 
trial, 171 babies; very low-quality evidence) (Martis 2016a). 
Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence suggested a benefit by a reduction for the risk of macrosomia (≥ 
4000 g) for babies born to mothers with GDM who were treated with intensive management 
compared to routine care. 
• Moderate-quality evidence showed no clear difference for the risk of macrosomia (not defined) 
for babies born to mothers with GDM who were treated with exercise versus control. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence suggested a benefit by a reduced risk of macrosomia for babies born to 
mothers with GDM who were treated with lifestyle intervention compared to usual care or diet 
alone (> 4 kg (5 trials) (≥ 4 kg (2 trials). 
• Very low-quality evidence suggested a benefit by a reduced risk of macrosomia for babies born 
to mothers with GDM who were treated with induction of labour compared to expectant 
management (> 4000 g); or the DASH diet compared to control diet with matching 
macronutrient contents (≥ 4000 g). 
• Low-quality evidence showed no clear difference for the risk of macrosomia for babies born to 
mothers with GDM who were treated with metformin versus glibenclamide (≥ 4000 g (1 trial) (≥ 
3700 g (1 trial); low-carbohydrate diet versus high-carbohydrate diet (> 4000 g); or high 
unsaturated fat diet versus low unsaturated fat diet with matching calories (> 4000 g). 
• Very low-quality evidence showed no clear difference for the risk of macrosomia for babies 
born to mothers with GDM who were treated with glibenclamide versus placebo (≥ 4000 g); 
glibenclamide versus acarbose (> 4000 g); low-moderate GI diet versus moderate-high GI diet 
(> 4000 g); energy restricted diet versus no energy restricted diet (> 4000 g and 4500 g); low-
GI diet versus high-fibre moderate-GI diet (> 4000 g); soy protein-enriched diet versus no soy 
protein diet (> 4000 g); ethnic specific diet versus standard healthy diet (> 4000 g); or strict 
intensity of glycaemic control versus less strict glycaemic control (> 4000 g). 
34.0 Small-for-gestational age (SGA) 
SGA was reported as an outcome by five reviews (Brown 2017a; Brown 2017b; Han 2012; Han 2017; 
Martis 2016a) (Table 2.13; Table 2.19). No definition of SGA was reported in the reviews. There was no 
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clear evidence of a difference for the risk of being born SGA for any of the comparisons reporting this 
outcome. The quality of the evidence ranged from moderate-to very low-quality. 
34.1 Oral antidiabetic agents versus placebo: There was no clear difference for the risk of SGA for 
babies born to mothers with GDM between the glibenclamide and placebo group (RR 1.11, 95% CI 0.58 
to 2.10; one trial, 375 babies; very low-quality evidence) (Brown 2017a). 
34.2 Glibenclamide versus acarbose: There were no events of SGA for babies born to mothers with 
GDM in either the glibenclamide or the acarbose group (RR not estimable; one trial, 43 babies; low-
quality evidence). There were no events of SGA reported in either groups (Brown 2017a). 
34.3 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference for the risk 
of SGA for babies born to mothers with GDM between the low-moderate GI diet and moderate-high GI 
diet group (RR 5.16, 95% CI 0.26 to 103.27; one trial, 63 babies; very low-quality evidence) (Han 2017). 
34.4 Low-carbohydrate diet versus high-carbohydrate diet: There was no clear difference for the 
risk of SGA for babies born to mothers with GDM between the low-carbohydrate and high-carbohydrate 
diet group (RR 0.68, 95% CI 0.29 to 1.56; one trial, 149 babies; low-quality evidence) (Han 2017). 
34.5 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference for the risk of 
SGA for babies born to mothers with GDM between the low-GI diet and high-fibre moderate-GI diet 
group (RR 1.20, 95% CI 0.34 to 4.18; one trial, 92 babies; very low-quality evidence) (Han 2017). 
34.6 Ethnic specific diet versus standard healthy diet: There was no clear difference for the risk of 
SGA for babies born to mothers with GDM between the ethnic specific diet and standard healthy diet 
group (RR 0.33, 95% CI 0.02 to 7.32; one trial, 20 babies; very low-quality evidence) (Han 2017). 
34.7 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the risk 
of SGA for babies born to mothers with GDM between the lifestyle intervention and usual care or diet 
alone group (RR 0.98, 95% CI 0.73 to 1.32; four trials, 2324 babies; moderate-quality evidence) (Brown 
2017b). 
34.8 Intensive management versus routine care: There was no clear difference for the risk of SGA 
for babies born to mothers with GDM between the intensive management and routine care group (RR 
1.53, 95% CI 0.81 to 2.88; three trials, 509 babies; very low-quality evidence) (Han 2012). 
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34.9 Strict intensity of glycaemic control versus less strict glycaemic control: There was no clear 
difference for the risk of SGA for babies born to mothers with GDM between the strict intensity of 
glycaemic control and less strict glycaemic control group (RR 1.12, 95% CI 0.48 to 2.63; one trial, 171 
babies; very low-quality evidence) (Martis 2016a). 
Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence showed no clear difference for the risk of SGA for babies born to 
mothers with GDM who were treated with lifestyle intervention versus usual care or diet alone. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for the risk of SGA for babies born to mothers 
with GDM who were treated with glibenclamide versus acarbose (no events); or low-
carbohydrate diet versus high-carbohydrate diet. 
• Very low-quality evidence showed no clear difference for the risk of SGA for babies born to 
mothers with GDM who were treated with glibenclamide versus placebo; low-moderate GI diet 
versus moderate-high GI diet; ethnic specific diet versus standard healthy diet; low-GI diet 
versus high-fibre moderate-GI diet; intensive management versus routine care; or strict 
intensity of glycaemic control versus less strict glycaemic control. 
35.0 Birth trauma (e.g. shoulder dystocia, bone fracture, nerve palsy) 
Birth trauma was reported as an outcome by five reviews (Boulvain 2001; Brown 2017a; Brown 2017b; 
Han 2012; Han 2017) (Table 2.13; Table 2.19). Birth trauma was variously shoulder dystocia, bone 
fracture, nerve palsy or as a general term of birth trauma that was not further defined. The quality of the 
evidence ranged from low- to very low-quality. 
35.1 Birth trauma (not defined) 
35.1.1 Metformin versus glibenclamide: There were no events of birth trauma for babies born to 
mothers with GDM in either the metformin or the glibenclamide group (RR not estimable; one trial, 159 
babies; low-quality evidence) (Brown 2017a). 
35.1.2 Glibenclamide versus acarbose: There were no events of birth trauma for babies born to 
mothers with GDM in either the glibenclamide or the acarbose group (RR not estimable; one trial, 43 
babies; low-quality evidence) (Brown 2017a). 
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35.1.3 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the 
risk of birth trauma for babies born to mothers with GDM between the lifestyle intervention and usual 
care or diet alone group (RR 0.48, 95% CI 0.12 to 1.90; three trials, 1930 babies; low-quality evidence) 
(Brown 2017b). 
35.2 Birth trauma: Shoulder dystocia 
35.2.1 Induction of labour versus expectant management: The evidence suggested a reduction in 
the risk of shoulder dystocia for babies of mothers with GDM whose labour was induced at 38 completed 
weeks of gestation compared to the expectant management group (RR 0.14, 95% CI 0.01 to 2.73; one 
trial, 200 babies; very low-quality evidence). There were three babies with shoulder dystocia in the 
expectant management group (Boulvain 2001). 
35.2.2 Oral antidiabetic agents versus placebo: There was no clear difference for the risk of shoulder 
dystocia for babies born to mothers with GDM between the glibenclamide and placebo group (RR 0.33, 
95% CI 0.01 to 8.00; one trial, 375 babies; very low-quality evidence) (Brown 2017a). 
35.2.3 Metformin versus glibenclamide: There was no clear difference for the risk of shoulder dystocia 
for babies born to mothers with GDM between the metformin and glibenclamide group (RR 0.99, 95% 
CI 0.14 to 6.89; two trials, 195 babies; low-quality evidence) (Brown 2017a). 
35.2.4 Energy restricted diet versus no energy restricted diet: There was no clear difference for the 
risk of shoulder dystocia for babies born to mothers with GDM between the energy restricted diet and 
no energy restricted diet group (RR 0.12, 95% CI 0.01 to 2.26; two trials, 418 babies; very low-quality 
evidence) (Han 2017). 
35.2.5 Intensive management versus routine care: There was no clear difference for the risk of 
shoulder dystocia for babies born to mothers with GDM between the intensive management and routine 
care group (RR 0.69, 95% CI 0.06 to 7.27; one trial, 83 babies; very low-quality evidence) (Han 2012). 
35.2.6 Lifestyle intervention versus usual care or diet alone: The evidence suggested a reduction 
in the risk of shoulder dystocia for babies born to mothers with GDM in the lifestyle intervention group 
compared to the usual care or diet alone group (RR 0.38, 95% CI 0.21 to 0.66; five trials, 2894 babies; 
low-quality evidence) (Brown 2017b). 
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35.3 Birth trauma: Bone fracture 
35.3.1 Induction of labour versus expectant management: There were no events of bone fracture 
for babies born to mothers with GDM in either the induction of labour or the expectant management 
group (RR not estimable; one trial, 200 babies; very low-quality evidence). There were no events of 
bone fracture reported in either group (Boulvain 2001). 
35.3.2 Oral antidiabetic agents versus placebo: There was no clear difference for the risk of bone 
fracture for babies born to mothers with GDM between the glibenclamide and placebo group (RR 0.74, 
95% CI 0.17 to 3.25; one trial, 375 babies; very low-quality evidence) (Brown 2017a). 
35.3.3. Energy restricted diet versus no energy restricted diet: There were no events of risk of bone 
fracture for babies born to mothers with GDM in either the energy restricted diet or the no energy 
restricted diet group (RR not estimable; one trial, 299 babies; low-quality evidence) (Han 2012). 
35.3.4 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the 
risk of bone fracture for babies born to mothers with GDM between the lifestyle intervention and usual 
care or diet alone group (RR 0.35, 95% CI 0.01 to 8.45; two trials, 1730 babies; low-quality evidence). 
Event rates were very low with one being reported in the control group (Brown 2017b). 
35.4 Birth trauma: Nerve palsy (brachial plexus) 
35.4.1 Induction of labour versus expectant management: There were no events of nerve palsy for 
babies born to mothers with GDM in either the induction of labour or the expectant management group 
(RR not estimable; one trial, 200 babies; very low-quality evidence) (Boulvain 2001). 
35.4.2 Oral antidiabetic agents versus placebo: There was no clear difference for the risk of nerve 
palsy for babies born to mothers with GDM between the glibenclamide and placebo group (RR 0.33, 
95% CI 0.01 to 8.00; one trial, 375 babies; very low-quality evidence) (Brown 2017a). 
35.4.3 Energy restricted diet versus no energy restricted diet: There were no events of nerve palsy 
for babies born to mothers with GDM between the energy restricted diet versus no energy restricted diet 
group (RR not estimable; one trial, 299 babies; low-quality evidence) (Han 2017). 
35.4. 4 Lifestyle interventions versus usual care or diet alone: There was no clear difference for the 
risk of nerve palsy for babies born to mothers with GDM between the lifestyle intervention and usual 
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care or diet alone group (RR 0.15, 95% CI 0.01 to 2.86; one trial, 1030 babies; low-quality evidence). 
Event rates were very low with three being reported in the control group (Brown 2017b). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to 
comment on the effectiveness, more evidence needed 
• Low-quality evidence suggested a benefit for a reduced risk of shoulder dystocia for 
babies born to mothers with GDM who were treated with lifestyle intervention compared 
to usual care or diet alone. 
• Very low-quality evidence suggested a benefit for a reduced risk of shoulder dystocia 
for babies born to mothers with GDM who were treated with induction of labour 
compared to expectant management. 
• Low-quality evidence showed no clear difference for the risk of birth trauma for babies 
born to mothers with GDM who were treated with metformin versus glibenclamide (not 
defined, no events); glibenclamide versus acarbose (not defined, no events); lifestyle 
intervention versus usual care or diet alone (not defined); metformin versus 
glibenclamide (shoulder dystocia); energy restricted diet versus no energy restricted 
diet (bone fracture and nerve palsy, no events); lifestyle intervention versus usual care 
or diet alone (bone fracture); or lifestyle intervention versus usual care or diet alone 
(nerve palsy). 
• Very low-quality evidence showed no clear difference for the risk of birth trauma for 
babies born to mothers with GDM who were treated with glibenclamide versus placebo 
(shoulder dystocia); energy restricted diet versus no energy restricted diet (shoulder 
dystocia); intensive management versus routine care (shoulder dystocia); induction of 
labour versus expectant management (bone fracture); glibenclamide versus placebo 
(bone fracture); induction of labour versus expectant management (bone fracture and 
nerve palsy, no events); or glibenclamide versus placebo (nerve palsy). 
36.0 Gestational age at birth 
Gestational age at birth was reported as an outcome by seven reviews (Brown 2016a; Brown 2017a; 
Brown 2017b; Brown 2017c; Han 2012; Han 2017; Martis 2016a) (Table 2.13; Table 2.19). The quality 
of the evidence ranged from moderate- to very low-quality. 
36.1 Oral antidiabetic agents versus placebo: There was no clear difference for gestational age at 
birth for babies born to mothers with GDM between the oral antidiabetic drug glibenclamide and placebo 
group (MD 0.0 weeks, 95% CI -0.32 to 0.32; one trial, 375 babies; very low-quality evidence) (Brown 
2017a). 
36.2 Metformin versus glibenclamide: There was no clear difference for gestational age at birth for 
babies born to mothers with GDM between the metformin and glibenclamide group (MD 0.03 weeks, 
95% CI -0.22 to 0.28; three trials, 508 babies; very low-quality evidence) (Brown 2017a). 
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36.3 Glibenclamide versus acarbose: There was no clear difference for gestational age at birth for 
babies born to mothers with GDM between the glibenclamide and acarbose group (MD -0.10 weeks, 
95% CI -0.82 to 0.62; one trial, 43 babies; low-quality evidence) (Brown 2017a). 
36.4 Myo-inositol versus placebo: Myo-inositol was associated with being born at a later gestational 
age for babies of mothers compared with placebo (MD 2.1 weeks, 95% CI 1.27 to 2.93; one trial, 73 
babies; moderate-quality evidence) (Brown 2016a). 
36.5 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference for 
gestational age at birth for babies born to mothers with GDM between the low-moderate GI diet and 
moderate-high GI diet group (MD 0.30 weeks, 95% CI -0.30 to 0.90; one trial, 62 babies; very low-quality 
evidence) (Han 2017). 
36.6 Energy restricted diet versus no energy restricted diet: There was no clear difference for 
gestational age at birth for babies born to mothers between the energy restricted diet and no energy 
restricted diet group (MD -0.16 weeks, 95% CI -0.67 to 0.36; two trials, 423 babies; moderate-quality 
evidence) (Han 2017). 
36.7 DASH diet versus control diet with matching macronutrient contents: There was no clear 
difference for gestational age at birth for babies born to mothers with GDM between the DASH diet and 
control diet with matching macronutrient contents group (MD 0.20 weeks, 95% CI -0.45 to 0.85; one 
trial, 52 babies; very low-quality evidence) (Han 2017). 
36.8 Low-carbohydrate diet versus high-carbohydrate diet: There was no clear difference for 
gestational age at birth for babies born to mothers with GDM between the low-carbohydrate and high-
carbohydrate diet group (MD 0.10 weeks, 95% CI -0.42 to 0.62; two trials, 180 babies; low-quality 
evidence) (Han 2017). 
36.9 High unsaturated fat diet versus low unsaturated fat diet with matching calories: There was 
no clear difference for gestational age at birth for babies born to mothers with GDM between the high 
unsaturated fat diet and low unsaturated fat diet with matching calories group (MD 0.25 weeks, 95% CI 
-0.51 to 1.01; two trials, 111 babies; low-quality evidence) (Han 2017). 
36.10 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference for gestational 
age at birth for babies born to mothers with GDM between the low-GI diet and high-fibre moderate-GI 
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diet group (MD -0.10 weeks, 95% CI -0.39 to 0.19; one trial, 92 babies; low-quality evidence) (Han 
2017). 
36.11 Soy protein-enriched diet versus no soy protein diet: There was no clear difference for 
gestational age at birth for babies born to mothers with GDM between the soy protein-enriched diet and 
no soy protein diet group (MD 0.40 weeks, 95% CI -0.23 to 1.03; one trial, 68 babies; very low-quality 
evidence) (Han 2017). 
36.12 High-fibre diet versus standard-fibre diet: There was no clear difference for gestational age at 
birth for babies born to mothers with GDM between high-fibre diet and standard-fibre diet (MD 0.0 
weeks, 95% CI -1.30 to 1.30; one trial, 22 babies; very low-quality evidence) (Han 2017). 
36.13 Ethnic specific diet versus standard healthy diet: There was no clear difference for gestational 
age at birth for babies born to mothers with GDM between the ethnic specific diet and standard healthy 
diet group (MD -0.40 weeks, 95% CI -1.15 to 0.35; one trial, 20 babies; very low-quality evidence) (Han 
2017). 
36.14 Lifestyle intervention versus usual care or diet alone: There was no clear difference for 
gestational age at birth for babies born to mothers with GDM between the lifestyle intervention and usual 
care or diet alone group (MD 0.04 weeks, 95% CI -0.13 to 0.20; five trials, 2057 babies; low-quality 
evidence) (Brown 2017b). 
36.15 Exercise versus control: There was no clear difference for gestational age at birth for babies 
born to mothers with GDM between the exercise and control group (MD-0.01 weeks, 95% CI -0.40 to 
0.38; four trials, 167 babies; low-quality evidence) (Brown 2017c). 
36.16 Intensive management versus routine care: There was no clear difference for gestational age 
at birth for babies born to mothers with GDM between the intensive management and routine care group 
(MD -0.18 weeks, 95% CI -0.43 to 0.07; four trials, 521 babies; very low-quality evidence) (Han 2012). 
36.17 Strict intensity of glycaemic control versus less strict glycaemic control: There was no clear 
difference for gestational age at birth for babies to mothers with GDM between the strict intensity of 
glycaemic control and less strict glycaemic control group (MD -0.30 weeks, 95% CI -0.73 to 0.13; one 
trial, 171 babies; very low-quality evidence) (Martis 2016a). 
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Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence suggested a benefit for birth at a later gestational age for babies of 
mothers with GDM who were treated with myo-inositol compared to placebo. 
Probably no difference between interventions: moderate-quality evidence; direction of the 
effect suggests benefit, but more evidence needed. 
• Moderate-quality evidence showed no clear difference for the risk of low gestational age at 
birth for babies born to mothers with GDM who were treated with energy restricted diet versus 
no energy restricted diet. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed. 
• Low-quality evidence showed no clear difference for the risk of low gestational age at birth for 
babies born to mothers with GDM who were treated with glibenclamide versus acarbose; low-
carbohydrate diet versus high-carbohydrate diet; high unsaturated fat diet versus low 
unsaturated fat diet with matching calories; low-GI diet versus high-fibre moderate-GI diet; soy 
protein-enriched diet versus no soy protein diet; lifestyle intervention versus usual care; or diet 
alone or exercise versus control. 
• Very low-quality evidence showed no clear difference for the risk of low gestational age at birth 
for babies born to mothers with GDM who were treated with glibenclamide versus placebo; 
metformin versus glibenclamide; DASH diet versus control diet with matching macronutrient 
contents; low-moderate GI diet versus moderate-high GI diet; high-fibre diet versus standard-
fibre diet; ethnic specific diet versus standard healthy diet; intensive management versus 
routine care; or strict intensity of glycaemic control versus less strict glycaemic control. 
37.0 Preterm birth (< 37 weeks’ gestation and < 32 weeks’ gestation) 
Preterm birth was reported as an outcome by six reviews (Brown 2016a; Brown 2017b; Brown 2017c; 
Brown 2017a; Han 2012; Han 2017) (Table 2.13; Table 2.19). 
None of the reviews reported data for preterm birth <32 weeks' gestation. The quality of the evidence 
ranged from moderate- to very low-quality. 
37.1 Metformin versus glibenclamide: There was no clear difference for the risk of preterm birth (< 
37 weeks) for babies born to mothers with GDM between the metformin and glibenclamide group (RR 
1.59, 95% CI 0.59 to 4.29; three trials, 508 babies; very low-quality evidence) (Brown 2017a). 
37.2 Glibenclamide versus acarbose: There were no events of preterm birth (< 37 weeks) for babies 
born to mothers with GDM in either the glibenclamide or the acarbose group (RR not estimable; one 
trial, 43 babies; low-quality evidence) (Brown 2017a). 
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37.3 Myo-inositol versus placebo: There was no clear difference for the risk of preterm birth (< 37 
weeks) for babies born to mothers with GDM between in the myo-inositol and the placebo group (RR 
1.00, 95% CI 0.09 to 10.56; one trial, 84 babies; very low-quality evidence) (Brown 2016a). 
37.4 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference for the risk 
of preterm birth (< 37 weeks) for babies born to mothers with GDM between the low-moderate GI diet 
and moderate-high GI diet group (RR 0.64, 95% CI 0.22 to 1.85; two trials, 146 babies; low-quality 
evidence) (Han 2017). 
37.5 High unsaturated fat diet versus low unsaturated fat diet with matching calories: There were 
no events of preterm birth (< 37 weeks) for babies born to mothers with GDM in either the high 
unsaturated fat diet or the low unsaturated fat diet with matching calories group (RR not estimable; one 
trial, 84 babies; low-quality evidence) (Han 2017). 
37.6 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference for the risk of 
preterm birth (< 37 weeks) for babies born to mothers between the low-GI diet and high-fibre moderate-
GI diet group (RR 0.96, 95% CI 0.14 to 6.53; one trial, 96 babies; very low-quality evidence) (Han 2017). 
37.7 Diet recommendation + diet-related behavioural advice versus diet recommendation only: 
There was no clear difference for the risk of preterm birth (< 37 weeks) for babies born to mothers with 
GDM between the diet recommendation + diet-related behavioural advice and diet recommendation 
only group (RR 0.51, 95% CI 0.10 to 2.66; one trial, 99 babies; very low-quality evidence) (Han 2017). 
37.8 Soy protein-enriched diet versus no soy protein diet: There was no clear difference for the risk 
of preterm birth (defined as < 37 weeks gestation in the review) for babies born to mothers with GDM 
between the soy protein-enriched diet and no soy protein diet group (RR 2.00, 95% CI 0.19 to 21.03; 
one trial, 68 babies; very low-quality evidence) (Han 2017). 
37.9 Lifestyle intervention versus usual care or diet alone: The evidence suggested a reduced risk 
of preterm birth (< 37 weeks) for babies born to mothers with GDM in the lifestyle intervention group 
compared to the usual care or diet alone group (RR 0.71, 95% CI 0.53 to 0.96; three trials, 1797 babies; 
moderate-quality evidence) (Brown 2017b). 
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37.10 Exercise versus control: There was no clear difference for the risk of preterm birth (not defined) 
for babies born to mothers with GDM between the exercise and control group (RR 0.95, 95% CI 0.39 to 
2.36; five trials, 302 babies; low-quality evidence) (Brown 2017c). 
37.11 Intensive management versus routine care: There was no clear difference for the risk of 
preterm birth (< 37 weeks) for babies born to mothers with GDM between the intensive management 
and routine care group (RR 1.00, 95% CI 0.26 to 3.82; two trials, 138 babies; low-quality evidence) (Han 
2012). 
Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence of benefit showed a reduction for the risk of preterm birth for babies 
born to mothers with GDM who were treated with lifestyle intervention compared to usual care 
or diet alone. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for the risk of preterm birth for babies born to 
mothers with GDM who were treated with glibenclamide versus acarbose (no events); low-
moderate GI diet versus moderate-high GI diet; high unsaturated fat diet versus low 
unsaturated fat diet with matching calories (no events); exercise versus control (not defined); 
or intensive management versus routine care. 
• Very low-quality evidence showed no clear difference for the risk of preterm birth for babies 
born to mothers with GDM who were treated with metformin versus glibenclamide; myo-inositol 
versus placebo; low-GI diet versus high-fibre moderate-GI diet; diet recommendation + diet-
related behavioural advice versus diet recommendation only; or soy protein-enriched diet 
versus no soy protein diet. 
38.0 Five-minute Apgar < 7 
A five-minute Apgar score <7 was reported as an outcome by three reviews (Brown 2017a; Brown 
2017b; Brown 2017c) (Table 2.13; Table 2.29). There was no clear evidence of a difference for the risk 
five-minute Apgar <7 for any of the comparisons reporting this outcome. The quality of the evidence 
ranged from moderate- to very low-quality. 
38.1 Metformin versus glibenclamide: There were no events of a five-minute Apgar < 7 score for 
babies born to mothers with GDM in either the metformin or the glibenclamide group (RR not estimable; 
one trial, 149 babies; low-quality evidence) (Brown 2017a). 
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38.2 Lifestyle intervention versus usual care or diet alone: There was no clear difference for of a 
five-minute Apgar < 7 score for babies born to mothers with GDM between the lifestyle intervention and 
usual care or diet alone group (RR 0.56, 95% CI 0.21 to 1.52; one trial, 1030 babies; moderate-quality 
evidence) (Brown 2017b). 
38.3 Exercise versus control: There was no clear difference for of a five-minute Apgar < 7 score for 
babies born to mothers with GDM between the exercise and control group (RR 0.33, 95% CI 0.01 to 
7.65; one trial, 34 babies; very low-quality evidence) (Brown 2017c). 
Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence showed no clear difference for the risk of five-minute Apgar < 7 at 
birth for babies born to mothers with GDM who were treated with lifestyle intervention versus 
usual care or diet alone. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for the risk of five-minute Apgar < 7 at birth 
for babies born to mothers with GDM who were treated with metformin versus glibenclamide. 
• Very low-quality evidence showed no clear difference for the risk of five-minute Apgar < 7 at 
birth for babies born to mothers with GDM who were treated with exercise versus control. 
39.0 Birthweight and z score 
Birthweight was reported as an outcome by seven reviews (Brown 2016a; Brown 2017a; Brown 2017b; 
Brown 2017c; Han 2012; Han 2017; Martis 2016a) Table 2.13; Table 2.19). None of the included reviews 
reported data for birthweight z scores. The quality of the evidence ranged from moderate- to very low-
quality. 
39.1 Oral antidiabetic agents versus placebo: There was no clear difference in birthweight for babies 
born to mothers with GDM between the glibenclamide and placebo group (MD -33.0 g, 95% CI -134.53 
to 68.53; one trial, 375 babies; very low-quality evidence) (Brown 2017a). 
39.2 Metformin versus glibenclamide: The evidence suggested a reduced birthweight for babies born 
to mothers with GDM in the metformin group compared to the glibenclamide group (MD -209.13 g, 95% 
CI -314.53 to 103.73; two trials, 349 babies; very low-quality evidence) (Brown 2017a). 
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39.3 Glibenclamide versus acarbose: There was no clear difference in birthweight for babies born to 
mothers with GDM between the glibenclamide and acarbose group (MD 153.0 g, 95% CI -123.52 to 
429.52; one trial, 43 babies; very low-quality evidence) (Brown 2017a). 
39.4 Myo-inositol versus placebo: There was no clear difference in birthweight for babies born to 
mothers with GDM between in the myo-inositol group and the placebo group (MD 16.00 g, 95% CI -
209.72 to 241.72; one trial, 73 babies; low-quality evidence) (Brown 2016a). 
39.5 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference in 
birthweight for babies born to mothers with GDM between the low-moderate GI diet and moderate-high 
GI diet group (MD -55.98 g, 95% CI -201.90 to 89.95; two trials, 145 babies; very low-quality evidence) 
(Han 2017). 
39.6 Energy restricted diet versus no energy restricted diet: There was no clear difference in 
birthweight for babies born to mothers with GDM between the energy restricted diet and no energy 
restricted diet group (MD -107.00 g, 95% CI -240.32 to 26.32; one trial, 299 babies; very low-quality 
evidence) (Han 2017). 
39.7 DASH diet versus control diet with matching macronutrient contents: The evidence 
suggested a reduced birthweight for babies born to mothers with GDM in the DASH diet group compared 
to the control diet with matching macronutrient contents (MD -.581.27 g, 95% CI -790.32 to -372.22; two 
trials, 86 babies; moderate-quality evidence) (Han 2017). 
39.8 Low-carbohydrate diet versus high-carbohydrate diet: There was no clear difference in 
birthweight for babies born to mothers with GDM between the low-carbohydrate and high-carbohydrate 
diet group (MD 22.00 g, 95% CI -241.06 to 285.06; one trial, 30 babies; very low-quality evidence) (Han 
2017). 
39.9 High unsaturated fat diet versus low unsaturated fat diet with matching calories: There was 
no clear difference for birthweight for babies born to mothers between the high unsaturated fat diet and 
low unsaturated fat diet with matching calories group (MD -138.19 g, 95% CI -292.59 to 16.21; two trials, 
111 babies; low-quality evidence) (Han 2017) 
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39.10 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference for birthweight 
for babies born to mothers with GDM between the low-GI diet and high-fibre moderate-GI diet group 
(MD 0.0 g, 95% CI -277.18 to 277.18; one trial, 92 babies; very low-quality evidence) (Han 2017). 
39.11 Soy protein-enriched diet versus no soy protein diet: There was no clear difference for 
birthweight for babies born to mothers with GDM between the soy protein-enriched diet and no soy 
protein diet group (MD -142.60 g, 95% CI -360.40 to 75.20; one trial, 68 babies; very low-quality 
evidence) (Han 2017). 
39.12 High-fibre diet versus standard-fibre diet: There was no clear difference for birthweight for 
babies born to mothers with GDM between high-fibre diet and standard-fibre diet (MD -94.00 g, 95% CI 
-446.71 to 258.71; one trial, 22 babies; very low-quality evidence) (Han 2017). 
39.13 Ethnic specific diet versus standard healthy diet: There was no clear difference for birthweight 
for babies born to mothers with GDM between the ethnic specific diet and standard healthy diet group 
(MD -370.00 g, 95% CI -928.87 to 188.87; one trial, 20 babies; very low-quality evidence) (Han 2017). 
39.14 Lifestyle intervention versus usual care or diet alone: The evidence suggested a reduced 
birthweight for babies born to mothers with GDM in the lifestyle intervention group compared to the usual 
care or diet alone group (MD -109.64 g, 95% CI -149.77 to -69.51; six trials, 3074 babies, moderate-
quality evidence) (Brown 2017b). This was without a consequent increase in the risk of SGA as 
previously reported. 
39.15 Exercise versus control: There was no clear difference for birthweight for babies born to mothers 
with GDM between the exercise and control group (MD -61.50 g, 95% CI -195.21 to 72.20; six trials, 
192 babies; very low-quality evidence) (Brown 2017c). 
39.16 Intensive management versus routine care: The evidence suggested a reduced birthweight for 
babies born to mothers with GDM in the intensive management compared to the routine care group (MD 
-117.33 g, 95% CI -198.72 to -35.94; four trials, 521 babies; very low-quality evidence) (Han 2012). 
39.17 Strict intensity of glycaemic control versus less strict glycaemic control: There was no clear 
difference for birthweight for babies born to mothers with GDM between the strict intensity of glycaemic 
control and less strict glycaemic control group ((MD -0.92 g, 95% CI -241.97 to 57.97; one trial, 171 
babies; very low-quality evidence) (Martis 2016a). 
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Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence of benefit showed a reduction of birthweight for babies born to 
mothers with GDM who were treated with the DASH diet compared to the control diet with 
matching macronutrient contents; or women with GDM treated with a lifestyle intervention 
compared to usual care or diet alone. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Very low-quality evidence of benefit showed a reduction of birthweight for babies born to 
mothers with GDM who were treated with metformin compared to glibenclamide, with no clear 
difference to gestational age at birth, SGA not reported. 
• Low-quality evidence showed no clear difference for birthweight for babies born to mothers 
with GDM who were treated with myo-inositol versus placebo; or high unsaturated fat diet 
versus low unsaturated fat diet with matching calories. 
• Very low-quality evidence showed no clear difference for the birthweight for babies born to 
mothers with GDM who were treated with glibenclamide versus placebo; glibenclamide versus 
acarbose; low-moderate GI diet versus moderate-high GI diet; energy restricted diet versus no 
energy restricted diet; low-carbohydrate diet versus high-carbohydrate diet; low-GI diet versus 
high-fibre moderate-GI diet; soy protein-enriched diet versus no soy protein diet; high-fibre diet 
versus standard-fibre diet; ethnic specific diet versus standard healthy diet; exercise versus 
control; intensive management versus routine care; or strict intensity of glycaemic control 
versus less strict glycaemic control. 
40.0 Head circumference and z score 
Head circumference was reported as an outcome by one review (Han 2017) (Table 2.13; Table 2.19). 
The review did not report data for head circumference z scores. The quality of the evidence ranged from 
moderate- to very low-quality.  
40.1 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference for head 
circumference at birth for babies born to mothers with GDM between the low-moderate GI diet and 
moderate-high GI diet group (MD 0.40 cm, 95% CI -0.58 to 1.38; one trial, 59 babies; very low-quality 
evidence) (Han 2017). 
40.2 DASH diet versus control diet with matching macronutrient contents: The evidence 
suggested a reduced head circumference at birth for babies born to mothers with GDM in the DASH 
diet group compared to the diet with matching macronutrient contents group (MD -0.90 cm, 95% CI -
1.44 to -0.36; one trial, 52 babies; moderate-quality evidence) (Han 2017). 
40.3 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference for head 
circumference at birth for babies born to mothers with GDM between the low-GI diet and high-fibre 
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moderate-GI diet group (MD -0.20 cm, 95% CI -0.91 to 0.51; one trial, 82 babies; very low-quality 
evidence) (Han 2017). 
40.4 Soy protein-enriched diet versus no soy protein diet: There was no clear difference for head 
circumference at birth for babies born to mothers between the soy protein-enriched diet and no soy 
protein diet group (MD -0.20, 95% CI -1.01 to 0.61; one trial, 68 babies; very low-quality evidence) (Han 
2017). 
Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence showed a reduction of head circumference at birth for babies born 
to mothers with GDM who were treated with the DASH diet compared to the control diet with 
matching macronutrient contents evidence. 
 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Very low-quality evidence showed no clear difference for head circumference at birth for babies 
born to mothers with GDM who were treated with low-moderate GI diet versus moderate-high 
GI diet; low-GI diet versus high-fibre moderate-GI diet; or soy protein-enriched diet versus no 
soy protein diet. 
41.0 Length and z score 
Length at birth was reported as an outcome by three reviews (Brown 2017b; Brown 2017c; Han 2017) 
(Table 2.13; Table 2.19). There was no clear evidence of a difference for length at birth for any of the 
comparisons reporting this outcome. The reviews did not report data for length z scores. The quality of 
the evidence ranged from low- to very low-quality.  
41.1 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference for length 
at birth for babies born to mothers with GDM between the low-moderate GI diet and moderate-high GI 
diet group (MD -0.50 cm, 95% CI -1.54 to 0.54; one trial, 60 babies; very low-quality evidence) (Han 
2017). 
41.2 DASH diet versus control diet with matching macronutrient contents: There was no clear 
difference for length at birth for babies born to mothers between the DASH diet and control diet with 
matching macronutrient contents group (MD -0.50 cm, 95% CI -1.59 to 0.59; one trial, 52 babies; low-
quality evidence) (Han 2017). 
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41.3 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference for length at birth 
for babies born to mothers with GDM between the low-GI diet and high-fibre moderate-GI diet group 
(MD 0.0 cm, 95% CI -0.83 to 0.83; one trial, 92 babies; very low-quality evidence) (Han 2017). 
41.4 Soy protein-enriched diet versus no soy protein diet: There was no clear difference for length 
at birth for babies born to mothers with GDM between the soy protein-enriched diet and no soy protein 
diet group (MD -0.10 cm, 95% CI -1.07 to 0.87; one trial, 68 babies; very low-quality evidence) (Han 
2017). 
41.5 Lifestyle intervention versus usual care or diet alone: There was no clear difference for length 
at birth for babies born to mothers with GDM between the lifestyle intervention and usual care or diet 
alone group (MD -0.10 cm, 95% CI -0.37 to 0.17; one trials, 700 babies; low-quality evidence) (Brown 
2017b). 
41.6 Exercise versus control: There was no clear difference for length at birth for babies born to 
mothers with GDM between the exercise and control group (MD -1.70 cm, 95% CI -3.41 to 0.01; one 
trial, 34 babies; very low-quality evidence) (Brown 2017c). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for length at birth for babies born to mothers 
with GDM who were treated with DASH diet versus control diet with matching macronutrient 
contents; or lifestyle intervention versus usual care or diet alone. 
• Very low-quality evidence showed no clear difference for length at birth for babies born to 
mothers with GDM who were treated with low-moderate GI diet versus moderate-high GI diet; 
low-GI diet versus high-fibre moderate-GI diet; soy protein-enriched diet versus no soy protein 
diet; or exercise versus control. 
42.0 Ponderal index 
Ponderal index was reported as an outcome by three reviews (Brown 2017a; Han 2012; Han 2017) 
Table 2.13; Table 2.19). The quality of the evidence ranged from moderate- to very low-quality. 
42.1 Metformin versus glibenclamide: The evidence suggested a reduced ponderal index for babies 
born to mothers with GDM in the metformin group compared to the glibenclamide group (MD -0.09 units, 
95% CI -0.17 to -0.01; one trial, 200 babies; low-quality evidence) (Brown 2017a). 
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42.2 Low-moderate GI diet versus moderate-high GI diet: There was no clear difference for the 
ponderal index at birth for babies born to mothers with GDM between the low-moderate GI diet and 
moderate-high GI diet group (MD -0.10 kg/m3, 95% CI -0.03 to 0.23; one trial, 60 babies; very low-quality 
evidence) (Han 2017). 
42.3 DASH diet versus control diet with matching macronutrient contents: The evidence 
suggested a reduced ponderal index at birth for babies born to mothers with GDM in the DASH diet 
group (MD -0.37 kg/m3, 95% CI -0.54 to -0.20; one trial, 52 babies; moderate-quality evidence) (Han 
2017). 
42.4 Low-GI diet versus high-fibre moderate-GI diet: There was no clear difference for the ponderal 
index at birth for babies born to mothers with GDM between the low-GI diet and high-fibre moderate-GI 
diet group (MD 0.20 kg/m3, 95% CI -0.79 to 1.19; one trial, 92 babies; very low-quality evidence) (Han 
2017). 
42.5 Intensive management versus routine care: The evidence suggested a reduced ponderal index 
for babies born to mothers with GDM in the intensive management group (MD -0.09 g x 100 m3, 95% 
CI -0.16 to -0.02; one trial, 300 babies; low-quality evidence) (Han 2012). 
Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence suggested a benefit of a reduction of ponderal index at birth for 
babies born to mothers with GDM who were treated with the DASH diet compared to the control 
diet with matching macronutrient contents evidence. This was less than 0.37 kg/m3 on average 
and the babies in this treatment group had also reduced macrosomia as previously reported. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence of a benefit by a small reduction in ponderal index at birth for babies born 
to mothers with GDM who were treated with intensive management compared to routine care; 
or metformin compared to glibenclamide. 
• Very low-quality evidence showed no clear difference for ponderal index at birth for babies 
born to mothers with GDM who were treated with low-moderate GI diet versus moderate-high 
GI diet; or low-GI diet versus high-fibre moderate-GI diet. 
43.0 Adiposity (including skinfold thickness measurements (mm), fat mass) 
Adiposity was reported as an outcome by one review (Brown 2017b). No other measures of adiposity 
were reported (Table 2.9; Table 2.19). The quality of the evidence was low-quality.  
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43.1 Lifestyle intervention versus usual care or diet alone: The evidence suggested a reduction for 
whole-body neonatal fat mass (estimated from skinfold thickness) for babies born to mothers with GDM 
in the lifestyle intervention group compared to the usual care or diet alone group (MD -37.30 g, 95% CI 
-63.97 g to -10.63 g; one trial, 958 babies; low-quality evidence) (Brown 2017b). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence suggested a benefit by a reduced whole-body neonatal fat mass for 
babies born to mothers with GDM who were treated with lifestyle intervention compared to 
usual care or diet alone. As previous reported there was also a reduction for preterm birth, 
birthweight and macrosomia for these babies in the treatment group. 
44.0 Neonatal hypoglycaemia (as defined in the reviews) 
Neonatal hypoglycaemia was reported as an outcome by six reviews (Boulvain 2001; Brown 2016a; 
Brown 2017a; Brown 2017b; Brown 2017c; Han 2017) (Table 2.9; Table 2.19). The quality of the 
evidence ranged from moderate- to very low-quality. In six reviews there was no definition provided for 
neonatal hypoglycaemia for specific comparisons and four reviews provided definitions for specific 
comparisons although these definitions varied. 
44.1 Neonatal hypoglycaemia (not defined in the reviews) 
44.1.1 Induction of labour versus expectant management: There was no clear difference for the risk 
of neonatal hypoglycaemia for babies born to mothers with GDM between the induction of labour and 
expectant management group (RR not estimable; one trial, 200 babies; very low-quality evidence) 
(Boulvain 2001). There were no neonatal hypoglycaemic events in both groups. 
44.1.2 Oral antidiabetic agents versus placebo: There was no clear difference for the risk of neonatal 
hypoglycaemia for babies born to mothers with GDM between the oral antidiabetic drug glibenclamide 
and placebo group (RR 1.97, 95% CI 0.36 to 10.62; one trial, 375 babies; very low-quality evidence) 
(Brown 2017a). 
44.1.3 Myo-inositol versus placebo: The evidence suggested a reduced risk of neonatal 
hypoglycaemia for babies born to mothers with GDM in the myo-inositol group compared with placebo 
group (RR 0.05, 95% CI 0.00 to 0.85; one trial, 73 babies; low-quality evidence) (Brown 2016a). 
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44.1.4 Energy restricted diet versus no energy restricted diet: There was no clear difference for the 
risk of neonatal hypoglycaemia for babies born to mothers with GDM between the energy restricted diet 
and no energy restricted diet group (RR 1.06, 95% CI 0.48 to 2.32; two trials, 408 babies; very low-
quality evidence) (Han 2017). 
44.1.5 Low-carbohydrate diet versus high-carbohydrate diet: There was no clear difference for the 
risk of neonatal hypoglycaemia for babies born to mothers with GDM between the low-carbohydrate and 
high-carbohydrate diet group (RR 0.91, 95% CI 0.39 to 2.12; one trial, 149 babies; very low-quality 
evidence) (Han 2017). 
44.1.6 Ethnic specific diet versus standard healthy diet: There was no clear difference for the risk 
of neonatal hypoglycaemia for babies born to mothers with GDM between the ethnic specific diet and 
standard healthy diet group (RR not estimable; one trial, 20 babies; very low-quality evidence). There 
were no neonatal hypoglycaemic events in both groups (Han 2017). 
44.1.7 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the 
risk of neonatal hypoglycaemia for babies born to mothers with GDM between the lifestyle intervention 
and usual care or diet alone group (Average RR 0.99, 95% CI 0.65 to 1.52; six trials, 3000 babies; 
moderate-quality evidence) (Brown 2017b). 
44.1.8 Exercise versus control: There was no clear difference for the risk of neonatal hypoglycaemia 
for babies born to mothers with GDM between the exercise and control group (RR 2.00, 95% CI 0.20 to 
20.04; one trial, 34 babies; low-quality evidence) (Brown 2017c). 
44.2 Neonatal hypoglycaemia (defined) 
44.2.1 Metformin versus glibenclamide: There was no clear difference for the risk of neonatal 
hypoglycaemia for babies born to mothers with GDM between the metformin and glibenclamide group 
(RR 0.86, 95% CI 0.42 to 1.77; four trials, 554 babies; low-quality evidence) (Brown 2017a). 
Hypoglycaemia defined as BGL < 2.2 mmol/L; < 40 mg/dL. 
44.2.2 Glibenclamide versus acarbose: There was no clear difference for the risk of neonatal 
hypoglycaemia for babies born to mothers with GDM between the glibenclamide and acarbose group 
(RR 6.33, 95% CI 0.87 to 46.32; one trial, 43 babies; low-quality evidence) (Brown 2017a). 
Hypoglycaemia defined as BGL < 2.2 mmol/L; < 40 mg/dL. 
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44.2.3 Soy protein-enriched diet versus no soy protein diet: There was no clear difference for the 
risk of neonatal hypoglycaemia for babies born to mothers with GDM between the soy protein-enriched 
diet and no soy protein diet group (RR 3.00, 95% CI 0.33 to 27.42; one trial, 68 babies; very low-quality 
evidence) (Han 2017). Hypoglycaemia defined as BGL < 1.7 mmol/L (< 30.6 mg/dL). 
44.2.4 Intensive management versus routine care: There was no clear difference for the risk of 
neonatal hypoglycaemia for babies born to mothers with GDM between the intensive management and 
routine care group (RR 0.39, 95% CI 0.06 to 2.54; two trials, 426 babies; very low-quality evidence) 
(Han 2012). Hypoglycaemia defined in one trial as BGL < 1.7 mmol/L in two consecutive measurements 
and as BGL < 1.94 mmol/L in the other trial. 
Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence showed no clear difference for the risk of neonatal hypoglycaemia 
(not defined) for babies born to mothers with GDM who were treated with lifestyle intervention 
versus usual care or diet alone. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence suggested a benefit by a reduced risk of neonatal hypoglycaemia for 
babies born to mothers with GDM who were treated with myo-inositol versus placebo 
(hypoglycaemia not defined). 
• Low-quality evidence showed no clear difference for the risk of neonatal hypoglycaemia for 
babies born to mothers with GDM who were treated with metformin versus glibenclamide; or 
glibenclamide versus acarbose (hypoglycaemia defined) or were treated with exercise versus 
control (hypoglycaemia not defined). 
• Very low-quality evidence showed no clear difference for the risk of neonatal hypoglycaemia 
for babies born to mothers with GDM who were treated with soy protein-enriched diet versus 
no soy protein diet; or intensive management versus routine care evidence (hypoglycaemia 
defined) or were treated with induction of labour versus expectant management; glibenclamide 
versus placebo; energy restricted diet versus no energy restricted diet; low-carbohydrate diet 
versus high-carbohydrate diet; or ethnic specific diet versus standard healthy diet 
(hypoglycaemia not defined). 
 
45.0 Respiratory distress syndrome (RDS) 
RDS was reported as an outcome by five reviews (Boulvain 2001; Brown 2017a; Brown 2017b; Brown 
2017c; Han 2017) (Table 2.13; Table 2.19). There was no clear evidence of a difference for RDS for 
any of the comparisons reporting this outcome. The quality of the evidence ranged from moderate- to 
very low-quality. Only one review provided a definition of RDS. 
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45.1 Induction of labour versus expectant management: There were no RDS (termed neonatal 
asphyxia in the review) events reported in either group. for babies born to mothers with GDM between 
the induction of labour and expectant management group (RR not estimable; one trial, 200 babies; very 
low-quality evidence) (Boulvain 2001). 
45.2 Metformin versus glibenclamide: There was no clear difference for the risk of RDS for babies 
born to mothers with GDM between the metformin and glibenclamide group (RR 0.51, 95% CI 0.10 to 
2.69; one trial, 159 babies; very low-quality evidence) (Brown 2017a). 
45.3 Glibenclamide versus acarbose: There were no RDS events reported in either group for babies 
born to mothers with GDM between the glibenclamide and acarbose group (RR not estimable; one trial, 
43 babies; low-quality evidence) (Brown 2017a). 
45.4 Ethnic specific diet versus standard healthy diet: There were no RDS events reported in either 
group for the risk of RDS for babies born to mothers with GDM between the ethnic specific diet and 
standard healthy diet group (RR not estimable; one trial, 20 babies; low-quality evidence) (Han 2017). 
45.5 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the risk 
of RDS for babies born to mothers with GDM between the lifestyle intervention and usual care or diet 
alone group (average RR 0.79, 95% CI 0.34 to 1.85; four trials, 2195 babies; moderate-quality evidence) 
(Brown 2017b). 
45.6 Exercise versus control: There were no RDS events reported in either group for babies born to 
mothers with GDM between the exercise and control group (RR not estimable; one trial, 34 babies; very 
low-quality evidence) (Brown 2017c). 
Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence showed no clear difference for the risk of RDS for babies born to 
mothers with GDM who were treated with lifestyle intervention versus usual care or diet alone. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence reported no events of RDS in either group for babies born to mothers 
with GDM who were treated with glibenclamide versus acarbose; or ethnic specific diet versus 
standard healthy diet. 
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Summary 
• Very low-quality evidence showed no clear difference for the risk of RDS for babies born to 
mothers with GDM who were treated with induction of labour versus expectant management 
(no events); metformin versus glibenclamide; or exercise versus control (no events). 
46.0 Neonatal jaundice (hyperbilirubinaemia) (as defined in the reviews) 
Neonatal jaundice (hyperbilirubinaemia) was reported as an outcome by five reviews (Brown 2017a; 
Brown 2017b; Brown 2017c; Han 2012; Han 2017 (Table 2.13; Table 2.19). Only one of the included 
reviews reporting this outcome provided a definition for neonatal jaundice. The quality of the evidence 
ranged from moderate- to very low-quality. 
46.1 Oral antidiabetic agents versus placebo: There was no clear difference for the risk of neonatal 
jaundice for babies born to mothers with GDM between the glibenclamide and placebo group (RR 1.97, 
95% CI 0.50 to 7.75; one trial, 375 babies; very low-quality evidence) (Brown 2017a). 
46.2 Metformin versus glibenclamide: There was no clear difference for the risk of neonatal jaundice 
for babies born to mothers with GDM between the metformin and glibenclamide group (RR 0.68, 95% 
CI 0.37 to 1.25; two trials, 1205 babies; moderate-quality evidence) (Brown 2017a). 
46.3 Energy restricted diet versus no energy restricted diet: There was no clear difference for the 
risk of neonatal jaundice for babies born to mothers with GDM between the energy restricted diet and 
no energy restricted diet group (RR 0.81, 95% CI 0.33 to 1.98; one trial, 299 babies; low-quality 
evidence) (Han 2017). 
46.4 Soy protein-enriched diet versus no soy protein diet: The evidence suggested a reduced risk 
of neonatal jaundice for babies born to mothers with GDM in the soy protein-enriched diet group 
compared to the no soy protein diet group (RR 0.27, 95% CI 0.08 to 0.89; one trial, 68 babies; very low-
quality evidence) (Han 2017). 
46.5 Ethnic specific diet versus standard healthy diet: There were no events of neonatal jaundice 
for babies born to mothers with GDM in the ethnic specific diet or the standard healthy diet group (RR 
not estimable; one trial, 20 babies; low-quality evidence) (Han 2017). 
46.6 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the risk 
of neonatal jaundice for babies born to mothers with GDM between the lifestyle intervention and usual 
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care or diet alone group (average RR 0.76, 95% CI 0.50 to 1.16; four trials, 2362 babies; moderate-
quality evidence) (Brown 2017b). 
46.7 Exercise versus control: There was no clear difference for the risk of neonatal jaundice for babies 
born to mothers with GDM between the exercise and control group (RR 0.33, 95% CI 0.01 to 7.65; one 
trial, 34 babies; very low-quality evidence) (Brown 2017c). There were no events of neonatal jaundice 
in the intervention group and one event in the control group. 
46.8 Intensive management versus routine care: There was no clear difference for the risk of 
neonatal jaundice for babies born to mothers with GDM between the intensive management and routine 
care group (RR 0.79, 95% CI 0.24 to 2.60; two trials, 426 babies; low-quality evidence) (Han 2012). 
Hyperbilirubinaemia was defined in the review from one trial as plasma bilirubin at least 205 μmol/l and 
as plasma bilirubin at least 670 μmol/l in the other included trial. 
Summary 
Probably no difference between intervention: the direction of the effect suggest benefit; 
moderate -quality evidence 
• Moderate-quality evidence showed no clear difference for the risk of neonatal jaundice for 
babies born to mothers with GDM who were treated with metformin versus glibenclamide (not 
defined); or lifestyle intervention versus usual care or diet alone (not defined). 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Very low-quality evidence of benefit showed a lower risk of neonatal jaundice for babies born 
to mothers with GDM who were treated with soy protein-enriched diet compared to no soy 
protein diet (not defined). 
• Low-quality evidence showed no clear difference for the risk of neonatal jaundice for babies 
born to mothers with GDM who were treated with energy restricted diet versus no energy 
restricted diet (not defined); ethnic specific diet versus standard healthy diet (not defined) (no 
events); or intensive management versus routine care (for definition see under heading: effects 
of interventions page 41. 
• Very low-quality evidence showed no clear difference for the risk of neonatal jaundice for 
babies born to mothers with GDM who were treated with glibenclamide versus placebo (not 
defined); or exercise versus control (not defined). 
47.0 Hypocalcaemia 
Hypocalcaemia was reported as an outcome by three reviews (Brown 2017b; Brown 2017c; Han 2017) 
(Table 2.13; Table 2.19). None of the included reviews reporting this outcome provided a definition for 
hypocalcaemia. The quality of the evidence ranged from moderate- to very low-quality.  
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47.1 Energy restricted diet versus no energy restricted diet: The evidence suggested an increased 
risk of hypocalcaemia for babies born to mothers with GDM in the energy restricted diet group compared 
to the no energy restricted diet group (RR 1.36, 95% CI 1.00 to 1.86; one trial, 299 babies; low-quality 
evidence) (Han 2017). 
47.2 Ethnic specific diet versus standard healthy diet: There were no events of hypocalcaemia 
reported for babies born to mothers with GDM in the ethnic specific diet or the standard healthy diet 
group (RR not estimable; one trial, 20 babies; low-quality evidence) (Han 2017). 
47.3 Lifestyle intervention versus usual care or diet alone: The evidence suggested an increased 
risk of hypocalcaemia for babies born to mothers with GDM in the lifestyle intervention group compared 
to the usual care or diet alone group (RR 1.38, 95% CI 1.01 to 1.88; two trials, 462 babies; moderate-
quality evidence) (Brown 2017b). 
47.4 Exercise versus control: There were no events of hypocalcaemia reported for babies born to 
mothers with GDM in the exercise or the control group (RR not estimable; one trial, 34 babies; very low-
quality evidence) (Brown 2017c). 
Summary 
Probably ineffective interventions: moderate-quality of evidence suggesting lack of 
effectiveness, more evidence needed 
• Moderate-quality evidence of harm showed an increased risk of hypocalcaemia for babies born 
to mothers with GDM who were treated with lifestyle intervention compared to usual care or 
diet alone. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence suggested harm by an increased risk of hypocalcaemia for babies born 
to mothers with GDM who were treated with energy restricted diet versus no energy restricted 
diet. 
• Low-quality evidence reported no events of hypocalcaemia for babies born to mothers with 
GDM who were treated with ethnic specific diet versus standard healthy diet. 
• Very low-quality evidence reported no events of hypocalcaemia for babies born to mothers with 
GDM who were treated with exercise versus control. 
48.0 Polycythaemia 
Polycythaemia was reported as an outcome by one review (Brown 2017b) (Table 2.13). The review did 
not provide a definition of polycythaemia. The quality of the evidence was low-quality. 
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48.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the risk 
of polycythaemia for babies born to mothers with GDM between the lifestyle intervention and usual care 
or diet alone group (RR 0.22, 95% CI 0.01 to 5.40; one trial, 165 babies; low-quality evidence) (Brown 
2017b). There was one case of polycythaemia in the control group. 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for the risk of polycythaemia for babies born 
to mothers with GDM who were treated with lifestyle intervention versus usual care or diet 
alone. 
Secondary outcomes - Later infant/childhood 
49.0 Weight and z scores 
Weight in later childhood was reported as an outcome by one review (Brown 2017b) (Table 2.14; Table 
2.19). The included review did not report data for weight z scores in the later infant/childhood. The quality 
of the evidence was low-quality. 
49.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for 
childhood weight (at four to five years of age) for children born to mothers who had GDM between the 
lifestyle intervention and usual care or diet alone group (MD -0.30 kg, 95% CI -1.29 to 0.69; one trial, 
199 children; low-quality evidence) (Brown 2017b). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference in weight for children born to mothers with 
GDM who were treated with lifestyle intervention versus usual care or diet alone at four to five 
years of age. 
 
50.0 Height and z scores 
Height in later childhood was reported as an outcome by one review (Brown 2017b) (Table 2.14; Table 
2.19). The included review did not report data for height z scores in the later infant/childhood. The quality 
of the evidence was low-quality.  
50.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for 
childhood height (at four to five years of age) for children born to mothers who had GDM between the 
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lifestyle intervention and usual care or diet alone group (MD -0.60 cm, 95% CI -2.05 to 0.85; one trial, 
199 children; low-quality evidence) (Brown 2017b). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference in height for children born to mothers with 
GDM who were treated with lifestyle intervention versus usual care or diet alone at four to five 
years of age. 
51.0 Adiposity (including BMI, skinfold thickness, fat mass) 
Adiposity was reported as an outcome by one review (Brown 2017b) (Table 2.9; Table 2.19). The 
included review did not report data for skinfold thickness or fat mass in the later infant/childhood. The 
quality of the evidence ranged from moderate- to very low-quality. 
51.1 Childhood BMI 
51.1.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for 
childhood BMI > 85th percentile (at four to five years follow-up in one trial, seven to 11 years follow-up in 
the second included trial and five to ten years follow-up in the third trial) for children born to mothers 
who had GDM between the lifestyle intervention and usual care or diet alone group (RR 0.91 kg/m2, 
95% CI 0.75 to 1.11; three trials, 767 children; moderate-quality evidence) (Brown 2017b). 
51.1.2 Childhood BMI z score 
Lifestyle intervention versus usual care or diet alone: There was no clear difference for childhood 
BMI z score (at four to five years follow-up) for children born to mothers who had GDM between the 
lifestyle intervention and usual care or diet alone group (MD 0.08, 95% CI -0.28 to 0.44; one trial, 199 
children; very low-quality evidence) (Brown 2017b). 
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Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence showed no clear difference for childhood BMI for children born to 
mothers with GDM who were treated with lifestyle intervention versus usual care or diet alone 
at four to five years of age (one trial), seven to 11 years of age (one trial) or five to 10 years of 
age (one trial). 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Very low-quality evidence showed no clear difference in childhood BMI z score for children 
born to mothers with GDM who were treated with lifestyle intervention versus usual care or diet 
alone at four to five years of age. 
52.0 Blood pressure 
Blood pressure was reported as an outcome in one review (Brown 2017b). The review reported no clear 
evidence of a difference in systolic or diastolic blood pressure from a single trial in children (at five to 10 
years follow-up) whose mothers with GDM were treated with either a lifestyle intervention or usual care 
(moderate-quality evidence). The data in the on included trial was not in a format suitable for inclusion 
in a meta-analysis. 
Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence showed no clear difference for childhood blood pressure for children 
born to mothers with GDM who were treated with lifestyle intervention versus usual care or diet 
alone at five to 10 years of age. 
53.0 Impaired glucose tolerance 
Impaired glucose tolerance was reported as an outcome in the later infant/childhood by one review 
(Brown 2017b) (Table 2.14; Table 2.19). The quality of the evidence was low-quality. Data were reported 
as fasting blood glucose and two-hour post-prandial blood glucose. 
53.1 Impaired glucose tolerance: fasting blood glucose 
53.1.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for 
impaired glucose tolerance (at seven to 11 years of age) for children born to mothers who had GDM 
between the lifestyle intervention and usual care or diet alone group (MD 0.10 mmol/L, 95% CI -0.10 to 
0.30; one trial, 68 children; low-quality evidence) (Brown 2017b). 
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53.2 Impaired glucose tolerance: two-hour post-prandial blood glucose 
53.2.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for 
impaired glucose tolerance (at seven to 11 years follow-up) for children born to mothers between the 
lifestyle intervention and usual care or diet alone group (MD 0.00 mmol/L, 95% CI -0.48 to 0.48; one 
trial, 68 children; low-quality evidence) (Brown 2017b). 
One further included trial in the (Brown 2017b) review reported data for impaired glucose tolerance in 
children (at five to 10 years follow-up). The data could not be combined in a meta-analysis. 
Summary 
No conclusions possible: low- to very low quality-evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference at fasting or two-hour post-prandial blood 
glucose for children born to mothers with GDM who were treated with lifestyle intervention 
versus usual care or diet alone at seven to 11 years of age. 
54.0 Dyslipidaemia or metabolic syndrome 
Dyslipidaemia or metabolic syndrome (total, LDL and HDL cholesterol) was reported as an outcome by 
one review (Brown 2017b). There were no data reported for metabolic syndrome (Table 2.14; Table 
2.19). The quality of the evidence was low-quality. 
54.1 Dyslipidaemia or metabolic syndrome: Total cholesterol 
54.1.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for total 
cholesterol concentration (at seven to 11 years follow-up) for children born to mothers who had GDM 
between the lifestyle intervention and usual care or diet alone group (MD -0.20 mg/dL, 95% CI -0.55 to 
0.15; one trial, 68 children; low-quality evidence) (Brown 2017b). 
54.2 Dyslipidaemia or metabolic syndrome: LDL cholesterol 
54.2.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for LDL 
cholesterol concentration (at seven to 11 years follow-up) for children born to mothers who had GDM 
between the lifestyle intervention and usual care or diet alone group (MD -0.12 mg/dL, 95% CI -0.50 to 
0.26; one trial, 68 children; low-quality evidence) (Brown 2017b). 
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54.3 Dyslipidaemia or metabolic syndrome: HDL cholesterol 
54.3.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for HDL 
cholesterol concentration (at seven to 11 years follow-up) for children born to mothers who had GDM 
between the lifestyle intervention and usual care or diet alone group (MD 0.10 mg/dL, 95% CI -0.05 to 
0.25; one trial, 68 children; low-quality evidence) (Brown 2017b). 
One included trial in the (Brown 2017b) review reported data for HDL cholesterol concentration (low) 
and triglyceride concentration (elevated) in children (at five to 10 years follow-up). The data could not 
be combined in a meta-analysis. Another included trial reported data for triglyceride concentration in 
children (at seven to 11 years follow-up) with no clear difference between lifestyle intervention versus 
usual care or diet alone group and not published as a meta-analysis. 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for total cholesterol, LDL cholesterol or HDL 
cholesterol for children born to mothers with GDM who were treated with lifestyle intervention 
versus usual care or diet alone at seven to 11 years of age. 
55.0 Pre-specified overview child as later infant/childhood secondary outcomes not reported in 
the included reviews 
None of the included reviews reported any data for the child as later infant/childhood secondary overview 
outcomes: head circumference and z scores, educational attainment, development of type 1 diabetes 
and development of type 2 diabetes. 
Secondary outcomes - Child as an adult 
None of the included reviews reported any data for the child as an adult for the following secondary 
overview outcomes: weight and z scores, height and z scores, adiposity (including BMI, skinfold 
thickness, fat mass), blood pressure, employment, education and social status/achievement, 
dyslipidaemia or metabolic syndrome, development of type 1 diabetes, development of type 2 diabetes 
and impaired glucose tolerance. 
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Secondary outcomes - Health service use 
56.0 Number of antenatal visits or admissions 
The number of antenatal visits or admissions was reported as an outcome by two reviews (Brown 2017b; 
Han 2017) (Table 2.10; Table 2.19). The quality of the evidence ranged from moderate- to very low-
quality. 
56.1 Soy protein-enriched diet versus no soy protein diet: There was no clear difference in the 
number of antenatal visits or admissions (defined as maternal hospitalisation) for women with GDM in 
the soy protein-enriched diet and no soy protein diet group (RR 0.75, 95% CI 0.18 to 3.10; one trial, 68 
women; very low-quality evidence) (Han 2017). 
56.2 Lifestyle intervention versus usual care or diet alone: There was no clear difference in the 
number of antenatal visits or admissions (not defined) for women with GDM between the lifestyle 
intervention and usual care or diet alone group (RR 1.06, 95% CI 0.87 to 1.29; one trial, 1000 women; 
moderate-quality evidence) (Han 2017). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to 
comment on the effectiveness, more evidence needed 
• Very low-quality evidence showed no clear difference in number of antenatal visits or 
admissions for health service use for women with GDM who were treated with soy protein-
enriched diet versus no soy protein diet. 
57.0 Number of hospital or health professional visits (including midwife, obstetrician, physician, 
dietitian, diabetic nurse) 
Number of hospital or health professional visits was reported as an outcome by one review (Brown 
2017b) (Table 2.15; Table 2.19). The review reported data for visits with a dietitian, diabetes educator, 
obstetrician and non-specified health professional. The quality of the evidence ranged from moderate- 
to low-quality. 
57.1 Visits with dietitian 
57.1.1 Lifestyle intervention versus usual care or diet alone: The evidence suggested an increase 
for the number of visits with a dietitian for women with GDM in the lifestyle intervention group compared 
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to the usual care or diet alone group (RR 9.24, 95% CI 7.12 to 12.01; one trial, 1000 women; moderate-
quality evidence) (Brown 2017b). 
57.2 Visits with diabetes educator 
57.2.1 Lifestyle intervention versus usual care or diet alone: The evidence suggested an increase 
for the number of visits with a diabetes educator for women with GDM in the lifestyle intervention group 
compared to the usual care or diet alone group (RR 8.55, 95% CI 6.67 to 10.96; one trial, 1000 women; 
moderate-quality evidence) (Brown 2017b). 
57.3 Visits with obstetrician 
57.3.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the 
number of visits with an obstetrician for women with GDM between the lifestyle intervention and usual 
care or diet alone group (MD 0.20 visits, 95% CI -0.21 to 0.61; one trial, 700 women; low-quality 
evidence) (Brown 2017b). 
57.4 Visits with healthcare provider (not specified) 
57.4.1 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the 
number of visits with a healthcare provider (not specified) for women with GDM between the lifestyle 
intervention and usual care or diet alone group (MD 0.10 visits, 95% CI -1.58 to 1.78; one trial, 197 
women; low-quality evidence) (Brown 2017b). 
Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence of an increased number of antenatal visits with a dietitian and 
diabetes educator for women with GDM who were treated with lifestyle intervention compared 
to usual care or diet alone. This would be expected as the intervention requires close 
surveillance. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference in number of antenatal visits with an 
obstetrician and other health providers (not defined) for women with GDM who were treated 
with lifestyle intervention versus usual care or diet alone. 
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58.0 Admission to neonatal intensive care unit/nursery 
Admission to the neonatal intensive care unit/nursery (NICU) was reported as an outcome by four 
reviews (Brown 2017a; Brown 2017b; Han 2012; Han 2017) (Table 2.15; Table 2.19). There was no 
clear evidence of a difference for the risk of admission to NICU for any of the comparisons reporting this 
outcome. The quality of the evidence ranged from moderate- to very low-quality. 
58.1 Oral antidiabetic agents versus placebo: There was no clear difference for the risk of admission 
to NICU for the babies born to mothers with GDM between the oral antidiabetic drug glibenclamide and 
placebo group (RR 1.16, 95% CI 0.53 to 2.53; one trial, 375 babies; very low-quality evidence) (Brown 
2017a). 
58.2 Metformin versus glibenclamide: There was no clear difference for the risk of admission to NICU 
for the babies born to mothers with GDM between the metformin and glibenclamide group (RR 1.52; 
95% CI 0.65 to 3.56; two trials, 349 babies; low-quality evidence) (Brown 2017a). 
58.3 Soy protein-enriched diet versus no soy protein diet: There was no clear difference of 
admission to NICU for babies born to mothers with GDM in the soy protein-enriched diet and no soy 
protein diet group (RR 0.14, 95% CI 0.02 to 1.10; one trial, 68 women; very low-quality evidence) (Han 
2017). (Admission was defined as "hypoxia, low-risk Apgar scores 6-7 (at 5 or 15 min of age), high-risk 
Apgar scores at 1 minute 0-5 and at 5 or 15 minutes less than 6, hyperbilirubinaemia, birth weight less 
than 2500 g, and/or gestational age less than 32 weeks, sepsis, pneumonia, or meningitis, 
hypoglycaemia (blood glucose < 1.7mmol/L")). 
58.4 Intensive management versus routine care: There was no clear difference for the risk of 
admission to NICU for the babies born to mothers with GDM between the intensive management and 
routine care group (RR 0.64, 95% CI 0.29 to 1.45; two trials, 426 babies; moderate-quality evidence) 
(Han 2012). 
58.5 Lifestyle intervention versus usual care or diet alone: There was no clear difference for the risk 
of admission to NICU for the babies born to mothers with GDM between the lifestyle intervention and 
usual care or diet alone group (Average RR 0.91, 95% CI 0.59 to 1.40; three trials, 2030 women; low-
quality evidence) (Brown 2017b). 
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Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence showed no clear difference for admission to neonatal intensive care 
unit/nursery for babies born to mothers with GDM who were treated with intensive management 
versus routine care. 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Low-quality evidence showed no clear difference for admission to neonatal intensive care 
unit/nursery for babies born to mothers with GDM who were treated with metformin versus 
glibenclamide; or lifestyle intervention versus usual care or diet alone. 
• Very low-quality evidence showed no clear difference for admission to neonatal intensive care 
unit/nursery for babies born to mothers with GDM who were treated with glibenclamide agents 
versus placebo; or soy protein-enriched diet versus no soy protein diet. 
59.0 Length of postnatal stay (baby) 
Length of postnatal stay was reported as an outcome by one review (Han 2017) (Table 2.10; Table 
2.10). The quality of the evidence was very low-quality evidence.  
59.1 Diet recommendation + diet-related behavioural advice versus diet recommendation only: 
There was no clear difference in length of postnatal stay (defined as more than four days) for babies 
born to mothers with GDM between the diet recommendation + diet-related behavioural advice and diet 
recommendation only group (RR 1.33, 95% CI 0.73 to 2.44; one trial, 99 babies; very low-quality 
evidence) (Han 2017). 
Summary 
No conclusions possible: low- to very low-quality evidence, or insufficient evidence to comment 
on the effectiveness, more evidence needed 
• Very low-quality evidence showed no clear difference for length of postnatal stay for babies 
born to mothers with GDM who were treated with diet recommendation + diet-related 
behavioural advice versus diet recommendation only. 
60.0 Costs associated with the treatment 
Costs associated with the treatment was reported as an outcome by one review (Brown 2017b) (Table 
2.20). 
60.1 Lifestyle intervention versus usual care or diet alone: Moderate-quality evidence showed costs 
(in AUD) were higher for women with mild GDM and a singleton pregnancy in the lifestyle intervention 
group compared to the usual care or diet alone group, which was mainly due to increased surveillance 
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and increased contact with health professionals (one trial, 1000 women) (Brown 2017b). The data were 
reported as direct costs per 100 women, but were not in a suitable format for inclusion in a meta-analysis 
and are summarised in (Table 2.20) 
Summary 
Promising interventions: moderate-quality evidence of effectiveness, more evidence needed 
• Moderate-quality evidence suggested increased total costs of approximately AU$33,00 
associated with the treatment and of approximately AU$ 6,000 associated costs for the families 
of women with GDM who were treated with lifestyle intervention compared to usual care or diet 
alone (Table 18). This was mainly due to increased surveillance and increased contact with 
health professionals. The table was reprinted with permission from the Brown 2017b review. 
 
Table 2.20: Costs associated with the treatment 
Crowther 2005 Lifestyle intervention Usual care 
Package of treatment for mild GDM versus usual care 
Direct costs per 100 women with a singleton 
pregnancy - including antenatal clinic 
visits, specialist clinics, dietician, diabetes 
educator, insulin therapy 
AUD67,432 AUD33,681 
In-patient costs - hospital costs AUD545,125 AUD524,891 
Total direct health service costs AUD612,557 AUD558,572 
Patient/family costs AUD36,749 AUD30,229 
Permission granted from John Wiley & Sons, Ltd. to use this treatment costs table from Brown 2017b (table 11, p. 127). 
61.0 Pre-specified overview health service use outcomes not reported in the included reviews 
None of the included reviews reported data for the following health services use secondary overview 
outcomes: length of stay in neonatal intensive care unit or special care baby unit, length of antenatal 
stay, length of postnatal stay (maternal), cost of maternal care, cost of neonatal/child/adult care and 
costs to families associated with the treatment (e.g. change of diet, extra antenatal visits, etc). 
2.2.5 Discussion 
Summary of main results   
This overview review includes eight Cochrane systematic reviews that reported data about treatments 
for women with GDM and borderline GDM. These eight Cochrane systematic reviews include 62 RCTs 
involving 9133 women, 8373 babies and 767 children. RCTs reported in multiple reviews have only been 
counted as one trial (Brown 2017b and Brown 2017c; Brown 2017b and Han 2017). However, when the 
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same trial was reported in multiple reviews but with participant numbers from different treatment arms 
(subsets) they were then counted as one trial each (Han 2017 and Brown 2017c; Han 2012 and Han 
2017; Brown 2017b and Brown 2017c). 
Data were available from the included reviews for 59 pre-specified overview outcomes of the 80 listed 
for this overview review. A summary of the main results according to these overview review outcomes, 
following the framework and its categories as outlined under the heading Data synthesis section page 
66 and under the heading Methods page 54, are presented in Table 2.18 (primary outcomes) and Table 
2.19 (secondary outcomes). 
We have collated the interventions for treatment of women with GDM, for the GRADE health outcomes 
of this overview, according to whether they have been found to be effective, promising, probably no 
difference, ineffective, probably ineffective or no conclusion about effectiveness for health outcomes 
identified as important for women and their babies: 
• Effective interventions: indicating that the review found high-quality evidence of effectiveness for an 
intervention. 
• Promising interventions (more evidence needed): indicating that the review found moderate-quality 
evidence of effectiveness for an intervention, but more evidence is needed. 
• Probably no difference between interventions: direction of effect suggests benefit/harm or 
ineffective, but more evidence is needed. 
• Ineffective interventions: indicating that the review found high-quality evidence of lack of 
effectiveness for an intervention. 
• Probably ineffective interventions (more evidence needed): indicating that the review found 
moderate-quality evidence suggesting lack of effectiveness for an intervention, but more evidence 
is needed. 
• No conclusions possible due to lack of evidence: indicating that the review found low- or very low-
quality evidence, or insufficient evidence to comment on the effectiveness of an intervention, more 
evidence needed. 
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For the mother: 
Hypertensive disorders of pregnancy 
Effective interventions: No treatment interventions for women with GDM were found to be effective at 
reducing hypertensive disorders of pregnancy. 
Promising interventions (more evidence needed): No treatment interventions for women with GDM 
were found to be promising at reducing hypertensive disorders of pregnancy. 
Probably no difference between interventions (more evidence is needed): For metformin compared 
with glibenclamide there was probably no difference in the rate of hypertensive disorders of pregnancy. 
Ineffective interventions: No treatment interventions for women with GDM were found to be ineffective 
at reducing hypertensive disorders of pregnancy. 
Probably ineffective interventions (more evidence needed): The DASH diet was probably ineffective 
at reducing the rate of hypertensive disorders in pregnancy versus a control diet. 
No conclusions possible due to lack of evidence: For the following interventions compared to other 
interventions, to a control, or to placebo, no conclusion was possible as to the effect on hypertensive 
disorders of pregnancy: glibenclamide versus placebo; low-moderate GI diet versus moderate-high GI 
diet; low carbohydrate diet versus high carbohydrate diet; high unsaturated fat diet versus low 
unsaturated fat diet with matching calories; ethnic specific diet versus standard healthy diet; energy 
restricted diet versus no energy restricted diet; lifestyle intervention versus usual care or diet alone; 
exercise versus control; intensive management versus routine care; metformin versus glibenclamide; or 
soy protein-enriched diet versus no soy protein diet. 
Caesarean section 
Effective interventions: No treatment interventions for women with GDM were found to be effective at 
reducing the risk of birth by caesarean section. 
Promising interventions (more evidence needed): The DASH diet and exercise were promising 
interventions for women with GDM for reducing the risk of birth by caesarean section compared with a 
control. 
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Probably no difference between interventions (more evidence is needed): No treatment 
interventions for women with GDM were found to be equivocal for the risk of birth by caesarean section. 
Ineffective interventions: No treatment interventions for women with GDM were found to be ineffective 
at reducing the risk of birth by caesarean section. 
Probably ineffective interventions (more evidence needed): No treatment interventions for women 
with GDM were found to be probably ineffective at reducing the risk of birth by caesarean section. 
No conclusions possible due to lack of evidence: For the following interventions compared to other 
interventions, to a control, or to placebo, no conclusion was possible as to the effect on risk of birth by 
caesarean section: glibenclamide versus placebo; metformin versus glibenclamide; glibenclamide 
versus acarbose; energy restricted diet versus no energy restricted diet; low carbohydrate diet versus 
high-carbohydrate diet; low-GI diet versus high-fibre moderate-GI diet; diet recommendation + diet-
related behavioural advice versus diet recommendation only; soy protein-enriched diet versus no soy 
protein diet; lifestyle intervention versus usual care or diet; low-moderate GI diet versus moderate-high 
GI diet; high unsaturated fat diet versus low unsaturated fat diet with matching calories; ethnic specific 
diet versus standard healthy diet; intensive management versus routine care; and strict intensity of 
glycaemic control versus less strict glycaemic control. 
Development of type 2 diabetes 
Effective interventions: No treatment interventions for women with GDM were found to be effective at 
reducing the risk of development of type 2 diabetes. 
Promising interventions (more evidence needed): No treatment interventions for women with GDM 
were found to be promising at reducing the risk of development of type 2 diabetes. 
Probably no difference between interventions (more evidence is needed): No treatment 
interventions for women with GDM were found to be equivocal for the risk of development of type 2 
diabetes. 
Ineffective interventions: No treatment interventions for women with GDM were found to be ineffective 
at reducing the risk of development of type 2 diabetes. 
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Probably ineffective interventions (more evidence needed): No treatment interventions for women 
with GDM were found to be probably ineffective at reducing the risk of development of type 2 diabetes. 
No conclusions possible due to lack of evidence: For the following interventions compared to other 
interventions, to a control, or to placebo, no conclusion was possible as to the effect on risk of 
development of type 2 diabetes: lifestyle intervention versus usual care or diet alone; high unsaturated 
fat diet versus low unsaturated fat diet with matching calories; low-GI diet versus high fibre moderate-
GI diet. 
Perineal trauma/tearing 
Effective interventions: No treatment interventions for women with GDM were found to be effective at 
reducing the risk of perineal trauma/tearing. 
Promising interventions (more evidence needed): No treatment interventions for women with GDM 
were found to be promising at reducing the risk of perineal trauma/tearing. 
Probably no difference between interventions (more evidence is needed): For lifestyle intervention 
versus usual care or diet alone there was probably no difference for women with GDM at reducing the 
risk of perineal trauma/tearing. 
Ineffective interventions: No treatment interventions for women with GDM were found to be ineffective 
at reducing the risk of perineal trauma/tearing. 
Probably ineffective interventions (more evidence needed): No treatment interventions for women 
with GDM were found to be probably ineffective at reducing the risk of perineal trauma/tearing. 
No conclusions possible due to lack of evidence: For the following interventions compared to other 
interventions, to a control, or to placebo, no conclusion was possible as to the effect on risk of perineal 
trauma/tearing metformin versus glibenclamide or glibenclamide versus placebo. 
Postnatal weight retention or return to pre-pregnancy weight 
Effective interventions: No treatment interventions for women with GDM were found to be effective at 
influencing postnatal weight retention or return to pre-pregnancy weight. 
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Promising interventions (more evidence needed): No treatment interventions for women with GDM 
were found to be promising at influencing postnatal weight retention or return to pre-pregnancy weight. 
Probably no difference between interventions (more evidence is needed): No treatment 
interventions for women with GDM were found to be equivocal for influencing postnatal weight retention 
or return to pre-pregnancy weight. 
Ineffective interventions: Exercise interventions for women with GDM were found to be ineffective for 
return to pre-pregnancy weight compared with a control. 
Probably ineffective interventions (more evidence needed): No treatment interventions for women 
with GDM were found to be probably ineffective at influencing postnatal weight retention or return to 
pre-pregnancy weight. 
No conclusions possible due to lack of evidence: For the following interventions compared to other 
interventions, to a control, or to placebo, no conclusion was possible as to the effect on postnatal weight 
retention or return to pre-pregnancy weight: lifestyle intervention compared to usual care or diet alone 
or low-GI diet versus high-fibre moderate-GI diet. 
Postnatal depression 
Effective interventions: No treatment interventions for women with GDM were found to be effective at 
reducing the risk of postnatal depression. 
Promising interventions (more evidence needed): No treatment interventions for women with GDM 
were found to be promising at reducing the risk of postnatal depression. 
Probably no difference between interventions (more evidence is needed): No treatment 
interventions for women with GDM were found to be equivocal for the risk of postnatal depression. 
Ineffective interventions: No treatment interventions for women with GDM were found to be ineffective 
at reducing the risk of postnatal depression. 
Probably ineffective interventions (more evidence needed): No treatment interventions for women 
with GDM were found to be probably ineffective at reducing the risk of postnatal depression. 
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No conclusions possible due to lack of evidence: No conclusion was possible as to the effect on 
lifestyle intervention compared to usual care or diet alone on postnatal depression. 
Induction of labour 
Effective interventions: No treatment interventions for women with GDM were found to be effective at 
reducing the rates of induction of labour. 
Promising interventions (more evidence needed): No treatment interventions for women with GDM 
were found to be promising at reducing the rates of induction of labour. 
Probably no difference between interventions (more evidence is needed): No treatment 
interventions for women with GDM were found to be equivocal for reducing the likelihood of induction of 
labour. 
Ineffective interventions: Lifestyle intervention for women with GDM was found to be ineffective at 
reducing the rates of induction of labour compared with usual care or diet alone. 
Probably ineffective interventions (more evidence needed): No treatment interventions for women 
with GDM were found to be probably ineffective at reducing the rates of induction of labour. 
No conclusions possible due to lack of evidence: For the following interventions compared to other 
interventions, to a control, or to placebo, no conclusion was possible as to the effect on induction of 
labour: intensive management compared to the routine care; glibenclamide versus placebo; metformin 
versus glibenclamide; low-moderate GI diet versus moderate-high GI diet; energy restricted diet versus 
no energy restricted diet; or exercise versus control. 
For the infant/child/adult 
Large-for-gestational age (LGA) 
Effective interventions: No treatment interventions for women with GDM were found to be effective at 
reducing the risk of their baby being born LGA. 
Promising interventions (more evidence needed): Lifestyle intervention was found to be a promising 
intervention for women with GDM for reducing the risk of their infant being born LGA compared to the 
usual care or diet alone. 
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Probably no difference between interventions (more evidence is needed): No treatment 
interventions for women with GDM were found to be equivocal for reducing the risk of their baby being 
born LGA. 
Ineffective interventions: No treatment interventions for women with GDM were found to be ineffective 
at reducing the risk of their baby being born LGA. 
Probably ineffective interventions (more evidence needed): No treatment interventions for women 
with GDM were found to be probably ineffective at reducing the risk of their baby being born LGA. 
No conclusions possible due to lack of evidence: For the following interventions compared to other 
interventions, to a control, or to placebo, no conclusion was possible as to the effect on the risk of their 
baby being born LGA: induction of labour compared to expectant management at 38 weeks' complete 
gestation; intensive management compared to routine care; metformin versus glibenclamide; 
glibenclamide versus acarbose; myo-inositol versus placebo; low-moderate GI diet versus moderate-
high GI diet; energy restricted diet versus no energy restricted diet; glibenclamide versus placebo; low 
carbohydrate diet versus high-carbohydrate diet; high unsaturated fat diet versus low unsaturated fat 
diet with matching calories; low-GI diet versus high-fibre moderate-GI diet; diet recommendation + diet-
related behavioural advice versus diet recommendation only; or ethnic specific diet versus standard 
healthy diet. 
Perinatal (fetal and neonatal death) and later infant mortality 
Effective interventions: No treatment interventions for women with GDM were found to be effective at 
reducing the risk of perinatal mortality. 
Promising interventions (more evidence needed): No treatment interventions for women with GDM 
were found to be promising at reducing the risk of perinatal mortality. 
Probably no difference between interventions (more evidence is needed): No treatment 
interventions for women with GDM were found to be equivocal for reducing the risk of perinatal mortality. 
Ineffective interventions: No treatment interventions for women with GDM were found to be ineffective 
at reducing the risk of perinatal mortality. 
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Probably ineffective interventions (more evidence needed): No treatment interventions for women 
with GDM were found to be probably ineffective at reducing the risk of perinatal mortality. 
No conclusions possible due to lack of evidence: For the following interventions compared to other 
interventions, to a control, or to placebo, no conclusion was possible as to the effect on perinatal 
mortality: glibenclamide versus acarbose; energy restricted diet versus no energy restricted diet; lifestyle 
intervention versus usual care; diet alone or exercise versus control; induction of labour versus 
expectant management; metformin versus glibenclamide; or low carbohydrate diet versus high-
carbohydrate diet. 
Death or serious morbidity composite 
Effective interventions: No treatment interventions for women with GDM were found to be effective at 
reducing the risk of a neonatal death or serious morbidity composite. 
Promising interventions (more evidence needed): Exercise was found to be a promising intervention 
for women with GDM for reducing the risk a neonatal death or serious morbidity composite compared 
to control. 
Probably no difference between interventions (more evidence is needed): No treatment 
interventions for women with GDM were found to be equivocal for reducing the risk of a neonatal death 
or serious morbidity composite. 
Ineffective interventions: No treatment interventions for women with GDM were found to be ineffective 
at reducing the risk of a neonatal death or serious morbidity composite. 
Probably ineffective interventions (more evidence needed): No treatment interventions for women 
with GDM were found to be probably ineffective at reducing the risk of a neonatal death or serious 
morbidity composite. 
No conclusions possible due to lack of evidence: For the following interventions compared to other 
interventions, to a control, or to placebo, no conclusion was possible as to the effect on a neonatal death 
or serious morbidity composite: metformin versus glibenclamide; ethnic specific diet versus standard 
healthy diet or with lifestyle intervention versus usual care or diet alone. 
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Neonatal hypoglycaemia 
Effective interventions: No treatment interventions for women with GDM were found to be effective at 
reducing the risk of neonatal hypoglycaemia. 
Promising interventions (more evidence needed): No treatment interventions for women with GDM 
were found to be effective at reducing the risk of neonatal hypoglycaemia. 
Probably no difference between interventions (more evidence is needed): No treatment 
interventions for women with GDM were found to be equivocal for reducing the risk of neonatal 
hypoglycaemia. 
Ineffective interventions: No treatment interventions for women with GDM were found to be ineffective 
at reducing the risk of neonatal hypoglycaemia. 
Probably ineffective interventions (more evidence needed): No treatment interventions for women 
with GDM were found to be probably ineffective at reducing the risk of neonatal hypoglycaemia. 
No conclusions possible due to lack of evidence: For the following interventions compared to other 
interventions, to a control, or to placebo, no conclusion was possible as to the effect on neonatal 
hypoglycaemia: myo-inositol versus placebo; metformin versus glibenclamide; glibenclamide versus 
acarbose; exercise versus control; soy protein-enriched diet versus no soy protein diet; intensive 
management versus routine care; induction of labour versus expectant management; glibenclamide 
versus placebo; energy restricted diet versus no energy restricted diet; low-carbohydrate diet versus 
high-carbohydrate diet; or ethnic specific diet versus standard healthy diet. 
Adiposity (including BMI, skinfold thickness, fat mass) 
Effective interventions: No treatment interventions for women with GDM were found to be effective at 
reducing the risk of childhood adiposity. 
Promising interventions (more evidence needed): No treatment interventions for women with GDM 
were found to be effective at reducing the risk of childhood adiposity. 
 
270 
Probably no difference between interventions (more evidence is needed): No treatment 
interventions for women with GDM were found to be equivocal for reducing the risk of childhood 
adiposity. 
Ineffective interventions: No treatment interventions for women with GDM were found to be ineffective 
at reducing the risk of childhood adiposity. 
Probably ineffective interventions (more evidence needed): No treatment interventions for women 
with GDM were found to be probably ineffective at reducing the risk of childhood adiposity. 
No conclusions possible due to lack of evidence: No conclusion was possible as to the effect on 
childhood adiposity for women with GDM who were treated with lifestyle intervention compared with 
usual care or diet alone. 
Development of type 1 diabetes or development of type 2 diabetes 
None of the included reviews reported on the outcome of development of type 1 diabetes or 
development of type 2 diabetes in later childhood or adulthood. 
Neurosensory disability in later childhood (as defined in reviews) 
None of the included reviews reported on the outcome of neurosensory disability in later childhood. 
Health service use 
Number of antenatal visits or admissions 
Effective interventions: No treatment interventions for women with GDM were found to be effective at 
influencing the number of antenatal visits or admissions. 
Promising interventions (more evidence needed): No treatment interventions for women with GDM 
were found to be promising at influencing the number of antenatal visits or admissions. 
Probably no difference between interventions (more evidence is needed): No treatment 
interventions for women with GDM were found to be equivocal for influencing the number of antenatal 
visits or admissions. 
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Ineffective interventions: No treatment interventions for women with GDM were found to be ineffective 
at influencing the number of antenatal visits or admissions. 
Probably ineffective interventions (more evidence needed): No treatment interventions for women 
with GDM were found to be probably ineffective at influencing the number of antenatal visits or 
admissions. 
No conclusions possible due to lack of evidence: No conclusion was possible as to the effect on the 
number of antenatal visits or admission for soy protein-enriched diet versus no soy protein diet. 
Length of postnatal stay (mother) 
None of the included reviews reported on the outcome of length of postnatal stay for the mother. 
Length of postnatal stay (baby) 
Effective interventions: No treatment interventions for women with GDM were found to be effective at 
reducing the length of the infant’s postnatal stay. 
Promising interventions (more evidence needed): No treatment interventions for women with GDM 
were found to be promising at reducing the length of the infant’s postnatal stay. 
Probably no difference between interventions (more evidence is needed): No treatment 
interventions for women with GDM were found to be equivocal for reducing the length of the infant’s 
postnatal stay. 
Ineffective interventions: No treatment interventions for women with GDM were found to be ineffective 
at reducing the length of the infant’s postnatal stay. 
Probably ineffective interventions (more evidence needed): No treatment interventions for women 
with GDM were found to be probably ineffective at reducing the length of the infant’s postnatal stay. 
No conclusions possible due to lack of evidence: No conclusion was possible as to the effect on the 
length of postnatal stay (baby) for diet recommendation + diet-related behavioural advice versus diet 
recommendation only. 
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Costs to families associated with the treatment, Costs associated with the treatment, cost of 
maternal care, cost of child (as neonate, child, adult) care. 
None of the included reviews reported clear data for the individual on the outcome of costs. 
The overall evidence of various interventions for the treatment of women with GDM and their effects on 
the health of the women and her baby are limited by quantity and quality. 
There was some high-quality evidence that exercise interventions for women with GDM were found to 
be effective for the return to pre-pregnancy weight compared with a control and that lifestyle 
interventions were ineffective for decreasing the likelihood of induction of labour compared with usual 
care/diet alone. No other high-quality evidence was found for treatment interventions on the short- or 
long-term GRADE maternal or neonatal outcomes of this overview. 
The available moderate-quality evidence suggests some promising interventions for which more high-
quality evidence is needed: 
• Exercise compared to control appears to be a promising intervention for reducing a death and 
serious infant morbidity, but it is difficult to single out which component of the exercises, if any, is 
the most effective. 
• The DASH diet which is rich in fruits, vegetables, whole grains and low-fat dairy products, and low 
in saturated fats, cholesterol, refined grains and sweets reduced rate of caesarean section. 
• Lifestyle interventions reduced the risk of LGA, neonatal hypoglycaemia and childhood BMI. As with 
the exercise interventions, the lifestyle interventions are multi-component and it is not possible to 
determine which, if any, components are effective. 
• Long-term health outcomes for women and their infants and costs are not well reported. 
• Most of the dietary treatments assessed were from interventions reported as single studies that had 
relatively small numbers of participants, and only a few trials have compared the same or similar 
dietary interventions. 
This overview summarises the evidence from Cochrane systematic reviews of randomised controlled 
trials for the treatments for women with GDM on relevant health outcomes and may be used by 
clinicians, clinical guideline developers, consumers, and policymakers to aid decision making to guide 
clinical practice, health services and future primary research. For further information we suggest 
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referring to the individual Cochrane systematic reviews for details for the context and components of the 
interventions. 
Overall completeness and applicability of evidence   
This overview review summarises published Cochrane systematic reviews of randomised controlled 
trials of different treatments for women with GDM and the effects on relevant health outcomes. Data 
were available from the included reviews for 59 pre-specified outcomes of the 80 overview review 
outcomes. We are aware of two further Cochrane protocols and two title registrations which include 
treatments for women with GDM such as insulin treatment, home- versus hospital-glucose monitoring, 
fetal biometry for guiding medical management, planned elective birth, probiotics and Chinese herbal 
medicines. In future updates of this overview, if these Cochrane systematic reviews have been 
published, we will assess for eligibility for their inclusion. The evidence of the overview review can be 
applied to women with GDM in most countries as the trials of the included reviews were conducted in a 
wide range of countries. Evidence from published or planned Cochrane systematic reviews is still lacking 
on the use of telemedicine to manage women with GDM and for the use of micronutrients and 
phytochemicals to treat women with GDM such as cinnamon, zinc, chromium, omega-3 fatty acids and 
magnesium. 
Quality of the evidence   
The included Cochrane systematic reviews were assessed with the AMSTAR tool to be of high quality 
overall (Table 2.16) and assessed with the ROBIS tool to be of low risk of bias overall (Table 2.17). 
Six of the eight included Cochrane systematic reviews (Brown 2017a; Brown 2017b; Brown 2017c; 
Brown 2016a; Han 2017; Martis 2016a) used GRADE to assess for the quality of evidence for agreed 
GRADE pre-specified outcomes. For Boulvain 2001 and Han 2012 we undertook the GRADE 
assessments and there are included in (Table 2.8; Table 2.9; Table 2.10). Seven out of the eight included 
reviews assessed the risk of bias of the included randomised trials, with the majority of reviews following 
the current guidance as outlined in the Cochrane Handbook for Systematic Reviews of Interventions 
(Higgins 2011). The quality of included randomised trials in these reviews were highly variable within 
and between the included reviews from high- to very low-quality. 
We assessed all the secondary outcomes for this overview using the four GRADE quality ratings for 
quality of evidence with information accessed from the Risk of Bias tables in the included reviews. The 
274 
quality of the randomised trials ranged from high- to very low-quality (Table 2.11; Table 2.12; Table 2.13; 
Table 2.14; Table 2.15. Evidence was often downgraded for imprecision as evidence was based on one 
trial with small numbers, with wide confidence intervals and performance bias for not blinding 
participants and personnel to the intervention, although for many of the interventions being assessed 
masking of participants and health professionals to the interventions was not possible. 
Potential biases in the overview process   
We were aware that there were risks of introducing bias at all stages of the overview review process 
and took steps to minimise this. All included Cochrane systematic reviews used a published protocol 
that aimed to minimise bias and we similarly developed and published a Cochrane overview protocol 
(Martis 2016b). A minimum of two overview authors independently assessed Cochrane systematic 
reviews for inclusion, carried out data extraction and quality assessment, and assessed the quality of 
the evidence using the ARMSTAR, ROBIS and GRADE approach. One potential source of bias relates 
to authors of this overview being authors of some of the included reviews. As pre-specified in our 
protocol, data extraction and quality assessment for these reviews was carried out by two overview 
authors who were not the review authors. 
We undertook a comprehensive search of the Cochrane Database of Systematic Reviews without 
language or date restrictions, and identified published reviews (Figure 2.1), as well as planned/ongoing 
reviews (title registrations/protocols) (Table 2.4). While the included reviews were judged to be of 
moderate (one review) to high quality (seven reviews) and unclear (one review) to low risk of bias (seven 
reviews), two included reviews were not considered 'up-to-date'. It is possible that additional trials 
assessing elective delivery management for women with GDM and interventions for women with 
hyperglycaemia not meeting gestational diabetes diagnostic criteria have been published, but are not 
yet included in the relevant Cochrane systematic reviews. Furthermore, recent trials for treatments for 
women with GDM may have been conducted but not yet published. Once published the trials may be 
included in the relevant Cochrane systematic reviews. Such new evidence will be considered for 
inclusion in an update of this overview. 
One included review (Boulvain 2001) assessed interventions for elective delivery versus expectant 
management for women diagnosed with pre-gestational diabetes or GDM together. The data could not 
be separated out for the two different groups. We agreed to include this review as the majority of the 
results were based on 187 (93.5 %) women with GDM with only 13 (6.5 %) women having pre-
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gestational diabetes (defined as type 1 and type 2 diabetes). Potentially this could bias the results of the 
overview review for elective delivery for women with GDM. In future up-dates of this review the results 
for women with GDM and women with pre-gestational diabetes. These data can be considered for 
revision in an update of this overview. Once this included review is up-dated with the separation for 
women with GDM and women with pre-gestational diabetes it will be incorporated into this overview 
review at its next up-date. 
One included review (Han 2012) assessed interventions for women with hyperglycaemia not meeting 
gestational diabetes and type 2 diagnostic criteria. We agreed to include the review into this overview 
review, as different countries have different diagnostic levels for confirming that a pregnant woman has 
GDM. It is highly possible that women with hyperglycaemia identified in one country as not meeting the 
gestational diagnostic threshold for GDM would be diagnosed as having GDM in another country. 
However, this could be a potential bias for over reporting results. 
Agreements and disagreements with other studies or reviews   
We did not identify any other overview of Cochrane systematic reviews or Cochrane systematic reviews 
assessing treatments for women with GDM. 
2.2.6 Authors' conclusions   
Implications for practice   
The overall evidence from a range of interventions for the treatment of women with GDM and their 
effects on the health of the women and her baby is limited by quantity and quality. There is insufficient 
high-quality evidence about the effects on health outcomes of relevance for women with GDM and their 
babies for many of the comparisons in this overview comparing treatment interventions for women with 
GDM. 
Lifestyle interventions that include advice on diet and physical activity have become the mainstay of 
treatment and are recommended in many national clinical practice guidelines. Most dietary treatments 
assessed are from interventions reported as single studies, with small number of participants, and only 
a few trials have compared the same or similar dietary interventions. 
High quality evidence suggested that lifestyle interventions were ineffective for reducing the likelihood 
of induction of labour compared with usual diet/diet alone and that exercise compared with control was 
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ineffective in improving the return to pre-pregnancy weight. However, many of the lifestyle and exercise 
interventions are multi-component and identifying which of any of the individual components are 
effective or not effective is not possible with the evidence currently available. No other high-quality 
evidence was found for any of the other GDM treatment interventions on the short- or long-term GRADE 
maternal or neonatal outcomes of this overview. 
The available evidence suggests some promising interventions for which more high-quality evidence is 
needed: Lifestyle interventions (reduced risk of LGA); exercise (reduced death and serious infant 
morbidity); and the DASH diet (reduced rate of caesarean section). Lifestyle interventions, exercise, and 
considering the DASH diet may be useful for some women with GDM as treatment interventions with or 
without additional pharmacotherapy with appropriate advice and/or supervision from a health 
professional. 
Long-term health outcomes for women and their infants and costs are not well reported. 
For further information we suggest referring to the individual Cochrane systematic reviews for details on 
the context and components of the interventions. 
Implications for research   
This overview review highlights that there is insufficient evidence to make conclusions on the effects on 
relevant health outcomes for many treatments for women with GDM. 
High-quality research is required to identify the most effective components or combination of 
components in lifestyle and exercise interventions. Further high-quality research with appropriate 
sample size is required using the DASH diet to confirm its effectiveness for improving short-and long-
term maternal and infant outcomes. 
Other dietary interventions may also be beneficial, but any effect is currently difficult to identify because 
of the multiple comparisons, small sample sizes and quantity of trials. 
Further research should be sufficiently powered to enable important differences in relevant core clinical 
outcomes, identified in this overview, for women with GDM and their infants to be detected. Outcomes 
should include long-term outcomes and the costs for treatments, family and service costs. 
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2.2.7 Plain language summary   
Treatments to improve pregnancy outcomes for women who develop diabetes during 
pregnancy, known as gestational diabetes mellitus: an overview of Cochrane systematic reviews 
What is the issue? 
Gestational diabetes mellitus (GDM) is a condition that may occur in the second half of the pregnancy 
when blood glucose control is more difficult to achieve, and a woman develops high blood glucose levels 
(hyperglycaemia). This may adversely affect the woman and her baby's health. For the women there 
may be an increased risk of developing high blood pressure and protein in the urine (pre-eclampsia), 
postnatal depression, or needing a caesarean section. Long term, women are at higher risk of 
developing type 2 diabetes and heart disease and stroke (cardiovascular disease) later in life. Babies 
born to mothers with poorly treated GDM are at increased risk of being too large, having low blood 
glucose (hypoglycaemia) after birth, and yellowing of the baby's skin and eyes (jaundice). Long term, 
children are at higher risk of being overweight and developing type 2 diabetes. 
Why is this important? 
Several Cochrane systematic reviews assess different treatments for women with GDM. This makes it 
difficult for consumers, clinicians, and guideline developers to easily interpret the available information. 
This Overview of Cochrane systematic reviews provides a one-stop resource summary of the effects for 
each treatment on the health outcomes for mothers and babies. This may simplify clinical treatment 
decision-making and assist with the process of guideline development. 
What evidence did we find? 
We searched the Cochrane Database of Systematic Reviews (28.06.17) for reviews and identified a 
total of eight Cochrane systematic reviews assessing the treatments for women with GDM. We identified 
a total of eight systematic reviews which provided data that could be used in this overview. They included 
62 RCTs and a total of 9133 women, 8373 babies and 767 children.  
We found that there was probably no difference (moderate-quality evidence) between the oral 
hypoglycaemic drugs metformin and glibenclamide in the number of women with high blood pressure 
disorders of pregnancy associated with GDM, compared with usual care or diet alone; nor in the risk of 
perineal tearing when women followed a lifestyle program. Keeping to the DASH (Dietary Approaches 
to Stop Hypertension) diet, which involves eating more fruits and vegetables, whole grains rather than 
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refined grains, fat-free or low-fat dairy products and lean protein sources like fish, poultry and bean, did 
not clearly reduce the risk of having to give birth by caesarean section, and appeared ineffective at 
reducing the number of women with high blood pressure disorders of pregnancy. 
High quality evidence showed lifestyle interventions for women with GDM compared with usual care/diet 
alone did not reduce the need for induction of labour and exercise interventions for women with GDM 
were found to be ineffective for the return to pre-pregnancy weight after the birth compared with a control 
intervention. 
For the babies (moderate-quality evidence) lifestyle programs were promising for reducing the risk of 
the baby being born large for its gestational age compared with usual care or diet alone. 
Conclusions on other outcomes were not possible because of low- or very-low quality evidence, or 
outcomes not being reported in the identified trials. 
Several interventions that were supported with moderate-quality evidence that improved one or more of 
the GRADE health outcomes for this overview. These included the DASH diet and lifestyle interventions. 
However, further research is needed to assess the effectiveness of these interventions. 
What does this mean? 
The current evidence for effective interventions for treating women with GDM is limited by the number 
and sample sizes of randomised controlled trials and the quality of the available evidence. Further high-
quality research is needed to identify effective interventions. Some of the interventions had several parts 
to them such as diet and exercise and education and it was not possible for us to find out which part of 
the intervention was the most effective. 
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Differences between published protocol (Martis 2016b) and review   
There are some differences between the published protocol and this review. 
Quality assessment of included reviews 
Additionally, to the ARMSTAR and the GRADE methodological quality instruments we further assessed 
the risk of bias of each included Cochrane systematic reviews with ROBIS (Risk Of Bias In Systematic 
reviews) (Whiting 2016). 
We reported the statistical summary by outcomes for clarity, not by interventions as stated in the 
protocol. 
After further discussion during the review writing process, the overview review authors decided that all 
secondary outcomes needed to be assessed for quality using the GRADE ratings as this would provide 
a more accurate and meaningful reporting of the evidence for a treatment intervention for women with 
GDM. Two overview review authors generated the 'Quality assessment tables' using GRADE ratings for 
all other overview review secondary outcomes, not only for the agreed pre-specified GRADE outcomes, 
as stated in the protocol. 
Outcomes 
For clarity, one outcome was renamed, and one was removed: 
1. Mode of birth (caesarean section) under primary outcomes (maternal) is now listed as caesarean 
section for clarity, as this is the outcome the overview authors agreed on as an important outcome for 
women with GDM. 
2. Development of type 1 diabetes for maternal long-term outcomes was removed, as this is an unlikely 
outcome to occur. 
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Chapter 3: Synthesising the current evidence from randomised controlled 
trials of different treatment targets for glycaemic control for women with 
gestational diabetes mellitus  
3.1 Preface 
This chapter presents a Cochrane systematic review published in the Cochrane Library entitled 
‘Different intensities of glycaemic control for women with gestational diabetes mellitus’. The 
chapter comprises the completed Cochrane systematic review, prepared following production of the 
review protocol that was peer reviewed and published in the Cochrane Library (Crawford 2015a). The 
systematic review assessed the available evidence from randomised controlled trials on the effect of 
different intensities of glycaemic control in pregnant women with GDM on maternal and infant health 
outcomes. 
 
The chapter aims to address Research Question 2 ‘Which glycaemic treatment targets best benefit the 
health of women diagnosed with GDM and their babies’. 
 
The chapter contains the unaltered manuscript accepted for publication. The abstract and key words 
were removed as directed by the University of Auckland (2016) Guide to thesis and dissertations. The 
‘Plain Language Summary’ from the published manuscript is presented at the end of the chapter. 
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3.2 Different intensities of glycaemic control for women with gestational 
diabetes mellitus (Review) 
3.2.1 Background 
Description of the condition 
Gestational diabetes mellitus (GDM) is a carbohydrate intolerance resulting in hyperglycaemia, or any 
degree of glucose intolerance with onset or first recognition during pregnancy from 24 weeks' gestation 
onwards and which resolves following the birth of the baby (WHO 2013; NICE 2015). The global 
prevalence of GDM is reported to be between 1% to 25.5%, depending on the diagnostic criteria used 
and women's ethnicity (ACOG 2013; Bottalico 2007; Cheung 2003; Ferrara 2007; NICE 2015; Sacks 
2012), and rates are likely to increase with the reported global obesity epidemic (Athukorala 2010; Kim 
2010; Rowlands 2010; Zhang 2010). Obesity has been identified as a significant risk factor for GDM 
(Boney 2005; Chu 2007; Mokdad 2003; Oteng-Ntim 2012; Rosenberg 2005; Torloni 2009). 
During pregnancy, hormones released by the placenta cause an increase in maternal insulin resistance 
to ensure a constant supply of glucose and other nutrients to the growing fetus (McCance 2011; Wilcox 
2005). The maternal pancreas compensates for the pregnancy-induced insulin resistance by secreting 
more insulin. GDM occurs when this compensatory mechanism fails and not enough insulin is available 
to metabolise glucose (McCurdy 2010; Wilcox 2005). The maternal blood glucose concentration then 
increases resulting in hyperglycaemia. Increased amounts of glucose cross the placenta, over-
nourishing the fetus, with increased fetal insulin secretion in response (Evans 2009; Ragnarsdottir 2010; 
Suman Rao 2013). Increased fetal insulin may act as a growth stimulating factor (Pedersen 1954). 
Recognised risk factors for developing GDM include obesity, advanced maternal age, weight gain in 
pregnancy, and a family history of type 2 diabetes (Athukorala 2010; Chu 2007; Kim 2010; Torloni 2009; 
Zhang 2010). Women of certain ethnicities, such as Asian, African American, Native American, 
Hispanic, and Pacific Island have an increased risk (Carolan 2012a; Chamberlain 2013; Kim 2013; 
Schneider 2012). 
GDM has major short- and long-term implications for both the mother and her baby.  Women with GDM 
are at higher risk of developing gestational hypertension and pre-eclampsia, and are at increased risk 
of having a caesarean section (Crowther 2005; HAPO 2008; McCance 2011; NICE 2015). In the long-
term, these women are at significantly increased risk of developing cardiovascular disease and over half 
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will develop type 2 diabetes within five to 10 years (Bellamy 2009). Infants of women with GDM have a 
greater incidence of being born large-for-gestational age and macrosomic (variously defined as 
birthweight greater than 4000 g to 4500 g) (Young 2013), which increases the risk of shoulder dystocia 
and associated birth trauma such as bone fractures and nerve palsy (Athukorala 2006). Macrosomia 
has been associated with developmental delay in childhood (Ornoy 2005; Slining 2010). In the neonatal 
period, these infants are at higher risk of hypoglycaemia due to fetal hyperinsulinaemia and need to 
adjust to not having the high maternal glucose supply (Devlieger 2008). Neonatal hypoglycaemia is 
associated with developmental delay in childhood (Lucas 1988). There are life-long health risks to the 
infants of mothers with GDM such as higher rates of obesity and type 2 diabetes in childhood (Page 
2014), and an increased risk of diabetes, hypertension, cardiovascular disease in later life (Ornoy 2011), 
and evidence from published cohort studies indicating an increased risk of postpartum depression 
(Kozhimannil 2009; Nicklas 2013). Observational neurodevelopmental studies of children of mothers 
with diabetes (including women with GDM), report a higher rate of neurosensory disability (including 
gross and fine motor abnormalities, attention deficit hyperactivity disorder (ADHD), learning difficulties, 
and possibly autism spectrum disorder (ASD)) (Gardener 2009; Krakowiak 2012; Nomura 2012; Ornoy 
2015). 
Screening and diagnosis of GDM remain controversial, with some countries recommending universal 
screening of all pregnant women between 24 to 28 weeks' gestation (Nankervis 2013), and others only 
recommending selective screening (NICE 2015). The amount of glucose recommended for the 
diagnostic oral glucose tolerance test (OGTT) differs between countries (75 g and 100 g) and there is 
significant variation in the fasting, one-, two- and three-hour postprandial plasma glucose concentrations 
above which GDM is diagnosed (ACOG 2013; Nankervis 2013; Ministry of Health 2014; NICE 2015; 
SIGN 2014; Thompson 2013; WHO 2013).  
Similarly, there is wide variation internationally in glycaemic treatment targets recommended for optimal 
outcomes for women with GDM and their babies (Table 3.1). As evidence emerges that current target 
thresholds may need to be lower than previously thought to reduce morbidity (Hernandez 2011; 
Hernandez 2015; Metzger 2008), professional organisations are increasingly advocating lower 
treatment targets that are closer to observed blood glucose concentrations in pregnant women without 
GDM (HSE 2010; Nankervis 2013). However, concerns have been raised that lower glycaemic targets 
may be associated with an increased risk of infants being born small-for-gestational age (Garner 1997; 
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Langer 1989; Langer 1994), and a potential increased risk of hypoglycaemia in the mother (DCCT 1996), 
and therefore in, the fetus. 
Table 3.1: GDM treatment targets for glycaemic control from clinical practice guidelines 
 
FPG 
mmol/L (mg/dL) * 
1-hour 
postprandial 
mmol/L (mg/dL) * 
2-hours 
postprandial 
mmol/L (mg/dL) * 
Australasian Diabetes in 
Pregnancy Society (ADIPS) 
Nankervis 2013 (p.5); 2014 (p. 6) 
and New Zealand Ministry of Health 
(Ministry of Health) 2014 (p. 32) 
≤ 5.0 (90) ≤ 7.4 (133) ≤ 6.7 (120) 
American Diabetes Association (ADA) 
ADA 2013 (S21) 
Canadian Diabetes Association (CDA) 
Thompson 2013 (S178) 
≤ 5.3 (95) ≤ 7.8 (140) ≤ 6.7 (120) 
National Institute of Health 
and Clinical Excellence (NICE) 
NICE 2015 (p. 21) 
< 5.3 (95) < 7.8 (140) < 6.4 (115) 
5th International Workshop on GDM 
Metzger 2007 (S254) 
5.0 (90) to 
5.5 (99) 
< 7.8 (140) < 6.7 (120) to 
7.1 (127) 
Scottish Intercollegiate Guidelines 
Network SIGN 2014 (p. 59) 
4.0 (72) to 
6.0 (108) 
< 8.0 (144) < 7.0 (126) 
German Diabetes Asociation (DDA)  
Kleinwechter 2014 (p. 404) 
3.6 (65) to 
5.3 (95) 
< 7.8 (140) < 6.7 (120) 
*RM converted all published glycaemic values for GDM treatment into both mmol/L or mg/dL 
Description of the intervention  
Treatment of GDM aims to reduce the associated risks of gestational diabetes for the mother and baby 
by controlling the high maternal blood glucose concentrations (Alwan 2009). Glycaemic control is usually 
measured by monitoring capillary blood glucose concentrations to ensure blood glucose concentrations 
are maintained within a pre-defined threshold (Metzger 2008). This may be achieved through the use of 
diet and lifestyle modifications (ADA 2001; Ministry of Health 2014; NICE 2015; SIGN 2014), or with the 
addition, if necessary, of pharmacological interventions such as oral hypoglycaemic medications or 
subcutaneous insulin (ACOG 2013; Ministry of Health 2014; NICE 2015; SIGN 2014). Trials of 
interventions for GDM usually compare different treatment strategies with glycaemic control as an 
outcome, not an intervention (Middleton 2012). The focus of this review is comparing different treatment 
targets of glycaemic control in women with GDM and the impact on maternal and fetal health. 
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How the intervention might work 
There is a continuous relationship between increasing maternal blood glucose concentrations and 
detrimental maternal and fetal outcomes (Langer 1994; Metzger 2008). Treatment of GDM aims to 
maintain maternal blood glucose concentrations within certain glycaemic target thresholds, reducing the 
physiological response of the fetus to elevated maternal blood glucose concentrations and has been 
shown to be beneficial in reducing perinatal morbidity (Crowther 2005; Landon 2009). The Maternal-
Fetal Medicine Units Network (MFMU) trial (Landon 2009) and the Australian Carbohydrate Intolerance 
Study in Pregnant Women (ACHOIS) trial (Crowther 2005), both compared treatment of GDM with no 
treatment. The MFMU Network trial had tighter glycaemic control targets (fasting plasma glucose < 5.3 
mmol/L (95 mg/dL) and two-hour postprandial < 6.7 mmol/L (120 mg/dL)) than the ACHOIS trial (fasting 
plasma glucose < 5.5 mmol/L (99 mg/dL) and two-hour postprandial < 7.0 mmol/L (126 mg/dL)), and 
demonstrated a reduction in the risk of caesarean section (risk ratio (RR) 0.79, 97% confidence interval 
(CI) 0.64 to 0.99) not shown in the ACHOIS trial (RR 0.97, 95% CI 0.81 to 1.16), although both trials 
demonstrated reductions in birthweight and large-for-gestational-age infants in women with GDM who 
received treatment compared with women who were not treated (Crowther 2005; Landon 2009; Ornoy 
2015). Such evidence suggests lower glycaemic targets may be of benefit.  
Why it is important to do this review  
The evidence for optimal glycaemic targets for women with GDM is limited and of varying quality 
(Hernandez 2015). It appears that women who have better controlled blood glucose concentrations in 
pregnancy have a lower incidence of pre-eclampsia and large-for-gestational-age babies (Crowther 
2005; Landon 2009). The infants of these women have a reduced incidence of neonatal hypoglycaemia 
and perinatal mortality (Landon 2009). Target recommendations from international professional 
organisations for maternal glycaemic control vary widely, all relying on consensus as there is a lack of 
high quality evidence (ADA 2013; Metzger 2007; Nankervis 2013; Ministry of Health 2014; NICE 2015; 
SIGN 2014; Thompson 2013). 
In assessing evidence related to determining the optimal degree of glycaemic targets, this review will 
contribute to knowledge that can be used to minimise the risk of adverse birth outcomes and diabetic 
complications for pregnant women and their babies. 
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3.2.2 Objectives  
The purpose of this review is to assess the effect of different intensities of glycaemic control in pregnant 
women with GDM on maternal and infant health outcomes. 
3.2.3 Methods 
Criteria for considering studies for this review   
Types of studies 
All published and unpublished randomised controlled trials, cluster-randomised and quasi-randomised 
controlled trials, including conference abstracts assessing different intensities of glycaemic control for 
women with GDM, were eligible for inclusion (Higgins 2011). Cross-over trials were not eligible for 
inclusion, as changes in insulin sensitivity throughout pregnancy make cross-over trials an inappropriate 
methodology for this review and women with GDM are usually advised of only one glycaemic target 
range to guide their treatment in their pregnancy. 
Types of participants   
All pregnant women diagnosed with GDM. Due to varying diagnostic methods and criteria used 
internationally, we defined screening and subsequent diagnosis and diagnostic criteria as identified in 
the individual trials. Women with known pre-existing type 1 or type 2 diabetes were excluded. 
Types of interventions   
The type of intervention includes any glycaemic treatment targets (blood glucose concentration) used 
for glycaemic control for women with GDM to guide treatment. For further clarity, we converted blood 
glucose values into both mmol/L and mg/dL as different countries express glucose values in either 
mmol/L or mg/dL. For example, most Europe, New Zealand, Australia and North America generally use 
mmol/L and America, China and Germany generally use mg/dL. Trials often express their interventions 
additionally in non-numerical terms for example: ‘loose’, 'standard care', 'low(er)', 'less tight', ‘moderate’, 
‘tight’, ‘very tight’, 'strict(er)', 'intensive therapy' and 'liberal'. We will use the trial definitions to assist with 
clarity when discussing the results instead of using the numerical ranges repeatedly. 
Types of outcome measures   
The primary and secondary maternal and infant outcome measures are based on consensus between 
the review authors and all other review authors of Cochrane systematic reviews for treatment of GDM. 
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Primary outcomes   
Maternal 
1. Hypertensive disorders of pregnancy (including pre-eclampsia, pregnancy-induced hypertension, 
eclampsia). 
2. Subsequent development of type 2 diabetes. 
Infant 
1. Perinatal (fetal and neonatal) mortality. 
2. Large-for-gestational age (birthweight greater than the 90th centile; or as defined by individual 
trial). 
3. Composite of mortality or serious morbidity (variously defined by trials, e.g. infant death, shoulder 
dystocia, bone fracture or nerve palsy). 
4. Neurosensory disability (variously defined by individual trials). 
Secondary outcomes   
Maternal 
1.  Caesarean section. 
2.  Maternal mortality. 
3.  Weight gain during pregnancy. 
4.  Placental abruption. 
5.  Induction of labour. 
6.  Perineal trauma. 
7.  Postpartum haemorrhage. 
8.  Postpartum infection requiring use of antibiotics (variously defined). 
9.  Maternal hypoglycaemia. 
10.  Glycaemic control during/end of intervention (as defined by trialists). 
11.  Use of pharmacological treatment (insulin, oral hypoglycaemics). 
12.  Relevant biomarker changes associated with the intervention (including adiponectin, free fatty 
acids, triglycerides, high density lipoproteins, low density lipoproteins, insulin). 
13.  Breastfeeding. 
14.  Adherence with treatment/management. 
15.  Sense of wellbeing and quality of life. 
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16.  Views of the intervention. 
17.  Behaviour change associated with the intervention. 
Long-term maternal outcomes 
1. Postnatal depression. 
2. Postnatal weight retention or return to pre-pregnancy weight. 
3. Body mass index (BMI). 
4. GDM in a subsequent pregnancy. 
5. Type 1 diabetes mellitus. 
6. Impaired glucose tolerance. 
7. Cardiovascular health (as defined by trialists, including blood pressure, hypertension, 
cardiovascular disease, metabolic syndrome). 
Infant 
1. Stillbirth. 
2. Neonatal death. 
3. Macrosomia (birthweight ≥ 4000 g, or as defined by individual trial). 
4. Small-for-gestational age (birthweight less than the 10th centile, or as defined by individual trial). 
5. Shoulder dystocia. 
6. Bone fracture. 
7. Nerve palsy. 
8. Preterm birth (< 37 weeks' gestation; < 32 weeks' gestation). 
9. Gestational age at birth. 
10. Birthweight and z score. 
11. Head circumference and z score. 
12. Length and z score. 
13. Ponderal index. 
14. Hypoglycaemia (variously defined). 
15. Respiratory distress syndrome. 
16. Neonatal jaundice (hyperbilirubinaemia). 
17. Hypocalcaemia. 
18. Adiposity (variously defined by trials, e.g. skinfold thickness, fat mass). 
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19. Polycythaemia. 
20. Apgar score < seven at five minutes. 
21. Relevant biomarker changes associated with the intervention (including cord c peptide, cord 
insulin). 
Later childhood 
1. Weight and z score. 
2. Height and z score. 
3. Head circumference and z score. 
4. Adiposity (including BMI, skinfold thickness). 
5. Blood pressure. 
6. Type 1 diabetes mellitus. 
7. Type 2 diabetes mellitus. 
8. Impaired glucose tolerance. 
9. Dyslipidaemia or metabolic syndrome. 
10. Educational achievement. 
Adulthood outcomes 
1. Weight. 
2. Height. 
3. Adiposity (including BMI, skinfold thickness, fat mass). 
4. Cardiovascular health (as defined by trialists, including blood pressure, hypertension, 
cardiovascular disease, metabolic syndrome). 
5. Type 1 diabetes mellitus. 
6. Type 2 diabetes mellitus. 
7. Impaired glucose tolerance. 
8. Dyslipidaemia or metabolic syndrome. 
9. Employment, education, and social status/achievement. 
Health services 
1. Number of antenatal visits or admissions. 
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2. Number of hospital or health professional visits (including midwife, obstetrician, physician, 
dietician, diabetic nurse). 
3. Admission to neonatal intensive care unit/nursery. 
4. Length of antenatal stay. 
5. Length of postnatal stay (maternal). 
6. Length of postnatal stay (baby). 
7. Cost of maternal care. 
8. Cost of offspring care. 
9. Costs associated with the intervention. 
10. Costs to families associated with the management provided. 
Search methods for identification of studies   
The following methods section of this review is based on a standard template used by the Cochrane 
Pregnancy and Childbirth Group. 
Electronic searches   
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register by contacting the Trials 
Search Co-ordinator (31 January 2016). The Register is a database containing over 20,000 reports of 
controlled trials in the field of pregnancy and childbirth. For full search methods used to populate the 
Pregnancy and Childbirth Group’s Trials Register including the detailed search strategies for CENTRAL, 
MEDLINE, Embase and CINAHL; the list of hand-searched journals and conference proceedings, and 
the list of journals reviewed via the current awareness service, please follow this link to the editorial 
information about the Cochrane Pregnancy and Childbirth Group in The Cochrane Library and select 
the ‘Specialized Register ’ section from the options on the left side of the screen. Briefly, the Cochrane 
Pregnancy and Childbirth Group’s Trials Register is maintained by the Trials Search Co-ordinator and 
contains trials identified from: 
• monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);  
• weekly searches of MEDLINE (Ovid); weekly searches of Embase (Ovid); monthly searches of 
CINAHL (EBSCO);  
• hand-searches of 30 journals and the proceedings of major conferences; 
•  weekly current awareness alerts for a further 44 journals  
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• monthly BioMed Central email alerts. 
Search results are screened by two people and the full text of all relevant trial reports identified through 
the searching activities described above is reviewed. Based on the intervention described, each trial 
report is assigned a number that corresponds to a specific Pregnancy and Childbirth Group review topic 
(or topics) and is then added to the Register. The Trials Search Co-ordinator searches the Register for 
each review using this topic number rather than keywords. This results in a more specific search set 
which has been fully accounted for in the relevant review sections (Included, Excluded, Awaiting 
Classification or Ongoing studies). 
In addition, we searched ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform 
(ICTRP) (1 February 2016) for unpublished, planned and ongoing trial reports using the following search 
terms: 
• glycemic control AND pregnancy 
• glycemic control AND pregnant  
• glycaemic control AND pregnancy  
• glycaemic control AND pregnant  
• glycaemic control AND gestational  
• glycemic control AND gestational 
• gestational diabetes mellitus AND treatment thresholds  
• gestational diabetes mellitus AND treatment targets 
Searching other resources   
We searched reference lists of retrieved studies. We did not apply any language or date restrictions. 
Data collection and analysis   
The following methods were used for assessing the eight reports that were identified as a result of the 
search and is based on a standard template used by the Cochrane Pregnancy and Childbirth Group. 
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Selection of studies   
Two review authors independently assessed for inclusion all the potential studies we identified as a 
result of the search strategy. We had no disagreement, hence did not require to consult with a third 
author. 
We created a Study flow diagram to map out the number of included and excluded records identified 
(Figure 3.1). 
Data extraction and management   
We used the Cochrane Pregnancy and Childbirth Group data extraction form. Two review authors (RM 
and JB) extracted data from the one identified study using the agreed form. We entered the data into 
Review Manager software (RevMan 2014) and checked for accuracy. 
Assessment of risk of bias in included studies   
Two review authors independently assessed risk of bias for the one included study using the criteria 
outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We 
resolved any disagreement by discussion or by involving a third author. Seeking statistical advice for 
calculating intra cluster correlations from cluster-randomised trials as outlined in our published protocol, 
was not required. 
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Figure 3.1: Study flow diagram 
 
(1) Random sequence generation (checking for possible selection bias) 
We described for the included study the method used to generate the allocation sequence in sufficient 
detail to allow an assessment of whether it should produce comparable groups. 
We assessed the method as: 
• low risk of bias (any truly random process, e.g. random number table; computer random number 
generator); 
• high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record 
number); 
• unclear risk of bias. 
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 (2) Allocation concealment (checking for possible selection bias) 
We described for the included study the method used to conceal allocation to interventions prior to 
assignment and assessed whether intervention allocation could have been foreseen in advance of, or 
during recruitment, or changed after assignment. 
We assessed the methods as: 
• low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque 
envelopes); 
• high risk of bias (open random allocation; unsealed or non-opaque envelopes, alternation; date of 
birth); 
• unclear risk of bias. 
 (3.1) Blinding of participants and personnel (checking for possible performance bias) 
We described for the included study the methods used, if any, to blind study participants and personnel 
from knowledge of which intervention a participant received. We considered that studies are at low risk 
of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results. 
We assessed blinding separately for different outcomes or classes of outcomes. 
We assessed the methods as: 
• low, high or unclear risk of bias for participants; 
• low, high or unclear risk of bias for personnel. 
(3.2) Blinding of outcome assessment (checking for possible detection bias) 
We described for the included study the methods used, to blind outcome assessors from knowledge of 
which intervention a participant received. We assessed blinding separately for different outcomes or 
classes of outcomes. 
We assessed methods used to blind outcome assessment as: 
• low, high or unclear risk of bias. 
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 (4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and 
handling of incomplete outcome data) 
We described for the included study, and for each outcome or class of outcomes, the completeness of 
data including attrition and exclusions from the analysis. We stated whether attrition and exclusions 
were reported, and the numbers included in the analysis at each stage (compared with the total 
randomised participants), reasons for attrition or exclusion where reported, and whether missing data 
were balanced across groups or were related to outcomes. We attempted to contact the trial authors for 
further information and planned to include any relevant missing data in the analyses which we 
undertook. 
We assessed methods as: 
• low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); 
• high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ 
analysis done with substantial departure of intervention received from that assigned at 
randomisation); 
• unclear risk of bias. 
(5) Selective reporting (checking for reporting bias) 
We described for the included study how we investigated the possibility of selective outcome reporting 
bias and what we found.  
We assessed the methods as: 
• low risk of bias (where it is clear that all of the study’s pre-specified outcomes and all expected 
outcomes of interest to the review have been reported); 
• high risk of bias (where not all the study’s pre-specified outcomes have been reported; one or more 
reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely 
and so cannot be used; study fails to include results of a key outcome that would have been 
expected to have been reported); 
• unclear risk of bias. 
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 (6) Other bias (checking for bias due to problems not covered by (1) to (5) above) 
We described for the included study any important concerns we have about other possible sources of 
bias. We assessed whether the study was free of other problems that could put it at risk of bias: 
• low risk of other bias; 
• high risk of other bias; 
• unclear whether there is risk of other bias. 
Overall risk of bias 
We made explicit judgements about whether the study was at high risk of bias, according to the criteria 
given in the Handbook (Higgins 2011). With reference to (1) to (6) above, we assessed the likely 
magnitude and direction of the bias and whether it impacted on the findings. We explored the impact of 
the level of bias through undertaking sensitivity analyses - see sensitivity analysis (page 353). 
Assessment of the quality of the evidence using the GRADE approach 
We assessed the quality of the evidence of the included trial using the GRADE approach as outlined in 
the GRADE Handbook Chapter 5 (Schünemann 2013) with the software GRADEpro GDT (GRADEpro 
GDT 2015) producing two 'Summary of findings' tables. A summary of the intervention effect and a 
measure of quality for each of the following outcomes was produced using the GRADE approach. 
GRADEpro five criteria (study limitations, consistency of effect, imprecision, indirectness, and 
publication bias) to assess the quality of the body of evidence for each outcome. We chose seven 
maternal and seven child (as neonate, child, adult) outcomes (seven are the maximum of outcomes 
permitted with this software), as listed below. These are based on consensus between the review 
authors and all other review authors of Cochrane systematic reviews for treatment of GDM. For the 
included trial the only outcome (maternal) able to be assessed for quality was caesarean section, no 
other data were available for the other listed outcomes. 
Maternal 
1. Hypertensive disorders of pregnancy (including pre-eclampsia, pregnancy-induced hypertension, 
eclampsia). 
2. Caesarean section. 
3. Subsequent development of type 2 diabetes. 
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4. Perineal trauma. 
5. Return to pre-pregnancy weight. 
6. Postnatal depression. 
7. Induction of labour. 
Child (as neonate, child, adult) 
1. Large-for-gestational age. 
2. Perinatal mortality. 
3. Composite of mortality and serious morbidity. 
4. Neonatal hypoglycaemia. 
5. Adiposity. 
6. Diabetes. 
7. Neurosensory disability. 
Measures of treatment effect   
Dichotomous data 
For dichotomous data, we presented results as summary risk ratio (RR) with 95% confidence intervals 
(CI). 
Continuous data 
For continuous data, we used the mean difference (MD). In future updates, if appropriate, we will use 
the standardised mean difference (SMD) to combine trials that measure the same outcome, but use 
different methods. 
Unit of analysis issues   
Cluster-randomised trials 
No cluster-randomised trials were identified. If cluster-randomised trials are identified in future updates 
of this review we will make adjustments to the standard errors using the methods described in the 
Handbook [Section 16.3.6] using an estimate of the intra cluster correlation co-efficient (ICC) derived 
from the trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from 
other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in 
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the ICC. We will consider it reasonable to combine the results from both cluster-randomised trials and 
individually-randomised trials if there is little heterogeneity between the study designs and the interaction 
between the effect of intervention and the choice of randomisation unit is considered to be unlikely. 
Multiple pregnancy 
The included trial did not report on multiple pregnancy. If in the future updates of this review, trials do 
report on multiple pregnancy, we will present maternal data as per woman randomised and neonatal 
data per infant. 
Multiple-arm studies 
The included trial is this review was not a multiple arm trial. In future updates of the review, where a trial 
has multiple intervention arms, we will avoid 'double counting' of participants by combining groups to 
create a single pair-wise comparison if possible. Where this is not possible, we will split the 'shared' 
group into two or more groups with smaller sample size and include two or more (reasonably 
independent) comparisons. 
Dealing with missing data   
For the included study, we noted the levels of attrition did not exceed 20%. In future updates of the 
review, we will explore the impact of including studies with high levels of missing data (> 20%) in the 
overall assessment of treatment effect by using sensitivity analysis. 
For all outcomes, we carried out analyses, as far as possible, on an intention-to-treat basis, i.e. we 
attempted to include all participants randomised to each group in the analyses, and all participants were 
analysed in the group to which they were allocated, regardless of whether or not they received the 
allocated intervention. The denominator for each outcome in each trial is the number randomised minus 
any participants whose outcomes are known to be missing. 
Assessment of heterogeneity   
We planned to assess statistical heterogeneity in each meta-analysis using the Tau², I² and Chi² 
statistics, but identified only one trial. If future updates include further trials then we will regard 
heterogeneity as substantial if an I² is greater than 30% and either a Tau² is greater than zero, or there 
is a low P value (less than 0.10) in the Chi² test for heterogeneity (Higgins 2011). 
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Assessment of reporting biases   
A single trial is included in this review. In future updates, if there are 10 or more studies in the meta-
analysis we will investigate reporting biases (such as publication bias) using funnel plots. We will assess 
funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform 
exploratory analyses to investigate it. 
Data synthesis  
We carried out statistical analysis using the Review Manager software (RevMan 2014). Only one trial 
was included so there are no data combined in meta-analysis. In future updates, we will use fixed-effect 
meta-analysis for combining data where it is reasonable to assume that studies are estimating the same 
underlying treatment effect: i.e. where trials are examining the same intervention, and the trials’ 
populations and methods are judged sufficiently similar. In future updates, if more trials are included and 
there is clinical heterogeneity sufficient to expect that the underlying treatment effects differ between 
trials, or if substantial statistical heterogeneity is detected, we will use random-effects meta-analysis to 
produce an overall summary, if an average treatment effect across trials is considered clinically 
meaningful. The random-effects summary will be treated as the average of the range of possible 
treatment effects and we will discuss the clinical implications of treatment effects differing between trials. 
If the average treatment effect is not clinically meaningful, we will not combine trials. If we use random-
effects analyses, the results will be presented as the average treatment effect with 95% confidence 
intervals, and the estimates of Tau² and I². 
Subgroup analysis and investigation of heterogeneity   
As there is currently only a single trial included in the review, we have not explored heterogeneity or 
subgroup analyses. If, in future updates, we identify substantial heterogeneity, we will investigate it using 
subgroup analyses and sensitivity analyses. We will consider whether an overall summary is meaningful, 
and if it is, use a random-effects model. 
We will not combine trials based on the individual trial definition of intensity of glycaemic control. We will 
use the mmol/L(mg/dL) thresholds used in the trials and subgroups based on these if there is significant 
heterogeneity. 
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1. Types of strategies used to target or achieve glycaemic control, or both 
i) Diet and lifestyle changes alone versus 
ii) Oral hypoglycaemics +\- diet and lifestyle changes versus 
iii) Insulin therapy +\- diet and lifestyle changes. 
2. Criteria used for diagnosis of GDM 
i) International Association of Diabetes in Pregnancy Study Group (IADPSG 2010), Australasian 
Diabetes in Pregnancy Society (Nankervis 2013); World Health Organization (WHO 2013); American 
Diabetes Association (ADA 2013); Scottish Intercollegiate Guidelines Network (SIGN 2014) versus 
ii) New Zealand Ministry of Health (Ministry of Health 2014) versus 
iii) National Institute of Health and Clinical Excellence (NICE 2015) versus 
iv) Canadian Diabetes Association (Thompson 2013) versus 
v) American College of Obstetricians and Gynecologists (ACOG 2013) versus 
vi) Carpenter et al (Carpenter 1982) versus 
vii) National Diabetes Data Group (National Data Group 1979) versus 
viii) Hoffmann et al (ADIPS) (Hoffman 1998), NICE (NICE 2008), WHO (WHO 1999) versus 
ix) Any others identified by individual trial. 
3. Gestational age at diagnosis 
i) < 24 weeks versus 
ii) 24 to < 28 weeks versus 
iii) ≥ 28 weeks. 
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4. Woman's ethnicity as identified from the trials  
5. Women who are primiparas versus multiparas 
6. Twin pregnancies versus singleton pregnancies 
The following outcomes would be used in any subgroup analyses: 
Maternal 
1. Hypertensive disorders of pregnancy. 
2. Subsequent development of type 2 diabetes. 
Infant 
1. Perinatal (fetal and neonatal) mortality. 
2. Large-for-gestational age (birthweight greater than the 90th centile; or as defined by individual 
trial). 
3. Composite of mortality or serious morbidity. 
In future updates if further trials are identified for inclusion, we will assess subgroup differences by 
interaction tests available within RevMan (RevMan 2014) and report the results of subgroup analyses 
quoting the Chi² statistic and P value, and the interaction test I² value. 
Sensitivity analysis   
Planned sensitivity analyses were not needed. In future updates will carry out sensitivity analysis, if 
required, to investigate the effect of the randomisation unit where we include cluster-randomised trials 
along with individually-randomised trials. We will also carry out sensitivity analysis to explore the impact 
of including studies assessed as high risk of bias due to randomisation method (e.g. quasi-
randomisation versus true randomisation), and allocation concealment on the primary outcomes in order 
to assess whether this makes any difference to the overall results. In addition, we will perform sensitivity 
analysis by excluding trials assessed as high risk of bias due to missing data. 
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3.2.4 Results   
Description of studies   
Results of the search   
We identified eight reports of six trials. Two trials (Garner 1997; Snyder 1998) are published (four 
reports) (Figure 3.1) and four (Ardilouze 2015; Crowther 2015; Hague 2014; Scifres 2015) are ongoing 
studies (Table 3.2).  
Table 3.2: Characteristics of ongoing studies 
Author and year (Study ID) Ardilouze 2015 
Study name Glycemic objectives of women with GDM. 
Methods Randomised controlled trial. Unblinded. 
Canada. 
Participants 30 women, 15-32 weeks' gestation. 
Excluded: known type 1 or type 2 diabetes, treatment interfering 
with glucose metabolism. 
Interventions Normal glycaemic control target: fasting: 5.3 mmol/L (95 mg/dL) 
and 2-hour after meals: 6.7 mmol/L (120 mg/dL). Using diet, 
physical exercise, or insulin to reach normal glycaemic control. 
Low glycaemic control target: fasting: 4.8 mmol/L (86 mg/dL) and 
2-hour after meals: 5.9 mmol/L (106 mg/dL). Using diet, physical 
exercise, or insulin to reach low glycaemic control. 
Outcomes Primary outcome: fetal glycated haemoglobin at delivery. 
Secondary outcome: treatment satisfaction. 
Starting date March 2015. 
Contact information Jean-Luc Ardilouze: Jean-Luc.Ardilouze@USherbrooke.ca 
Julie Menard: jumenard.chus@ssss.gouv.qc.ca 
Notes Clinical Trial Identifier: NCT02478762. 
 
Author and year (Study ID) Crowther 2015 
Study name Optimal glycaemic targets for women with gestational diabetes: 
the randomised trial - TARGET. 
Methods Multi-centre, stepped wedge, cluster-randomised controlled trial. 
Funding: Health Research Council of New Zealand. 
Participants A total sample size of 1080 participant from 10 hospitals in New 
Zealand providing care for women newly diagnosed with GDM. 
Inclusion criteria: pregnant women newly diagnosed with GDM 
between 24-34 weeks' gestation and receiving treatment for 
GDM. 
Exclusion criteria: pregnant women with GDM where the fetus 
has a major anomaly. 
Interventions Less tight glycaemic targets for glycaemic control in women 
newly diagnosed with GDM - fasting plasma glucose < 5.5 
mmol/L (99 mg/dL); 1-hour postprandial < 8.0 mmol/L (144 
mg/dL); 2-hour postprandial < 7.0 mmol/L (126 mg/dL). 
These targets will be used by the responsible clinician for 
glycaemic control following diagnosis of GDM until the birth of the 
baby until stepped wedged cluster-randomisation occurs for the 
intervention to: 
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Author and year (Study ID) Crowther 2015 
tight glycaemic targets for glycaemic control in women newly 
diagnosed with GDM fasting plasma glucose ≤ 5.0 mmol/L (90 
mg/dL); 1-hour postprandial ≤ 7.4 mmol/L 133mg/dL); 2-hour 
postprandial ≤ 6.7 mmol/L (120 mg/dL). 
These targets will be used by the responsible clinician for 
glycaemic control following diagnosis of GDM until the birth of the 
baby. 
Outcomes Primary outcome: large-for-gestational-age infant (birthweight 
>90th centile using customised charts). 
Secondary outcomes: up to the time of hospital discharge after 
birth: 
for the woman: pre-eclampsia, induction of labour, mode of 
birth, gestational weight gain, maternal hypoglycaemia, mean 
daily fasting and postprandial capillary glucose concentration 
during treatment, proportion of glucose values within target, diet 
quality, physical activity, length of postnatal stay, health status, 
anxiety, depression and breastfeeding at discharge, resource 
utilisation. 
for the baby: perinatal death, birth trauma, nerve palsy, bone 
fracture, shoulder dystocia; gestational age at birth, birthweight, 
macrosomia, small-for-gestational age, length, head 
circumference, fat mass, respiratory support, hypoglycaemia, 
hyperbilirubinaemia, lipid and inflammatory markers from cord 
blood, neonatal intensive care unit admission, length of postnatal 
stay, resource utilisation. 
Starting date 29.05.2015. 
Contact information Professor Caroline Crowther, The Liggins Institute, The University 
of Auckland 
85 Park Road, Grafton, Auckland 1023, New Zealand. Ph.+64 9 
923 6011; c.crowther@auckland.ac.nz 
Notes Clinical Trial Identifier: ACTRN12615000282583. 
 
Author and year (Study ID) Hague 2014 
Study name An evaluation of the safety of very tight glycaemic control versus 
tight glycaemic control in women with gestational diabetes - GluT 
pilot. 
Methods Randomised controlled trial. 
Funding: Women's and Children's Hospital, Adelaide, SA, 
Australia; Robinson Research Institute University of Adelaide, 
SA, Australia; Novo Nordisk Regional Support Scheme for 2013, 
Baulkham Hills, NSW, Australia. 
Participants 40 women with GDM diagnosed on 75 g OGTT: fasting glucose ≥ 
5.5 mmol/L (99 mg/dL) and 2 hours glucose ≥ 8.5 mmol/L (153 
mg/dL), between 12 and 30 weeks' gestation, with a singleton or 
twin pregnancy, not previously diagnosed as diabetic, attending 
antenatal care at collaborating hospitals, and giving informed 
written consent. Minimum age 18 years. 
Exclusion criteria > 30 + 0 weeks' gestation, or with triplets or 
higher order gravidity, or with major active medical disorders 
(including psychiatric disease requiring antipsychotic medication 
and inflammatory disorders requiring corticosteroid therapy, but 
not including chronic hypertension). 
Interventions Very tight glycaemic control as monitored by self-monitoring of 
blood glucose with a memory glucometer, aiming to keep fasting 
capillary blood glucose < 5.0 mmol/L (90 mg/dL) and 2-hour 
postprandial capillary blood glucose < 6.7 mmol/L (120 mg/dL) 
until birth, using diet, exercise, insulin, other drugs, as necessary, 
and at appropriate doses to maintain the control, under the 
supervision of an obstetric physician and a diabetes nurse 
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Author and year (Study ID) Hague 2014 
educator and tight glycaemic* control as monitored by self-
monitoring blood glucose with a memory glucometer, aiming to 
keep fasting capillary blood glucose < 5.5 mmol/L (99 mg/dL) and 
2-hour postprandial < 7.0 mmol/L (126 mg/dL) until birth, using 
diet, exercise, insulin, other drugs, as necessary, and at 
appropriate doses to maintain the control, under the supervision 
of an obstetric physician and a diabetes nurse educator. 
*email correspondence confirmed the tight glycaemic targets as 
stated above. On the ANZCTR very tight and tight glycaemic 
targets are listed as the same glycaemic targets, which according 
to Hague is a typo and will be rectified soon. At time of 
submission of this review it had not been corrected. 
Outcomes Primary outcomes: maternal hypoglycaemia: self-monitoring 
capillary blood glucose < 3.0 mmol/L (54 mg/dL) - number of 
episodes, symptomatic or not and severe maternal 
hypoglycaemia: self-monitoring capillary blood glucose < 2.5 
mmol/L (45 mg/dL) - number of episodes. 
Secondary outcomes: birthweight; neonatal hypoglycaemia in 
whole blood from heel prick < 2.6 mmol/L (47 mg/dL); severe 
neonatal hypoglycaemia in whole blood from heel prick < 2.0 
mmol/L (36 mg/dL). 
Starting date 23.12.2014. 
Contact information Professor William "Bill" Hague, Women's and Children's Hospital, 
72 King William Road, North Adelaide, SA 5006, Australia, Ph. 
+61 4 11114575; bill.hague@adelaide.edu.au 
Notes Clinical Trial Identifier: ACTRN12614001250628. 
 
Author and year (Study ID) Scifres 2015 
Study name Randomised controlled clinical pilot trial of intensive management 
for gestational diabetes (GDM-MOMS). 
Methods Randomised clinical pilot trial designed to assess the feasibility of 
randomising obese women with GDM to lower glycaemic 
thresholds compared to standard care. 
Neither patients nor their providers will be blinded to patient study 
group. All women will receive standard nutritional counselling at 
the time of diagnosis, and they will also be treated with either 
glyburide or insulin as dictated by standard care. 
Participants 60 obese women with a new diagnosis of GDM using the 
Carpenter-Coustan criteria, singleton gestation, between 20-30 
weeks of gestation. 
Interventions Active comparator "Standard care": target fasting blood glucose 
values < 95 mg/dL (5.3 mmol/L) and 1-hour postprandial values < 
140 mg/dL (7.8 mmol/L). 
Experimental "Intensive therapy": target fasting blood glucose 
values < 90 mg/dL (5.0 mmol/L) and 1-hour postprandial values < 
120 mg/dL (6.7 mmol/L). 
Outcomes Primary outcome: change in baseline maternal glycaemia at 32-
36 weeks' gestation. Secondary outcomes: neonatal body 
composition, cytokine measurements, physical activity, sleep 
assessments, patient questionnaires, lipid measurements, 
glucose measurements. 
Starting date June 2015 (estimated study completion date: September 2018, 
estimated primary outcome measure completion date: September 
2017). 
Contact information Christina Scifres, MD, University of Oklahoma 
christy-zornes@ouhsc.edu and stephanie-boothroyd@ouhsc.edu 
Notes Clinical Trial Identifier: NCT02530866. 
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Included studies   
We included one study (Snyder 1998) in this review. The publication, from Canada, was in abstract form 
only. No full-text publication has been identified. RM emailed co-author (Meltzer) for further information, 
as Meltzer was the only author with a contact email address found via the Internet. Synder, the main 
author and co-authors Morin and Nadeau were not contactable. No response from Meltzer was received 
at time of submission. 
Snyder 1998, was conducted in Canada and involved 180 women. The women were diagnosed with 
GDM between 20 to 32 weeks' gestation and were recruited over a 12-month period (1996 to 1997). 
The study compared strict versus liberal glycaemic targets for glycaemic control for women treated with 
insulin. Strict glycaemic targets for insulin treatment were defined as (pre-prandial: 5.0 mmol/L (90 
mg/dL) and at one-hour postprandial: 6.7 mmol/L (120 mg/dL)) and liberal glycaemic targets were 
defined as (pre-prandial: 5.8 mmol/L (104 mg/dL) and at one-hour postprandial: 7.8 mmol/L (140 
mg/dL)). No other inclusion criteria were detailed. Data for other characteristics (pre-pregnancy body 
mass index (BMI), maternal age, gestational age at diagnosis and length of treatment) and the criteria 
used to diagnose GDM were not reported. No funding sources were identified (Table 3.3). 
Table 3.3: Characteristics of included studies 
Author and year (Study ID)  Snyder 1998 
Methods Randomised controlled trial. 
Participants 180 women. 
Inclusion criteria: pregnant women, 20 to 37 weeks' gestation, referred 
for GDM (no details of diagnostic criteria). 
Exclusion criteria: no details. 
Setting: Royal Victoria Hospital, McGill University, Montreal, Canada. 
Timing: 1996 to 1997. 
Interventions Liberal glycaemic control criteria: before meal 5.8 mmol/L (104 mg/dL) 
and 1-hour postprandial 7.8 mmol/L (140 mg/dL). Monitored weekly and 
twice a week after 32 weeks'. Birth planned before 40 weeks' gestation 
(n = 86). Treated with Insulin if outside liberal glycaemic targets. 
Strict glycaemic control criteria: before meal 5.0 mmol/L (90 mg/dL) and 
1-hour postprandial 6.7 mmol/L (120 mg/dL). Monitored weekly and 
twice a week after 32 weeks'. Birth planned before 40 weeks' gestation 
(n = 85). Treated with Insulin if outside strict glycaemic targets. 
Outcomes Insulin therapy, caesarean section, gestational age at birth, birthweight, 
birthweight > 4 kg, small-for-gestational age, induction of labour, 
neonatal birth trauma, neonatal metabolic disturbances. 
Notes Sample size calculation - not reported. 
ITT analysis - not clear, data reported for 171/180 women. 
Conference abstract only. 
One of the authors, Sara Meltzer, was contacted via email to request 
further information, e.g. study protocol or any further unpublished 
papers. No response was received at time of submission. 
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Excluded studies   
We excluded one study (Garner 1997) as it was a study of intensification of treatment, not of comparing 
different intensities of glycaemic control targets in women diagnosed with GDM (Table 3.4). 
Table 3.4: Characteristics of excluded studies 
Author and year (Study ID) Garner 1997 
Reason for exclusion In this Canadian study, 300 women diagnosed with GDM were 
randomised to either receive 'intensive' follow-up care or 'routine care'. 
'Intensive' follow-up care took place with an obstetrician and an 
endocrinologist in a tertiary setting and after receiving dietary 
counselling women were placed on a calorie-restricted diet. Daily 
blood glucose estimations were obtained, women were seen bi-weekly 
at the hospital where biophysical profiles were performed at each visit 
and ultra-sonographic assessments for fetal growth, amniotic fluid 
volume and cardiac size performed. In the 'routine care' group, women 
were not seen by a dietician, advised stay on an unrestricted healthy 
diet, performed only 2 glucose levels weekly at home and returned for 
follow-up care to their primary obstetric care provider in the 
community. No high-risk monitoring of the fetus unless there was an 
indication. 
All women in the trial were recommended to maintain their fasting 
glucose level < 4.4 mmol/L (79 mg/dL) and 1-hour postprandial < 7.8 
mmol/L (140 mg/dL). The intensification of the treatment was 
compared between the 2 groups, not different intensities of glycaemic 
control. 
 
Risk of bias in included studies   
The overall quality of the included study was judged to be unclear as it was only published as a 
conference abstract and provided limited information about the methods used. 
The 'Risk of bias' summaries (Table 3.5; Figure 3.2; Figure 3.3) present the review authors' judgements 
about each 'Risk of bias' item from the included study. 
Table 3.5: Risk of bias summary for included study Snyder 1998 
Bias Authors’ judgement Support for judgement 
Random sequence generation 
(selection bias) 
Unclear risk 'Randomised' no other details provided. 
Allocation concealment (selection 
bias) 
Unclear risk No details. 
Blinding of participants and 
personnel (performance bias) 
High risk No details but blinding unlikely. 
Blinding of outcome assessment 
(detection bias) 
Unclear risk No details as to whether outcome assessors 
were blinded. 
Incomplete outcome data (attrition 
bias) 
Unclear risk Data reported on 171 of 180 women enrolled. 
No details on loss to follow-up. 
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Bias Authors’ judgement Support for judgement 
Selective reporting (reporting bias) High risk Conference abstract only. Data not reported 
for all outcomes, only stated that no 
differences. 
Other bias High risk Authors state that there was no difference 
between groups at baseline, but no data 
provided. No protocol has been identified for 
this trial and no full publication has been 
identified. 
 
 
Figure 3.2: ‘Risk of bias’ summary: review authors’ judgements about each risk of bias item 
from the included study 
 
 
Figure 3.3: ‘Risk of bias’ graph: review authors’ judgements about each risk of bias item 
presented as percentages from the included study 
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Allocation (selection bias)  
The method of random sequence generation was not described in detail. Allocation concealment was 
not described. 
Blinding (performance bias and detection bias)  
In this study the blinding of women, their clinical carers and the researcher to group allocation was most 
likely not feasible. A lack of blinding may have influenced the study outcomes. No details were provided 
as whether or not there was blinding of outcome assessors. 
Incomplete outcome data (attrition bias)  
 Data are reported for 171 of 180 women who were recruited to the study (Snyder 1998). No data for 
the missing nine women were provided. Intention-to-treat analysis is not reported. 
Selective reporting (reporting bias)   
As the included study was only published in abstract form it is unclear if the data reported represent all 
of the pre-specified outcomes for the study or if only selected outcomes are reported. 
Other potential sources of bias   
It was not possible to judge if there were other sources of bias as little information is provided in the 
conference abstract. The statement "the groups were comparable for pre-pregnancy body mass, 
maternal age, gestational age at diagnosis and length of treatment" is not substantiated with any data. 
Effects of interventions   
Summary of findings for the main comparison are presented in the following tables: Intensity of 
glycaemic control for women with GDM – strict versus liberal glycaemic targets (maternal outcomes) 
(Table 3.6) and for their children (as neonate, child, adult) (Table 3.7). 
 
309 
Table 3.6: Summary of findings: Intensity of glycaemic control for women with gestational diabetes mellitus - strict glycaemic targets versus liberal 
glycaemic targets (Maternal outcomes) 
Patient or population: Women with GDM            Setting: Canada 
Intervention: Strict intensity of glycaemic control: pre-prandial: 5.0 mmol/L (90 mg/dL) and at one-hour postprandial: 6.7 mmol/L (120 mg/dL) 
Comparison: Less strict glycaemic control: pre-prandial 5.8 mmol/L (104 mg/dL) and at one-hour postprandial 7.8 mmol/L (140 mg/dL) 
Outcomes Anticipated absolute effects* (95% CI) Relative 
effect 
(95% CI) 
No of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments 
Risk with less strict 
glycaemic control 
Risk with strict 
glycaemic control 
Hypertensive disorders of 
pregnancy 
  
not estimable (0 studies) 
 
No data reported for hypertensive 
disorders of pregnancy. 
Caesarean section 244 per 1000 330 per 1000 
(203 to 532) 
RR 1.35  
(0.83 to 2.18) 
171 
(1 study) 
⊕⊝⊝⊝ 
very low1,2,3 
 
Subsequent development of 
type 2 diabetes 
  
not estimable (0 studies) 
 
No data reported for subsequent 
development of type 2 diabetes.  
Perineal trauma 
  
not estimable (0 studies) 
 
No data reported for perineal trauma.  
Return to pre-pregnancy 
weight 
  
not estimable (0 studies) 
 
No data reported for return to pre-
pregnancy weight. 
Postnatal depression 
  
not estimable (0 studies) 
 
No data reported for postnatal 
depression. 
Induction of labour (IOL) 
  
not estimable (0 studies) 
 
No data reported for IOL. 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and 
its 95% CI). CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; 
GRADE Working Group grades of evidence: High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further 
research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an 
important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. 
1 Lack of detail to make a judgement about random sequence generation, allocation concealment, attrition bias and reporting bias. Open label study. No details regarding 
blinding of 
  outcome assessors.  
2 Wide confidence intervals that cross the line of no effect. 3 Evidence based on a single trial that was only published in conference abstract form. 
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Table 3.7: Intensity of glycaemic control for women with gestational diabetes mellitus - strict glycaemic targets versus liberal glycaemic targets 
(Child (as neonate, child, adult) outcomes) 
Patient or population: Children (as neonate, child, adult) of women with GDM Setting: Canada 
Intervention: Strict intensity of maternal glycaemic control: pre-prandial: 5.0 mmol/L (90 mg/dL) and at one-hour postprandial: 6.7 mmol/L (120 mg/dL) 
Comparison: Less strict maternal glycaemic control: pre-prandial 5.8 mmol/L (104 mg/dL) and at one-hour postprandial 7.8 mmol/L (140 mg/dL) 
Outcomes Anticipated absolute effects*(95%CI) Relative 
effect 
(95% CI) 
№ of 
participants 
(studies) 
Evidence 
Quality  
(GRADE)* 
Comments 
Risk with less strict 
glycaemic control 
Risk with strict 
glycaemic control 
Large-for-gestational age - not 
reported 
see comment see comment not 
estimable 
(0 studies) - No data reported for large-for-gestational age 
in the included study. 
Perinatal mortality - not reported see comment see comment not 
estimable 
(0 studies) - No data reported for perinatal mortality in the 
included study. 
Composite of mortality and 
serious morbidity - not reported 
see comment see comment not 
estimable 
(0 studies) - No data reported for composite of mortality 
and serious morbidity in the included study. 
Neonatal hypoglycaemia - not 
reported 
see comment see comment not 
estimable 
(0 studies) - No data reported for neonatal hypoglycaemia 
in the included study. 
Adiposity - not reported see comment see comment not 
estimable 
(0 studies) - No data reported for adiposity in the included 
study. 
Diabetes - not reported see comment see comment not 
estimable 
(0 studies) - No data reported for diabetes in the included 
study. 
Neurosensory disability - not 
reported 
see comment see comment not 
estimable 
(0 studies) - No data reported for neurosensory disability 
in the included study. 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and 
its 95% CI). CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; 
GRADE Working Group grades of evidence: High quality: We are very confident that the true effect lies close to that of the estimate of the effect. 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is 
substantially different. Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. Very low 
quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. 
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Primary outcomes 
Maternal outcomes 
No data were reported for hypertension disorders of pregnancy or subsequent development of 
type 2 diabetes. 
Infant outcomes 
No data were reported for any of the neonatal primary outcomes for this review (perinatal (fetal and 
neonatal) mortality; large-for-gestational age; composite of death or severe morbidity or later 
childhood neurosensory disability). 
Secondary outcomes 
Table 3.8: Comparison 1: Intensity of glycaemic control – strict glycaemic targets versus liberal 
glycaemic targets 
 
Maternal outcomes 
Twenty-eight of 85 (33%) women in the strict group had a caesarean section compared with 21 of 86 
women (24%) in the liberal group. There was no difference in risk of birth by caesarean section (risk 
ratio (RR) 1.35, 95% confidence interval (CI) 0.83 to 2.18, one trial, 171 women), (Table 3.8; Table 3.9). 
Caesarean section was the only pre-specified outcome with available data for GRADE assessment. The 
quality of the evidence for caesarean section was judged to be very low due to lack of details for the 
individual components of risk of bias, evidence of imprecision and publication bias. The chance of birth 
by caesarean section in the liberal glycaemic target group was 24%; for women in the strict glycaemic 
control group the chance of birth by caesarean section ranged from 20% to 53%. 
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Table 3.9: Analysis comparison I: Intensity of glycaemic control - strict glycaemic targets versus 
liberal glycaemic targets. Outcome 1: Caesarean section 
 
Strict glycaemic targets were associated with an increase in the use of pharmacological therapy 
(identified as the use of insulin in this study) (33/85; 39%) compared with liberal glycaemic targets 
(18/86; 21%) (RR 1.85, 95% CI 1.14 to 3.03; one trial, 171 women), (Table 3.8; Table 3.10). CIs are 
wide suggesting imprecision and caution is required when interpreting the data. 
Table 3.10: Analysis comparison I: Intensity of glycaemic control – strict glycaemic targets versus 
liberal glycaemic targets. Outcome 2: Use of pharmacological therapy 
 
No data were reported for any of the other maternal secondary outcomes for this review (maternal 
mortality; weight gain during pregnancy; placental abruption; induction of labour; perineal trauma; 
postpartum haemorrhage; postpartum infection requiring use of antibiotics (variously defined); maternal 
hypoglycaemia; glycaemic control during/end of intervention (as defined by trialists); use of 
pharmacological treatment (oral hypoglycaemic); relevant biomarker changes associated with the 
intervention (including adiponectin, free fatty acids, triglycerides, high density lipoproteins, low density 
lipoproteins, insulin); breastfeeding; adherence with treatment/management; sense of wellbeing and 
quality of life; views of the intervention; behaviour change associated with the intervention). 
Long-term maternal outcomes 
No data were reported for any of the long-term maternal outcomes for this review (postnatal depression; 
postnatal weight retention or return to pre-pregnancy weight; BMI; GDM in a subsequent pregnancy; 
type 1 diabetes mellitus; impaired glucose tolerance; cardiovascular health (as defined by trialists, 
including blood pressure, hypertension, cardiovascular disease, metabolic syndrome)). 
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Infant outcomes 
There were no clear differences for babies born to women receiving strict glycaemic targets for insulin 
treatment when compared to babies born to women receiving liberal glycaemic targets for insulin 
treatment for: 
• macrosomia (birthweight > 4000 g) RR 1.35, 95% CI 0.31 to 5.85; one trial, 171 babies, (Table 3.8; 
Table 3.11); 
Table 3.11: Analysis comparison I: Intensity of glycaemic control – strict glycaemic targets versus 
liberal glycaemic targets. Outcome 3: Macrosomia 
 
• small-for-gestational age RR 1.12, 95% CI 0.48 to 2.63; one trial, 171 babies, (Table 3.8; Table 
3.12); 
Table 3.12: Analysis comparison I: Intensity of glycaemic control – strict glycaemic targets versus 
liberal glycaemic targets. Outcome 4: Small-for-gestational-age 
 
• gestational age at birth mean difference (MD) -0.30 weeks, 95% CI -0.73 to 0.13; one trial, 171 
babies, (Table 3.8; Table 3.13); 
Table 3.13: Analysis comparison I: Intensity of glycaemic control – strict glycaemic targets versus 
liberal glycaemic targets. Outcome 5: Gestational age at birth (weeks) 
 
• birthweight MD -92.00 g, 95% CI -241.97 to 57.97; one trial, 171 babies, (Table 3.8; Table 3.14). 
314 
Table 3.14: Comparison I: Intensity of glycaemic control – strict glycaemic targets versus 
liberal glycaemic targets, Outcome 6: Birthweight 
 
No data were reported for any of the other neonatal outcomes for this review (stillbirth; neonatal death; 
shoulder dystocia; bone fracture; nerve palsy; preterm birth (< 37 weeks' gestation; < 32 weeks' 
gestation); birthweight z score; head circumference and z score; length and z score; ponderal index; 
hypoglycaemia; respiratory distress syndrome; hyperbilirubinaemia; hypocalcaemia; adiposity; 
polycythaemia; Apgar score < seven at five minutes; relevant biomarker changes associated with the 
intervention). 
Later childhood outcomes 
No data were reported for any of the childhood outcomes for this review (weight and z score; height and 
z score; head circumference and z score; adiposity (including BMI, skinfold thickness); blood pressure; 
type 1 diabetes mellitus; type 2 diabetes mellitus; impaired glucose tolerance; dyslipidaemia or 
metabolic syndrome; educational achievement). 
Adulthood outcomes 
No data were reported for any of the adulthood outcomes for this review (weight; height; adiposity 
(including skinfold thickness, fat mass); cardiovascular health (as defined by trialists, including blood 
pressure, hypertension, cardiovascular disease, metabolic syndrome); type 1 diabetes mellitus; type 2 
diabetes mellitus; impaired glucose tolerance; dyslipidaemia or metabolic syndrome; employment, 
education and social status/achievement). 
Health services outcomes 
No data were reported for any of the health service outcomes for this review (number of antenatal visits 
or admissions; number of hospital or health professional visits (including midwife, obstetrician, physician, 
dietician, diabetic nurse); admission to neonatal intensive care unit/nursery; length of antenatal stay; 
length of postnatal stay (maternal); length of postnatal stay (baby); cost of maternal care; cost of 
offspring care; costs associated with the intervention; costs to families associated with the management 
provided). 
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3.2.5 Discussion   
Summary of main results   
The effect of different intensities of glycaemic control in pregnant women with GDM for improving 
maternal and infant outcomes was assessed in this review. Only one study (involving 180 women) was 
identified that met the inclusion criteria for this systematic review (Snyder 1998). In the trial, the capillary 
glycaemic targets compared were: pre-prandial: 5.0 mmol/L (90 mg/dL) and at one-hour postprandial: 
6.7 mmol/L (120 mg/dL) for the strict group and for the liberal glycaemic group: pre-prandial 5.8 mmol/L 
(104 mg/dL) and at one-hour postprandial 7.8 mmol/L (140 mg/dL). The strict glycaemic targets were 
associated with an increase in the use of insulin requirements. No clear differences were seen for any 
of the secondary outcomes for this systematic review. Based on the current limited data it remains 
unclear which glycaemic targets should be recommended for women with GDM for improving their 
health and the health of their babies. 
Overall completeness and applicability of evidence   
There is currently very limited evidence on the effectiveness of different intensities of glycaemic control 
in women with GDM. The available data are from one small (n = 180 women) Canadian study that has 
only been published as a conference abstract (Snyder 1998). The study reported no data for this reviews' 
primary maternal or infant outcomes. No data were available for maternal and child long-term outcomes 
or health service outcomes. Limited secondary outcomes for this review were reported. 
Although an increased use of insulin treatment was associated with women randomised to the strict 
glycaemic control group, there are no data reported in adverse effects such as maternal hypoglycaemia. 
The study recruited "women between 20-37 gestation referred for GDM who were then randomised to 
receive insulin at either the recommended liberal or strict criteria". It did not include other treatments for 
example, oral hypoglycaemic agents or diet and lifestyle interventions. 
Due to one included study with small numbers of participants, receiving insulin as the only treatment 
option when treatment was needed and overall unclear risk of bias, the generalisability of the current 
evidence is very limited. 
Four ongoing trials were identified and data from these studies, when published, will be included in 
future updates of this systematic review (Table 3.2). 
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Quality of the evidence   
For the one included study, random sequence generation and allocation concealment were judged to 
be unclear due to lack of detail. Performance bias was judged to be of high risk as the study was unlikely 
to have been blinded. There was insufficient detail to make a judgement about detection bias. Attrition 
bias was judged to be unclear as of the 180 women recruited, outcome data were available for 171 
women and babies. The reasons for the missing participants were not explained. Selective reporting 
was judged to be of high risk as the conference abstract is likely to have reported on a selection of 
outcomes from the study rather than the pre-specified study outcomes. The study was only reported as 
a conference abstract and no full publication was found. 
We graded the quality of the evidence for caesarean section as very low due to poor reporting of risk of 
bias, imprecision and publication bias. Data for the other selected outcomes for GRADE were not 
reported in the included study (Table 3.6; Table 3.7). 
Potential biases in the review process   
Systematic searches of all potential eligible trials were carried out by the Trials Search Co-ordinator for 
the Cochrane Pregnancy and Childbirth Group and the authors of this review. We also searched the 
Cochrane Pregnancy and Childbirth Group's Trials Register, ClinicalTrials.gov, the WHO International 
Clinical Trials Registry Platform (ICTRP) and the reference lists of the identified trials. One author was 
contacted for the included study via email for additional data, but no response was received. No 
evidence of potential bias was identified through these systematic searches for published and 
unpublished studies. If we identify any studies in future searches, we will assess them for potential 
inclusion in this review. As the quality of the included trial is unclear and outcome data are missing, a 
potential for bias is present. Therefore, the study results should be interpreted with caution. 
Agreements and disagreements with other studies or reviews   
In this review we did not find sufficient evidence to fully evaluate which intensity of glycaemic control for 
women with GDM was most effective for improving the health outcomes for women and their babies. 
Results from only one published study (Snyder 1998) are available, but the overall risk of bias from this 
small trial is unclear (Figure 3.2; Figure 3.3). 
There is limited evidence to guide clinical practice for targets for glycaemic control for women with GDM 
to minimise adverse effects on maternal and fetal health. Glycaemic target recommendations from 
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international professional organisations for maternal glycaemic control vary widely and are reliant on 
consensus given the lack of high-quality evidence (ADA 2013; Metzger 2007; Nankervis 2013; Ministry 
of Health 2014; NICE 2015; SIGN 2014; Thompson 2013) (Table 3.1). The evidence on which these 
recommendations have been made is generally unclear. 
Prutsky and colleagues published a systematic review that included 34 observational studies, involving 
9433 women (Prutsky 2013), summarising the evidence for glycaemic targets in pregnant women with 
GDM, type 1 diabetes and type 2 diabetes. No relevant randomised controlled trials were identified. 
Twenty-six of the 34 observational studies included women with GDM. Overall, the quality of the 
evidence of the observational studies included was judged to be low, with the literature limited and 
heterogeneity amongst the studies high. The results of Prutsky's systematic review showed that a fasting 
glucose target of < 5.0mmol/L was associated with a significant reduction in macrosomia (P < 0.01), 
large-for-gestational-age infants (P = 0.01), neonatal hypoglycaemia (P = 0.01), and neonatal jaundice 
(P = 0.01). For the mother, there was a significant reduction in pre-eclampsia during the third trimester 
of pregnancy (P = 0.01) (Prutsky 2013). Based on the results from these observational studies, the 
authors concluded that it remains unclear whether glucose targets above or below a fasting glucose 
threshold of < 5.0 mmol/L offer a better balance of benefits and risks. There was insufficient evidence 
on postprandial measures to assess different cut-off points and health outcomes. The review authors 
highlighted that there have been no well-conducted large randomised controlled trials comparing any 
two glycaemic thresholds that report on benefits and harms for the mother and her baby. In the light of 
the current evidence assessed in our review, we have reached the same conclusion. 
3.2.6 Authors' conclusions   
Implications for practice   
The overall risk of bias of the single included study was judged to be unclear as it has only been reported 
as an abstract and provided very little information about the study method used. Women using stricter 
glycaemic targets in the included study used more insulin therapy, which would be expected, but no 
data were provided for adverse effects such as maternal hypoglycaemia. There was no difference in the 
risk of being born small-for-gestational age. It is important to note that these findings are based on 
limited data from one small randomised trial with evidence of imprecision for the few published 
outcomes. There is currently insufficient evidence to support strict over more liberal glycaemic treatment 
targets for women with GDM. It will also be important to evaluate women’s views of adhering to different 
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glycaemic intensities and how this affected their daily life to understand and overcome impracticalities 
and inconveniences such as hospital clinic attendances and the effect of blood glucose monitoring. 
Implications for research   
Further larger high-quality trials are needed that compare different intensities of glycaemic control 
targets to guide the treatment of women with GDM. High-quality trials should evaluate different blood 
glycaemic targets to guide treatment, assess both short-term and long-term health outcomes for women 
and their babies, include women's experiences and assess health services costs. Four ongoing 
randomised controlled trials were identified and data from these studies, if published, (Ardilouze 2015; 
Crowther 2015; Hague 2014; Scifres 2015) (Table 3.2) will be included in future updates of this review. 
These trials are of varying sizes, with Ardilouze 2015, Hague 2014 and Scifres 2015 involving 30, 40 
and 60 women with GDM, respectively and Crowther 2015 involving 1080 women. All trials are 
comparing glycaemic control targets for women with GDM. Crowther 2015, Hague 2014 and Scifres 
2015 are using the same glycaemic targets for their intervention group (5.0 mmol/L (90 mg/dL) pre-
prandial and at two hours postprandial 6.7 mmol/L (120 mg/dL)). Non-numerical terms used to describe 
the intervention range from 'normal', 'standard care', 'low', 'less tight', 'tight' to 'very tight' and 'intensive 
therapy'. 
3.2.7 Plain Language Summary 
What is the most effective blood sugar range to guide treatment for women who develop 
gestational diabetes mellitus (GMD) in their pregnancy? 
What is the issue? 
Up to a quarter of pregnant women develop gestational diabetes mellitus (GDM) depending on their 
ethnicity and the diagnostic criteria used. GDM is evident as high blood sugar levels (hyperglycaemia) 
during pregnancy and is associated with an increased risk of developing high blood pressure 
(hypertension) and protein in the urine during pregnancy (pre-eclampsia). These women are more likely 
to have a caesarean birth, develop type 2 diabetes, postnatal depression, and cardiovascular disease 
later on in life. The high blood sugar levels that are associated with GDM often return to normal as soon 
as the baby is born, but women with GDM are at risk of again developing GDM in future pregnancies. 
Babies whose mothers have been diagnosed with GDM are at an increased risk of having a birthweight 
greater than 4000 g, increased risk of birth trauma because of their size and developing breathing 
difficulties after birth. The babies are also at risk of future obesity and type 2 diabetes. 
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Why is this important? 
Women with GDM are treated with the aims of controlling high maternal blood sugar levels and reducing 
the risks of GDM for the mother and the baby. Blood sugar control is monitored by measuring blood 
sugar concentrations to ensure they are maintained within a pre-defined level or range. The blood sugar 
results are usually obtained by the mother using a finger prick to collect a drop of her blood on a test 
strip, which is inserted into a small machine (a glucometer) that reads the sugar level of the blood on 
the test strip. The glucometer reading alerts the pregnant woman to her current blood sugar level and is 
used to guide her treatment. For example, how many units of insulin she requires before eating. 
However, it is currently unclear how to advise pregnant women with newly diagnosed GDM what is the 
most effective blood sugar range to aim for and guide treatment. 
What evidence did we find? 
We searched for evidence on 31 January 2016 and found one small randomised controlled trial (abstract 
only) that was of poor quality and involved 180 women from Canada. The trial compared two blood 
sugar ranges, one strict the other more liberal, and reported a very few health outcomes for the pregnant 
woman and her baby. 
The trial did not provide any data for this review's main outcomes. For the woman, these related to the 
development of high blood pressure and protein in the urine during pregnancy, developing type 2 
diabetes. For the baby, these outcomes related to death of the baby, increased birthweight, increased 
risk of birth trauma because of their size, and disability. 
More women were on insulin in the strictly controlled group (but this result is based on very low-quality 
evidence). No clear differences were reported for caesarean section rates. No other secondary outcome 
data for women with GDM relevant to this review were reported. No differences were reported for the 
number of babies that had a birthweight greater than 4000 g or were small-for-gestational age. No other 
secondary outcomes for the babies relevant to this review were reported. The study did not report on 
adverse events. 
What does this mean? 
This review found that there is not yet enough evidence from randomised controlled trials to determine 
the best blood sugar range for improving health for pregnant women with GDM and their babies. Four 
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studies are ongoing but not yet complete. More high-quality studies are needed that compare different 
targets for blood sugar levels and assess both short-term and long-term health outcomes for women 
and their babies to guide treatment. Studies should include women's experiences and assess health 
services costs. 
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Differences between protocol and review   
The published protocol listed seven maternal and child outcomes together to be assessed for quality 
using the GRADEpro approach. This has now changed for this review to seven outcomes each, maternal 
and child (as neonate, child, adult). The authors identified that mother and child outcomes needed to be 
assessed for quality separately. 
We have modified some of the outcomes for this review based on consensus between the review 
authors and other review authors of Cochrane reviews for treatment of GDM. The outcomes are now in 
line with the updated outcomes across GDM reviews. 
Primary outcomes 
For the mother - caesarean section was amended from being a primary outcome to a secondary 
outcome. Pre-eclampsia was amended to hypertensive disorders of pregnancy (including pre-
eclampsia, pregnancy-induced hypertension and eclampsia). Subsequent development of type 2 
diabetes was moved from a long-term maternal outcome to a primary outcome. 
For the infant - death or severe morbidity (variously defined by trials, e.g. infant death, shoulder 
dystocia, bone fracture or nerve palsy) was amended from a secondary outcome to a primary outcome. 
Secondary outcomes 
Deleted outcomes 
The following maternal secondary outcomes were deleted: mode of birth (normal vaginal birth, 
operative vaginal birth, caesarean section); hyperglycaemia requiring changes in management during 
pregnancy; diabetic ketoacidosis; anxiety. 
The following long-term maternal secondary outcomes were deleted: postnatal glucose tolerance; 
development of type 2 diabetes mellitus; hypertension; blood lipids. 
The following neonatal secondary outcomes were deleted: death in infancy or childhood; congenital 
fetal anomaly; Z scores of birthweights, head circumference, length; neonatal infection; neonatal 
hyperglycaemia. 
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The following later childhood secondary outcomes were deleted: appropriate weight for age; 
anthropometry (weight, height, head circumference, adiposity, skinfold thickness, fat mass); 
developmental delay (variously defined by individual trials). 
The following health service outcome was deleted: length of stay in neonatal intensive care unit/nursery. 
Amended outcomes 
The following maternal secondary outcomes were amended: hypoglycaemia requiring treatment 
during pregnancy amended to maternal hypoglycaemia. Glycaemic control achieved (e.g. blood glucose 
or HbA1c concentrations) (proportion of blood glucose concentrations within target) amended to 
glycaemic control during/end of intervention (as defined by trialists). Satisfaction with 
treatment/management amended to views of the intervention; postnatal weight retention amended to 
postnatal weight retention or return to pre-pregnancy weight. Postnatal depression was moved to long-
term maternal outcomes. 
The following neonatal secondary outcomes were amended: preterm birth amended to preterm birth 
(< 37 weeks' gestation; < 32 weeks' gestation); birthweight, head circumference and length amended to 
birthweight and z score; head circumference and z score and length and z score. Fetal adiposity 
amended to adiposity; neonatal hypoglycaemia amended to hypoglycaemia (variously defined). 
The following adulthood secondary outcomes were amended: metabolic syndrome was amended 
to dyslipidaemia or metabolic syndrome; glucose tolerance/type 2 diabetes mellitus was amended to 
type 1 diabetes, type 2 diabetes, Impaired glucose tolerance. Blood pressure and blood lipids were 
amended to cardiovascular health (as defined by trialists, including blood pressure, hypertension, 
cardiovascular disease, metabolic syndrome). 
The following health service secondary outcomes were amended: maternal antenatal admission 
amended to length of antenatal stay; additional requirements for families (such as change of diet, 
exercise, extra antenatal visits, glucose monitoring and strips) amended to costs to families associated 
with the management provided. Use of healthcare services in pregnancy (consultations, blood glucose 
monitoring, length and number of antenatal visits, and to whom - midwife/obstetrician/physician) 
amended to number of antenatal visits or admissions and number of hospital or health professional visits 
(including midwife, obstetrician, physician, dietician, diabetic nurse). 
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Additional outcomes 
The following maternal secondary outcomes were added: behaviour change associated with the 
intervention; relevant biomarker changes associated with the intervention (including adiponectin, free 
fatty acids, triglycerides, high density lipoproteins, low density lipoproteins, insulin); sense of wellbeing 
and quality of life. 
The following long-term maternal secondary outcomes were added: GDM in a subsequent 
pregnancy; type 1 diabetes mellitus; impaired glucose tolerance; cardiovascular health (as defined by 
trialists, including blood pressure, hypertension, cardiovascular disease, metabolic syndrome). 
The following neonatal secondary outcomes were added: Apgar score < seven at five minutes; 
polycythaemia; relevant biomarker changes associated with the intervention (including cord c peptide, 
cord insulin).  
The following later childhood secondary outcomes were added: weight and z score; height and z 
score; head circumference and z score; adiposity (including body mass index (BMI), skinfold thickness); 
blood pressure; type 1 diabetes mellitus; type 2 diabetes mellitus; impaired glucose tolerance; 
dyslipidaemia or metabolic syndrome; educational achievement. 
The following adulthood secondary outcomes were added: weight, height, adiposity (including BMI, 
skinfold thickness); employment, education and social status/achievement. 
The following health service secondary outcomes were added: costs associated with the 
intervention; length of postnatal stay (baby) 
Subgroup analysis and investigation of heterogeneity. Within the methods for subgroup analysis, 
the following subgroup has been added:   
4. Woman's ethnicity as identified from the trials  
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Chapter 4: Quantitative study identifying barriers and enablers among 
women with gestational diabetes mellitus 
4.1 Preface 
This chapter is a manuscript published by the Journal of Diabetes Research entitled ‘Views and 
experiences of New Zealand women with gestational diabetes in achieving glycaemic control 
targets. The VIEWS study’. This study reports the results of a survey administered to sixty women 
diagnosed with gestational diabetes mellitus (GDM) to identify existing barriers and enablers to 
achieving optimal capillary blood glucose control. 
This study addressed the overarching research question of: What do women with GDM say are the 
barriers and enablers for their glycaemic targets and are there any differences of barriers and enablers 
identified for women with GDM between less tight and tighter glycaemic targets from a quantitative 
research perspective? 
The chapter contains the unaltered published manuscript. The abstract and key words were removed 
as directed by the University of Auckland (2016) Guide to thesis and dissertations. 
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4.2 Views and experiences of New Zealand women with gestational 
diabetes in achieving glycaemic control targets. The Views Study.  
4.2.1 Introduction 
Globally there are increasing rates of diabetes, including gestational diabetes mellitus (GDM) (Wild 
2004; Ministry of Health 2014). The prevalence of GDM varies among populations but probably affects 
10–25% of pregnancies (Guariguata 2014; Kampmann 2015; WHO 2016). 
Short- and long-term health risks for women with GDM include pre-eclampsia, induction of labour, 
caesarean section, and postnatal depression for the women (Metzger 2008; Nicklas 2013; NICE 2015). 
For the baby health risks include shoulder dystocia, nerve palsy, preterm birth, neonatal hypoglycaemia, 
respiratory distress syndrome and the risk of developing obesity and type 2 diabetes (T2DM) in 
childhood (Lucas 1988; Mitanchez 2015a; Ornoy 2015).  
Treatments for women with GDM that maintain glycaemic control within specified targets have a 
significant impact on short- and long-term health for the woman and her baby (Crowther 2005; Landon 
2009; Poolsup 2014). Treatments for GDM include dietary and exercise advice alone or combined with 
pharmacological therapy (Kalra 2013; Kavitha 2013; Ryu 2014; Brown 2017; Nachum 2017). 
While some published studies have described women’s experiences of developing GDM 
(Bandyopadhyay 2011a; Hirst 2012; Lapolla 2012; Trutnovsky 2012; Morrison 2014; Parsons 2014), 
little is known as to how women feel about achieving their glycaemic treatment targets. This nested 
study within the TARGET trial (Australian New Zealand Trial Registry: ACTRN12615000282583) aimed 
to explore women’s views and experiences in achieving their recommended glycaemic treatment targets 
and to identify potential barriers and enablers. 
4.2.2 Materials and Methods 
Participant Selection 
Women diagnosed with GDM were eligible to participate if they had a singleton pregnancy, could 
communicate in English, had been self-monitoring their capillary blood glucose concentrations for at 
least two weeks and provided written consent. Eligible women were sent an email invitation that included 
a participant information sheet and consent form. Women could choose to be interviewed face-to-face, 
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or to be telephoned. Women were aware that the survey was not an assessment of their knowledge 
about GDM and advised that all their information would be kept confidential.  
Hospital sites from two different geographical locations in New Zealand participated. Twenty women, 
recruited from Canterbury District Health Board (DHB) in the South Island, were using less tight 
glycaemic treatment targets (fasting blood glucose <5.5 mmol/L; 1-hour postprandial <8.0 mmol/L; 2-
hours postprandial <7.0 mmol/L). Forty women were using tighter glycaemic treatment targets (fasting 
blood glucose ≤5.0 mmol/L; 1-hour postprandial ≤7.4 mmol/L; 2-hours postprandial ≤6.7 mmol/L); twenty 
women recruited from Canterbury DHB in the South Island and twenty women recruited from Counties 
Manukau DHB, in the North Island. 
Local hospital policies differed for testing of capillary blood glucose. Canterbury DHB moved from initially 
less tight targets to tighter glycaemic treatment targets during the survey time. Women were asked to 
test their capillary blood glucose at one-hour postprandial. Counties Manukau DHB was using tighter 
glycaemic treatment targets during the survey time. Women were asked to test their capillary blood 
glucose two-hours postprandial.  
The Survey 
The survey comprised 45 questions. Twenty questions identified participant demographics and twenty-
five their views and knowledge of their glycaemic treatment targets. Questions included identifying what 
had been helpful in learning how to self-monitor capillary blood glucose concentrations, support received 
from family, friends and health professionals, access to written information, costs associated with their 
GDM management and treatment, and experience of hunger. The survey was piloted with three women 
following which three questions were modified. There was an opportunity for women to provide 
additional information. All women answered all the survey questions. 
Analysis 
Data analysis was conducted using Pivot Tables in Microsoft Office Excel 2016 calculating frequency 
and corresponding percentage to describe the responses to the survey questions and included mean 
and standard deviation for normally distributed data. All analyses were undertaken in Microsoft Office 
Excel 2016, reporting descriptive statistics for baseline demographics and using simple numeric 
calculations for survey responses. 
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Ethical Approval 
The VIEWS Survey was nested within the TARGET Trial approved by the New Zealand Health and 
Disability Ethics committee (HDEC) Ref. 14/NTA/163 and research registration number 1965.  
4.2.3 Results  
Participants 
Sixty-six eligible women were approached and sixty women consented to participate in the survey. Six 
women did not participate because they were too busy, having a family crisis or not responding to the 
invitations (Figure 4.1).  
Figure 4.1: Flowchart of recruitment 
 
Face-to-face surveys were conducted with 34 (57%) women and 26 (43%) of women chose to be 
surveyed by telephone. The average age of participating women was 33 years (standard deviation (SD) 
± 4.5). Just under half of the women (27, 45%) were primigravid, had a family history of diabetes (27, 
45%) and two-thirds were classified as obese or overweight in early pregnancy (39, 65%) (Table 4.1). 
Most women were European (24, 40%) followed by Asian ethnicity (22, 37%). Women taking part were 
evenly distributed across the deprivation index: 18 (30%) women least deprived (level 1-3), 19 (32%) 
women (level 4-6) and 22 (37%) women most deprived (level 7-10) (Table 4.1). The demographics of 
the participating women are reflective of a cross section of the demographics of New Zealand’s pregnant 
population (Census Count 2013; Counties Manakau Count n.d.; Canterbury Count n.d.).  
Eligible women approached 
N = 66 
Canterbury DHB  n = 44    Counties Manukau DHB  n = 22 
Women declined or unable to be contacted 
N = 6 
Canterbury DHB   n = 4     Counties Manukau DHB   n = 2 
Women surveyed and interviewed 
N = 60 
Canterbury DHB  n = 40     Counties Manukau DHB  n = 20 
Reason for declining 
Canterbury DHB 
  
- Family crisis (1 woman) 
- Non-delivered email, not 
  answering (1 woman) 
- Too busy (2 women) 
Reason for declining 
Counties Manukau DHB 
 
- Non-delivered email, not 
  answering (2 women) 
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Women were diagnosed with GDM at a mean of 27.8 ±2.0 weeks’ gestation. At the time of the survey 
participants had been checking their daily capillary blood glucose for an average of 6.8 ±2.3 weeks 
(Table 4.1), with just over half checking their blood glucose four times a day (32, 53%) and the other 
participants six times a day (28, 47%). Ten women (17%) reported having a diagnosis of GDM from a 
previous pregnancy. Almost a third of women (18, 30%) were treated with diet alone; the remainder 
received a combination of dietary advice and medications. Thirteen (22%) women were treated with 
subcutaneous insulin for their GDM, 17 (28%) women metformin and 12, 20% women were treated with 
insulin and metformin (Table 4.1). 
Table 4.1: Demographic characteristics of women who participated in the survey 
Characteristics Women with less tight* 
glycaemic targets 
 
n=20 (% or ± of 20) 
Women with tighter** 
glycaemic targets 
 
n=40 (% or ± of 40) 
Women total 
 
N=60 
(% or ± of 60) 
Age (years)† 34 (±4.3) 32 (±4.5) 33 (±4.5) 
Primigravida (G1P0) 9 (45) 18 (45) 27 (45) 
BMI category‡ 
- Normal 8 (40) 13 (32.5) 21 (35) 
- Overweight 5 (25) 6 (15) 11 (18.3) 
- Obese (Class I) 2 (10) 9 (22.5) 11 (18.3) 
- Obese (Class II) 2 (10) 6 (15) 8 (13.3) 
- Obese (Class II) 3 (15) 6 (15) 9 (15) 
- Total obese 7 (35) 21 (52.5) 28 (46.6) 
Ethnicity§ 
- European 12 (60) 12 (30) 24 (40) 
- Māori - 6 (15) 6 (10) 
- Asian 7 (35) 15 (37.5) 22 (36.7) 
- Pacific Peoples - 7 (17.5) 7 (11.6) 
- MELAA 1 (5) - 1(1.7) 
Highest educational qualifications after leaving school 
1.  No qualification 1 (5) 2 (5) 3(5) 
2.  Level 1 certificate - 2 (5) 2 (3.3) 
3.  Level 2 certificate 2 (10) 2 (5) 4 (6.7) 
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Characteristics Women with less tight* 
glycaemic targets 
 
n=20 (% or ± of 20) 
Women with tighter** 
glycaemic targets 
 
n=40 (% or ± of 40) 
Women total 
 
N=60 
(% or ± of 60) 
4.  Level 3 certificate 2 (10) 4 (10) 6 (10) 
5.  Level 4 certificate - 4 (10) 4 (6.7) 
6.  Level 5 and level 6 
diploma 
4 (20) 9 (22.5) 13 (21.7) 
7.  Bachelor degree and 
level 7 qualification 
8 (40) 17 (42.5) 
 
25 (41.6) 
8.  Post-graduate and 
honours degree 
1 (5) - 1 (1.7) 
9.  Master degree 2 (10) - 2 (3.3) 
NZ Deprivation index 
- 1 (least deprived) 3 (15) 5 (12.5) 8 (13.5) 
- 2 2 (10) 3 (7.5) 5 (8.4) 
- 3 2 (10) 3 (7.5) 5 (8.4) 
- 4 4 (20) 6 (15) 10 (16.7) 
- 5 2 (10) 5 (12.5) 7 (11.8) 
- 6 1 (5) 1 (1.7) 2 (3.4) 
- 7 2 (10) 3 (7.5) 5 (8.5) 
- 8 3 (15) 3 (7.5) 6 (10) 
- 9 1 (5) 4 (10) 5 (8.7) 
- 10 (most deprived) - 6 (15) 6 (10) 
Lead Maternity Carer (LMC) 
- Midwife 19 (95) 36 (90) 55 (91.7) 
- Obstetrician 1 (5) - 1 (1.7) 
- Hospital Team - 4 (10) 4 (6.7) 
Gestational age at GDM 
diagnosis† (weeks) 
27.7 (±1.9) 
 
27.9 (±2.0) 27.8 (±2.0) 
 
Time of self-testing 
capillary blood glucose for 
(weeks)† 
7.6 (±2.5) 6.4 (±2.1) 6.8 (±2.3) 
 
Previous GDM 4 (20) 6 (15) 10 (16.7) 
Previous hypertension 2 (10) - 2 (3.3) 
Current hypertension - 3 (7.5) 3 (5) 
Family history of 
hypertension 
8 (45) 16 (40) 24 (40) 
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Characteristics Women with less tight* 
glycaemic targets 
 
n=20 (% or ± of 20) 
Women with tighter** 
glycaemic targets 
 
n=40 (% or ± of 40) 
Women total 
 
N=60 
(% or ± of 60) 
Family history of diabetes 7 (35) 20 (50) 27 (45) 
Current smoker - 3 (7.5) 3 (15) 
Current treatment 
- Diet only 7 (35) 11 (27.5) 18 (30) 
- Insulin and diet 2 (10) 11 (27.5) 13 (21.7) 
- Metformin and diet 5 (25) 12 (30) 17 (28.3) 
- Insulin, Metformin, 
and diet 
6 (30) 6 (15) 12 (20) 
Figures are number and percentage. 
*Less tight glycaemic treatment targets for women with GDM: fasting blood glucose <5.5 mmol/L; 1 hour 
postprandial <8.0 mmol/L; 2 hours postprandial <7.0 mmol/L. 
**Tighter glycaemic treatment targets for women with GDM: fasting blood glucose ≤5.0 mmol/L; 1 hour 
postprandial ≤7.4 mmol/L; 2 hours postprandial ≤6.7 mmol/L. 
†Mean and standard deviation. 
‡BMI categories:  Underweight < 18.50; Normal range: ≥ 18.55 - 24.99; Overweight: ≥ 25.00–29.99; Obese (Class 
I) ≥ 30.00–34.99; Obese (Class II): Severe obese ≥ 35.00–39.99; Obese (Class II): Morbid obese: ≥ 40.00 
according WHO 2000 and Ministry of Health 2015 categories. 
§as categorised by New Zealand government statistics groups for major ethnic groups. MELAA is an acronym for 
Middle Eastern/Latin American/African. http://www.stats.govt.nz/Census/2013-census/profile-and-summary-
reports/infographic-culture-identity.aspx  
as categorised by New Zealand government statistics groups. http://www.stats.govt.nz/Census/2013-
census/profile-and-summary-reports/qstats-education-training/highest-qualification.aspx 
as categorised by New Zealand 2013 Deprivation Index, University of Otago, Department of Public Health. 
Deprivation score was unknown for one woman, as her address had no meshblock listed 
http://www.otago.ac.nz/wellington/departments/publichealth/research/hirp/otago020194.html 
A lead maternity carer (LMC) in New Zealand provides lead maternity care (is in charge). This can be either a 
Midwife, Obstetrician, or GP. https://www.midwife.org.nz/in-new-zealand/contexts-for-practice 
Views and experiences about achieving recommended glycaemic treatment targets 
The majority of women correctly identified their glycaemic treatment targets (59, 98%) and viewed it as 
very important or important to try to adhere to these targets (Table 4.2).  
Documenting the blood glucose results were viewed as less important (56, 93%) compared to viewing 
adherence to the targets because women knew the results could be downloaded from the glucometer. 
These findings were similar across participants regardless of their glycaemic treatment targets (Table 
4.2). 
Almost two thirds of women (37, 62%) described achieving their morning fasting glycaemic target as 
most difficult. These findings were similar across participants, regardless of their recommended 
glycaemic targets (12, 60% for less tight targets and 25, 62.5% for tighter targets) (Table 4.2). The next 
most frequent difficulty reported for women to achieve their recommended glycaemic targets was after 
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their evening meal (11, 18%).  Again, these findings were similar across participants regardless of their 
glycaemic targets (Table 4.2). Almost two thirds of women (37, 62%) experienced being always or 
frequently hungry (Table 4.4). 
Table 4.2: Participants views and experiences of capillary blood glucose monitoring 
 Women with less tight 
glycaemic targets 
n=20 (% of 20) 
Women with tighter 
glycaemic targets 
n=40 (% of 40) 
Women total 
 
N=60 (%) 
Knew their glycaemic targets 19 (98.3) 40 (100) 59 (98.3) 
Viewed achieving their glycaemic 
targets as very important or 
important 
20 (100) 39 (97.5) 59 (98.3) 
Viewed documenting capillary 
blood glucose results as very 
important or important 
18 (90) 37 (92.5) 56 (93.3) 
Experienced difficulty achieving 
their fasting glycaemic target 
before breakfast 
12 (60) 25 (62.5) 37 (61.6) 
Experienced difficulty with 
achieving their postprandial 
glycaemic target after dinner 
3 (15) 8 (20) 11 (18.3) 
Enablers to achieving optimal blood glucose control 
Participants were asked to identify what helped them when learning to test their capillary blood glucose 
concentrations. All 60 (100%) women indicated that the health professional demonstrating collection 
capillary blood glucose on themselves and then watching the participant perform it was helpful (Table 
4.3). Fifty-six (93%) women opted to comment further about other factors that they felt were helpful for 
learning self-monitoring of blood glucose. These related mainly to group or individual teaching (Table 
4.3). Forty-four (79%) of the women who commented further stated that they found group sessions 
helpful with some women explaining that they enjoyed talking to other women and recognising that they 
are not alone living with GDM (Table 4.3).  
A smaller proportion of women (12, 21%) received additional one to one teaching sessions and enjoyed 
them as it enabled them to ask ‘stupid’ questions, could slow the teacher down when English was the 
second language, or they felt less as though ‘mass produced’, and treated more as an individual (Table 
4.3). Over a third of women (22, 37%) identified Google as a helpful tool.  It is unclear which websites 
they visited and in which language (Table 4.3). 
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Support from family, friends and work colleagues was seen as enabling for achieving glycaemic control. 
Over half of the women 33 (55%) indicated that they found it helpful to be asked about their capillary 
blood glucose concentrations and being reminded to do them by partners, their children, extended family 
members and work colleagues (Table 4.3). Having their meals cooked by either their partners or 
extended family members, who incorporated the GDM diet recommendations, was found to be helpful 
by nearly half of the women (28, 47%) (Table 4.3). Comments indicated that this enabled women to eat 
more vegetables and stopped them from buying confectionary or sugar-sweetened beverages (fizzy 
drinks). Further comments around supportive provision of food by others included colleagues organising 
healthy morning teas at work and friends providing healthy food choices for baby showers. While nearly 
two thirds of women (37, 62%) indicated that the cost associated with the GDM diagnosis, such as food, 
petrol or child care, stayed the same, some women (8, 13%) reported reduced food costs since being 
diagnosed with GDM as an enabler due to buying fewer take-away meals (fast foods) (Table 4.3).  
All women attended Diabetes in Pregnancy Services where they saw a range of health professionals. 
Most women (47, 78%) attended the clinic fortnightly. Support from health professionals was valued. 
Over two thirds of the women (41, 68%) appreciated that health professionals took time to listen and 
explain (Table 4.3). One (1.7%) woman could email the endocrinologist for advice and appreciated their 
prompt response.    
Table 4.3:  Enablers identified by women with GDM1 
1Multiple answers were possible for this part of the survey            2Capillary Blood Glucose Testing 
3Resutls from 56 women                                                                 4Capillary Blood Glucose Concentrations 
Enablers Women with less tight 
glycaemic targets 
n=20 (% of 20) 
Women with tighter 
glycaemic targets 
n=40 (% of 40) 
Women total 
 
N=60 (%) 
Health professional demonstrating 
on themselves CBGT2 
20 (100) 40 (100) 60 (100) 
Watching participants perform 
CBGT2 
20 (100) 40 (100) 60 (100) 
Group teaching 11 (55) 33 (82.5) 443 (78.5) 
One to one teaching 6 (30) 6 (15) 123 (21.4) 
Health professionals listening and 
explaining 
6 (30) 35 (87.5) 41 (68.3) 
Being ask about their CBGC4 and 
reminded to do them  
7 (35) 26 (65) 33 (55) 
Others cooking incorporating 
GDM diet  
11 (55) 17 (42.5) 28 (46.6) 
Using Google 9 (45) 13 (32.5) 22 (36.6) 
Going for walks/exercising 
together 
6 (30) 9 (45) 15 (25) 
Less Costs 3 (15) 5 (12.5) 8 (13.3) 
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Barriers to achieving optimal blood glucose control 
All women received written information about GDM, that explained the importance of healthy eating and 
its effect on blood glucose and how to self-monitor capillary blood glucose concentrations. Barriers to 
this written information included feeling overwhelmed with the amount of written material, and not being 
able to read it in their first language.  Women requested to receive visual information (16, 27%) rather 
than words for food choices, food label reading, how to perform the finger pricks for capillary blood 
glucose collection and how to give subcutaneous insulin injections (Table 4.4). Over half of the women 
(33, 55%) found it difficult that the written information was in English and wanted the health information 
in their first language for themselves and for their families to better understand what GDM is and what 
optimal capillary blood glucose control meant (Table 4.4).  Hindi was the language most frequently 
requested (9, 27% women), followed by Samoan (6, 18% women) then Chinese and Māori each by 5 
(15%) women. This reflects the ethnic diversity of this cohort of women (Table 4.1).  
Over a third of women (23, 38%) reported being offered unhealthy food by family, friends, and work 
colleagues and their lack of understanding as a barrier to achieving optimal glycaemic control (Table 
4.4).  
When engaging with the Diabetes in Pregnancy Services women, just over a fifth of women (13, 22%) 
reported a judgemental attitude by health professionals, being impatient with them and not believing that 
they had tried their hardest to stay within their recommended glycaemic treatment targets as a barrier 
(Table 4.4). Inconsistent information by health professionals (10, 17%), never seeing the same health 
professional twice (8, 13%) and long waiting hours at the clinic (7, 12%), were also experienced as 
difficult (Table 4.4). An increased cost for buying more vegetables, fresh fruits, and wholemeal bread 
was reported as a barrier by a quarter of women (15, 25%) (Table 4.4). 
Table 4.4:  Barriers identified by women with GDM 
Barriers Women with less tight 
glycaemic treatment 
targets 
n=20 (% of 20) 
Women with tighter 
glycaemic treatment 
targets 
n=40 (% of 40) 
Women total 
 
 
N=60 (%) 
Health information available only in 
English 
8 (40) 25 (62.5) 33 (55) 
Health information in words not 
visual 
5 (25) 11 (27.5) 16 (26.6) 
Being offered unhealthy food by 
family, friends, work colleagues 
5 (25) 14 (35) 23 (38.3) 
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Barriers Women with less tight 
glycaemic treatment 
targets 
n=20 (% of 20) 
Women with tighter 
glycaemic treatment 
targets 
n=40 (% of 40) 
Women total 
 
 
N=60 (%) 
Impatient, not being believed and 
being judged by health 
professionals 
7 (35) 6 (15) 13 (21.6) 
Inconsistent information by health 
professionals 
4 (20) 6 (15) 10 (16.6) 
Never seeing the same health 
professional twice 
3 (15) 5 (12.5) 8 (13.3) 
Long waiting hours at clinic 4 (20) 3 (7.5) 7 (11.6) 
Being hungry 14 (70) 23 (57.5) 37 (61.6) 
Increased costs 7 (35) 8 (20) 15 (25) 
4.2.4 Discussion 
In this survey women with GDM identified enablers and barriers to achieving optimal glycaemic control. 
While achieving optimal glycaemic control was viewed as important, most women found it difficult to 
achieve their morning fasting glycaemic treatment targets, experienced hunger and wanted the health 
information in their first language or visually displayed. For most women food costs were not reported 
as a concern for the family budget. Being taught blood glucose testing in a group setting was considered 
helpful. Health professionals and family, friends and work colleagues support was valued. Barriers 
reported include long clinic waiting hours, inconsistent advice, judgemental attitudes, impatience and 
not being believed by health professionals and unhealthy food being offered by family members, friends, 
and work colleagues. 
Health care providers recognise that teaching moments can be maximised by incorporating specific 
adult-learning principles and learning styles into their teaching strategies and provide written information 
that supports these learning styles (Russell 2006).  The survey results showed participants wished to 
be provided with better visual information and to have written information in their own language. Most 
women enjoyed group teaching sessions, although some preferred one-to-one sessions.  
We found no published studies reporting on the effects of providing visual learning aids for women with 
gestational diabetes or the impact of having the information in their first language. One mixed method 
study (Frøisland 2012) among young people with type 1 diabetes (T1DM) in Norway found that a pictorial 
diary as a mobile phone app covering the topics diet, insulin dosage, physical activity, and pre- and 
post-prandial glucose measurements all led to a change in the participants’ applied knowledge about 
the management of their diabetes. This is an area requiring further research. For information to make 
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sense and motivate behaviour change it needs to be provided in a language best understood by the 
women with GDM (Bandyopadhyay 2011a; Hirst 2012; Lapolla 2012; Devsam 2013). Women identified 
Google as a helpful tool. Health professionals need to be aware that women will access information 
beyond the clinic environment and the quality of this information may vary. Diabetes in Pregnancy 
Services should consider how they provide health information and the content of their teaching sessions. 
Health literacy providing clear and relevant health messages has been identified as an effective way to 
help people manage their own health care (Devsam 2013; Work Base Education Trust 2014; Ministry 
of Health 2015a; Bhavadharini 2017). It would be challenging for Diabetes in Pregnancy services to 
provide the information for women with GDM in all the languages identified through this survey. The 
solution may be to provide increased visual information that requires little language and/or translate the 
written information for the languages identified. The use of trained translators has been encouraged, as 
family members are often unfamiliar with the health care medical terms, may find it difficult talking about 
sensitive matters and may have different degrees of English fluency (Gray 2013). 
Achieving adequate fasting blood glucose control prior to breakfast, also known as the dawn 
phenomenon, (Carroll 2005) was identified as a challenge for most women in this survey, regardless 
whether their recommended glycaemic targets were identified as less tight or tighter. In the literature, 
this has been identified previously for people with T1DM and T2DM (Porcellati 2013) but we could not 
find any publications specifically relating to gestational diabetes.  Anecdotal evidence through social 
media indicates that women with GDM, do find this control difficult (Gestational Diabetes UK n.d.). 
Various recommendations for achieving glycaemic control include subcutaneous insulin, walking after 
dinner, restricting carbohydrate intake at dinner time, late protein snack before bed time and staying 
hydrated (Sheehan 2004) but require further research for women with GDM. Two thirds of women 
commented on being hungry. It is unclear from the survey if this relates to women trying to lower their 
morning fasting blood glucose with eating less at dinner-time or eating very low carbohydrate meals. 
This would benefit from further exploration.  
Some women identified barriers regarding health professional’s attitude to not achieving adequate 
glycaemic control. These included judgmental attitude, not being believed when women stated that they 
were trying their hardest to follow all diet and pharmaceutical recommendations and seeing a different 
health professional at each visit receiving inconsistent information. Findings from other qualitative 
studies reiterate these findings (Fahy 2012; Devsam 2013; Janes 2013) and highlights the importance 
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for health professional to have a woman centred approach, not only focusing on blood glucose 
concentrations, but investing time to listen, believing what the women says is true, provide consistent 
information and continuity of care (Janes 2013). 
Support from family, friends, and work colleagues was appreciated by the women surveyed. These 
results are consistent with other studies (Mayberry 2012; Miller 2013). Barrier identification included 
unhealthy food being offered to them by family members, friends, and work colleagues, indicating a lack 
of understanding. Pregnancy in Diabetes services may consider providing opportunity for family and 
friends to attend information sessions about GDM and its implication or include discussions about 
effective strategies for difficult situations at clinic appointments. 
This study had some limitations. The participants were from two selected areas in New Zealand and 
while they were a cross-sectional representation of the demographics of the New Zealand population, 
this did not include women living in rural or remote areas. The findings may not be able to be generalised 
as different District Health Board provide care for women with GDM through different models of care.  
4.2.5 Conclusions 
This survey identified barriers and enablers for women with GDM in achieving optimal glycaemic control 
from two different geographical locations in New Zealand. The results provide insights to women’s views 
and experiences with GDM in achieving glycaemic control targets. Two thirds of women found it difficult 
to achieve adequate fasting capillary blood glucose control, regardless of their recommended glycaemic 
targets, and identified the need for better strategies and adequate health professional and family support 
to manage this difficulty.  Barriers for health information and literacy identified that health professionals 
need to consider using a women-centred and adult learning style approach, provide visual aids, provide 
written information in relevant languages, and include extended family members when imparting 
knowledge or teaching GDM related skills. Long clinic waiting hours, inconsistent advice, judgmental 
attitudes and not being believed by health professionals requires further consideration when providing 
a health care service for women with GDM. Findings from this survey will be useful for developing 
strategies for Diabetes in Pregnancy Services to support women with GDM in achieving their glycaemic 
control. 
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Chapter 5: Qualitative study identifying enablers and barriers among 
women with gestational diabetes mellitus 
5.1 Preface 
This chapter is a manuscript submitted for publication to the BMC Pregnancy and Childbirth Journal 
entitled ‘Enablers and barriers for women with gestational diabetes mellitus to achieve optimal 
glycaemic control – a qualitative study using the Theoretical Domains Framework’. 
This study addressed the overarching Research Question ‘What are women’s experiences, enablers 
and barriers with their glycaemic targets’ from a qualitative research perspective. 
Sixty women diagnosed with gestational diabetes mellitus (GDM) who had at least two weeks 
experience with capillary blood glucose testing completed a semi-structured interview. The results 
identified existing behavioural factors for women with GDM in achieving optimal glycaemic control. 
This chapter contains the unaltered manuscript as it is submitted. The abstract and key words were 
removed as directed by the University of Auckland (2016) Guide to thesis and dissertations.  
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5.2 Enablers and barriers for women with gestational diabetes mellitus to 
achieve optimal glycaemic control – a qualitative study using the 
Theoretical Domains Framework  
5.2.1 Background 
In New Zealand one in eleven pregnant women is diagnosed with gestational diabetes mellitus (GDM) 
(ADHB 2016). Maternal hyperglycaemia associated with GDM is a potentially serious complication that 
can result in short- and long-term health risks for the woman and her baby (Bellamy 2009; Garrison 
2015; McCance 2011; Wu 2012). Optimal blood glucose regulation within recommended glycaemic 
targets using lifestyle changes and/or pharmacological treatments aims to reduce or prevent the adverse 
outcomes associated with GDM (Crowther 2005; Landon 2009; Tieu 2010). A woman’s perceptions of 
GDM may influence whether she embraces any lifestyle changes, complies with the recommended 
treatment, and achieves optimal blood glucose control (Lawrence 2011). 
The New Zealand Health and Disability Commissioner has identified that consumer (a health system 
user) involvement is a priority in health decision making (Coney 2004). Legislation such as the Health 
and Disability Commissioner Act 1994 (Health and Disability Commissioner 1994), and the Health and 
Disability Services Consumers' Rights 1996 Code (Health and Disability Services 1996) support this. 
International organisations including Cochrane and the World Health Organisation (WHO) concur (Boote 
2013; Morley 2016). They recommend that for any research involving consumers, their experiences 
should be investigated to support the research results.   
In 2015 the National Institute for Health and Care Excellence (NICE) published an up-dated guideline 
for ‘Diabetes in pregnancy: management from preconception to the postnatal period’ and recommended 
that further robust qualitative studies were needed to explore enablers and barriers for women with GDM 
to maintain optimal glycaemic blood control (NICE 2015). Increased understanding of the enablers and 
barriers for women with GDM may help facilitate behaviour change and assist health care professionals 
to support women with GDM more effectively to overcome the barriers identified and support the 
enablers. 
The use of the Theoretical Domains Framework (TDF), which informed data analysis, is an effective tool 
to identify enablers and barriers and to understand, inform and facilitate effective behavioural change 
and health service provision (Michie 2005; Michie 2008; Michie 2011). TDF was developed using an 
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expert consensus process and validation to identify psychological and organisational theory relevant to 
behaviour change (Michie 2005, Michie 2008; Michie 2011; Atkins 2017). The most recent validated 
version of the TDF includes 14 domains and their component constructs (Cane 2012) (Table 5.1). The 
TDF has been used in health care to identify factors influencing health practitioner’s clinical behaviour 
and behaviour change (Cane 2012; Davies 2010; French 2012) but is increasingly being used to identify 
enablers and barriers for the consumer (user of health care) to understand their experiences and views 
to adherence of treatment and lifestyle changes (Burgess 2014; McGoldrick 2016; Nicholson 2014; Penn 
2014).  
Table 5.1: Refined Theoretical Domains Framework  
Theoretical Domains  Generic Definitions Constructs 
Knowledge An awareness of the existence of 
something 
- Knowledge (including knowledge 
  of condition/scientific rationale) 
- Procedural knowledge 
- Knowledge of task environment 
Skills An ability or proficiency acquired 
through practice 
- Skills 
- Skills development 
- Competence 
- Ability 
- Interpersonal skills 
- Practice 
- Skill assessment 
Social/Professional 
 Role & Identity 
A coherent set of behaviours and 
displayed personal qualities of an 
individual in a social or work setting 
- Professional identity 
- Professional role 
- Social identity 
- Identity 
- Professional boundaries 
- Professional confidence 
- Group identity 
- Leadership 
- Organisational commitment 
Beliefs about  
capabilities 
Acceptance of the truth, reality or 
validity about an ability, talent, or facility 
that a person can put to constructive 
use 
- Self-confidence 
- Perceived competence 
- Self-efficacy 
- Perceived behavioural control 
- Beliefs 
- Self-esteem 
- Empowerment 
- Professional confidence 
Optimism The confidence that things will happen 
for the best or that desired goals will be 
attained 
- Optimism 
- Pessimism 
- Unrealistic optimism 
- Identity 
Beliefs about consequences Acceptance of the truth, reality, or 
validity about outcomes of a behaviour 
in a given situation 
- Beliefs 
- Outcome expectancies 
- Characteristics of outcome 
  expectancies 
- Anticipated regret 
- Consequents 
Reinforcement Increasing the probability of a response 
by arranging a dependent relationship, 
- Rewards (proximal/distal, valued/not 
valued, probable/improbable) 
- Incentives 
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Theoretical Domains  Generic Definitions Constructs 
or contingency, between the response 
and a given stimulus 
- Punishment 
- Consequents 
- Reinforcement 
- Contingencies 
- Sanctions 
Intentions A conscious decision to perform a 
behavior or a resolve to act in a certain 
way 
- Stability of intentions 
- Stages of change model 
- Transtheoretical model and 
   stages of change 
Goals Mental representations of outcomes or 
end states that an individual wants to 
achieve 
- Goals (distal/proximal) 
- Goal priority 
- Goal/target setting 
- Goals (autonomous/controlled) 
- Action planning 
- Implementation intention 
Memory, attention, and 
decision processes 
The ability to retain information, focus 
selectively on aspects of the 
environment and choose between two 
or more alternatives 
- Memory 
- Attention 
- Attention control 
- Decision making 
- Cognitive overload/tiredness 
Environmental context and 
resources 
Any circumstance of a person’s situation 
or environment that discourages or 
encourages the development of skills 
and abilities, independence, social 
competence, and adaptive behaviour 
- Environmental stressors 
- Resources/material resources 
- Organisational culture/climate 
- Salient events/critical incidents 
- Person × environment interaction 
- Barriers and facilitators 
Social influences  Those interpersonal processes that can 
cause individuals to change their 
thoughts, feelings or behaviours 
- Social pressure 
- Social norms 
- Group conformity 
- Social comparisons 
- Group norms 
- Social support 
- Power 
- Intergroup conflict 
- Alienation 
- Group identity 
- Modelling 
Emotion A complex reaction pattern, involving 
experiential, behavioural and 
physiological elements, by which the 
individual attempts to deal with a 
personally significant matter or event 
- Fear 
- Anxiety 
- Affect 
- Stress 
- Depression 
- Positive/negative affect 
- Burn-out 
Behavioural regulation Anything aimed at managing or 
changing objectively observed or 
measured actions 
- Self-monitoring 
- Breaking habit 
- Action planning 
Source: Adapted from Cane 2012 and Atkins 2017 
The aims of this study were to explore the views and experiences of women with GDM with a focus on 
enablers and barriers to achieving optimal CBG control. Initially women were asked about how they felt 
and reacted when they were first diagnosed with GDM and if these impressions changed over time. To 
achieve the aims of the study, three broad questions were explored with participating women:  
1. What is it like for a woman to monitor their CBG concentrations? 
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2. What affects a woman’s capillary CBG concentrations and how does she maintain optimal CBG 
control with this knowledge? 
3. What support have women found helpful/not helpful in learning about and maintaining optimal 
CBG control? 
5.2.2 Methods 
Study design and procedure 
This was a qualitative descriptive study and thematic content analysis as informed by Braun and Clarke 
and the Theoretical Domains Framework was used to analyse the data (Braun 2006; Michie 2011; Cane 
2012; Kim 2017). Semi-structured interviews enabled women with GDM to express their views and 
experiences in their own words (Glanz 2008; Sandelowski 2010). Women could choose to be 
interviewed face-to-face, or to be telephoned. Women were made aware that the interview was not an 
assessment of their knowledge about GDM and that they could stop the interview at any time. They 
were advised that all their information would be kept confidential. All women chose a pseudonym at the 
end of the interview for de-identifying their data and for use when disseminating the results. 
This qualitative study was nested within the TARGET Trial (Optimal Glycaemic Targets for Gestational 
Diabetes), a stepped wedge randomised controlled trial (Australian New Zealand Trial Registry: 
ACTRN12615000282583), which is assessing less tight and tighter glycaemic targets for women with 
GDM and the effect on maternal and perinatal morbidities. The study was approved by the New Zealand 
Health and Disability Ethics committee (HDEC) Ref. 14/NTA/163, research registration number 1965. 
Locality agreements were obtained from Canterbury and Counties Manukau District Health Boards 
(DHB). 
Study setting 
Two New Zealand tertiary hospitals participated, one from the South Island (Canterbury DHB)) and one 
from the North Island (Counties Manukau DHB). Hospital policies differed for glycaemic targets and 
testing of capillary blood glucose (CBG). During the study, Canterbury DHB moved from initially less 
tight glycaemic targets (fasting blood glucose <5.5 mmol/L; 1-hour postprandial <8.0 mmol/L; and 2-
hours postprandial <7.0 mmol/L) to tighter targets (fasting blood glucose ≤5.0 mmol/L; 1-hour 
postprandial ≤7.4 mmol/L; and 2-hours postprandial ≤6.7 mmol/L). Women were asked to test their CBG 
at one-hour postprandial. Counties Manukau DHB used tighter glycaemic targets during the study 
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(fasting blood glucose ≤5.0 mmol/L; 1-hour postprandial ≤7.4 mmol/L; and 2-hours postprandial ≤6.7 
mmol/L) and women were asked to test their CBG two-hours postprandial. 
Study participants 
Women with GDM were eligible to participate if they had not yet given birth, had a singleton pregnancy, 
were able to communicate in English and had been self-monitoring their CBG concentrations for at least 
two weeks.  All women with GDM recruited between August 2016 to February 2017 for the TARGET 
Trial at Canterbury and Counties Manukau DHB were sent an email invitation to consider participation 
in this nested study with a participant information sheet and consent form attached. Eligible women who 
wished to participate signed a consent form for this study. 
Study materials 
A question guide to facilitate the semi-structured interview was developed and pilot tested with three 
women who had GDM. This resulted in the addition of one question about hunger and adding the request 
for a pseudonym for identification rather than only a number to identify the data of participants.  The 
data from these three women involved in piloting the question guide was included in the analyses. If 
women needed further guidance to share their thoughts, the question guide listed prompts and sub-
questions for each broad question.  
The semi-structured interview 
One researcher (RM), with facilitating skills, conducted all the interviews over a six months’ time period 
(August 2016 to February 2017). The woman’s choice directed the place and timing of the interview. 
Consequently, face-to-face interviews were conducted at a variety of settings including a woman’s 
home, work place, botanical gardens, cafés, on farms and hospital sites. No time constraints were 
applied for the interviews with most lasting about 40 minutes.  
Data collection and analysis 
All interviews were recorded using a digital recorder and were transcribed verbatim using Microsoft 2010 
by independent transcribers, who had signed a confidentiality agreement. The transcripts were verified 
by the researcher (RM) and entered into NVivo11 for windows (QSR 2011) for data management and 
analysis. Thematic content analysis was conducted initially using an inductive approach (Braun 2006) 
where transcripts were read and re-read in full for familiarisation with the data and analysed using open 
coding techniques assigning a code to each meaningful segment of text. As the open codes became 
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saturated, a list of specific themes was generated, compared and categorised to broader overarching 
themes, following Braun’s steps 1-5 (Braun 2006) (Table 5.2). This was followed by a deductive 
approach assigning the themes with meaningful text to one or more of the 14 theoretical domains 
reflected in the Theoretical Domain’s Framework (Michie 2011; Cane 2012; Atkins 2017) (Table 5.1).   
Table 5.2: Braun’s (2006) Thematic Analysis Approach  
Steps Content 
1. Familiarisation with the data Reading and re-reading the data, to become immersed and 
intimately familiar with its content 
2. Coding Generating succinct labels (codes) that identify important features 
of the data that might be relevant to answering the research 
question. It involves coding the entire dataset, and after that, 
collating all the codes and all relevant data extracts, together for 
later stages of analysis. 
3. Searching for themes Examining the codes and collated data to identify significant 
broader patterns of meaning (potential themes). It then involves 
collating data relevant to each candidate theme, so that you can 
work with the data and review the viability of each candidate theme. 
4. Reviewing themes Checking the candidate themes against the dataset, to determine 
that they tell a convincing story of the data, and one that answers 
the research question. In this phase, themes are typically refined, 
which sometimes involves them being split, combined, or 
discarded. 
5. Defining and naming themes Developing a detailed analysis of each theme, working out the 
scope and focus of each theme, determining the ‘story’ of each. It 
also involves deciding on an informative name for each theme. 
6. Writing up Weaving together the analytic narrative and data extracts and 
contextualising the analysis in relation to existing literature. 
Source: Adapted from Braun 2006 
Two researchers (RM and JB) coded and classified the data and consulted with the other authors (JMC 
and CAC) to discuss and revise synthesising the text into the final behavioural domains with enablers 
and barriers identification for aspects of optimal glycaemic control. Where text fitted into multiple 
domains, two researchers (RM and JB) discussed and decided which text should be coded into the 
domain that best reflects the key theme (Atkins 2017) and whether a statement represented a barrier or 
enabler to achieving optimal glycaemic control. Reporting of this study was based on the COREQ 
(Consolidated Criteria for Reporting Qualitative Research) checklist (Tong 2007). 
5.2.3 Results  
During the study period, sixty-six eligible women with GDM consecutively recruited to the TARGET Trial 
were approached. Six women declined to be part of this study because they were too busy, having a 
family crisis or did not respond to the email invitation (Figure 5.1).  
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Twenty women with GDM were recruited from the Counties Manukau DHB site and 40 women with 
GDM from Canterbury DHB site, giving a total of 60 participants. 
Figure 5.1: Flowchart of recruitment 
 
The sociodemographic characteristics of the women who participated are reflective of a cross section 
of the demographics of New Zealand’s pregnant population (Census NZ 2013; Counties Manakau Count 
n.d.; Canterbury Count n.d.) (Table 5.3). Data were analysed and coded from 858 transcribed pages 
(249,692 words). 
Women were diagnosed with GDM at a mean gestational age of 27.8 weeks (standard deviation (SD) ± 
2.0.  Ten women (16.7%) reported having GDM in a previous pregnancy and twenty-seven (45%) 
women reported a family history of diabetes (Table 5.3). When interviewed, the women had been 
checking their daily CBG for an average of 6.8 ± 2.3 weeks (Table 5.3). Twenty-eight women (47%) 
were checking their daily CBG concentration six times (before and after breakfast, lunch and dinner) 
and thirty-two women (53%) were checking CBG concentrations four times a day (before breakfast and 
after breakfast, lunch and dinner) (Table 5.3). Almost a third of women (18, 30%) were treated with diet 
alone. Thirteen (21.7%) women were treated with subcutaneous insulin for their GDM, 17 (28.3%) 
women with metformin and 12 (20%) women were treated with insulin and metformin (Table 5.3). For 
the interview 34 (57%) women chose to be interviewed face-to-face and 26 (43%) women by telephone 
(Table 5.3). 
Eligible women approached 
N = 66 
Canterbury DHB  n=44 Counties Manukau DHB  n=22 
Women declined or unable to be contacted 
N = 6 
Canterbury DHB  n=4    Counties Manukau DHB  n=2 
Women surveyed and interviewed 
N = 60 
Canterbury DHB  n=40  Counties Manukau DHB  n=20 
Reason for declining 
Canterbury DHB  
- Family crisis (1 woman) 
- Not responding to repeat emails  
  (1 woman) 
- Too busy (2 women) 
 
Reason for declining 
Counties Manukau DHB  
- Not responding to repeat emails  
  (2 women) 
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Table 5.3: Demographic characteristics of women who participated in the interviews 
Characteristics Women total 
n=60 (%) 
Age (years)§ 33 (±4.5) 
Primigravida (G1P0)  27 (45) 
BMI category† 
 - Normal   21 (35) 
 - Overweight   11 (18.3) 
 - Obese (Class I)   11 (18.3) 
 - Obese (Class II)   8 (13.3) 
 - Obese (Class II)   9 (15) 
 - Total obese   28 (46.6) 
  
Ethnicity‡ 
 - European 24 (40) 
 - Māori 6 (10) 
 - Asian  22 (36.7) 
 - Pacific Peoples 7 (11.6) 
 - MELAA 1(1.7) 
  
Highest educational qualifications after leaving school* 
1.  No qualification 3(5) 
2.  Level 1 certificate 2 (3.3) 
3.  Level 2 certificate 4 (6.7) 
4.  Level 3 certificate 6 (10) 
5.  Level 4 certificate 4 (6.7) 
6.  Level 5 and level 6 
     Diploma 
13 (21.7) 
7.  Bachelor degree 
     and level 7 
     qualification 
25 (41.6) 
8.  Post-graduate and  
     honours degree 
1 (1.7) 
9.  Master degree 2 (3.3) 
New Zealand Deprivation index** 
 - 1 (least deprived)  8 (13.5) 
 - 2 5 (8.4) 
 - 3 5 (8.4) 
 - 4 10 (16.7) 
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Characteristics Women total 
n=60 (%) 
 - 5  7 (11.8) 
 - 6  2 (3.4) 
 - 7 5 (8.5) 
 - 8 6 (10) 
 - 9  5 (8.7) 
 - 10 (most deprived) 6 (10) 
Lead Maternity Carer (LMC)*** 
 - Midwife 55 (91.7) 
 - Obstetrician 1 (1.7) 
 - Hospital Team 4 (6.7) 
Health history 
Gestational age at GDM diagnosis (weeks)§ 27.8 (±2.0) 
Previous GDM 10 (16.7) 
Previous hypertension 2 (3.3) 
Current hypertension 3 (5) 
Family history of hypertension 24 (40) 
Family history of diabetes 27 (45) 
Current smoker 3 (15) 
Capillary blood glucose testing (CBG) 
Weeks of self-testing capillary blood glucose at 
interview§ 
6.8 (±2.3) 
Daily self-testing CBG: four times 
(Before breakfast, after breakfast, after lunch and after 
dinner) 
32 (53) 
Daily self-testing CBG: six times 
(Before and after breakfast, lunch and dinner) 
28 (47) 
Current treatment 
 - Diet only 18 (30) 
 - Insulin and diet 13 (21.7) 
 - Metformin and diet 17 (28.3) 
 - Insulin, Metformin and diet 12 (20) 
Interview type 
Face-to-face interview 34 (57) 
Phone interview 26 (43) 
Figures are numbers and percentages 
§Mean and standard deviation 
†BMI categories:  Underweight < 18.50; Normal range: ≥ 18.55 - 24.99; Overweight: ≥ 25.00–29.99; Obese (Class 
I) ≥ 30.00–34.99; Obese (Class II): Severe obese ≥ 35.00–39.99; Obese (Class II): Morbid obese: ≥ 40.00 
(according to WHO 2000 and Ministry of Health 2015 categories) 
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‡as categorised by New Zealand government statistics groups for major ethnic groups. MELAA is an acronym for 
Middle Eastern/Latin American/African. http://www.stats.govt.nz/Census/2013-census/profile-and-summary-
reports/infographic-culture-identity.aspx  
*as categorised by New Zealand government statistics groups. http://www.stats.govt.nz/Census/2013-
census/profile-and-summary-reports/qstats-education-training/highest-qualification.aspx 
**as categorised by New Zealand 2013 Deprivation Index, University of Otago, Department of Public Health. 
Deprivation score was unknown for one woman, as her address had no meshblock listed 
http://www.otago.ac.nz/wellington/departments/publichealth/research/hirp/otago020194.html 
***A Lead Maternity Carer (LMC) in New Zealand provides lead maternity care (is in charge). This can be either a 
Midwife, Obstetrician, or GP. https://www.midwife.org.nz/in-new-zealand/contexts-for-practice 
Women’s initial response to being diagnosed with GDM  
As an introduction to the interview, women were asked how they responded when diagnosed with GDM 
and if that response changed over time. This enabled women to share their emotions and thoughts 
about GDM, to recognise how far they had come on their journey with GDM and provided an effective 
platform for discussing enablers and barriers to achieving optimal glycaemic control (Edwards 2013). 
Over a third of the women described their initial response as being shocked (21, 35%). 
“Shocked, I don’t feel like I have diabetes, as I feel normal and okay” (Belle 19A). 
Seven (11.7%) women described it as unexpected, while five (8.3%) women felt okay about the 
diagnosis. 
 “The initial gut reaction is like, oh my God, I did not expect this and what does this mean for my 
baby?” (Karen 09A). 
“I felt okay, because I know lots of Asian people, my friends around, they are pregnant.  And a lot of 
Asian women they very, very easily get diabetes, pregnancy diabetes.  So, I am prepared.  I am okay” 
(Casey 01A). 
The remainder of women described their initial response as being disappointed (4, 6.7%), gutted (3, 
5%), annoyed (3, 5%), upset (3, 5%), guilty (3, 5%), devastated (3, 5%), defeated (2, 3.3%), freaked out 
(2, 3.3%), angry (2, 3.3%) miffed (1, 1.7%) and heart-broken (1, 1.7%). 
 “I think disappointing, because my diet’s pretty clean anyway.  In that sense, it was disappointing” 
(Sian 11A). 
“Can’t be true, gutted, made them do another test, otherwise I would not do the treatment” (Larissa 
01B). 
Women’s response to living with GDM at the time of the interview 
Women at the time of the interview had been living with GDM for an average of 6.8 ± 2.3 weeks (Table 
5.3). Most of the women commented that they had moved on from their initial response (49, 81.7%). 
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They accepted the diagnosis as ‘okay’ because it would only last a finite time, but did not like the focus 
on the numbers of their glycaemic targets, their CBG results, weight gain and 90th percentile of fetal 
growth. 
“It’s hard because we have to change our routine, we have to change our food patterns and all those 
sort of things, changing our life to be frank, but when it comes to the reality, that makes you know, a 
huge difference, in our life, so it’s a big change, a big challenge but we have to accept it, even though 
the numbers run my life but we have to do the things. The other good thing after my delivery, it will go 
away” (Anna 07). 
 “It’s quite overwhelming in the beginning you kind of realise now that it’s not as big it kind of first 
seems. You just kind of adjust to it I guess and then its ok, always have to keep a look out for the 
numbers though” (Collette 09B). 
Theoretical Domains Framework – enablers and barriers 
Following Braun’s (Braun 2006) (Table 5.2) thematic content analysis, the emerging themes were 
categorised into the TDF domains assigning the themes with meaningful text to one or more of the 14 
theoretical domains (Michie 2008; Cane 2012) (Table 5.1) for enablers and barriers identification.  The 
results are reported for each of the study questions. The 10 categorised domains, their definitions and 
identified enablers and barriers from women with GDM are listed in Tables 5.4 to 5.6. 
What is it like for a woman to monitor her CBG concentrations? 
The themes emerging from the interviews from women with GDM for the first research question ‘What 
is it like for a woman to monitor her CBG concentrations?’ were categorised within nine out of the 
possible fourteen TDF domains. These were: Knowledge, Skills, Beliefs about capabilities, Beliefs about 
consequences, Memory, attention and decision process, Environmental context and resources, Social 
influences, Emotion and Behavioural regulation (Table 5.4). The domains represented most strongly in 
the interviews in the context of this question were: Beliefs about capabilities, Social influences and 
Emotions. 
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Table 5.4: Enablers and Barriers for women with GDM to monitor their CBG concentration 
Domains and Definitions  Enablers Barriers 
Knowledge 
Refers to a woman knowing her glycaemic targets and 
procedural knowledge of how to test accurately 
Glycaemic targets on: 
- sticker on the recording booklet  
- post-it notes on work computer 
- mobile phone notebook 
- visual step-by-step pamphlet 
- list how to perform CBG testing 
- different glycaemic targets to previous pregnancy 
- unable to read the ‘how to do it list’ in 
  first language 
- no visual images of how to perform 
  CBG testing 
Skills 
Refers to a woman’s ability to perform the CBG testing, working 
the glucometer correctly and documenting results and 
completing a food diary 
Techniques for CBG flow: 
- alternating warm fingers & hands 
- not using soap 
- pricking on side of finger pads 
 
Food diary documenting 
- no apps available for recording CBG results 
- food diary writing space too small 
- food diary not in first language 
- not knowing how to go back on glucometer 
Beliefs about capabilities 
Refers to a woman’s beliefs about her capability  
to perform, control and monitor her CBG concentration 
- can-do attitude 
- perceived control of GDM 
- in control of CBG testing  
- capable of interpreting CBG 
  results and adjusting food intake  
- can’t-do it attitude, too difficult 
- belief that it is not necessary to test regularly 
- perceived lack of control 
Beliefs about consequences 
Refers to a woman’s expectations about optimal  
CBG control 
Anticipated positive consequences:  
- adhering to glycaemic targets will 
  control GDM 
- secure healthy future for the baby 
- baby will be a normal size 
- belief future health will be better 
- belief family health will be better 
Anticipated negative consequences:  
- fingerpicks damage finger pads, too 
  difficult to play the piano or guitar 
- testing and controlling CBG did not work last time 
 
Memory, attention, and decision process 
Refers to a woman’s ability to remember when and decide 
where, to perform CBG testing 
- mobile phone alarm reminder 
- setting timer on microwave 
- dedicated bag ready access to 
  glucose testing equipment 
- able to decide where to do CBG 
  testing 
- forgetful 
- no reminder plan in place 
- unable to think outside the square 
- concern for doing CBG testing 
  outside the home 
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Domains and Definitions  Enablers Barriers 
Environmental context and resources  
Refers to a woman’s access to equipment  
and to a health professional when unsure  
about results 
- free resources for CBG testing 
- phone access to diabetes midwife 
- booklet fits into glucometer bag 
- pharmacist teaching CBG testing 
- group teaching sessions for 
  learning CBG testing 
- costs of resources needed for CBG testing 
- no phone access to diabetes health professionals 
- booklet too big for glucometer bag 
- health professional not believing results 
Social influences 
Refers to a woman’s social interactions for CBG monitoring and 
maintaining optimal CBG control 
- supportive and engaged social  
  interactions 
- do it wherever, no concern 
- work colleagues remind them 
- provide healthy food at work 
- social pressure and loss of choice 
- worried about performing CBG testing 
  in public, being judged 
- being told to leave restaurant for CBG testing 
- work demands, meetings, unable to 
  stop work for CBG testing 
Emotion 
Refers to a woman’s reaction/feelings to monitoring and 
maintaining her CBG concentrations 
- privilege to have been diagnosed 
- enabled learning a new skill that  
  directed positive lifestyle changes 
- fun doing everyone’s CBG level 
- not as painful as anticipated 
- anxiety, scared, needle phobia 
- stress to remember doing CBG testing, 
- feeling guilty when forgotten 
- focus on numbers not the woman 
- not enjoying reading  
Behavioural regulation 
Refers to a woman’s focus on self-monitoring effectively and 
planning how to incorporate this  
into her daily life 
- action plan to monitor CBG 
- motivated by the baby to monitor 
  CBG regularly 
- documenting honestly 
- sharing on social media glycaemic 
  target achievements 
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Knowledge 
The domain ‘Knowledge’ in the context of monitoring optimal CBG control refers to a woman knowing 
her glycaemic targets and procedural knowledge of how to test accurately. Nearly all women knew their 
glycaemic targets and most understood the importance of adhering to them, enabling the process of 
performing routinely CBG testing. Enablers to assist this knowledge were identified as having 
information aids, such as stickers at the front of the recording booklet displaying the glycaemic targets, 
post-it notes for a work computer and glycaemic targets recorded on their mobile phone. Using a visual 
step-by-step pamphlet to ensure correctly obtaining capillary blood for glucose testing enabled 
procedural knowledge retention.  
“I actually understood why I had to do this air tight control, so I do it. The sticker on the booklet 
reminds me of my numbers and the booklet in glucometer with pictures reminds me what to know” 
(Erin 04B). 
Women reported barriers as being confused by different glycaemic targets compared to their last 
pregnancy with GDM and information that would have aided their procedural knowledge not being 
provided in enough visual detail or the information was not in their first language. 
 “The consultant gave me something that I haven’t looked at but it was ‘I quit sugar’ and I wouldn’t 
recommend that, as it sounded like sugars poison and all this kind of stuff. Pictures would be so much 
better” (Alice 10A).  
“I think it’s important to give us something to take away, and some bullet points or pictures, now that 
you are diagnosed, these things you need to do, why we are doing it and in the right language” 
(Christina 15A). 
Skills 
The domain ‘Skills’ refers to a woman’s ability to perform the CBG testing, working the glucometer 
correctly and documenting results and completing a food diary. Women identified various effective 
techniques to enable good capillary blood flow and reducing discomfort. This included not using soap 
for washing hands (as a belief that soap contains sugar), pricking on the edge of the finger pads, placing 
sufficient pressure on finger pads, wiping the first blood spot off and alternating of warm fingers and 
hands. Keeping a food diary helped women to make a connection between what they ate and what the 
test results meant, encouraging the up-keep of both regular accurate testing and recording in the food 
diary. 
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“Just pressing your fingers firmly against the end of the pricky thing on the side, because no one 
wants to do it twice. Next time either side of the next finger and then keep going to the next finger, all 
makes it less painful and better blood drops” (Toni 03B). 
Barriers included having a needle phobia and women feeling frustrated that a phone app for recording 
CBG results was not available or not being able to document into an electronically food diary. Over half 
of the women wanted instructions for CBG testing in their first language, the opportunity to record their 
food diary in their first language and more writing space in the hard copy food diary. Some women did 
not know how to go back on the glucometer to check their previous results. All these barriers prevented 
women from either mastering or performing regular glucose testing and recording their food intake. 
 “To be honest, the diabetes books are quite small to write in what you are eating and that can be off 
putting, for me I found anyway. It would so much better to have everything on my phone, like a phone 
app for the blood sugars and like a kind of electronic diary, everything else is on my phone, then I 
would do it more regularly I think” (Janet 07A). 
 “I think they give you a lot of information that.... I mean it’s good to have. But then again, yeah, I’m 
probably not much of a reader. I just like to speak to thing, maybe give me a YouTube clip [link], and 
have picture that remind me how to, that would definitely help especially if it’s your first language” 
(Larissa 01B) 
Beliefs about capabilities 
‘Belief about capabilities’ refers to a woman’s belief about her capability to perform, control and monitor 
her CBG concentration. The most common reported constructs were self-confidence and having control 
to help women to do their CBG testing without concerns, alter their food intake accordingly and 
developed a ‘can-do attitude’. Barriers were identified as having a ‘can’t-do’ attitude, believing that it is 
not necessary to test their CBG concentrations regularly and a feeling of not being in control. 
 “The dietician and the doctor were very impressed with my numbers, and that made me feel amazing 
and proud, and chuffed with myself. I can do this” (Anneri 14B). 
 “It’s too hard, I can’t do it” (Yoko 15B). 
Women who had firm beliefs about their capability reported how they were not concerned to do the CBG 
testing in public or at work and were highly motivated to do the testing at the appropriate times, even if 
it meant interrupting what they were doing. 
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 “I am good at this”, do it always on time. I do it when I am commuting on the bus or when I am 
attending mass. Even though I am in the middle of kneeling and everyone is quiet, I will just quickly 
get out my kit and quickly prick myself even though it may make some noise” (Karroll 05B). 
Women with uncertain beliefs about their capabilities became increasingly scared to do their CBG 
testing. They had to repeat tests more often, as there was either not enough blood for the test or the 
glucometer would show error messages, which led them to test less often than recommended, or not at 
all. Women’s feelings voiced of not being in control, as the CBG concentrations directed their food, 
exercise and/or medication intake, contributed to low self-belief in their capabilities. 
 “Yes, I get frustrated with it and then the glucometer does not work.  Yes, I have my days where I’m 
tired and I’m sick of it, and belief I can’t do it. I don’t do my blood tests then, and I don’t manage my 
food. It just runs my life” (Karrena 17B). 
Beliefs about consequences 
This domain refers to a woman’s expectations about optimal CBG control. Participating women reported 
that anticipated positive or negative consequences strongly influenced their actions; whether they tested 
their CBG concentrations, adhered to the glycaemic targets, changed their food intake and physical 
activities, or took their medication.  This domain was represented strongly throughout the interviews.  
 “They did tell us like that if mums are not taking care, there may be a chance for the baby to have the 
diabetes when the baby is a teenager or when it is little, that was a good thing, that is the one reason 
which I’m more careful, which I don’t want to give anything to my kids which is from me you know, 
whatever the life brings to them that’s their luck you know, but I don’t want to give anything from me to 
my next generation, so you know, if I can be more careful about that then I have to, totally changed 
everything and never forget to do blood sugars” (Anna 07). 
 “Well, can I play the guitar with so many holes in my fingers? Who wants that? So, pricking only 
alternative days makes and not on my left hand is sort of ok, but if I have to play in church, I don’t do it 
the week before” (Yasmin 01). 
Memory, attention, and decision process 
This domain refers to a woman’s ability to remember when, and decide where, to perform CBG testing. 
Women identified memory aids, such as alarms on mobile phones, setting a timer and having a 
dedicated bag for all the CBG testing equipment to aid their memory and the decision process of 
performing the test, regardless of where they were. Forgetfulness was identified as a perceived barrier 
for doing regular CBG testing, in particular when away from their home, causing considerable frustration 
and anger for some women. 
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 “Yeah husband reminds me at night most of the time (Amali 16). I get my partner to ring me and then 
do it. A couple of times when I’ve been driving I did it while I was driving” (Angela 15). “I keep my 
alarm on the phone, as otherwise you know, I can’t remember the particular time” (Hana 11B). “Just 
put an alarm in my head and watch my clock every couple of hours” (Neethu 02). 
 “I do it anywhere… And they will ask me what are you doing? And that is the time I start talking to 
them about gestational diabetes and I say, ‘you know I have gestational diabetes and I have to do 
this’. And then about at the same time I am like a tool for everybody to find out about diabetes and 
they learn about it” (Karroll 05B). 
I tend to stress about it for the first half an hour after a meal, that I’ve got to remember, and then it just 
slips your mind some days, so frustrating (Erin 18B). 
Environmental context and resources  
‘Environmental context and resources’ refers to a woman’s access to equipment and to a health 
professional when unsure about results. The most commonly reported barrier was the cost of resources, 
no phone access to a health professional when the woman was unsure about results and health 
professionals not believing the women’s documented CBG results. Different sizes of CBG recording 
booklets were either experienced as enablers or barriers. Some women found it frustrating that their 
CBG recording booklet did not fit into the glucometer bag, which meant it had to be carried separately. 
This meant for some women CBG results were not recorded when outside their homes.  
In New Zealand women receive a free glucometer, blood lancets, and testing strips from the diabetes in 
pregnancy services at their local hospital or they are given a prescription for these resources to be 
picked up from their local pharmacy. While some women could pay the costs of the prescription fee, 
some women found it too difficult over time and then did not continue CBG testing. 
“It’s definitely more expensive … and then prescriptions fees for the testing bits. It all adds up and you 
want to be sure it’s worth it. Some weeks it is not” (Jean 16B).  
 “Yeah, like insinuating that I eat overnight, because my levels are high in the morning, like no, I am 
busy sleeping actually, but yeah that I struggled with, not being believed by the diabetes consultant. 
Why should I continue testing then?” (Alice 10A). 
Social influences 
In the context of this study the domain ‘social influences’ refers to a woman’s social interactions for CBG 
monitoring and maintaining optimal CBG control. Engaged social interactions, such as work colleagues 
asking after CBG concentrations and reminding women to do their testing, as well as providing healthy 
food choices and stopping meetings to provide opportunity for the women to do their testing were 
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enablers. Barriers were being told to leave the restaurant (or other public places) when performing CBG 
testing and being unable to stop work for the testing. Women working as managers, bus drivers, factory 
workers, nurses and doctors in particular found it difficult to adhere to the post-prandial timeframes for 
CBG testing, as there was often little opportunity to stop their work. 
 “Well, at work they gave me private corner to do it [CBG testing] and they are really interested what 
my levels are. My colleagues remind me. So helpful” (Yoko 15B). 
“I feel bad if I don’t do it, but yeah it’s usually as I’ve just been somewhere where I feel I couldn’t do 
it, or I can’t stop at work, especially now that I had the experience of being told to leave the 
restaurant and they think you are a druggie scum bag” (J.M.T.J.M.P. 14). 
Emotion 
The domain ‘Emotion’ in this study refers to a woman’s reaction and feelings to monitoring and 
maintaining her CBG concentrations. Some women felt it was a privilege to have been diagnosed with 
GDM as it meant they learnt new skills that directed positive lifestyle changes. The sense of 
achievements in mastering CBG collection and staying within recommended glycaemic targets enabled 
optimal glucose monitoring. This led to testing family and friends without understanding that this would 
be recorded on the glucometer as their results.  
 “It’s been a good adjustment, kind of a joy, I learnt how to test blood sugars and I am living healthy, 
it’s kind of like a good stepping stone to continue that healthy life. It’s kind of giving you this mirror 
glass into the future that you could have diabetes in the future (Esther 07B). I'm brave, I never forget 
to do the pricks” (Raynia 09) 
Barriers included emotions of stress and being scared to do the capillary testing at the appropriate times, 
especially where a needle phobia existed. The constant focus on the numbers discouraged some 
women from performing regular CBG testing. 
“Ah yes, I am scared, first of all ‘cause I hate needles. One thing, it should be different that putting like, 
when we test our diabetes, the needle we put in our fingers, it’s very painful, like all my fingers have 
holes, because every day I prick and then I stop. So, there should be different type of thing we can 
measure the diabetes” (Shairin 11).  
“Um, I guess, having had that experience before as part of my medical training, I kinda knew what it 
was like [being a doctor], but I think it’s the repetitiveness, focusing on numbers and having to do it so 
many times a day, I mean I wince at the lancet, when it goes off as its getting to the point where it’s 
actually getting, you know, traumatised by the pain that comes from the pricked fingers” (Christina 
15A). 
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Behavioural regulation 
‘Behavioural regulation’ refers to a woman’s focus on self-monitoring effectively and planning how to 
incorporate this into her daily life. Women who decided to have all their testing and documentation 
equipment in a dedicated bag and leaving it at dedicated place at home indicated how helpful this was 
to undertake the testing regularly. Sharing their glycaemic target achievements on social media, with 
overseas GDM Facebook groups, and thinking of the health of their baby were identified as motivators 
to regulate behaviour.  
 “You just put yourself into a routine. You just have to, for the baby, and have all your gear in a bag, 
ready to be used anytime and anywhere” (Sabrina 05). 
“Yes, having it all planned helps. Every morning at 10.30 I have 30 minutes’ walk.  And also after 
afternoon tea and dinner I have 30 minutes walking.  It’s very good, and I feel I have more energy” 
(Casey 01A). 
What affects a woman’s CBG concentration and how does she maintain optimal glycaemic 
control with this knowledge? 
The themes emerging from the interviews from women with GDM relating to the second research 
question ‘What affects a woman’s CBG concentration and how does she maintain optimal CBG control 
with this knowledge?‘ were categorised into five of the theoretical domains. These were: Knowledge, 
Beliefs about consequences, Environmental context and resources, Emotion, and Behavioural 
regulation (Table 5.5). The domains: Belief about consequences, Environmental context and resources 
and Behavioural regulation were represented most strongly in the context of this question.  
Knowledge 
In the context of the second research question the domain ‘knowledge’ refers to a woman’s 
understanding of what affects her CBG concentrations. Women who knew the differences between 
carbohydrates, proteins, and fats, could read food labels and understood how exercises affected their 
blood glucose concentrations were more likely to embrace dietary and exercise changes and continue 
with regular blood glucose monitoring.  
 “You just fill it up with other stuff, like veggies, depends on what you eat regularly, it you eat KFC all 
the time then your buggered” (Danielle 06) 
“Yeah, so whenever I do my walking after meal, my blood sugar gets low right away, but if I snuggle in 
the bed after a meal, the blood sugar is high, that’s what I notice” (Belle 19A). 
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Barriers identified included not knowing how to read food labels or how food intake and activity levels 
impact on glycaemic control or unable to read the information provided, as it was not in the woman’s 
first language. Two women knew how to increase their subcutaneous insulin, so they could continue 
eating their favourite sweets and carbohydrates and not be concerned about any behavioural lifestyle 
changes. 
“I don’t really understand what these food labels mean. I eat the same stuff anyway, not much use 
knowing it” (Jisha 04). 
 “So, I ask them, can I just have some insulin, and they say, "Okay".  They give me the long-term 
insulin and now I can have sweets, but my levels are ok” (Casey 01A). 
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Table 5.5: Enablers and barriers for women with GDM understanding what effects their CBG concentrations 
Domains and Definitions  Enablers Barriers 
Knowledge 
Refers to a woman’s understanding of what  
affects her CBG concentrations 
- understanding the difference between carbohydrates, 
  proteins, and fats 
- ability to read and comprehend food labels 
- able to understand how physical activity or inactivity 
  affects their CBG concentrations  
- lack of understanding which foods and exercises raise the 
CBG concentrations 
- not knowing how to read food labels 
- knowing how to increase insulin to eat favourite 
  sweets 
Belief about consequences 
Refers to a woman’s expectations about what 
affects her CBG concentration 
- eating the same food every day for optimal control  
- using commercially available, pre-assembled ready for 
cooking, health food bags for optimal control 
- hearing other women’s stories encourages  
  anticipated regret 
- regular activities easy to incorporate into daily life and 
ensures healthy baby 
- belief only medication controls CBG concentrations 
- belief that exercises have no effect on CBG concentrations 
- belief that physical activity can cause pre- term labour 
Environmental context and resources 
Refers to a woman’s access to food, exercise 
equipment and health professionals 
- access to dietitian and group sessions 
- food diary and discussion 
- food costs are less (no fast foods) 
- vegetable garden 
- recipes on social media 
- stickers identifying pantry food which are suitable  
- being organised 
- appropriate food available when not at home 
- access to exercise equipment (bicycle, tread mill) 
- family and children creating motivating resources 
- dietetic service unavailable  
- transport and time issues 
- not documenting a food diary or not knowing about it 
- health professionals do not discuss content of food 
  diary 
- food is more expensive (fruit, special bread) 
- no ethnic food options included 
- unavailable professional assessment for exercise or physical 
activities 
- easy access to sugary food and drinks 
Emotions 
Refers to a woman’s reaction/feelings to what 
affects her CBG concentrations 
- excited to understand the link between food and 
  exercise and CBG concentrations  
- stressed about trying hard but not able to achieve 
  optimal CBG concentrations 
- feeling hungry most of the time 
Behavioural regulation 
Refers to a woman’s focus on self-monitoring 
effective food intake and exercise and planning how 
to incorporate this into daily life 
- self-monitoring with food diary 
- developing an activity diary 
- calling exercise physical activity  
- calling diet food intake, or what to eat 
- action plan for physical activities 
- creatively incorporating family exercises  
- family and children creating resources together 
- dislike of exercises 
- medication and food is enough to maintain CBG  
  concentrations 
- stress or excitement increases CBG concentrations, 
  too hard to control 
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Belief about consequences 
The ‘Belief about consequences’ domain refers to a woman’s expectations about what affects her CBG 
concentration. Several women started eating the same food every day. Some women ordered weekly 
commercially available, pre-assembled ready for cooking, health food bags, as this enabled women to 
keep their CBG concentrations within the recommended glycaemic targets. While this method of food 
intake was identified as an enabler by the women, it is unclear how effective long-term lifestyle changes 
would be sustained, as the women were not planning to eat in a similar way after the baby was born.  
Further enablers were identified as hearing other women’s stories about GDM, which encouraged 
anticipated regret (‘I know if I do this I will regret it, therefore I will not do it’). This meant women were 
diligent about routinely exercising and following their diabetic diet.   
 “I focused on it’s a short period of time, eating the same every day, you can get through it, and after 
pregnancy it’s going to be so awesome that you can eat what you want to eat, you focus on the fact 
that it’s not forever, I always think of trying to push a baby out that is too big, that’s an incentive, they 
can dislocate if it’s too wide, so I just focus on every little bit, makes a difference, that’s what I picked 
up from the obstetrician, you might go “oh this biscuit won’t hurt” but yeah it makes a difference, no 
option but do it consistently. I know of women who so regretted that they did not do it properly” (Annie 
16A). 
Women in the study who believed that exercises had no effect on CBG concentration were not likely to 
engage in any physical activity. Women who believed that too much physical activity may cause pre-
term labour would do occasionally a short walk. The belief that the diabetes medication would control 
CBG concentrations prevented women from engaging in understanding the effects of food intake and 
glycaemic control. 
 “I’ve never tested after doing exercise, yeah, so I couldn’t say, I don’t belief it makes a difference, so 
don’t do it really” (Alice 10A). 
 “I don’t want my baby to come before 35 weeks, you know, I’m scared it comes early, more exercise 
makes it too early, but I will walk or swim after that time if it makes a difference” (Anna 07). 
 “I feel better now that I’m on the right medication. My sugars are well controlled and I don’t need to 
worry about eating and walking” (Erin 04B).  
Environmental context and resources 
In the context of this research question this domain refers to a woman’s access to food, exercise 
equipment and health professionals. Women in this study, who had access to group or individual 
sessions with a dietitian, could understand and alter their food intake and keep a food diary. Being taught 
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CBG testing by a pharmacist or by a diabetes midwife in a group session was experienced as an enabler 
by most women interviewed. Having easy access to exercise equipment, such as a tread-mill or 
stationary bicycle, enabled women to exercise if they were unable to leave the house. Other enablers 
were identified as ensuring ‘right’ food in the pantry, having access to a vegetable garden, lower food 
costs, less fast food meals, and easy phone access to a diabetes dietitian. 
 “Walking through a personalised diet is really helpful, and not just a mass-produced ‘try these things’ 
and straight access to the dietitian via phone or email. I know what I can and can’t eat now. Keeping a 
food diary has been good” (Anneri 14B). 
 “I bought a walker machine [treadmill] after being diagnosed with GDM to exercise. Every time I eat I 
do it. It is working well” (Belle 19A). 
Barriers were identified as lack of or limited access to, resources and health professionals. This included 
lack of access to transport to attend group or individual sessions with a dietitian, no considerations for 
ethnic food options, not being able to discuss the effects on glycaemic control in the woman’s first 
language, health professionals not looking at the food diary, higher food costs and unclear or no 
guidance about physical activities/exercises and its effect on CBG concentrations.   
 “Not sure if some food puts it up, it’s possible, if I did a food diary I guess I could look it up, but that’s 
a bit tedious” (Toni 03). 
“I didn’t read it, because it’s easier for him to read in English about what types of food you need to eat, 
it should be in colour and pictures. He doesn’t like to read either, but when you give me a colour 
picture, these are the things you need to eat a lot, and these are things you need to not eat in colour, 
that would make a difference, then I would understand” (Zeinab 12A). 
“I don’t do much exercise because I am working all the time. Don’t know how to fit it in. Maybe 
someone needs sit down with me and show me how and when?” [to exercise] (Fiona 02A). 
Emotions 
The domain ‘Emotion’ refers to a woman’s reaction and feelings as to what affects her CBG 
concentrations. Enablers most commonly reported were positive emotions, such as being happy and 
excited to understand the link between food intake and exercises and glycaemic control. Barriers most 
commonly reported related to negative emotions, such as being stressed about not seeing any 
difference in glycaemic control despite trying hard to follow the dietary guidelines and feeling hungry 
most of the time when trying to achieve optimal glycaemic control. 
363 
“There are days when I am so worried that I am eating the wrong food and might hurt my baby, where 
I have checked myself 12 times just to see where I am staying at because the strict diet does not 
make a difference [to CBG concentrations], maybe I should just stop altogether? If you don’t know, 
you don’t know” (Aroha 10B). 
“…but if I’m too hungry then I don’t care, which is quite often” (Elizabeth 08B). 
“I was kind of worried about what the dietician was going to say because I did have a few highs like in 
my first week of trying and I remember just feeling so overwhelmed and walking in she said, ‘are you 
OK?’ and I just burst into tears, it was just one of those things. She said: “Oh my goodness, I’m not 
going to tell you off or anything, we'll work through it” (Collette 09B). 
Behavioural regulation 
The domain ‘Behavioural regulation’ refers to a woman’s focus on self-monitoring effective food intake 
and exercise and planning how to incorporate this into daily life. Women who had action plans in place 
for physical activity and food intake, for example to do 20-minute exercise after each main meal, bathing 
the toddler after the evening meal, playing ball games with the family, and starting a food and activity 
diary, found it easy to incorporate the changes into their daily life. Renaming exercise as physical activity 
and diet as food intake made a significant difference for women’s confidence level to self-monitor these. 
 “Oh, you will laugh, but I don’t try to vacuum the floor, I brush the floor every night time on my knees 
with a brush and shovel, because I can’t go out and I get cold. My levels are good when I do this. No 
good levels when I do not do it” (Jisha 04A). 
Barriers to changing and regulating behaviour were mainly the dislike of having to exercise or to focus 
constantly on what to eat. Women noted that both stress and excitement would increase CBG 
concentrations and this discouraged effective self-monitoring.   
 “For the baby shower, I was so good with the food but my levels were still high, it’s not just stress but 
also excitement that puts it up. So, what use is that then not to feel happy. May as well not do the 
testing” (Raman 17B). 
What support have women found helpful/not helpful in learning about and maintaining 
CBG control? 
The key themes emerging from the interviews for women with GDM relating to the third research 
question ‘What support have women found helpful/not helpful in learning about and maintaining CBG 
control?’ were categorised into four of the theoretical domains. These are: Beliefs about consequences, 
Reinforcement, Environmental context and resources and social influences (Table 5.6). The domains 
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Environmental context and resources and Social influences were represented most strongly in the 
context of this question. 
Beliefs about consequences 
The domain ‘Beliefs about consequences’ refers to a woman’s expectation to sharing her diagnosis of 
GDM with others. Women shared their diagnosis and management of GDM with significant others and 
work colleagues when they believed this would gain them support for learning more about and 
maintaining optimal glycaemic control. Interestingly, when women perceived that sharing their diagnosis 
would generate a judgement and/or unhelpful advice they would not ‘tell’. Some women did not ‘tell’ 
because they felt protective towards their family members and did not want to worry them unnecessarily. 
This created a lonely place for some women. 
“It helps them to be more supportive if they know. I told them all. I don’t want them to bring sugary 
items when they visit” (Collette 09B). 
“Did not tell, as I am big and people will say, ah, yes, you are fat, that did it”  
(Jean 16B).  
“Did not tell parents and friends, as they get too worried, but a bit lonely and hard doing it without 
them” (Aliisa 02B). 
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Table 5.6: Enablers and barriers of support for women with GDM about maintaining optimal CBG control 
Domains and Definitions Enablers Barriers 
Beliefs about consequences 
Refers to a woman’s expectation to sharing 
her diagnosis of GDM with others 
- telling others about GDM diagnosis gains valuable 
  support 
 
Not telling others about GDM diagnosis because: 
- concern for other family members 
- being judged by family, friends and work colleagues 
- being told what and what not to eat 
Reinforcement 
Refers to a woman’s ability to reinforce skills 
and coping strategies for self-support in 
maintaining optimal  
glycaemic control 
- continuing with food diary, feeling better 
- photos of food eaten instead of written food dairy 
- self-rewards with non-food items 
- documenting CBG results  
- activities connected with family fun 
 
Environmental context and resources 
Refers to a woman’s ability to have access to 
learning resources and professional services 
for optimal glycaemic control 
- written information in first language 
- visual information 
- informative websites 
- partner and extended family able to 
  attend teaching or clinic sessions 
- work colleagues enquiring and providing healthy food 
  options 
- efficient clinic appointment system 
- health professional phone support 
- free health shuttle for appointments 
- hospital crèche 
- stickers with healthy GDM messages encourages 
  adherence to healthy food and exercises 
- health professional impatient 
- health professionals inconsistent with advice 
- not seeing the same health professional twice 
- long waiting times at clinic 
- not taught in first language 
- unable to write the food dairy in first language 
- no visual information available 
- website information random and scary 
- poor parking facilities 
- no transport available 
- unable to pay for petrol 
- no child care support 
- restaurants unable provide an ingredients list for meals 
- partner and extended family provide unhealthy meals 
Social influences 
Refers to a woman’s access to social 
interaction to learning/reinforcing  
optimal glycaemic control 
- social media (Facebook) 
- sharing recipes 
- group teaching 
- meeting other women with GDM 
- partner, family, and friend’s interest 
- work colleagues support 
- unsupportive family members and workplaces  
- no social media groups or support groups in NZ 
- not knowing anyone with GDM 
- unable to perform testing in public 
- told what to eat by family members 
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Reinforcement 
‘Reinforcement’ here refers to a woman’s ability to reinforce skills and coping strategies for self-support 
in maintaining optimal CBG control. Continuing with a written or creating a pictorial food diary (taking 
photos with a mobile phone camera), honestly and diligently documenting CBG results and rewarding 
glycaemic achievements with non-food items or activities (for example, going to the movies) were 
identified as enabling reinforcement of skills and coping strategies. Family activities such as family 
members guessing around the dinner table what the CBG concentrations will be before and after the 
meal, creating a graph for the fridge for charting CBG concentrations for all to view and using stickers 
to identify in the pantry/fridge which foods are healthy options for women with GDM to consume were 
further reinforcing enablers.  
 “It’s kind of a fun time.  My husband and my daughter guess what the number should be after I have 
done the pricking. If we are all right we reward us with going to the playground park with my daughter, 
she loves it and so do we” (BC 17A). 
Environmental context and resources 
The domain ‘Environmental context and resources’ refers to a woman’s ability to have access to learning 
resources and health professional services for optimal glycaemic control. Visual information, such as a 
food plate with portion sizes and access to informative websites about GDM were identified as enablers. 
Provision of a free health shuttle for clinic appointments, a hospital crèche for child care, an efficient 
appointment system reducing waiting times and partner and extended family welcomed at teaching 
sessions and clinic appointments contributed to women’s ability to perform CBG testing confidently and 
of feeling supported. Telephone access to discuss CBG results was available for most women and while 
only a few women used it, telephone access was considered a reassuring support. Provision of healthy 
food options by family and work colleagues was reported as a significant support. 
 “Yeah husband attending info sessions was good but next time not during office time, evenings or 
weekends would be better. The food plate was very helpful, but maybe more Asian food on it would 
help too” (Amali 16).  
Several women had experienced barriers to accessing learning resources and health professional 
services for optimal glycaemic control. These included health professionals being impatient and 
inconsistent in their advice; not seeing the same health professional twice; not being taught how to 
check the glucometer; long waiting times at clinic appointments; not being taught in their first language, 
being unable to write into their food diaries in their first language; having no transport to attend teaching 
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sessions or clinic appointments and poor parking facilities.  Of the women who searched for information 
through Google, some became scared and would have preferred guidance to visit a website with clear 
and supportive information.  Restaurants being unable to provide an ingredients list for meals on the 
menu was identified as another inaccessible resource.  Provision of unhealthy food by family and work 
colleagues was reported as a significant barrier. 
 “Google was a bit scary.  So, it’s better just to stay away from it and get your questions answered at 
the clinic. But that google information was in Russian, and that was good. Yeah, they need to tell me 
where to look on the internet. Same with menus from restaurants, their ingredients could be listed on-
line” (Lilly 18A). 
“I saw a registrar who seemed very junior and gave me quite conflicting information to what everybody 
else had given me.  So, I actually went back yesterday and saw a consultant, because I wasn’t happy. 
That improved things, but it took more time and to find a carpark is nearly impossible” (Erin 18B). 
“He says, “Just eat whatever you want”, because he likes sweet stuff”. Hard not to give in” (Tara 19B). 
Social influences 
The domain ‘Social influences’ refers to a woman’s access to social interaction to learning/reinforcing 
optimal blood glucose control. Some women joined an American Facebook group for women with GDM. 
While the glycaemic targets were different for the American counterparts, women in this study enjoyed 
swapping recipes, sharing tips about CBG testing, celebrating successes of achieving and maintaining 
glycaemic control and providing encouragement when glycaemic challenges were shared. Family and 
friend’s interest in all aspect of glycaemic control and meeting other women with GDM contributed to 
feeling supported and reinforcement for optimal glycaemic control. 
 “So, I soon realised, after joining a [American] Facebook group, that most people struggle with 
cereals.  So, I removed the cereal and just went to a two-egg breakfast, and that just evened it out.  
So, then I felt a bit better again” (Anneri 14B). 
“Yes, in the morning, if I want to sleep in then he will do for me the fingerpicks”  
(Shairin 11). 
Participating women identified social disconnections as barriers for learning and reinforcing optimal 
glycaemic control. This included unsupportive family members and workplaces, unavailability of a 
support group for women with GDM in New Zealand, on-line or face-to-face, being judged in public and 
being constantly’ told what to eat and what not to eat by family members.  
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 “…I guess that’s why I eat my chocolate with my yoghurt. I like chocolate, I’m going to have 
chocolate. You tell me I can’t, then I’m not going to listen. And I’m going to want it more and I’m going 
to binge eat it and don’t worry about my levels” (Aroha 10B). 
The results from the three questions explored in this study identified enablers and barriers for women 
with GDM representing their experiences of monitoring CBG concentrations, what affects this monitoring 
and what supports have been helpful for them to achieve optimal glycaemic control.  As a summary, 
Table 5.7 outlines some considerations for practice and research that may be useful for health 
professionals and diabetes in pregnancy services providing care for women with GDM.  
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Table 5.7: Considerations for practice and research 
Practice considerations 
Monitoring for optimal glycaemic control 
Research considerations 
Monitoring for optimal glycaemic control 
• Enable women with GDM to attend group teaching for CBG  
testing and interpretation, and include women who have had GDM to share their stories. 
• Discuss individual strategies for regular CBG monitoring, food intake and physical activity. 
• Encourage partner and family attendance at any clinic or teaching sessions  
(may need to be offered at evenings or weekends). 
• Provide information relating to GDM in a woman’s first language and/or more visually, 
including ethnic food suggestions. 
• Investigate the possibility of community pharmacists’ involvement in teaching  
CBG testing. 
• Explore opportunities for companies to create phone Apps, e.g. for electronic food 
and activity diaries, recording of CBG results and medication intake. 
• Do phone apps have an impact on optimal glycaemic control for women with 
GDM? 
• Does a name change for GDM reduce anxiety in pregnant women? 
Dietary intake and exercise for glycaemic control Dietary intake and exercise for glycaemic control 
• Enable easy access to a diabetes dietitian with diet recommendations tailored to an 
individual woman’s context (cultural, financial, and emotional). 
• Engage in meaningful discussions about the content in a food  
diary and provide multi-modal opportunity for the woman to record the food diary 
 in her first language or enable mobile phone photo collection of food intake. 
• Regularly address hunger for women with GDM. 
• Encourage a physical activity diary alongside the food diary. 
• Consider engaging a physical therapist for clear in-depth assessment and guidance  
of exercise that women can incorporate into their daily life.    
• Does keeping a physical activity diary impact on glycaemic control? 
• Does engaging a physical activity therapist contributes to the understanding and 
up-take of physical activity for women with GDM? 
• Why do women with GDM seem to be hungry despite quality dietary 
recommendations? 
• What affect has self-imposed dietary practices by women with GDM during their 
pregnancy on long term lifestyle behaviour? 
 
Support for optimal glycaemic control Support for optimal glycaemic control 
• Provide free CBG monitoring equipment, health shuttles and child care when attending 
clinic appointments and reduce clinic waiting times. 
• Consider face-to-face support groups for women with GDM. 
• Consider setting up a social media group for women. with current GDM (e.g. Facebook). 
• Include regular mental health assessment for women with GDM. 
• Provide direct phone access to multi-disciplinary health professionals. 
• Limited research available for regular mental health assessment for women with 
GDM. 
• Limited research about the effect of a GDM diagnosis on partners and family 
members. 
• Limited research on how partners and families can best support a woman with 
GDM in their context. 
• Does social media or face-face group support make a difference for women with 
GDM for maintaining optimal glycaemic control? 
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5.2.4 Discussion 
Our results highlight the complex interactions between women with GDM monitoring their CBG 
concentrations, their understanding of the link between dietary intake, exercise and glycaemic control, 
having stress-free access to health care providers and resources, and their social context and support. 
The study used interviews and the validated TDF to determine the enablers and barriers women with 
GDM experience to achieve optimal CBG control. We categorised emerging enablers and barriers into 
a total of nine domains across three study questions. These were: Knowledge, Skills, Beliefs about 
capabilities, Beliefs about consequences, Reinforcement, Memory, attention and decision processes, 
Environmental context and resources, Social influences, Emotion and Behaviour regulation (Table 5.4 
to 5.6). Through our iterative process we identified when no new themes were emerging within the TDF 
domains, thus ensuring that data saturation had been achieved (Sanders 2010; Wright 2011). Transcript 
analysis revealed a range of enablers and barriers that impact on a woman’s ability to achieve optimal 
glycaemic control. 
The initial response of women being diagnosed with GDM was predominantly of being shocked. At the 
time of the interview the women had generally accepted the diagnosis, knowing it would only last a finite 
time and were motivated by making a difference for the baby. Maternal shock, fear and anxiety 
associated with a diagnosis of GDM have been reported in the literature with a trend towards acceptance 
as the pregnancy progressed (Persson 2010; Collier 2011; Hirst 2012; Morrison 2014; Parsons 2014; 
Kaptein 2015). Kalra and colleagues (2013) suggest that these findings support an onomastic (re-
naming) opportunity, arguing that the phrase gestational diabetes can cause significant psychosocial 
morbidity. Alternative names suggested for GDM were Gestational Dysglycemia of Nutritional Origin 
(GDNO) or Pregnancy Related Intolerance to Glucose (PRIG). This indicates further research is needed 
to determine if an onomastic change would achieve less maternal psychosocial morbidity. Some women 
in our study, once they overcame the initial shock, thought that it was a ‘privilege ‘and a ‘good thing’ to 
have been diagnosed with GDM, as this supported change to a healthier lifestyle and provided them 
with skills such as being able to read and understand food labels. This advocates for an opportunity for 
promoting lasting lifestyle changes during the remainder of the pregnancy. Other studies reiterate these 
findings, and found that for some women with GDM, the knowledge gained enhanced the motivation 
and self-efficacy to initiate lasting lifestyle changes (Evans 2005; Devsam 2013; Morrison 2014). 
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While most women accepted that they had GDM and adapted to the change, many women disliked the 
change of focus for their pregnancy to numbers of CBG concentrations, glycaemic targets, 90th 
percentile for fetal growth and maternal weight. This contributed to a feeling of reduced control, which 
exacerbated emotions and created barriers for some women. This meant a few women in the study did 
not continue with or reduced their self-monitoring of CBG concentrations, decided they were too busy 
to attend some of the clinic appointments, refused referrals for serial growth scans and were less 
committed to adhere to diet recommendations. Negative feelings acting as a deterrent to intervention 
up-take has been reported for women with GDM by some studies (Razee 2010; Parsons 2014; Carolan-
OIah 2016). This suggests that emotional support and mental health assessments need to be an 
imperative part of heath care for women with GDM. 
Monitoring for optimal glycaemic control 
Nearly all women in our study knew their optimal glycaemic targets and the importance to adhere to 
them. Despite this knowledge, participating women reported that this did not necessarily mean they 
would self-monitor their glycaemic control as advised. Responses varied on how they felt about their 
self-monitoring skills, if they had access to equipment, and their context, evident through the most 
strongly represented domains of Belief about capabilities, Emotions and Social influences. Women were 
less likely to do the CBG testing or stopped altogether for a variety of reasons. These included being 
scared and unsure about pricking their finger for CBG testing, playing a musical instrument, believing 
high CBG concentrations would harm their baby, being asked to leave a restaurant when testing, not 
being able to take a break to perform the test because of the nature of their work, and not being believed 
that their recorded CBG results were correct. Women were more likely to continue with regular CBG 
testing if they thought it was less painful than anticipated, attended a group session to learn how to 
perform CBG testing, took family members to teaching sessions, were shown by a community 
pharmacist how do to the testing, had the belief they knew how to do it, were praised by health 
professionals for their efforts, and had fun ‘pricking’ friends and family. There is a need for health 
professionals to provide clear and meaningful information about CBG testing, discuss strategies for 
overcoming barriers particularly in work situations, enable family members to be part of this process and 
to believe a woman’s CBG recordings (Table 5.7). These findings are echoed in other literature (Carolan 
2012b; Parsons 2014). The notion for a community pharmacist to initially teach women diagnosed with 
GDM how to perform CBG testing may be a valuable option to consider when time, cost and distance 
are a barrier. Some studies involving patients (pre-diabetic or with T2DM) self-monitoring their CBG 
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concentration have found community pharmacies specialised in diabetes care can provide this service 
effectively (Müller 2006; Mansell 2016). An extensive literature search did not identify any studies 
involving women with GDM and the effects of being taught CBG testing by a local community 
pharmacist. Clearly this is an area where further research is required (Table 5.7).  
Dietary intake and exercise for optimal glycaemic control 
Our study demonstrated that the domains Belief about consequences, Environmental context and 
resources and Behavioural regulation were represented most strongly in the context of dietary intake 
and exercise for enabler and barrier identification. Studies have reported that women with GDM who 
were treated with dietary advice and were self-monitoring CBG concentrations had fewer macrosomic 
babies, less maternal weight gain and less birth trauma (Crowther 2005; Hawkins 2009).  
A Cochrane systematic review assessed evidence from 19 trials for ten different dietary interventions 
and concluded that while dietary advice is the main strategy for managing GDM it remains unclear which 
type of diet is best (Han 2017).  Dietary self-management guided by CBG concentrations alone without 
a particular diet may be difficult for women with GDM. In our study, participants who understood the 
benefits and consequences of dietary self-management and regular exercise for controlling their CBG 
concentrations had access to professional dietetic advice and could incorporate effective physical 
activities into their daily life achieved optimal glycaemic control most of the time. This is consistent with 
other studies (Persson 2010; Carolan 2012b; Hui 2014; Wang 2016).  
Women in our study saw self-imposed dietary restrictions such as eating the same meal every day or 
ordering commercially pre-packed health food options as enablers, and for them these were solutions 
to their current hyperglycaemia, as GDM was understood to be transitory. This self-imposed practice 
resulted in a woman’s CBG concentrations staying within her recommended glycaemic targets most of 
the time. It is questionable if this approach would achieve long-term lifestyle changes. It is possible that 
the women in our study may not have understood the link between GDM and the risk for subsequent 
development of T2DM, and the importance of health behaviour regulation for reducing future diabetes 
risk (Kapur 2008; Balas-Nakash 2010; Hirst 2012). Health professionals need to ascertain from women 
the reasons for any self-imposed dietary practices and ensure future health implications are understood. 
Further research is needed to explore in depth if self-imposed dietary practices by women with GDM 
during their pregnancy affect long term lifestyle behaviour (Table 5.7). 
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Over half of the women in this study identified a barrier to written information, as it was only provided in 
English. They wanted the health information in either their first language or for it to be more visually 
presented to better understand their GDM diagnosis, what optimal blood glucose control meant and to 
include ethnic food options (Table 5.7). These are similar findings reported by qualitative studies for 
women with GDM in Vietnam (Hirst 2012), Italy (Lapolla 2012) and South Tamil Nadu (Bhavadharini 
2017). Women in our study identified Google as a helpful tool, especially if they could access websites 
in their first language through Google. Health professionals need to be aware that women will access 
information beyond the clinic environment and that the quality of this information may vary. Health 
literacy providing clear and relevant health messages for women with GDM or other types of diabetes 
has been identified as an effective way to help people manage their own health care (Al Sayah 2013; 
Work Base Education Trust 2014; Hussain 2015; Ministry of Health 2015a). 
Most women commented on being hungry, but felt they could endure this for their babies’ health, if it 
kept their CBG concentrations within the recommended glycaemic targets. Dietetic advice needs to 
include how to address hunger for women with GDM (Table 5.7). 
Regular aerobic exercises involving large muscle groups such as walking, swimming and stationary 
cycling have been reported to be beneficial in pregnancy and are not associated with harms to the baby 
(ACOG 2015; Russo 2015). The prevalence of exercise for women with GDM during their pregnancy 
appeared to be related to their understanding of what type of exercise they could do and its duration. 
This was further compounded by their inability to incorporate exercises into their busy daily life and the 
fact that it was called exercise. The lack of specific recommendation on type, intensity, and duration of 
exercises from health professionals and women’s beliefs that exercises could cause pre-term labour or 
that rest is required when pregnant has been reported in the literature (Mudd 2013; Carolan-OIah 2016; 
Momeni 2016; Wang 2016).  
Participating women, who approached exercises as meaning to be physical activity, were more likely to 
think outside the (exercise) square, and welcomed discovering which physical activity, such as bathing 
the toddler after the evening meal, had an impact on their glycaemic control.  
A Cochrane systematic review on exercise for pregnant women with GDM for improving maternal and 
fetal outcomes summarised evidence from 11 randomised controlled trials and found while exercises 
appeared to lower fasting and post-prandial CBG concentrations, they did not find any differences in 
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other outcomes for pregnant women with GDM (Brown 2017). However, even if exercise does not 
provide any benefit during pregnancy, this change in lifestyle may persist after birth, and may help 
prevent the onset of type 2 diabetes and its long-term complications. A prospective study of 4554 women 
with previous GDM, who were followed for 16 years showed that increased physical activity levels 
lowered T2DM development and its risks (Bao 2014).  
This may mean that for women with GDM it could be worthwhile to record physical activities alongside 
or as part of their food diary for them to understand the effect physical activities have on their CBG 
concentrations (Table 5.7). It is common practice for the dietitian or the Lead Maternity Carer (LMC) 
midwife to recommended daily walking but without further in-depth guidance. Meeting with a physical 
activity professional or therapist who assesses where and what physical activities could be adapted to 
a woman’s daily context, alongside other health professionals at the diabetes in pregnancy clinic, may 
be an option to consider and would benefit from further research (Table 5.7).  
Support for glycaemic optimal control 
Women reported that support from partners, family, friends, work colleagues and health professionals 
made a significant difference for them to accept their diagnosis, adhere to prescribed treatment and 
maintain optimal glycaemic control. This support facilitated self-management and healthy lifestyle 
behaviours. Partners and extended family support was reported as valuable in particular for increasing 
exercise and the provision of healthy meals. Similar findings have been reported in the literature 
(Carolan 2012b; Devsam 2013; Parsons 2014; Kaptein 2015). The key domains identified for this section 
of social influences and belief about consequences reflect this. Other suggestions for support included 
joining a social media network for women with current GDM, for example on Facebook, and/or attend a 
local support group for women with GDM. Neither of these are currently available in New Zealand and 
support organisations for Diabetes or DHB’s may want to consider this (Table 5.7).  
Some women in this study found their family’s excessive concerns or providing unhealthy meals a 
challenge and reported that this contributed to them feeling stressed and unable to perform CBG 
monitoring. A qualitative study of perceived needs in women with GDM found similar findings and 
indicates the importance for health professionals to increase their awareness for the need of social 
support for women with GDM (Khooshehchin 2016). Other studies including women with borderline 
GDM and T2DM reiterate this (Mayberry 2012; Miller 2013; Greenhalgh 2015; Han 2017) and 
recommend, that health professionals as part of clinic appointments need to include discussions about 
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effective strategies to cope with situations that are challenging for women with GDM. Research about 
the effect of a GDM diagnosis on partners and family members and how they can best support a woman 
with GDM in their context is limited (Table 5.7). Complexities of social determinants of health is often 
studied with ethnographic research (Bandyopadhya 2011b) and it may be appropriate to encourage this 
type of research for partner and family experience who are living and supporting women with GDM.  
Within the identified key domain of belief about consequences, a surprise finding was that several 
women reported not sharing their GDM diagnosis with anyone other than their partners. The main 
reasons for this decision was fear of being judged, not wanting to be scrutinised for daily activities 
including food intake, or not wanting to worry extended family members. This created social isolation, 
and contributed to a woman’s feeling of shame, guilt, and reduced her ability to achieve optimal 
glycaemic control. Qualitative studies support these findings (Abdoli 2012; Collier 2011; Ghaffari 2014; 
Schabert 2013). The women in our study had not shared this decision with their respective health 
professionals. This suggests the need for greater awareness among health professionals that some 
women with GDM ‘do not tell’ and on-going assessment of a woman’s mental well-being should be 
included in the health services provision (Morrison 2014).  
This study adds to the body of knowledge about enabling women with GDM to achieve optimal 
glycaemic control. While some studies have explored the GDM experience from the woman’s point of 
view, none have specifically studied the enablers and barriers to achieving optimal glycaemic control 
using the validated Theoretical Domains Framework. The sample size was reflective of a cross section 
of the demographics of New Zealand’s pregnant population and reached data saturation.  
Limitations of our study were that participating women were not from rural or remote areas in New 
Zealand and only women who were fluent in English were eligible. Women from different cultural 
backgrounds were well represented in this study (Table 5.3). It is unclear if the interviews with women 
in their first language would have elicited different enablers and barriers for optimal glycaemic control. 
Women interviewed often asked for information in their first language. Future research should consider 
conducting interviews in a participant’s first language.   
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5.2.5 Conclusions 
This qualitative study has identified enablers and barriers for women with GDM to achieve optimal 
glycaemic control providing insights as to how women accept a diagnosis of GDM, adapt to regular CBG 
self-monitoring, adhere to recommended treatments, undertake necessary lifestyle changes and can be 
supported. The enablers and barriers identified are multidimensional and may assist health 
professionals and diabetes in pregnancy services on how best to meet the needs of this diverse group 
of women and their families to achieve optimal CBG control and so reduce adverse outcomes for women 
with GDM and their babies.  
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Chapter 6: Summary conclusion 
This thesis aimed to address the research gaps identified after reviewing the literature on treatments 
and experiences for women with GDM. The gaps highlighted the need to synthesise the evidence from 
systematic reviews on treatments for women with GDM and from randomised controlled trials of 
glycaemic treatment targets for women with GDM, as well as the need to investigate women’s views 
and experiences, barriers, and enablers for improving health outcomes. In this chapter, the key findings 
from each study will be summarised and the implications for clinical practice and further research 
identified presented. 
6.1 Research question 1: Which treatments are effective for women with GDM? 
6.1.1 Aim: To synthesise the current research evidence of Cochrane systematic reviews 
on treatments for women with GDM and to identify specific research gaps of 
treatments for women with GDM requiring further primary research.  
A comprehensive overview of existing Cochrane systematic reviews on treatments for women with GDM 
was prepared, summarising the available evidence on the effectiveness of treatments for women with 
GDM and their infants. This included quality assessments for the included studies and the pre-specified 
primary and secondary outcomes. The Overview was entitled: Treatments for women with gestational 
diabetes mellitus: an overview of Cochrane systematic reviews. It is hoped that the Overview can 
be used as a one-stop resource to inform health professionals, consumers, clinical guideline developers, 
health policy makers and researchers. 
Summary of findings 
The Overview included eight Cochrane systematic reviews that reported on 62 randomised trials that 
included 9133 women, 8373 babies and 767 children. All the included systematic reviews were of high-
quality and of low-risk of bias (AMSTAR and ROBIS).  
The quality of the evidence from the randomised trials included in the eligible systematic reviews ranged 
from high- to very low-quality (GRADE) with most of the included trials being assessed as low- to very 
low-quality. Data were available from the included reviews for 59 (74%) pre-specified overview 
outcomes of the 80 listed in the protocol for this Overview.  
Findings from high-quality evidence in the Overview suggest that lifestyle interventions are ineffective 
for reducing the likelihood of induction of labour compared with usual diet/diet alone and that exercise 
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compared with control is ineffective in improving the return to pre-pregnancy weight. No other high-
quality evidence was found. 
The available moderate-quality evidence does suggest some promising interventions for which more 
high-quality evidence is needed: Lifestyle interventions (reduced risk of LGA) and the DASH diet 
(reduced rate of caesarean section). Lifestyle interventions and considering the DASH diet may be 
useful for some women with GDM as treatment interventions with or without additional pharmacotherapy 
alongside appropriate advice and/or supervision from a health professional (Table 6.1). Long-term 
health outcomes for women and their infants and costs have not been well reported (Table 6.1). 
Implications for clinical practice from the Overview findings 
Lifestyle interventions, that include advice on diet and physical activity, have become the mainstay of 
treatment for women with GDM and are recommended in many national clinical practice guidelines. 
However, many of the lifestyle and exercise interventions are multi-component and identifying which of 
the individual components are effective or not effective is impossible with the currently available 
evidence reported in the Overview.  
Most dietary treatments assessed in this Overview are from interventions reported as single studies, 
often with a small number of participants, and only a few trials have compared the same or similar dietary 
interventions. Therefore, there is limited high-quality evidence about the effects on health outcomes of 
relevance for women with GDM and their babies to guide or inform clinical practice (Table 6.1). 
Considerations for future research from the Overview 
This Overview highlights that there is limited evidence to make conclusions on the effects on relevant 
health outcomes for many current treatments for women with GDM. Further high-quality research is 
required to identify the most effective components or combination of components for the lifestyle and 
exercise interventions (Table 6.1).  
Other dietary interventions may be beneficial, but any effect is currently difficult to identify because of 
multiple comparisons, small sample sizes and the limited quantity and quality of trials. 
Further large high-quality studies with appropriate sample sizes are required, particularly for the DASH 
diet, to assess their effectiveness for improving short-and long-term maternal and infant outcomes and 
to assess the costs for treatments, family and services (Table 6.1). 
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6.2 Research question 2: Which glycaemic treatment targets best benefit the 
health of women diagnosed with GDM and their babies? 
6.2.1 Aim: To synthesise and assess the current research evidence from randomised 
controlled trials on the effect of different glycaemic targets for women with GDM 
and their children and to identify specific research gaps of glycaemic targets to 
guide treatment for women with GDM requiring further primary research.  
A Cochrane systematic review entitled: Different intensities of glycaemic control for women with 
gestational diabetes mellitus was prepared, following production of a systematic review protocol that 
was peer reviewed, and published in the Cochrane Library (Martis 2016a). The systematic review 
assessed the available evidence from randomised controlled trials on the effect of different treatment 
targets for glycaemic control in pregnant women with GDM on maternal and infant health outcomes.  
Summary of the Cochrane systematic review findings 
Only one randomised controlled trial, involving 180 women, was identified that met the inclusion criteria 
for this systematic review. In this trial, the capillary glycaemic targets compared were: pre-prandial: 5.0 
mmol/L (90 mg/dL) and at one-hour postprandial: 6.7 mmol/L (120 mg/dL) for the strict group and for 
the liberal glycaemic group: pre-prandial 5.8 mmol/L (104 mg/dL) and at one-hour postprandial 7.8 
mmol/L (140 mg/dL).  
The included trial did not report on any of the systematic review’s primary outcomes but did report data 
relating to some of the maternal and infant secondary outcomes. For the use of pharmacological 
therapy, a maternal secondary outcome, the strict glycaemic targets were associated with a non-
significant increase in the use of insulin requirements (33/85; 39%) compared with liberal glycaemic 
targets (18/86; 21%) (RR 1.85, 95% CI 1.14 to 3.03; one trial, 171 women). The confidence intervals 
are wide suggesting imprecision and caution is required when interpreting the data. No clear differences 
were seen for any of the other secondary outcomes, including long-term outcomes. Based on the current 
limited data it remains unclear which glycaemic targets should be recommended for women with GDM 
for improving their health and the health of their babies.  
Implications for clinical practice the Cochrane systematic review 
There was non-significant evidence that women using stricter glycaemic targets in the included study 
used more insulin therapy. No data were provided for adverse effects such as maternal hypoglycaemia. 
There was no difference in the risk of the infant being born small-for-gestational age. There is currently 
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insufficient evidence to support stricter over more liberal glycaemic treatment targets for women with 
GDM for guiding clinical practice (Table 6.1). Although the current available evidence provides limited 
guidance for clinical practice, four ongoing randomised controlled trials have been identified and data 
from these studies will increase the knowledge base and once published will be included in future 
updates of this systematic review. 
Considerations for future research the Cochrane systematic review 
This systematic review highlights the need for further larger, high-quality trials that compare different 
intensities of glycaemic control targets to guide the treatment of women with GDM. High-quality trials 
should evaluate different glycaemic targets to guide treatment for GDM and assess both short- and long-
term health outcomes for mothers and their infants including health costs for services and women with 
GDM. It is also important to evaluate women’s views of adhering to different glycaemic intensities and 
how this affects their daily life to understand and overcome impracticalities and inconveniences such as 
hospital clinic attendances, and the effects of capillary blood glucose monitoring, as well as financial 
costs (Table 6.1).  
6.3 Research question 3: What do women with GDM say are the barriers and 
enablers for their glycaemic targets?  
6.3.1 Aim: To investigate how women with GDM view their glycaemic treatment targets 
and identify the barriers and enablers for them in achieving optimal glycaemic 
control using a quantitative research approach. 
This published quantitative study reports the results of a face-to-face and telephone survey administered 
to 60 women diagnosed with GDM at two distinct different geographic locations in New Zealand to 
investigate existing barriers and enablers to achieving optimal capillary blood glucose control. 
Summary of findings of this survey 
The majority of women correctly identified their glycaemic treatment targets (59, 98%) and viewed it as 
very important or important to try to adhere to these targets. Documenting the blood glucose results 
were viewed as less important (56, 93%) by the women compared to viewing adherence to the targets 
because women knew the results could be downloaded from the glucometer. These findings were 
similar across participants regardless of their glycaemic treatment targets.  
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Nine barriers and ten enablers were identified. Almost two thirds of women found it difficult to achieve 
adequate morning fasting capillary blood glucose control, regardless of their recommended glycaemic 
targets, and identified the need for better strategies and adequate health professional and family support 
to manage this difficulty.  Barriers for health information and literacy identified that health professionals 
need to consider using a women-centred and adult learning style approach, provide visual aids, provide 
written information in relevant languages, and include extended family members when imparting 
knowledge or teaching GDM related skills. Long clinic waiting hours, inconsistent advice, judgmental 
attitudes and not being believed by health professionals requires further consideration when providing 
a health care service for women with GDM. 
Implications for clinical practice from this survey 
A wide range of barriers and enablers were reported. The findings from this survey will be useful for 
developing strategies within Diabetes in Pregnancy Services to better support women with GDM achieve 
their glycaemic control. Diabetes in Pregnancy Services and health professionals may wish to consider 
offering group teaching sessions for women with GDM, providing more GDM information with visual 
aids, providing written information in relevant first languages, and including extended family members 
when imparting knowledge or teaching GDM related skills (Table 6.1).  
Considerations for future research from this survey 
We found no published studies that reported on the effects of providing visual learning aids for women 
with GDM or the impact of having the information about GDM in their first language (Table 6.1). Further 
research should support the development of effective GDM resources for women with GDM.  New 
Zealand based social media, as in Facebook, was identified as another potential virtual community 
support by the women surveyed, as this is currently not available. Research into setting up a New 
Zealand virtual community support group and its effectiveness for women with GDM needs to be 
considered (Table 6.1). Two thirds of women reported being hungry. It is unclear from the survey if this 
relates to women trying to lower their morning fasting capillary blood glucose by eating less at dinner-
time or eating very low carbohydrate meals. This would benefit from further research to explore and 
then guide how to overcome this identified barrier (Table 6.1).  
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6.4 Research question 4: What are women’s experiences, barriers, and 
enablers with their glycaemic targets from a qualitative perspective? 
6.4.1 Aim: To examine behavioural factors impacting on women with GDM in achieving 
optimal glycaemic control.  
This qualitative study through semi-structured interviews was conducted with 60 women diagnosed with 
GDM who had a least two weeks’ experience with CBG testing. Using the TDF framework for analysis 
the results identified existing behavioural factors for women with GDM in achieving optimal glycaemic 
control. 
Summary of findings from the semi-structured interviews  
Women reported a shift from their initial negative response of the diagnosis of GDM to accepting their 
diagnosis but disliked the constant focus on numbers. Barriers and enablers were categorised into 10 
theoretical domains across three main areas. The areas comprised:  
1. Monitoring for optimal glycaemic control 
2. Dietary intake and exercise for optimal glycaemic control  
3. Support for optimal glycaemic control  
Barriers included: lack of health information, teaching sessions, consultations, and food diaries in a 
woman’s first language; long waiting times at clinic appointments; seeing a different health professional 
every clinic visit; inconsistent advice; no tailored physical activities assessments; not knowing where to 
access appropriate information on the internet; unsupportive partners, families, and workplaces; and 
unavailability of social media or support groups for women with GDM. Perceived judgement by others 
led some women only to share their GDM diagnosis with their partners. This created social isolation.  
Enablers included: the ability to attend group teaching sessions with family and hear from women who 
have had GDM; easy access to a diabetes dietitian with diet recommendations tailored to a woman’s 
context including ethnic food and financial considerations; free CBG monitoring equipment, health 
shuttles to take women to appointments; child care when attending clinic appointments; and being taught 
CBG testing by a community pharmacist. 
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1. Monitoring for optimal glycaemic control: Implications for clinical practice from the semi-
structured interviews 
There is a need for health professionals to provide clear and meaningful information about CBG testing, 
discuss strategies for overcoming barriers particularly in work situations, enable family members to be 
part of this process and to believe a woman’s CBG recordings (Table 6.1). Providing information relating 
to GDM in a woman’s first language and/or more visually, including ethnic food suggestions may 
increase adherence to glycaemic targets and regular CBG monitoring (Table 6.1). The notion for a 
community pharmacist to initially teach women diagnosed with GDM how to perform CBG testing may 
be a valuable option to consider in clinical practice when time, cost and distance are a barrier (Table 
6.1). 
1. Monitoring for optimal glycaemic control: Considerations for future research from the semi-
structured interviews 
Women repeatedly asked for easier ways of recording their CBG concentration results or food diary 
entries. Further research should include exploring opportunities for companies to create phone Apps for 
electronic food and activity diaries, recording of CBG results and medication intake and assess its 
effectiveness for monitoring effective glycaemic control (Table 6.1). Some literature suggest that 
women’s anxiety increases after being diagnosed with GDM because of their own and societal 
connotations attached to the term GDM and have suggested a name change. Alternative names 
suggested for GDM were Gestational Dysglycemia of Nutritional Origin (GDNO) or Pregnancy Related 
Intolerance to Glucose (PRIG). Further research is needed exploring if a name change for GDM does 
reduce anxiety in pregnant women diagnosed with GDM (Table 6.1). Some women in the study were 
taught CBG testing by their community pharmacists and had reported this to be a positive experience. 
No research has been published for women with GDM in this area that we could find. Research 
considerations could include exploring the experiences for women newly diagnosed with GDM being 
taught by a community pharmacist, and its time and costs effectiveness (Table 6.1). 
2. Dietary intake and exercise for optimal glycaemic control: Implications for clinical practice 
from the semi-structured interviews 
Health professionals need to seek from women the reasons for any self-imposed dietary practices and 
ensure potential future health implications are understood (Table 6.1). Health professionals need to be 
aware that women will access information beyond the clinic environment, that the quality of this 
information may vary and that there is a need for guidance to trustworthy internet sites or web pages  
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Table 6.1: Considerations for clinical practice and research 
Clinical practice considerations Research considerations 
Treatments for women with GDM Treatments for women with GDM 
• Consider lifestyle interventions for reducing the risk of LGA, promising 
evidence 
• Consider exercise for reducing death and serious infant morbidity; promising 
evidence 
• Consider the DASH diet for reducing caesarean section rate; promising 
evidence 
• High-quality trials needed for the effective components or combinations of 
lifestyle interventions 
• High-quality trials needed for the effective components or combinations of 
exercise interventions 
• Further high-quality trials needed with appropriate sample size for the DASH 
diet to confirm effectiveness for improving short and long-term outcomes 
• Other dietary interventions need exploring as currently only small size dietary 
trials available with multiple comparisons; too difficult to identify any benefits 
• Cost for treatments, family and service requires sufficient powered trials 
• Long-term outcomes for women with GDM and their children need to be 
included in any research 
• Women’s experiences of the treatment require further research 
Glycaemic targets for women with GDM Glycaemic targets for women with GDM 
• Insufficient evidence to recommend stricter or more liberal glycaemic targets 
for women with GDM; consensus-based recommendations for glycaemic 
targets 
• Large high-quality trials needed to compare different intensities of glycaemic 
control targets including short and long-term outcomes  
• Women’s experiences with glycaemic targets requires further research 
• Explore differences and similarities between survey and semi-structured 
interview method in identifying barriers and enablers for women with GDM and 
their different glycaemic targets or if a mixed method design is more effective 
Monitoring for optimal glycaemic control Monitoring for optimal glycaemic control 
• Enable women with GDM to attend group teaching for CBG  
testing and interpretation, and include women who have had GDM to share 
their stories. 
• Discuss individual strategies for regular CBG monitoring, food intake and 
physical activity. 
• Encourage partner and family attendance at any clinic or teaching sessions 
(may need to be offered at evenings or weekends). 
• Explore opportunities for companies to create phone Apps, e.g. for electronic 
food and activity diaries, recording of CBG results and medication intake. 
• Do phone apps have an impact on optimal glycaemic control for women with 
GDM? 
• Does a name change for GDM reduce anxiety in pregnant women? 
•  How effective are visual learning aids for women with GDM? 
• How effective is having information or clinic appointments in a woman’s first 
language?     
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Clinical practice considerations Research considerations 
• Provide information relating to GDM in a woman’s first language and/or more 
visually, including ethnic food suggestions and food label reading skills. 
• Investigate the possibility of community pharmacists’ involvement in teaching 
CBG testing. 
Dietary intake and exercise for glycaemic control Dietary intake and exercise for glycaemic control 
• Enable easy access to a diabetes dietitian with diet recommendations tailored 
to an individual woman’s context (cultural, financial, and emotional). 
• Engage in meaningful discussions about the content in a food  
diary and provide multi-modal opportunity for the woman to record the food 
diary in her first language or enable mobile phone photo collection of food 
intake. 
• Regularly address hunger for women with GDM. 
• Encourage a physical activity diary alongside the food diary. 
• Consider engaging a physical therapist for clear in-depth assessment and 
guidance of exercise that women can incorporate into their daily life.    
• Does keeping a physical activity diary impact on glycaemic control? 
• Does engaging a physical activity therapist contributes to the understanding 
and up-take of physical activity for women with GDM? 
• Why do women with GDM seem to be hungry despite quality dietary 
recommendations? 
• What affect has self-imposed dietary practices by women with GDM during their 
pregnancy on long term lifestyle behaviour? 
 
Support for optimal glycaemic control Support for optimal glycaemic control 
• Provide free CBG monitoring equipment, health shuttles and child care when 
attending clinic appointments and reduce clinic waiting times. 
• Consider face-to-face support groups for women with GDM. 
• Consider setting up a social media group for women. with current GDM (e.g. 
Facebook). 
• Include regular mental health assessment for women with GDM. 
• Provide direct phone access to multi-disciplinary health professionals. 
• Limited research available for regular mental health assessment for women with 
GDM. 
• Limited research about the effect of a GDM diagnosis on partners and family 
members. 
• Limited research on how partners and families can best support a woman with 
GDM in their context. 
• Cost-effective analysis for free CBG equipment, free health shuttle and free 
child care for attending clinic appointments 
• Does face-face group support make a difference for women with GDM for 
maintaining optimal glycaemic control? 
• How effective is creating a virtual community support group (social media e.g. 
Facebook) for women with GDM? 
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(Table 6.1). Dietetic advice needs to include how to read food labels and address hunger for women 
with GDM (Table 6.1). Meeting with a physical activity professional or therapist who assesses where 
and what physical activities could be adapted to a woman’s daily context, alongside other health 
professionals at the diabetes in pregnancy clinic may be a valuable consideration for clinical practice 
(Table 6.1). 
2. Dietary intake and exercise for optimal glycaemic control: Considerations for future 
research from the semi-structured interviews 
The study identified that little information and assessments were provided to participants regarding 
exercise/physical activity. Further research in this area could clarify its effectiveness including if keeping 
a physical activity diary, engaging a physical activity therapist and family activity involvement makes a 
difference for optimal glycaemic control (Table 6.1). Women indicated being hungry most of the time.  
There is a need for further research to investigate why women with GDM seem to be hungry despite 
receiving quality dietary recommendations (Table 6.1). Some women ate the same food every day to 
achieve optimal glycaemic control. It is unclear if this self-imposed practice is beneficial for short term 
and long-term lifestyle behaviour and would benefit from further research (Table 6.1).  
3. Support for optimal glycaemic control: Implications for clinical practice from the semi-
structured interviews 
Health professionals need to include discussions at clinic appointments about effective strategies to 
cope with situations that are challenging for women with GDM when family, friends and work colleagues 
offer unhealthy food and do not understand the importance of regular CBG monitoring (Table 6.1). 
Health service provision may need to consider including on-going assessment of a woman’s mental 
well-being and an increased awareness among health professionals that some women with GDM do 
not share their diagnosis of GDM (Table 6.1). Direct phone access to multi-disciplinary health 
professionals, provision of free CBG monitoring equipment, free health shuttles, free child care when 
attending clinic appointments and reduce clinic waiting times all may be considered for clinical practice 
implications (Table 6.1). 
3. Support for optimal glycaemic control: Considerations for future research from the semi-
structured interviews  
There appears to be an urgent need for further research in the area of support for women with GDM, as 
there is limited research available in the literature about the effectiveness of regular mental health 
389 
assessment for women with GDM, about the effect of a GDM diagnosis on partners and family members 
and effective copying strategies and about how partners and families can best support a woman with 
GDM in their context (Table 6.1). There are no face-to-face support or social media groups available in 
New Zealand. Further research could explore and/or compare if these support groups make a difference 
for women with GDM for maintaining optimal glycaemic control (Table 6.1). 
It is of interest to note that the survey and the semi-structured interview identified similar but also some 
different barriers and enablers for women with GDM. Further research could explore these differences 
and similarities and assess if one method of identifying barriers and enablers is more effective than the 
other or if a mixed-method design is more comprehensive to identifying barriers and enablers to achieve 
optimal glycaemic control for women with GDM (Table 6.1). 
6.5 Overall conclusions from this thesis 
This thesis presented a comprehensive Cochrane Overview of the current evidence on treatments for 
women with GDM. The Overview provided a summary of the effects on relevant health outcomes of 
different treatments for women with GDM and identified remaining research gaps. A lack of quality 
evidence was found in the prepared Cochrane systematic review on the optimal glycaemic treatment 
targets for women with GDM and identified the need for large multi-centred well-conducted randomised 
trials.  The thesis presents many multidimensional barriers and enablers identified by women with GDM 
aiming to achieve optimal glycaemic control.  Health professionals with the Diabetes in Pregnancy 
Services will need to consider these for strategic planning and how best to provide care for women with 
GDM in New Zealand to achieve optimal glycaemic control. 
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